0000885725-23-000026.txt : 20230504 0000885725-23-000026.hdr.sgml : 20230504 20230504160719 ACCESSION NUMBER: 0000885725-23-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 23888676 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-Q 1 bsx-20230331.htm 10-Q bsx-20230331
000088572512/312023Q1false00008857252023-01-012023-03-310000885725us-gaap:CommonStockMember2023-01-012023-03-310000885725bsx:SeniorNotedue2027Member2023-01-012023-03-310000885725bsx:A550MCPSSeriesAMember2023-01-012023-03-31iso4217:USDxbrli:shares00008857252023-04-28xbrli:sharesiso4217:USD00008857252022-01-012022-03-3100008857252023-03-3100008857252022-12-310000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:PreferredStockMember2021-12-310000885725us-gaap:PreferredStockMember2023-01-012023-03-310000885725us-gaap:PreferredStockMember2022-01-012022-03-310000885725us-gaap:PreferredStockMember2023-03-310000885725us-gaap:PreferredStockMember2022-03-310000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:CommonStockMember2021-12-310000885725us-gaap:CommonStockMember2023-01-012023-03-310000885725us-gaap:CommonStockMember2022-01-012022-03-3100008857252022-03-310000885725us-gaap:CommonStockMember2023-03-310000885725us-gaap:CommonStockMember2022-03-310000885725us-gaap:TreasuryStockCommonMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2021-12-310000885725us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000885725us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000885725us-gaap:TreasuryStockCommonMember2023-03-310000885725us-gaap:TreasuryStockCommonMember2022-03-310000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000885725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000885725us-gaap:AdditionalPaidInCapitalMember2023-03-310000885725us-gaap:AdditionalPaidInCapitalMember2022-03-310000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:RetainedEarningsMember2021-12-310000885725us-gaap:RetainedEarningsMember2023-01-012023-03-310000885725us-gaap:RetainedEarningsMember2022-01-012022-03-310000885725us-gaap:RetainedEarningsMember2023-03-310000885725us-gaap:RetainedEarningsMember2022-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000885725us-gaap:NoncontrollingInterestMember2022-12-310000885725us-gaap:NoncontrollingInterestMember2021-12-310000885725us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000885725us-gaap:NoncontrollingInterestMember2022-01-012022-03-310000885725us-gaap:NoncontrollingInterestMember2023-03-310000885725us-gaap:NoncontrollingInterestMember2022-03-3100008857252021-12-310000885725us-gaap:SubsequentEventMemberbsx:ApolloMember2023-04-04xbrli:pure0000885725us-gaap:SubsequentEventMemberbsx:ApolloMember2023-04-042023-04-040000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMember2023-02-202023-02-20iso4217:KRW0000885725bsx:AcotecMember2023-01-012023-03-310000885725bsx:AcotecMember2023-03-310000885725bsx:AcotecMember2023-02-200000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2023-01-012023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMembersrt:WeightedAverageMember2023-03-310000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2023-03-310000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMember2023-01-012023-03-310000885725bsx:AcotecMemberus-gaap:CustomerRelationshipsMembersrt:WeightedAverageMember2023-03-310000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-03-310000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-01-012023-03-310000885725bsx:AcotecMembersrt:WeightedAverageMemberus-gaap:OtherIntangibleAssetsMember2023-03-310000885725bsx:BaylisMedicalMember2023-01-012023-03-310000885725bsx:BaylisMedicalMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2023-01-012023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMembersrt:WeightedAverageMember2023-03-310000885725bsx:AllBusinessAcquisitionsMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMembersrt:MinimumMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RDRegulatoryandCommercializationbasedMilestoneMembersrt:WeightedAverageMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMembersrt:MinimumMember2023-03-31utr:Rate0000885725us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberbsx:RevenueBasedPaymentsMember2023-03-310000885725us-gaap:ValuationTechniqueDiscountedCashFlowMemberbsx:RevenueBasedPaymentsMembersrt:WeightedAverageMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725us-gaap:PatentsMember2023-03-310000885725us-gaap:PatentsMember2022-12-310000885725us-gaap:OtherIntangibleAssetsMember2023-03-310000885725us-gaap:OtherIntangibleAssetsMember2022-12-310000885725us-gaap:GoodwillMember2023-03-310000885725us-gaap:GoodwillMember2022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2023-03-310000885725us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-03-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:MedsurgMember2022-12-310000885725bsx:CardiovascularMember2022-12-310000885725bsx:MedsurgMember2023-01-012023-03-310000885725bsx:CardiovascularMember2023-01-012023-03-310000885725bsx:MedsurgMember2023-03-310000885725bsx:CardiovascularMember2023-03-310000885725bsx:December2027NotesMember2023-03-31iso4217:EUR0000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-03-31bsx:derivative_instrument0000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberbsx:ForeigncurrencydenominatedindebtMember2022-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-03-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-31bsx:units0000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberbsx:ForeigncurrencydenominatedindebtMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2023-01-012023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2022-01-012022-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberbsx:ForeigncurrencydenominatedindebtMember2022-01-012022-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2023-03-310000885725us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMember2023-03-310000885725us-gaap:InterestRateContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2023-03-310000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-03-310000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2023-03-310000885725us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-03-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000885725us-gaap:FairValueMeasurementsRecurringMember2023-03-310000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel3Member2023-03-310000885725bsx:LicensingarrangementassetsMember2023-03-310000885725bsx:LicensingarrangementassetsMembersrt:WeightedAverageMember2023-03-310000885725bsx:LicensingarrangementliabilitiesMembersrt:MinimumMember2023-03-310000885725srt:MaximumMemberbsx:LicensingarrangementliabilitiesMember2023-03-310000885725bsx:LicensingarrangementliabilitiesMembersrt:WeightedAverageMember2023-03-310000885725bsx:LicensingarrangementassetsMember2023-01-012023-03-310000885725bsx:LicensingarrangementliabilitiesMember2023-01-012023-03-310000885725bsx:March2024NotesMember2023-03-310000885725bsx:March2024NotesMember2022-12-310000885725bsx:March2025NotesMember2023-03-310000885725bsx:March2025NotesMember2022-12-310000885725bsx:June2025NotesMember2023-03-310000885725bsx:June2025NotesMember2022-12-310000885725bsx:March2026NotesMember2023-03-310000885725bsx:March2026NotesMember2022-12-310000885725bsx:December2027NotesMember2022-12-310000885725bsx:March2028SeniorNotesMember2023-03-310000885725bsx:March2028SeniorNotesMember2022-12-310000885725bsx:March2028NotesMember2023-03-310000885725bsx:March2028NotesMember2022-12-310000885725bsx:March2029NotesMember2023-03-310000885725bsx:March2029NotesMember2022-12-310000885725bsx:June2030NotesMember2023-03-310000885725bsx:June2030NotesMember2022-12-310000885725bsx:March2031NotesMember2023-03-310000885725bsx:March2031NotesMember2022-12-310000885725bsx:March2034NotesMember2023-03-310000885725bsx:March2034NotesMember2022-12-310000885725bsx:November2035NotesMember2023-03-310000885725bsx:November2035NotesMember2022-12-310000885725bsx:March2039NotesMember2023-03-310000885725bsx:March2039NotesMember2022-12-310000885725bsx:January2040NotesMember2023-03-310000885725bsx:January2040NotesMember2022-12-310000885725bsx:March2049NotesMember2023-03-310000885725bsx:March2049NotesMember2022-12-310000885725us-gaap:SeniorNotesMember2023-03-310000885725us-gaap:SeniorNotesMember2022-12-310000885725us-gaap:CapitalLeaseObligationsMember2023-03-310000885725us-gaap:CapitalLeaseObligationsMember2022-12-310000885725us-gaap:RevolvingCreditFacilityMemberbsx:The2018FacilityDomain2021-05-100000885725us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberbsx:RevolvingCreditFacility2021Member2021-05-102021-05-100000885725us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberbsx:RevolvingCreditFacility2021Member2023-03-310000885725us-gaap:RevolvingCreditFacilityMemberbsx:The2018FacilityDomain2022-12-310000885725bsx:CurrentRequirementMember2023-03-310000885725bsx:ActualCovenantMember2023-03-310000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2023-03-310000885725bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember2023-03-310000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2023-03-310000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2023-03-310000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2023-03-310000885725bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember2023-03-310000885725us-gaap:CommercialPaperMember2023-01-012023-03-310000885725us-gaap:CommercialPaperMember2023-03-310000885725bsx:TheOfferingAggregatePrincipalAmountMember2023-03-3100008857252022-01-012022-12-310000885725bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember2023-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-01-012023-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-03-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-01-012023-03-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-03-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-01-012023-03-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-01-012022-12-3100008857252023-01-312023-01-310000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725bsx:A550MCPSSeriesAMember2023-03-310000885725bsx:A550MCPSSeriesAMemberus-gaap:SubsequentEventMember2023-04-242023-04-240000885725us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000885725us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000885725bsx:A550MCPSSeriesAMember2023-01-012023-03-310000885725bsx:A550MCPSSeriesAMember2022-01-012022-03-3100008857252020-12-14bsx:reportablesegments0000885725bsx:MedsurgMember2022-01-012022-03-310000885725bsx:CardiovascularMember2022-01-012022-03-310000885725bsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725bsx:BSXReportableSegmentsMember2022-01-012022-03-310000885725bsx:TotalAllocatedToReportableSegmentsMember2023-01-012023-03-310000885725bsx:TotalAllocatedToReportableSegmentsMember2022-01-012022-03-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-01-012023-03-310000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2022-01-012022-03-310000885725bsx:SpecialChargesMember2023-01-012023-03-310000885725bsx:SpecialChargesMember2022-01-012022-03-31bsx:business0000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-01-012023-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2023-01-012023-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2022-01-012022-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMemberus-gaap:NonUsMember2022-01-012022-03-310000885725bsx:GlobalEndoscopyEndoReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-03-310000885725country:USbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-03-310000885725country:USbsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-03-310000885725bsx:MedsurgMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-01-012023-03-310000885725bsx:MedsurgMembercountry:US2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:MedsurgMember2022-01-012022-03-310000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-01-012023-03-310000885725bsx:InterventionalCardiologyTherapiesMember2023-01-012023-03-310000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2022-01-012022-03-310000885725bsx:InterventionalCardiologyTherapiesMember2022-01-012022-03-310000885725bsx:WatchmanMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-01-012023-03-310000885725bsx:WatchmanMember2023-01-012023-03-310000885725bsx:WatchmanMembercountry:US2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:WatchmanMember2022-01-012022-03-310000885725bsx:WatchmanMember2022-01-012022-03-310000885725bsx:CardiacRhythmManagementMembercountry:US2023-01-012023-03-310000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2023-01-012023-03-310000885725bsx:CardiacRhythmManagementMember2023-01-012023-03-310000885725bsx:CardiacRhythmManagementMembercountry:US2022-01-012022-03-310000885725bsx:CardiacRhythmManagementMemberus-gaap:NonUsMember2022-01-012022-03-310000885725bsx:CardiacRhythmManagementMember2022-01-012022-03-310000885725country:USbsx:ElectrophysiologyEPMember2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2023-01-012023-03-310000885725bsx:ElectrophysiologyEPMember2023-01-012023-03-310000885725country:USbsx:ElectrophysiologyEPMember2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2022-01-012022-03-310000885725bsx:ElectrophysiologyEPMember2022-01-012022-03-310000885725country:USbsx:GlobalCardiologyReportingUnitMember2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalCardiologyReportingUnitMember2023-01-012023-03-310000885725country:USbsx:GlobalCardiologyReportingUnitMember2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalCardiologyReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-03-310000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-03-310000885725country:USbsx:CardiovascularMember2023-01-012023-03-310000885725us-gaap:NonUsMemberbsx:CardiovascularMember2023-01-012023-03-310000885725country:USbsx:CardiovascularMember2022-01-012022-03-310000885725us-gaap:NonUsMemberbsx:CardiovascularMember2022-01-012022-03-310000885725country:US2023-01-012023-03-310000885725us-gaap:NonUsMember2023-01-012023-03-310000885725country:US2022-01-012022-03-310000885725us-gaap:NonUsMember2022-01-012022-03-310000885725country:USbsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725country:USbsx:BSXReportableSegmentsMember2022-01-012022-03-310000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725us-gaap:EMEAMemberbsx:BSXReportableSegmentsMember2022-01-012022-03-310000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2022-01-012022-03-310000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2023-01-012023-03-310000885725bsx:LatinAmericaandCanadaMemberbsx:BSXReportableSegmentsMember2022-01-012022-03-310000885725bsx:EmergingMarketsMember2023-01-012023-03-310000885725bsx:EmergingMarketsMember2022-01-012022-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                         (Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per shareBSX PR ANew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The number of shares outstanding of Common Stock, $0.01 par value per share, as of April 28, 2023 was 1,437,698,101.


TABLE OF CONTENTS
2

PART I
FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended
March 31,
(in millions, except per share data)20232022
Net sales$3,389 $3,026 
Cost of products sold1,040 955 
Gross profit2,349 2,071 
Operating expenses:
Selling, general and administrative expenses1,215 1,060 
Research and development expenses337 319 
Royalty expense11 12 
Amortization expense203 198 
Contingent consideration net expense (benefit)12 12 
Restructuring net charges (credits)20 4 
 1,797 1,605 
Operating income (loss)552 466 
Other income (expense):
Interest expense(65)(279)
Other, net(43)(31)
Income (loss) before income taxes444 156 
Income tax expense (benefit)131 45 
Net income (loss)314 110 
Preferred stock dividends(14)(14)
Net income (loss) attributable to noncontrolling interests  
Net income (loss) attributable to Boston Scientific common stockholders$300 $97 
Net income (loss) per common share — basic$0.21 $0.07 
Net income (loss) per common share — diluted$0.21 $0.07 
Weighted-average shares outstanding
Basic1,435.8 1,427.8 
Diluted1,446.0 1,438.4 




Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
3

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended
March 31,
(in millions)20232022
Net income (loss)$314 $110 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment(42)(64)
Net change in derivative financial instruments(43)23 
Net change in defined benefit pensions and other items(5) 
Other comprehensive income (loss)(91)(41)
Comprehensive income (loss)223 69 
Comprehensive income attributable to noncontrolling interests  
Comprehensive income attributable to Boston Scientific common stockholders$223 $69 








































Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
4

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
 As of
(in millions, except share and per share data)March 31, 2023December 31, 2022
ASSETS  
Current assets:  
Cash and cash equivalents$570 $928 
Trade accounts receivable, net2,076 1,970 
Inventories2,050 1,867 
Prepaid income taxes296 264 
Other current assets711 731 
Total current assets5,704 5,760 
Property, plant and equipment, net2,478 2,446 
Goodwill13,269 12,920 
Other intangible assets, net6,060 5,902 
Deferred tax assets3,900 3,942 
Other long-term assets1,482 1,500 
TOTAL ASSETS$32,892 $32,469 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Current debt obligations$510 $20 
Accounts payable868 862 
Accrued expenses1,918 2,160 
Other current liabilities787 761 
Total current liabilities4,083 3,803 
Long-term debt8,495 8,915 
Deferred income taxes210 144 
Other long-term liabilities1,995 2,035 
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 2022
  
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 2022
17 17 
Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022
(2,251)(2,251)
Additional paid-in capital20,356 20,289 
Accumulated deficit(450)(750)
Accumulated other comprehensive income (loss), net of tax178 269 
Total stockholders’ equity17,850 17,573 
Noncontrolling interests259  
Total equity18,109 17,573 
TOTAL LIABILITIES AND EQUITY$32,892 $32,469 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
5


BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

Three Months Ended
March 31,
(in millions, except share data)20232022
Preferred stock shares issued
   Beginning10,062,500 10,062,500 
Preferred stock issuance  
   Ending10,062,500 10,062,500 
Common stock shares issued
   Beginning1,696,633,993 1,688,810,052 
Common stock issuance  
Impact of stock-based compensation plans4,194,880 4,018,935 
   Ending1,700,828,873 1,692,828,987 
Preferred stock
   Beginning$ $ 
Preferred stock issuance  
   Ending$ $ 
Common stock
   Beginning$17 $17 
Common stock issuance  
Impact of stock-based compensation plans  
   Ending$17 $17 
Treasury Stock
Beginning$(2,251)$(2,251)
Repurchase of common stock  
Ending$(2,251)$(2,251)
Additional Paid-In Capital
Beginning$20,289 $19,986 
Impact of stock-based compensation plans68 57 
Ending$20,356 $20,043 
Accumulated Deficit
Beginning$(750)$(1,392)
Net income (loss)314 110 
Preferred stock dividends(14)(14)
Ending$(450)$(1,296)
Accumulated Other Comprehensive Income (Loss), Net of Tax
Beginning$269 $263 
Changes in other comprehensive income (loss)(91)(41)
Ending$178 $222 
Total stockholders' equity$17,850 $16,735 
Noncontrolling interests
Beginning$ $ 
Net income (loss) attributable to noncontrolling interests  
Changes in other comprehensive income (loss)  
Changes to noncontrolling ownership interest259  
Ending$259 $ 
Total equity$18,109 $16,735 
Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended March 31,
(in millions)20232022
Net income (loss)$314 $110 
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization285 274 
Deferred and prepaid income taxes19 (75)
Stock-based compensation expense55 52 
Net loss (gain) on investments and notes receivable31 20 
Contingent consideration net expense (benefit)12 12 
Inventory step-up amortization 17 
Debt extinguishment costs 194 
Other, net(2)19 
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(86)(66)
Inventories(185)(108)
Other assets(41)(140)
Accounts payable, accrued expenses and other liabilities(211)(368)
Cash provided by (used for) operating activities190 (58)
Investing activities:  
Purchases of property, plant and equipment and internal use software(111)(121)
Proceeds from sale of property, plant and equipment3 8 
Payments for acquisitions of businesses, net of cash acquired(375)(1,471)
Proceeds from (payments for) investments and acquisitions of certain technologies(10)(10)
Proceeds from royalty rights9 19 
Cash provided by (used for) investing activities(484)(1,574)
Financing activities:  
Payment of contingent consideration previously established in purchase accounting(34)(20)
Payments for royalty rights(34)(39)
Payments on short-term borrowings (250)
Net increase (decrease) in commercial paper 223 
Payments on long-term borrowings and debt extinguishment costs (3,184)
Proceeds from long-term borrowings, net of debt issuance costs 3,271 
Cash dividends paid on preferred stock(14)(14)
Cash used to net share settle employee equity awards(50)(46)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans63 52 
Cash provided by (used for) financing activities(69)(6)
Effect of foreign exchange rates on cash  
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(363)(1,639)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,126 2,168 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$763 $529 

Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
7

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(SUPPLEMENTAL INFORMATION)

Three Months Ended March 31,
(in millions)20232022
Supplemental Information
Stock-based compensation expense$55 $52 
Non-cash impact of transferred royalty rights(9)(19)

As of March 31,
Reconciliation to amounts within the unaudited consolidated balance sheets:20232022
Cash and cash equivalents$570 $325 
Restricted cash and restricted cash equivalents included in Other current assets
135 146 
Restricted cash equivalents included in Other long-term assets
57 59 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$763 $529 
























Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
8

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their financial statements on a one quarter lag. Accordingly, their results of operations for the period following the closing of the transaction on February 20, 2023 are omitted from the Company’s unaudited consolidated statements of operations for the quarter ended March 31, 2023.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies and Note I – Stockholders' Equity for further details.

NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

2023 Acquisitions

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement consisted of an upfront cash payment of $10.00 per share, or approximately $615 million. The Apollo business is being integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.


9

Purchase Price Allocation

We accounted for the Acotec transaction as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase price was comprised of the amount presented below:

(in millions)
Payment for majority interest acquisition, net of cash acquired (1)
$375 
$375 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction.

We recorded the assets acquired, liabilities assumed and the noncontrolling interest at their respective fair values as of the closing of the transaction. The preliminary purchase price allocation was comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:

(in millions)
Goodwill$336 
Amortizable intangible assets334 
Other assets acquired61 
Liabilities assumed(23)
Net deferred tax liabilities(74)
Fair value of noncontrolling interest$(259)
$375 

The fair value of the noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and is not deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG and VersaCrossTransseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.




10

Purchase Price Allocation

We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805, Business Combinations. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 

We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and is deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
Contingent Consideration

None of our acquisitions that closed during the first quarters of 2023 or 2022 contained contingent consideration arrangements. Changes in the fair value of our contingent consideration liability during the first quarter of 2023 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2022$149 
Contingent consideration net expense (benefit)12 
Contingent consideration payments(68)
Balance as of March 31, 2023$93 

The payments made during the first quarter of 2023 were primarily related to our 2021 acquisition of Farapulse, Inc. As of March 31, 2023, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $359 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.

11

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$80 millionDiscounted Cash FlowDiscount Rate6%-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to research and development (R&D), regulatory and commercialization-based milestones and revenue-based payments are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of March 31, 2023.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2023December 31, 2022
Equity method investments$166 $188 
Measurement alternative investments(1, 2)
219 219 
$385 $407 
(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2)    Includes publicly-held securities measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of March 31, 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $209 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

12

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,707 $(7,553)$12,397 $(7,378)
Patents473 (381)486 (394)
Other intangible assets2,005 (1,422)1,960 (1,400)
Amortizable intangible assets$15,185 $(9,357)$14,843 $(9,173)
    
Goodwill$23,169 $(9,900)$22,820 $(9,900)
IPR&D$112 $112 
Technology-related120 120 
Indefinite-lived intangible assets$232 $232 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of a majority stake investment in Acotec completed in the first quarter of 2023.

The following represents a roll-forward of our goodwill balance by global reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired 336 336 
Impact of foreign currency fluctuations and purchase price adjustments 13 13 
As of March 31, 2023$4,237 $9,032 $13,269 

Goodwill and Intangible Asset Impairments
We did not record any goodwill impairment charges in the first quarters 2023 or 2022. Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and actively monitoring counterparty credit ratings. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a
13

consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of March 31, 2023 and December 31, 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% euro-denominated senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the Cumulative Translation Adjustment (CTA) component of Other Comprehensive Income (OCI). We reclassify these gains and losses to current period earnings within Other, net in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of March 31, 2023 or December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.
14


The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2023December 31, 2022
Forward currency contractsCash flow hedge$2,673 $2,725 
Forward currency contractsNet investment hedge365 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,623 4,235 
Total Notional Outstanding$7,657 $8,321 
(1)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

As of March 31, 2023, the remaining time to maturity is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and three years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.


15

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
6 (1)4 Interest expense65 (3)1 (2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)4 (14)Other, net43    
Interest rate derivative contracts
Cash flow hedges   Interest expense65 1  1 


Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2022
Forward currency contracts
Cash flow hedges$45 $(10)$35 Cost of products sold$955 $(30)$7 $(23)
Net investment hedges(2)
15 (3)11 Interest expense279 (2) (2)
Foreign currency-denominated debt
Net investment hedges(3)
24 (5)18 Other, net31    
Interest rate derivative contracts
Cash flow hedges   Interest Expense279 14 (3)11 

(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
16


As of March 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below:
(in millions)FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$189 
Forward currency contractsNet investment hedgeInterest expense9 
Interest rate derivative contractsCash flow hedgeInterest expense(3)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20232022
Net gain (loss) on currency hedge contractsOther, net$(8)$(29)
Net gain (loss) on currency transaction exposuresOther, net(6)21 
Net currency exchange gain (loss)$(14)$(9)

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other
17

observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2023December 31, 2022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$168 $196 
Forward currency contractsOther long-term assets132 149 
  299 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets19 36 
Total Derivative and Nonderivative Assets $319 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther long-term liabilities0 1 
Foreign currency-denominated debt(2)
Long-term debt971 952 
  972 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities37 52 
Total Derivative and Nonderivative Liabilities $1,009 $1,005 
(1)    We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
18

Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$170 $ $ $170 $673 $ $ $673 
Publicly-held equity securities2   2 2   2 
Hedging instruments 319  319  381  381 
Licensing arrangements  113 113   127 127 
 $172 $319 $113 $604 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$ $1,009 $ $1,009 $ $1,005 $ $1,005 
Contingent consideration liability  93 93   149 149 
Licensing arrangements  120 120   159 159 
 $ $1,009 $213 $1,222 $ $1,005 $308 $1,313 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $170 million invested in money market funds and time deposits as of March 31, 2023 and $673 million as of December 31, 2022, we held $400 million in interest-bearing and non-interest-bearing bank accounts as of March 31, 2023 and $256 million as of December 31, 2022.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value in our accompanying unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of March 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$113 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$120 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

19

Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2022$127 
Proceeds from royalty rights(18)
Fair value adjustment (expense) benefit4 
Balance as of March 31, 2023$113 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2022$159 
Payments for royalty rights(43)
Fair value adjustment expense (benefit)5 
Balance as of March 31, 2023$120 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations was $8.467 billion as of March 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.


20

NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $9.005 billion as of March 31, 2023 and $8.935 billion as of December 31, 2022, with current obligations of $510 million as of March 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2023
December 31,
2022
March 2024 Senior Notes(4)
February 2019March 2024 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,088 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027979 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028816 800 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 344 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031816 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034544 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(73)(76)
Finance Lease ObligationVarious5 5 
Long-term debt$8,495 $8,915 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated senior notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3)    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2023 and December 31, 2022, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below.

Revolving Credit Facility

On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility as of March 31, 2023 or December 31, 2022.

21

Financial Covenant

As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended.
Covenant RequirementActual
 as of March 31, 2023as of March 31, 2023
Maximum permitted leverage ratio(1)
3.75 times2.52 times
(1)Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times through the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for any qualified acquisitions due to our funding of these acquisitions using cash on hand.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of March 31, 2023, we had $457 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022 for a total of $1.443 billion. As of March 31, 2023, we had $1.424 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We had no commercial paper outstanding as of March 31, 2023 or December 31, 2022. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility.

Senior Notes

We had senior notes outstanding of $9.067 billion as of March 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds,
22

and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in Interest expense within our accompanying unaudited consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of March 31, 2023As of December 31, 2022
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$188 5.5 %$161 2.4 %
Yen denominated188 0.5 %194 0.6 %
Renminbi denominated
14 3.0 %13 3.1 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $143 million as of March 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2023 and December 31, 2022 we had not recognized a related liability for any outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. where our suppliers can opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $128 million as of March 31, 2023 and $129 million as of December 31, 2022.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.

NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)March 31, 2023December 31, 2022
Trade accounts receivable$2,194 $2,079 
Allowance for credit losses(118)(109)
 $2,076 $1,970 
23


The following is a roll forward of our Allowance for credit losses:
Three Months Ended March 31,
(in millions)20232022
Beginning balance$109 $108 
Credit loss expense16 11 
Write-offs(6)(5)
Ending balance$118 $113 

In accordance with FASB ASC Topic 326, Financial Instruments - Credit Losses (FASB ASC Topic 326), we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach, applying country or region-specific factors, to determine the reserve to record at accounts receivable commencement for certain customers. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic and geopolitical conditions. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other entities, and, in southern Europe, relative to those in other countries. In addition, we have seen an increase in the volume of our U.S. business conducted in ambulatory surgery centers and office-based laboratories. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions based on collection trends.

Inventories
 As of
(in millions)March 31, 2023December 31, 2022
Finished goods$1,223 $1,171 
Work-in-process176 147 
Raw materials651 548 
 $2,050 $1,867 

Other current assets
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash and restricted cash equivalents$135 $149 
Derivative assets187 232 
Licensing arrangements56 60 
Other333 290 
 $711 $731 
24


Property, plant and equipment, net
 As of
(in millions)March 31, 2023December 31, 2022
Land$141 $137 
Buildings and improvements1,763 1,695 
Equipment, furniture and fixtures3,367 3,297 
Capital in progress567 598 
 5,837 5,728 
Less: accumulated depreciation3,359 3,282 
 $2,478 $2,446 

Depreciation expense was $82 million for the first quarter of 2023 and $76 million for the first quarter of 2022.

Other long-term assets
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash equivalents$57 $48 
Operating lease right-of-use assets399 386 
Derivative assets133 149 
Investments385 407 
Licensing arrangements57 67 
Indemnification asset170 172 
Other280 271 
 $1,482 $1,500 

Accrued expenses
 As of
(in millions)March 31, 2023December 31, 2022
Legal reserves$207 $231 
Payroll and related liabilities661 830 
Rebates347 352 
Contingent consideration83 74 
Other620 674 
 $1,918 $2,160 

Other current liabilities
 As of
(in millions)March 31, 2023December 31, 2022
Deferred revenue$231 $220 
Licensing arrangements57 79 
Taxes payable281 232 
Other217 230 
 $787 $761 
25


Other long-term liabilities
 As of
(in millions)March 31, 2023December 31, 2022
Accrued income taxes$608 $597 
Legal reserves209 212 
Contingent consideration10 75 
Licensing arrangements63 80 
Operating lease liabilities360 347 
Deferred revenue290 289 
Other457 434 
 $1,995 $2,035 

NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20232022
Effective tax rate from continuing operations29.4 %29.1 %

The changes in our reported tax rates for the first quarter of 2023, as compared to the same period in 2022, relate primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include debt extinguishment charges recorded in the first quarter of 2022, as well as certain discrete tax items primarily related to provision-to-return adjustments recorded in the first quarter of 2023.

As of March 31, 2023, we had $501 million of gross unrecognized tax benefits, of which a net $415 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to positions on new entities we acquired through recent acquisitions and restructuring activities.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $77 million.

NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

26

In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $416 million as of March 31, 2023 and $443 million as of December 31, 2022 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $135 million as of March 31, 2023 and $149 million as of December 31, 2022. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the first quarter of 2023 or 2022.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In
27

February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023.

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.

28

In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On February 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa.

NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of March 31, 2023, our MCPS had an aggregate liquidation preference of $1.006 billion.

During the first quarter of 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, a cash dividend of $1.375 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. On April 24, 2023 the Committee declared a cash dividend of $1.375 per MCPS share to holders of our MCPS as of May 15, 2023,
29

representing a dividend period from March through May 2023. We have presented cumulative, unpaid dividends within Accrued expenses within our accompanying unaudited consolidated balance sheet as of March 31, 2023.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended March 31,
(in millions)20232022
Weighted average shares outstanding — basic1,435.8 1,427.8 
Net effect of common stock equivalents10.2 10.6 
Weighted average shares outstanding - diluted1,446.0 1,438.4 

The following securities were excluded from the calculation of diluted weighted average shares outstanding because their effect in the periods presented below would have been anti-dilutive:
Three Months Ended March 31,
(in millions)20232022
Stock options outstanding(1)
33
MCPS(2)
2424
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

For the first quarter of 2023 and 2022, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders.

We issued approximately four million shares of our common stock in the first quarter of 2023 and 2022 following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first quarter of 2023 or 2022. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2023, we had the full amount remaining available under the authorization.
30

NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP.

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).

Three Months Ended
March 31,
Net Sales20232022
MedSurg$1,252 $1,164
Cardiovascular2,049 1,902
Total net sales of reportable segments3,301 3,066
Impact of foreign currency fluctuations88 (40)
$3,389 $3,026
Income (loss) before income taxes
MedSurg$400 $371
Cardiovascular541 477
Total operating income of reportable segments940 847
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(75)(66)
Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(110)(117)
Amortization expense(203)(198)
Operating income (loss)552 466
Other expense, net(108)(310)
Income (loss) before income taxes$444 $156

Three Months Ended March 31,
Operating income margin of reportable segments20232022
MedSurg31.9 %31.8 %
Cardiovascular26.4 %25.1 %

31

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended March 31,
20232022
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$351 $226 $577 $312 $220 $531 
Urology326 143 469 286 127 413 
Neuromodulation172 62 234 161 49 209 
MedSurg850 430 1,280 758 395 1,153 
   Interventional Cardiology Therapies183 408 591 186 358 544 
   Watchman265 25 291 203 23 226 
   Cardiac Rhythm Management345 203 548 325 195 519 
    Electrophysiology85 91 177 50 68 118 
Cardiology879 727 1,606 764 644 1,407 
Peripheral Interventions275 229 503 256 210 465 
Cardiovascular1,154 956 2,110 1,019 853 1,873 
Total Net Sales$2,003 $1,386 $3,389 $1,778 $1,248 $3,026 

Refer to Note K- Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20232022
U.S.$2,003 $1,778 
Europe, Middle East and Africa712 624 
Asia-Pacific548 517 
Latin America and Canada126 107 
Total Net Sales$3,389 $3,026 
Emerging Markets(1)
$529 $440 
(1)Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $521 million as of March 31, 2023 and $509 million as of December 31, 2022. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $42 million in the first quarter that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.
32


Variable Consideration

For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(63)35 0 (27)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(12)0 (14)
Total other comprehensive income (loss)(64)23 0 (41)
Balance as of March 31, 2022$29 $229 $(36)$222 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2023, we implemented the following standards on a prospective basis, none of which had a material impact on our financial position or results of operations.

ASC Update No. 2022-01

ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods.

ASC Update No. 2022-02

ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as
33

amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13.

ASC Update No. 2022-04

ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50) enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude.

Standards to be Implemented

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.

34

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 40 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Financial Summary

Three Months Ended March 31, 2023

Our net sales for the first quarter of 2023 were $3.389 billion, as compared to $3.026 billion for the first quarter of 2022. This increase of $363 million, or 12.0 percent, included operational1 net sales growth of 14.9 percent and the negative impact of 290 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 14.0 percent and the positive impact of 90 basis points from our acquisition of Baylis Medical Company, Inc. (Baylis Medical) during the first quarter of 2022 for which there is less than a full period of comparable sales. The increase in our net sales was primarily driven by recent acquisitions as well as the strength and diversity of our product portfolio coupled with growth in the underlying markets in which we compete and strong commercial execution. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income attributable to Boston Scientific common stockholders for the first quarter of 2023 was $300 million, or $0.21 per diluted share. Our reported results for the first quarter of 2023 included certain charges and/or credits totaling $373 million (after-tax), or $0.26 per diluted share. Excluding these items, adjusted net income available to Boston Scientific common stockholders3 was $673 million, or $0.47 per diluted share.

Our reported net income available to common stockholders for the first quarter of 2022 was $97 million, or $0.07 per diluted share. Our reported results for the first quarter of 2022 included certain charges and/or credits totaling $465 million (after-tax), or $0.32 per diluted share. Excluding these items, adjusted net income available to common stockholders3 was $562 million, or $0.39 per diluted share.















1Operational net sales growth excludes the impact of foreign currency fluctuations.
2Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3Adjusted measures, including operational and organic net sales growth, exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.
35

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:
 Three Months Ended March 31, 2023
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(4)
Reported$444 $131 $314 $(14)$300 $0.21 
Non-GAAP adjustments:
Amortization expense203 28 175 — 175 0.12 
Acquisition/divestiture-related net charges (credits)59 (7)66 — 66 0.05 
Restructuring and restructuring-related net charges (credits)44 37 — 37 0.03 
Investment portfolio net losses (gains)21 16 — 16 0.01 
European Union (EU) Medical device regulation (MDR) implementation costs16 14 — 14 0.01 
Deferred tax expenses (benefits)— (41)41 — 41 0.03 
Discrete tax items— (25)25 — 25 0.02 
Adjusted$787 $100 $687 $(14)$673 $0.47 

 Three Months Ended March 31, 2022
(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(4)
Reported$156 $45 $110 $(14)$97 $0.07 
Non-GAAP adjustments:
Amortization expense198 28 170 — 170 0.12 
Acquisition/divestiture-related net charges (credits)72 — 72 — 72 0.05 
Restructuring and restructuring-related net charges (credits)29 25 — 25 0.02 
Investment portfolio net losses (gains)— 0.00 
European Union (EU) Medical device regulation (MDR) implementation costs16 14 — 14 0.01 
Debt extinguishment charges194 45 149 — 149 0.10 
Deferred tax expenses (benefits)— (30)30 — 30 0.02 
Adjusted$671 $96 $575 $(14)$562 $0.39 













(4) For the first quarter of 2023 and 2022, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP Net loss and Adjusted net loss were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating GAAP Net loss attributable to Boston Scientific common stockholders.

36


Quarterly Results and Business Overview

The following section describes our net sales and results of operations by reportable segment and business unit. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K.
 Three Months Ended March 31,
(in millions)20232022Increase/(Decrease)
Endoscopy
$577 $531 8.6%
Urology469 413 13.5%
Neuromodulation
234 209 11.9%
MedSurg1,280 1,153 11.0%
Cardiology1,606 1,407 14.1%
Peripheral Interventions
503 465 8.2%
Cardiovascular2,110 1,873 12.7%
Net Sales$3,389 $3,026 12.0%

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less-invasive technologies. Net sales of Endoscopy products of $577 million for the first quarter of 2023 represented 17 percent of our consolidated net sales. Endoscopy net sales increased $46 million, or 8.6 percent, during the first quarter of 2023, compared to the prior year period. During the first quarter of 2023, this increase included operational net sales growth of 11.5 percent and a negative impact of 290 basis points from foreign currency fluctuations, compared to the prior year period. This growth was primarily driven by our biliary franchise led by our AXIOS Stent and Delivery System, and our hemostasis, infection prevention and single use imaging franchises. Within our single use imaging franchise, during the first quarter of 2023 we launched our third generation EXALT D Single-use Duodenoscope featuring several design updates based on physician feedback that are intended to improve the overall user experience.

Urology

Our Urology business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies. Net sales of Urology products of $469 million for the first quarter of 2023 represented 14 percent of our consolidated net sales. Urology net sales increased $56 million, or 13.5 percent, during the first quarter of 2023, compared to the prior year period. During the first quarter of 2023, this increase included operational net sales growth of 15.6 percent and a negative impact of 210 basis points from foreign currency fluctuations, compared to the prior year period. This growth was driven by our stone management franchise led by our LithoVue™ Single-Use Digital Flexible Ureteroscope System, our prosthetic urology franchise led by our AMS 700™ Inflatable Penile Prosthesis Device and our prostate health franchise led by our Rezum™ Water Vapor Therapy System.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Net sales of Neuromodulation products of $234 million for the first quarter of 2023 represented 7 percent of our consolidated net sales. Neuromodulation net sales increased $25 million, or 11.9 percent, during the first quarter of 2023 compared to the prior year period. During the first quarter of 2023, operational net sales growth of 13.7 percent was offset by a negative impact of 180 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth for the first quarter of 2023 was primarily due to strong procedural volume growth within our spinal cord stimulation (SCS) franchise driven by our WaveWriter Alpha™ SCS System, as well as growth within our Brain franchise primarily driven by the recent U.S. launch of the Guide™ XT software.
37

Cardiovascular

Cardiology

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart. Net sales of Cardiology products of $1.606 billion for the first quarter of 2023 represented 47 percent of our consolidated net sales. Cardiology net sales increased $199 million, or 14.1 percent, during the first quarter of 2023 compared to the prior year period. During the first quarter of 2023, this increase included operational net sales growth of 17.3 percent and a negative impact of 310 basis points from foreign currency fluctuations, compared to the prior year period. Operational net sales growth included organic net sales growth of 15.4 percent in the first quarter of 2023 and the positive impact of 190 basis points from our acquisition of Baylis Medical in the first quarter of 2022.

Organic net sales growth was primarily driven by continued market expansion of Left Atrial Appendage Closure (LAAC) procedures with our WATCHMAN™ FLX LAAC Device, as well as growth of our percutaneous coronary intervention guidance, diagnostics, access solutions and structural heart valve franchises and our Farapulse™ Ablation System.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. Net sales of Peripheral Interventions products of $503 million for the first quarter of 2023 represented 15 percent of our consolidated net sales. Peripheral Interventions net sales increased $38 million, or 8.2 percent, during the first quarter of 2023 compared to the prior year period. During the first quarter of 2023, this increase included operational net sales growth of 11.5 percent and a negative impact of 340 basis points from foreign currency fluctuations, compared to the prior year period.

Organic net sales growth was primarily driven by our Ranger™ Drug-Coated Balloon and Eluvia™ Drug-Eluting Stent System, as well as our interventional oncology franchise led by our Therasphere™ Y-90 Radioactive Glass Microspheres and our EMBOLD™ Fibered Coil. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their results of operations on a one quarter lag. Accordingly, their net sales for the period following the closing of the transaction on February 20, 2023 are omitted from our unaudited consolidated statements of operations for the quarter ended March 31, 2023.

Emerging Markets

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation. Our Emerging Markets net sales represented 16 percent and 15 percent of our consolidated net sales during the first quarter of 2023 and 2022, respectively. During the first quarter of 2023, our Emerging Markets net sales grew 20.2 percent on a reported basis, which included operational net sales growth of 26.3 percent and a negative impact of 600 basis points from foreign currency fluctuations, compared to the prior year period. Operational growth was driven primarily by growth in China with previously delayed procedures driving increased demand.

Economic Trends

Our business has been impacted by global supply chain disruptions. In particular, we have experienced increases in cost and limited availability of raw materials, components, and other inputs necessary to manufacture and distribute our products due to constraints and inflation within the global supply chain, as well as increases in wage costs and the cost and time to distribute our products. Uncertainty around inflationary pressures, rising interest rates, monetary policy and changes in tax laws could potentially cause new, or exacerbate existing, economic challenges that we may face, including the impact of foreign currency fluctuations on our results of operations. These conditions could worsen, or others could arise, if the U.S. and global economies were to enter recessionary periods, triggered or exacerbated by monetary policy designed to curb inflation. Existing and future potential geopolitical dynamics, including matters related to the Russia/Ukraine war, as well as the tension between China/Taiwan, may create economic, supply chain, energy, and other challenges, which impact, and may in the future negatively impact our business. In particular, international conflicts may result in sanctions, tariffs, and other measures that restrict international trade and negatively affect our business operations and results.
38

Gross Profit

Our Gross profit was $2.349 billion for the first quarter of 2023 and $2.071 billion for the first quarter of 2022. As a percentage of net sales, our Gross profit increased to 69.3 percent during the first quarter of 2023, as compared to 68.4 percent in the first quarter of 2022. The following is a reconciliation of our gross profit margin and a description of the drivers of the changes from period to period:
Percentage of Net Sales
Three Months
Gross profit margin - period ended March 31, 202268.4%
Sales pricing, volume and mix0.9
Manufacturing and supply costs
1.5
Net impact of foreign currency fluctuations(1.2)
All other, including other period expenses(0.4)
Gross profit margin - period ended March 31, 202369.3%

The increase in our gross profit margin resulted primarily from favorable sales mix and increased sales of higher margin products, as well as improvements in manufacturing and supply costs. While global supply chain challenges persist, we experienced improvement in the first quarter as recovery continues. These impacts were partially offset by the unfavorable impact of foreign currency and period expenses. We expect our gross profit margin for the first half of 2023 to be higher than the second half primarily due to timing of foreign currency movements in the prior year period.

Operating Expenses

The following table provides a summary of certain of our operating expenses:
 Three Months Ended March 31,
 20232022
(in millions)$% of Net Sales$% of Net Sales
Selling, general and administrative expenses$1,215 35.9 %$1,060 35.0 %
Research and development expenses337 9.9 %319 10.5 %

Selling, general and administrative expenses (SG&A Expenses)

During the first quarter of 2023, SG&A expenses increased $155 million, or 15 percent, as compared to the prior year period and were 90 basis points higher as a percentage of net sales. The increase in SG&A expenses were primarily due to higher selling costs driven by higher global net sales.

Research and development expenses (R&D Expenses)

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. During the first quarter of 2023, R&D expenses increased $17 million, or 5 percent, as compared to the prior year period and were 60 basis points lower as a percentage of net sales. R&D expenses increased as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.
39


Other Operating Expenses

The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

During the first quarter of 2023, Amortization expense increased $5 million, or 2 percent, compared to the prior year period. The increase in Amortization expense was driven by the addition of amortizable intangible assets associated with our recent acquisitions.

Contingent Consideration Net Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded net charges of $12 million in the first quarter of 2023 and 2022, respectively. Refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration arrangements.

Restructuring Charges (Credits)

On February 22, 2023, our Board of Directors approved, and we committed to, a new global restructuring program (the 2023 Restructuring Plan). The 2023 Restructuring Plan is intended to meet evolving global market demands and conditions by ensuring that we are structured and resourced to support our strategic imperatives and deliver sustainable value. For more information, refer to 2023 Restructuring Plan contained in Item 7 of our most recent Annual Report on Form 10-K.

Pursuant to this program, we recorded restructuring charges in accordance with to FASB ASC Topic 420, Exit or Disposal Cost Obligations of $20 million in the first quarter of 2023. In addition, we recorded restructuring-related charges of $24 million in the first quarter of 2023 primarily within Cost of products sold and Selling, general and administrative expenses. During the first quarter of 2022, we recorded restructuring charges of $4 million and restructuring-related charges of $25 million associated with our 2019 Restructuring Plan, which was substantially completed as of December 31, 2022.

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
Three Months Ended March 31,
20232022
Interest expense (in millions)
$(65)$(279)
Average borrowing rate2.8 %11.5 %

Interest expense and our average borrowing rate decreased during the first quarter of 2023 compared to the prior year period, due to $194 million of charges associated with the early extinguishment of $3.275 billion of certain of our senior notes, including payment of tender premiums and the acceleration of unamortized debt issuance costs, as well as the to the issuance of euro-denominated bonds, which carry lower interest rates, during the first quarter of 2022. For the first quarter of 2022, the weighted average borrowing rate associated with our outstanding senior notes was 3.7 percent. Refer to Liquidity and Capital Resources and Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for information regarding our debt obligations.

40

Tax Rate

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20232022
Effective tax rate from continuing operations29.4 %29.1 %

The changes in our reported tax rates for the first quarter of 2023, as compared to the same period in 2022, relate primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include debt extinguishment charges recorded in the first quarter of 2022, as well as certain discrete tax items primarily related to provision-to-return adjustments recorded in the first quarter of 2023.

Critical Accounting Policies and Estimates

Our financial results are affected by the selection and application of accounting policies and methods. During the first quarter of 2023, there were no material changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future.

As of March 31, 2023, we had $570 million of unrestricted Cash and cash equivalents on hand, including approximately $140 million held by Acotec, a less than wholly owned entity of which we acquired a majority stake investment during the first quarter of 2023. The balance is comprised of $170 million invested in money market funds and time deposits and $400 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer.

During 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, as well as modification to the calculation of consolidated EBITDA, described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. As of March 31, 2023, we had no commercial paper debt outstanding, resulting in the full $2.750 billion of available liquidity under the 2021 Revolving Credit Facility. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility.

For additional details related to our debt obligations, including our financial covenant requirement, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

41

The following provides a summary and description of our net cash inflows (outflows):
Three Months Ended March 31,
(in millions)20232022
Cash provided by (used for) operating activities$190 $(58)
Cash provided by (used for) investing activities(484)(1,574)
Cash provided by (used for) financing activities(69)(6)

Operating Activities

During the first quarter of 2023, cash provided by (used for) operating activities increased $248 million as compared to the prior year period primarily due to comparatively higher net sales and operating income as well as lower acquisition-related and restructuring-related payments.

Investing Activities

During the first quarter of 2023, cash provided by (used for) investing activities included cash payments of $375 million, net of cash acquired, for the acquisition of a majority stake in Acotec, as well as purchases of property, plant and equipment and internal use software of $111 million. During the first quarter of 2022, cash used for investing activities included a net cash payment of $1.471 billion for the acquisition of Baylis Medical. For more information, refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q. In addition, we made purchases of property, plant and equipment and internal use software of $121 million during the first quarter of 2022.

Financing Activities

Cash provided by (used for) financing activities in the first quarter of 2023 included cash used to net share settle employee equity awards of $50 million and proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans of $63 million. In the first quarter of 2022, we completed a public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs. We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. For more information, refer to Note E – Contractual Obligations and Commitments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Financial Covenant

As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended, as described below.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times through the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for any qualified acquisitions due to the funding of these acquisitions using cash on hand. We believe that we have the ability to comply with the financial covenant for the next 12 months.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of March 31, 2023, we had $457 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation
42

receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022 for a total of $1.443 billion. As of March 31, 2023, we had $1.424 billion of the litigation exclusion remaining.
Contractual Obligations and Commitments

Certain of our acquisitions involve the payment of contingent consideration. Refer to Note B – Acquisitions, Divestitures and Strategic Investments to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions. There have been no other material changes to our contractual obligations and commitments as of March 31, 2023.

Equity

We received $63 million during the first quarter of 2023 and $52 million during the first quarter of 2022 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.

We did not repurchase any shares of our common stock during the first quarter of 2023 or 2022. On December 14, 2020, our Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2023, we had the full amount remaining available under the authorization.

Legal Matters

For a discussion of our material legal proceedings refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.
Recent Accounting Pronouncements
Information regarding new accounting pronouncements implemented since December 31, 2022 and relevant accounting pronouncements to be implemented in the future are included in Note N – New Accounting Pronouncements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Additional Information

Corporate Responsibility

Our sustainable environmental, social and governance practices underpin all aspects of our global business. Our approach is aligned with the United Nations Sustainable Development Goals and our material topics and practices are informed by a broad range of internal and external stakeholders – locally, nationally and globally. Our employees around the world work with suppliers and other organizations that share our commitment to these practices that help address issues related to health inequity, economic disparity, climate change and environmental protection. These efforts are supported by our cross-functional Corporate Social Responsibility Steering Committee, our Corporate Social Responsibility Council, our Environmental Health and Safety teams and policies, our Global Council for Inclusion, as well as our local, regional and national employee and community engagement programs. In addition, since 2021, our annual bonus plan has included performance measured against certain environmental, social and governance goals. For additional information on our sustainability efforts, as well as our Diversity, Equity and Inclusion (DE&I) initiatives, refer to our most recent Annual Report on Form 10-K. For additional information on our annual bonus plan, refer to our Proxy Statement for the 2023 Annual Meeting of Shareholders.

Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of
43

impact. Matters determined to present potential material impacts to the Company’s financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that management responsible for overseeing the effectiveness of disclosure controls is informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made or updated, as appropriate. 
International conflicts, including, but not limited to the Russia/Ukraine war and tension between China/Taiwan, have heightened cybersecurity risks on a global basis. While there is significant uncertainty around implications of cybersecurity attacks resulting from the conflict, we have taken steps to better understand our readiness, including the resilience of our critical business functions, with the goal of reducing the impact if such an event were to occur.

Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President and Chief Executive Officer, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, certain individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments which need to be made public before the individual may participate in the market.

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about the Company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.

44

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share - diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Quarterly Report.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

45

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly Report on Form 10-Q. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: the impact of foreign currency fluctuations, future U.S. and global economic, political, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; the impact of the COVID-19 pandemic on our operations and financial results; disruptions caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict, including those that have emerged or may increase in significance or likelihood as a result of the COVID-19 pandemic. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, refer to Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K.

Our Businesses
Labor shortages and the impact of inflation on the cost of raw materials and direct labor,

Risks associated with challenging or uncertain domestic and international economic conditions, including those related to rising interest rates, inflation, adverse developments and volatility in the banking industry, currency devaluations or economies entering into periods of recession,

The impact of the COVID-19 pandemic and economic conditions created in part by the pandemic on worldwide economies, financial markets, manufacturing and distribution systems, including disruption in the manufacture or supply of certain components, materials or products, and business operations,

The impact of natural disasters, climate change, additional future public health crises and other catastrophic events on our ability to manufacture, distribute and sell our products,

The impact of competitive offerings, value-based procurement practices, government-imposed payback provisions and changes in reimbursement practices and policies on average selling prices for our products,
46


The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
Variations in clinical results, reliability or product performance of our and our competitors' products,

Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

The effect of consolidation and competition in the markets in which we do business or plan to do business,

Our ability to achieve our projected level or mix of product sales, as some of our products are more profitable than others,

Our ability to attract and retain talent, including key personnel associated with recent acquisitions, and to maintain our robust corporate culture,

The impact of enhanced requirements to obtain and maintain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval,
 
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies,

The issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission, and

The impact of potential goodwill and intangible asset impairment charges on our results of operations.

Regulatory Compliance, Litigation and Data Protection

The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

The effect of global legal, regulatory or market responses to climate change, including increased compliance burdens and costs to meet regulatory obligations,

Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

Costs and risks associated with current and future asserted litigation,

47

The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provisions and cash flows,
 
The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

The possibility of failure to protect our intellectual property rights and the outcome of patent litigation,

Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war, and

The potential impact to internal control over financial reporting relating to potential restrictions to access to consigned inventory at customer locations for our inventory count procedures.

Innovation and Certain Growth Initiatives

The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable net sales growth opportunities as well as to maintain the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

Our ability to develop, manufacture and market new products and technologies successfully and in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

The potential failure to complete, successfully integrate and/or realize the expected benefits, including cost synergies, from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

Our dependency on international net sales to achieve growth, and our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in Emerging Markets such as Brazil, India and China,

The timing and collectability of customer payments, as well as our ability to continue factoring customer receivables where we have factoring arrangements, or to enter new factoring arrangements with favorable terms,

The impact on pricing due to national and regional tenders, including value-based procurement practices and government-imposed payback provisions,

Geopolitical and economic conditions, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures,
48


The impact of the Russia/Ukraine war and tension between China/Taiwan, and related, downstream effects thereof, including the impact of sanctions on U.S. manufacturers doing business in these regions,

Protection of our intellectual property,

Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA, EU MDR and similar laws in other jurisdictions,

Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

The impact of significant developments or uncertainties stemming from changes in the U.S. government following congressional elections, including changes in U.S. trade policies, tariffs and the reaction of other countries thereto, particularly China, and

The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, operating expenses and resulting profit margins.

Liquidity

Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and financial covenant compliance,

Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

The unfavorable resolution of open litigation matters, exposure to additional loss contingencies and legal provisions,

The impact of examinations and assessments by domestic and international taxing authorities on our tax provisions, financial condition or results of operations,

The possibility of counterparty default on our derivative financial instruments, and

Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs, and

Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.
49

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $6.660 billion as of March 31, 2023 and $7.324 billion as of December 31, 2022. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $241 million as of March 31, 2023 as compared to $208 million as of December 31, 2022. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $294 million as of March 31, 2023 as compared to $254 million as of December 31, 2022. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations.
Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of March 31, 2023 and December 31, 2022. As of March 31, 2023, $9.067 billion in aggregate principal amount of our outstanding debt obligations was at fixed interest rates, representing approximately 100 percent of our total debt, on an amortized cost basis. As of March 31, 2023, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.

50

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of March 31, 2023, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

During 2022, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation is expected to occur in phases over the next several years. The portion of the transition to the new ERP system which we have completed to date resulted in changes in our internal control over financial reporting in the first quarter of 2023. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and will evaluate quarterly whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting.

51

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to Note G – Income Taxes and Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to other information contained elsewhere in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report filed on Form 10-K, which could materially affect our business, financial condition or future results.

ITEM 6. EXHIBITS (* documents filed or furnished with this report; # compensatory plans or arrangements)
10.1
10.2*
10.3*
10.4*
10.5*
22
31.1* 
 
31.2* 
 
32.1* 
 
32.2* 
 
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
52

104Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
53

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May 4, 2023.

 
BOSTON SCIENTIFIC CORPORATION
 
 By:/s/ Daniel J. Brennan
   
  Name:Daniel J. Brennan
  Title:Executive Vice President and
Chief Financial Officer 
54
EX-10.2 2 ex102-2023grantxnqagreemen.htm EX-10.2 Document
Exhibit 10.2
    Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Non-Qualified Stock Option Agreement

This Global Non-Qualified Stock Option Agreement (the “Agreement”), is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the Non-Qualified Stock Option Award granted to you by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). This Agreement sets forth the terms and conditions relating to your Stock Option pursuant to the Plan. Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

    1.    Grant of Stock Option. The Committee hereby grants you a Stock Option to purchase that number of shares of Stock set forth in your Equity Award and Acceptance Summary (the “Option Shares”) at the price set forth herein (the “Grant Price”). The Grant Price is equal to the Fair Market Value of the Company’s Stock on the Grant Date.

    2.    Term and Vesting of Stock Option. Except as otherwise provided in Section 4 below, your Stock Option shall have a term of ten (10) years from date of grant until the “Expiration Date” and shall vest in accordance with the vesting schedule. If the Expiration Date falls on a date on which the New York Stock Exchange is closed for trading, the Expiration Date shall be the trading day immediately prior to the Expiration Date.

    3.    Exercise of Stock Option. While this Stock Option remains exercisable, you may exercise any vested portion of the Option Shares by delivering to the Company or its designee, in the form and at the location specified by the Company, notice stating your intent to exercise a specified number of Option Shares and payment of the full Grant Price for the specified number of Option Shares. Payment in full for the Option Shares being exercised may be paid in such manner as the Committee may specify from time to time, in its sole discretion, including, but not limited to the following: (a) in cash, (b) by certified check or bank draft payable in U.S. dollars (US$) to the order of the Company, (c) in whole or in part in shares of Stock owned by you, valued at Fair Market Value, or (d) if available to you, via cashless exercise, by which you deliver to your securities broker instructions to sell a sufficient number of shares of Stock to cover the Grant Price for the Option Shares, any applicable tax obligations and the brokerage fees and expenses associated therewith. Notwithstanding the foregoing, if you reside in a country where the local laws and/or regulations preclude the remittance of currency out of the country for purposes of paying the Grant Price for the Option Shares being exercised, require the Company, its Affiliates and/or you to secure any legal or regulatory approvals or complete any legal or regulatory filings, or undertake any additional steps for remitting currency out of the country, the Company may restrict the method of exercise to a form of cashless exercise (either a cashless “sell all” exercise and/or a cashless “sell to cover” exercise) as it shall determine in its sole discretion.

    The exercise date applicable to your exercise of the specified number of Option Shares pursuant to this Section 3 will be deemed to be the date on which the Company receives your irrevocable commitment to exercise the Option Shares in writing, subject to your payment in full of the Option Shares to be exercised within 10 (ten) days of the notice of exercise of the Option Shares to be exercised. The notice and payment in full of the Option Shares being exercised, must be received by the Company or its designee on or prior to the last day of the Stock Option term, as set forth in Section 2 above, except as provided in Section 4 below.

–Rev 12.2022
1



    Upon the Company’s determination that there has been a valid exercise of the Option Shares, the Company shall issue certificates in accordance with the terms of this Agreement or cause the Company’s transfer agent to make the necessary book entries for the shares of Stock subject to the exercised Option Shares. However, the Company shall not be liable to you, your personal representative or your successor(s)-in-interest for damages relating to any delays in issuing the certificates or in making book entries, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in making book entries, or in the certificates themselves.

    4.    Termination of Employment.

        a.    In the event that your employment terminates due to death or Disability (as such term is defined in the Plan or determined under local law, as applicable), all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you or your appointed representative, as the case may be, until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option.

        b.    Provided that you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date, in the event your employment terminates due to Retirement, all remaining unexercised portion(s) of your Stock Option shall immediately vest and become exercisable by you until the expiration of the term of the Stock Option or such other term as the Committee may determine at or after grant, provided that such exercise period does not extend beyond the original term of the Stock Option. 

        c.    In the event that your employment terminates due to Retirement prior to the first anniversary of the Grant Date, the Option Shares shall immediately be forfeited in their entirety.

        d.    Upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, you shall have the shorter of (i) one (1) year from the date of termination and (ii) the remaining term of the Stock Option to exercise all vested Option Shares. Immediately upon termination of your employment for reasons other than for Cause, death, Disability or Retirement, all unvested Option Shares shall be forfeited; provided, however, that the Committee, in its sole discretion, may extend the exercise period and/or accelerate vesting of any unvested Option Shares (provided that such exercise period does not extend beyond the original term of the Stock Option). Your termination date shall be the last day of your active service with the Company or an Affiliate (if applicable).

        e.    Immediately upon notice of termination of your employment for Cause, all unexercised Option Shares, whether vested or unvested, shall be forfeited.

        f.    The Option Shares, to the extent unexercised on the date following the end of any period described above or the term of the Stock Option set forth above in Section 2, shall thereupon be forfeited.

        g.    Notwithstanding anything to the contrary in the Plan or the Agreement, and for purposes of clarity, any termination of employment shall be effective as of the date your active employment ceases and shall not be extended by any statutory or common law notice of termination period.

–Rev 12. 2022
2



        h.    Any one of your permitted transferee(s) (pursuant to Section 7 below) shall receive the rights herein granted subject to the terms and conditions of this Agreement and any applicable Addendum. No transfer of this Stock Option shall be approved and effected by the Administrator unless (i) the Administrator shall have been timely furnished with written notice of such transfer and any copies of such notice as the Committee may deem, in its sole discretion, necessary to establish the validity of the transfer; (ii) the transferee or transferees shall have agreed in writing to be bound by the terms and conditions of this Agreement and any applicable Addendum; and (iii) such transfer complies with applicable laws and regulations.

        i.    If you are a resident or employed in a country that is a member of the European Union, the grant of the Stock Option and this Agreement are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Stock Option is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

        j.    If you reside or work in a country where the local foreign exchange rules and regulations require the repatriation of sale proceeds, the Company may require you to sell any Option Shares you acquire under the Plan immediately or within a specified period following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    5.    Change in Control. To the extent that you have not entered into a Change in Control Agreement with the Company and except as the Administrator (as defined in the Plan) may otherwise determine, immediately prior to a Change in Control (as defined in the Plan), any unvested portion of the Stock Option shall vest and become exercisable. In addition, the Stock Option shall terminate immediately prior to the Change in Control unless the Stock Option is exercised coincident therewith or assumed in accordance with the immediately following sentence. If there is a surviving or acquiring entity, the Administrator may provide for a substitution or assumption of the Stock Option by the acquiring or surviving entity or an affiliate thereof, on such terms as the Administrator determines. If there is no surviving or acquiring entity, or if the Administrator does not provide for a substitution or assumption of the Stock Option, any unvested portion of the Stock Option shall vest and become exercisable on a basis that gives you a reasonable opportunity to participate as a stockholder in the Change in Control. If you have entered into a Change in Control agreement with the Company, the Stock Option will vest according to the provisions of the Change in Control agreement.

    6.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 6, shall have the meaning set forth below:

–Rev 12. 2022
3



            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unexercised Stock Options, whether vested or unvested.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    7.    Restrictions on Shares; Legend on Certificate. Shares of Stock issued to you in certificate form or to your book entry account upon exercise of the Stock Option may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    8.    Transferability. Except as required by law, you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of the Stock Option granted under this Agreement other than by will or the laws of descent and distribution or without payment of consideration to your Family Members or to trusts or other entities for the benefit of your Family Members. During your lifetime, the Stock Option is exercisable only by you, subject to Section 4 above.

    9.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Stock Option, including the grant of the Stock Option, the vesting of the Stock Option, the exercise of the Stock Option, the subsequent sale of any shares of Stock acquired upon exercise of the Stock Option and the receipt of any dividends, and (b) do not commit to structure the terms of the grant or any aspect of the Stock Option to reduce or eliminate your liability for Tax-Related Items.

    Prior to the delivery of shares of Stock upon exercise of the Stock Option, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may withhold a sufficient whole number of shares of Stock otherwise issuable upon exercise of the Stock Option that has an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of

–Rev 12. 2022
4


Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, withhold shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by withholding shares of Stock to be issued upon exercise of the Stock Option, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Stock Option, notwithstanding that a number of shares of Stock are withheld solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the Stock Option, you expressly consent to the withholding of shares of Stock as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon exercise resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the exercised Stock Option.

    All other Tax-Related Items related to the Stock Option and any shares of Stock delivered in payment thereof are your sole responsibility. In no event, shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Stock Option is intended to be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    10.    Repatriation and Legal/Tax Compliance Requirements. If you are a resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Stock Option) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).

–Rev 12. 2022
5



11.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Stock Option grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Stock Options awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.
You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon exercise of the Stock Option. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consent herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.


–Rev 12. 2022
6


    12.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:
(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Stock Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Stock Options, even if Stock Options have been granted in the past;

(c)all decisions with respect to future grants of Stock Options, if any, will be at the sole discretion of the Administrator;

(d)the Stock Option grant and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Stock Option is not intended to replace any pension rights or compensation;

(g)the Stock Option, the shares of Stock subject to the Stock Option, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the shares of Stock subject to the Stock Option is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Stock Option resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;
(k)for purposes of the Stock Option, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the period (if any) during which you may exercise the Option will commence as of such date and will not be extended by any notice period mandated under employment laws in the jurisdiction where you are employed or the terms

–Rev 12. 2022
7


of your employment agreement, if any; the Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Stock Option, the shares of Stock subject to the Stock Option, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Stock Option or of any amount due to you pursuant to the exercise of the Stock Option or the subsequent sale of any shares of Stock acquired upon exercise.

    13.    Securities Laws. Upon the acquisition of any shares of Stock pursuant to the exercise of the Stock Option, you will make or enter into such written representations, warranties and agreements as the Company may reasonably request in order to comply with applicable securities laws or with the Plan.

    14.    Not a Public Offering. Neither the grant of the Stock Option under the Plan nor the issuance of the underlying shares of Stock upon exercise of the Stock Option is intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law.

    15.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding whether you should purchase shares of Stock under the Plan. Investment in shares of Stock involves a degree of risk. Before deciding to purchase shares of Stock pursuant to the Stock Option, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Stock Option and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    16.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Stock Options) or rights linked to the value of shares of Stock (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to a personal advisor on this matter.

    17.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Stock Option and participation in the Plan, or future grants of Stock Options that may be granted under the Plan, by electronic means unless otherwise

–Rev 12. 2022
8


prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party-designated by the Company.

    18.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Stock Option, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Stock Option translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    19.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Stock Option shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    20.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Stock Option, any shares of Stock acquired pursuant to the Stock Option and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    21.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal executive office of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    22.    Choice of Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflicts of laws principles) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston or the federal courts for the United States for the District of Massachusetts, and no other courts where the grant of the Stock Option is made and/or to be performed.

    23.    Award Subject to Plan; Conflicts.    The Stock Option granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This

–Rev 12. 2022
9


Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Stock Option granted under this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Stock Option subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.

    24.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    25.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable

26.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    27.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.


–Rev 12. 2022
10


    
    IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Optionee have executed and delivered this Agreement effective as of the date and year first above written.



                    BOSTON SCIENTIFIC CORPORATION        
image_0.jpg                image_1.jpg
                    Michael F. Mahoney
President and Chief Executive Officer
































–Rev 12. 2022
11


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO NON-QUALIFIED STOCK OPTIONS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Stock Option is subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 19 of the Agreement, if you transfer your residence and/or employment to another country reflected in an Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Personal Data. This provision replaces Section 11 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Stock Option and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

–Rev 12. 2022
12



The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Stock Option to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Stock Option, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Securities Notification. If you acquire shares of Stock under the Plan and offers such shares of Stock for sale to a person or entity resident in Australia, the offer may be subject to disclosure

–Rev 12. 2022
13


requirements under Australian law. You are advised to obtain legal advice regarding your disclosure obligations prior to making any such offer.

Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your vested Stock Option will no longer be exercisable after the earlier of: (i) thirty (30) days from the date of termination of employment; and (ii) the Expiration Date specified in Section 2 of the Agreement.

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

AUSTRIA

No country-specific provisions.

BELGIUM

Acceptance of Stock Option. In order for the Stock Option to be subject to taxation at the time of grant, you must affirmatively accept the Stock Option in writing within 60 days after the offer date by signing below and returning this original executed Addendum to:
Boston Scientific
Green Square
Lambroekstraat 5D
1831 Diegem
Belgium
Attn.: Nathalie Derue

I hereby accept ________ (number) Option Shares underlying the Stock Option granted to me by the Company on the Grant Date.

The undersigned acknowledges that he/she has been encouraged to discuss this matter with a financial and/or tax advisor and that this decision is made in full knowledge.

Employee Signature:        _______________________________

Employee Printed Name:    _______________________________

Date of Acceptance:        _______________________________

If you fail to affirmatively accept the Stock Option in writing within 60 days after the offer date, the Stock Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date you exercise the Stock Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

Undertaking for Qualifying Option. If you are accepting the Stock Option in writing within 60 days after the offer date and wish to have the Stock Option subject to a lower valuation for

–Rev 12. 2022
14


Belgium tax purposes pursuant to the article 43, §6 of the Belgian law of 26 March 1999, you may agree and undertake to (a) not exercise the Stock Option before the end of the third calendar year following the calendar year in which the offer date falls, and (b) not transfer the Stock Option under any circumstances (except upon on rights your heir might have in the Stock Option upon your death). If you wish to make this undertaking, you must sign below and return this executed Addendum to the address listed above.
Employee Signature:        _______________________________

Employee Printed Name:    _______________________________
    
BRAZIL

Compliance with Law. By accepting the Stock Option, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the Stock Option, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 12 of the Agreement:

By accepting the Stock Option, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Stock Option, if any, is not part of your remuneration from employment.

CANADA

Use of Previously Owned Shares. Notwithstanding any provision in Section 3 of the Agreement or the Plan to the contrary, if you are resident in Canada, you may not use previously-owned shares of Stock to pay the Grant Price or any Tax-Related Items in connection with the Stock Option.

Personal Data. This provision supplements Section 11 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares of Stock are listed (i.e., the New York Stock Exchange).

Tax Information. All or a portion of the shares of Stock subject to the Stock Option may be “non-qualified securities” within the meaning of the Income Tax Act (Canada).


–Rev 12. 2022
15


Nature of Grant. The following provision supplements Section 12(k) of the Agreement:

For purposes of the Stock Options, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Stock Option grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation
explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Stock Options, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

French Language Documents. The following provision will apply if you are a resident of Quebec:

A French translation of this Agreement and certain other documents related to the Stock Option will be made available to you as soon as reasonably practicable. You understand that, from time to time, additional information related to the Stock Option may be provided in English and such information may not be immediately available in French. However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless you indicate otherwise, the French translation of this Agreement and certain other documents related to the Stock Option will govern your participation in the Plan.

CHILE

Securities Law Information. The offer of the Stock Option constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of the Stock Option is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Stock Option is not registered in Chile, the Company is not required to provide public information about the Stock Option or the shares of Stock in Chile. Unless the Stock Option and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.
Esta oferta de opción sobre acciones (“Opción”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Opción se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Opciónes de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública

–Rev 12. 2022
16


respecto de los Opciónes or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Limitations on Exercisability Following Termination of Employment. Notwithstanding any provision in the Agreement or the Plan to the contrary, in the event your employment terminates for any reason, your Stock Option will no longer be exercisable after the earlier of: (i) the period set forth in Section 4 of the Agreement; (ii) the last day of the 90 day period beginning on the date of termination of employment (or such earlier date as may be required by China State Administration of Foreign Exchange (“SAFE”)); and (iii) the Expiration Date specified in Section 2 of the Agreement.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may need to be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company and its Affiliates in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.


–Rev 12. 2022
17


BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 12 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Stock Option Upon Termination of Employment. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Stock Option upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is being provided to comply with the Stock Option Act.

FINLAND

No country-specific provisions.

FRANCE

Nature of the Award. The Stock Option is not granted under the French specific regime provided by Articles L. 225-177 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.


–Rev 12. 2022
18


Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Stock Option and shares of Stock issued upon exercise do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Stock Option is intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

Wages. The Stock Option and shares of Stock subject to the Stock Option do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of Scheme. You understand that the Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”).

INDIA

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

INDONESIA

No country-specific provisions.

–Rev 12. 2022
19



IRELAND

No country-specific provisions.

ISRAEL

102 Sub-Plan. The Stock Option is granted to you pursuant to the Israeli Sub-Plan to the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Israeli Sub-Plan”), and is subject to the terms and conditions stated in the Israeli Sub-Plan, the Plan, and the Agreement, including this Addendum. By accepting the Stock Option you acknowledge and agree to be bound by the terms of the Israeli Sub-Plan and consent to the terms of the “Consent Letter - 102 Capital Gain Awards” attached hereto as Appendix A (the “Consent Letter”). If you do not affirmatively accept the Stock Option (and accordingly, the terms of the Israeli Sub-Plan, the Agreement and the Consent Letter) within ninety (90) days after the Grant Date, the Stock Option may not qualify under the capital gain tax treatment.

Until further election by the Company, the Stock Option and any shares of Stock received upon exercise of the Stock Option are intended to qualify for the tax treatment available in Israel pursuant to the provisions of the “capital gain track” under Section 102 (“Section 102”) of the Israeli Income Tax Ordinance [New Version], 1961 (the “ITO”), including the provisions of the Income Tax Rules (Tax Benefits in Shares Issuance to Employees), 2003 and any Tax Ruling. However, in the event the Stock Option does not meet the requirements of Section 102 of the ITO, such Stock Option and the underlying shares of Stock shall not qualify for the favorable tax treatment under the capital gain track. The Company makes no representations or guarantees that the Stock Option will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102.

The Stock Option is subject to the trust (the “Trust”) established by the trust and services agreement (the “Trust Agreement”) with ESOP Management and Trust Services Ltd. (the “Trustee”). To receive the tax treatment provided for in Sections 102(b)(2) and 102(b)(3) of the ITO, shares of Stock acquired by you upon exercise of the Stock Option will be issued directly to the Trustee or controlled by the Trustee under a supervisory trustee arrangement, and will be held by the Trustee on your behalf or controlled by the Trustee at least until the end of the Required Holding Period (as defined in the Israeli Sub-Plan), which is currently twenty-four (24) months from the Grant Date, or any other period determined under the ITO as now in effect or as hereafter amended or by the Israeli Income Tax Authority. Subject to the conclusion of the Required Holding Period and any further period included herein, shares of Stock acquired by you upon exercise of the Stock Option will be held or controlled by the Trustee until their sale, unless you request to release the shares of Stock to your direct holding, in which case the release will be subject to the receipt by the Trustee of an acknowledgment from the Israeli Income Tax Authority that you have paid all applicable taxes due pursuant to the ITO and Section 102, or the Trustee withholds any applicable tax due pursuant to the ITO and Section 102. Notwithstanding the foregoing, in the event you elect to sell or release any shares of Stock acquired upon exercise of the Stock Option prior to the conclusion of the Required Holding Period, the tax consequences under Section 102 shall apply to and shall be borne solely by you, as further set forth in the Israeli Sub-Plan.

The Company may at its sole discretion replace the Trustee from time to time and instruct the transfer of all Stock Options and shares of Stock held and/or administered by such Trustee at

–Rev 12. 2022
20


such time to its successor and the provisions of your Agreement shall apply to the new Trustee mutatis mutandis.

Any and all Tax-Related Items due in relation to the Stock Option and shares of Stock shall be borne solely by you and in the event of death, by your heirs. The Company, the Employer and/or the Trustee shall withhold Tax-Related Items according to the requirements under the applicable laws, the rules, and regulations, including withholding Tax-Related Items at source. Furthermore, you hereby agree to indemnify the Company, the Employer and/or the Trustee and hold them harmless against and from any and all liability for any such Tax-Related Items or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such Tax-Related Items from any payment made to you. The Company, the Employer and/or the Trustee, to the extent permitted by law, shall have the right to deduct from any payment otherwise due to you, or from proceeds of the sale of any shares of Stock, an amount equal to any Tax-Related Items required by law to be withheld with respect to such shares of Stock. You will pay to the Company, the Employer or the Trustee any Tax-Related Items that the Company, the Employer or the Trustee may be required to withhold with respect to any shares of Stock that cannot be satisfied by the means previously described. The Company may refuse to deliver any shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items as described in this section. Any fees associated with any vesting, sale, transfer or any act in relation to the Stock Option and the shares of Stock, shall be borne by you. The Trustee, the Company and/or the Employer shall be entitled to withhold or deduct such fees from payments otherwise due to/from the Company, the Employer or the Trustee.

Securities Law Information.  The Company has obtained from the Israel Securities Authority an exemption from the requirement to file a prospectus in relation to the Plan. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by contacting your local human resources manager.

ITALY

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

Plan. This provision supplements Section 12 of the Agreement: You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Grant of Stock Option, Exercise of Stock Option, Termination of Employment, Recoupment Policy, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of Shares to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer

–Rev 12. 2022
21


is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 11 of the Agreement in its entirety:


–Rev 12. 2022
22


You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Stock Options or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.

You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon exercise of the Stock Option may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Stock Options or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian Opsyen saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua Opsyen saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad Opsyen mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan Opsyen saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817.

–Rev 12. 2022
23



MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Stock Option and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Stock Option may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Stock Option, you acknowledge that have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in Section 12 of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at exercise of the Stock Option.
Reconocimiento del Contrato. Al aceptar la Opción, Usted reconoce que ha recibido una copia del Plan y del contrato, incluyendo este Apéndice, mismos que ha revisado. Usted reconoce, además, que acepta todas las disposiciones del Plan, y del contrato, incluyendo este Apéndice. También reconoce que ha leído y aprueba de forma expresa los términos y condiciones establecidos en la sección doce 12 del contrato que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan su participación en el mismo son ofrecidos por la Compañía de forma totalmente discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    La Compañía y sus afiliados no son responsables por cualquier disminución en el valor de las Acciones adquiridas al momento de tener derecho conforme a la Opción.

–Rev 12. 2022
24


Labor Law Acknowledgement and Policy Statement. By accepting the Stock Option, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely responsible for the administration of the Plan. You further acknowledge your participation in the Plan, the grant of the Stock Option and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ley Laboral y Declaración de la Política. Al aceptar el Otorgamiento de la Opción, Usted reconoce que Boston Scientific Corporation, con oficinas registradas en 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es únicamente responsable de la administración del Plan. Usted además reconoce que su participación en el Plan, la concesión de Opción y cualquier adquisición de acciones de conformidad con el Plan no constituyen una relación de trabajo entre Usted y Boston Scientific Corporation, ya que Usted está participando en el Plan sobre una base totalmente comercial y su único patrón es una sociedad mercantil Mexicana (“Boston Scientific-México”). Derivado de lo anterior, Usted expresamente reconoce que el Plan y los beneficios que pueden derivarle de la participación en el Plan no establecen ningún derecho entre Usted y su Patrón, Boston Scientific-México, y no forman parte de las condiciones de trabajo y/o prestaciones otorgadas por Boston Scientific-México, y cualquier modificación al Plan o su terminación no constituirá un cambio o perjuicio de los términos y condiciones de su trabajo.
Usted además entiende que su participación en el Plan es resultado de una decisión unilateral y discrecional de Boston Scientific Corporation, por lo tanto Boston Scientific Corporation se reserva el derecho absoluto de modificar el Plan y/o discontinuar su participación en el Plan en cualquier momento, sin responsabilidad alguna para hacia Usted.
Finalmente, Usted declara que no se reserva acción o derecho alguno para presentar una reclamación o demanda en contra de Boston Scientific Corporation por cualquier compensación o daño o perjuicio en relación con cualquier disposición del Plan o los beneficios derivados del Plan y, por lo tanto, otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliados, afiliadas, sucursales, oficinas de representación,

–Rev 12. 2022
25


accionistas, directores, funcionarios, agentes y representantes con respecto a cualquier reclamación o demanda que pudiera surgir.
NETHERLANDS

Waiver of Termination Rights. By accepting the Stock Option, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with Boston Scientific Corporation and the Employer for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Plan, or (ii) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information

Warning

This is an offer of a Stock Option which, upon exercise and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the exercise and settlement of the Stock Option, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Stock Option may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:

–Rev 12. 2022
26


1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5. Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of the Stock Option is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Stock Option. By accepting the Stock Option, you understand, acknowledge and agree that the Stock Option is being granted ex gratia by the Company.

PHILIPPINES

Mandatory Cashless Sell-All Exercise. As permitted under Section 3 of the Agreement and unless and until the Committee determines otherwise, the method of exercise of the Stock Option shall be limited to mandatory cashless, sell-all exercise.

POLAND

No country-specific provisions.

–Rev 12. 2022
27



PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of the Stock Option, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea opțiune de stoc, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA

U.S. Transaction. You understand that the Stock Option shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon exercise of the Stock Option, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon exercise of the Stock Option will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Stock Option, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Stock Option nor the shares of Stock may be used for offering or public circulation in Russia.
Cashless Exercise Provision. Notwithstanding anything to the contrary in the Agreement, depending on the development of local regulatory requirements, the Company reserves the right to restrict exercise of your Stock Option to a cashless exercise through a licensed securities broker acceptable to the Company, such that all shares of Stock subject to the exercised Stock Option will be sold immediately upon exercise and the proceeds of sale, less the Grant Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you in accordance with any applicable exchange control laws and regulations.

–Rev 12. 2022
28



Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.

The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.

Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company). Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon exercise of the Stock Option after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Vesting and Exercise of Stock Option. Depending on the development of local regulatory requirements, the Company reserves the right to postpone the vesting and/or the ability to exercise the Stock Option, to restrict exercise of the Stock Option to a cashless sell-all exercise and/or to pay any proceeds related to the Stock Option to you through local payroll, or to cancel the Stock Option for no consideration.
SAUDI ARABIA

Securities Law Information. The grant of the Stock Option is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Stock Option under the Plan is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Stock Option is subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the Stock Option in Singapore, unless such sale or offer in is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA.


–Rev 12. 2022
29


SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.    Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.
2.    The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
3.    Boston Scientific Corporation Non-Qualified Stock Option Grant and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
4.    Boston Scientific Corporation Equity Award and Acceptance Summary: This
document can be accessed at https://us.etrade.com/home -> My Stock Plan ->
Holdings -> click on a grant date and select “View Grant Documents”.

You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 11 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 11 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the Stock Option grant, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.


–Rev 12. 2022
30


You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Stock Options under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Stock Option is granted on the assumption and condition that the Stock Option and the shares of Stock acquired upon exercise of the Stock Option shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the Stock Option grant shall be null and void.

You understand and agree that, as a condition of the Stock Option grant, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Stock Option to the extent the Stock Option has not vested as of date you cease active employment. In particular, you understand and agree that any unvested Stock Option as of the date you cease active employment and any vested portion of the Stock Option not exercised within the post-termination exercise period set out in the Agreement will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Stock Option.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 9 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 9 of the Agreement, in accepting the grant of the Stock Option, you authorize the Company to sell shares of Stock otherwise deliverable to you upon exercise of the Stock Option to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Stock Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly

–Rev 12. 2022
31


available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 9 of the Agreement:
Without limitation Section 9 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by HM Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

–Rev 12. 2022
32



Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 9 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

*    *    *    *


–Rev 12. 2022
33


APPENDIX A

CONSENT LETTER
102 CAPITAL GAIN AWARDS FOR PARTICIPANTS RESIDING IN ISRAEL
Dear Participant,
Boston Scientific Corporation (the “Company”) has elected to apply the capital gains route in accordance with the provisions of Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”) on awards granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Incentive Plan”) to Israeli Participants (as defined in the Israeli sub-plan to the Incentive Plan (the “Israel Sub-Plan”), which was approved by the Executive Compensation and Human Resources Committee of the Company’s Board of Directors on November 14, 2022) and any future incentive plan implemented by the Company in Israel (“Awards” and “Capital Gains Route”), subject to the Company’s absolute discretion to change such election on future grants, with or without advance notice. Unless otherwise notified to you in writing by the Company, the Awards shall be granted to you under the Capital Gains Route, subject to compliance with the requirements of such tax route.
The Capital Gains Route election will enable you to enjoy lower tax rates on a portion of the income received upon disposition of the shares of Company common stock (“Shares”) issued to you from or in connection to the Awards, provided however that all the requirements under Section 102 of the Ordinance and the Income Tax (Tax Abatement on the Grant of Shares to Employees) Regulations 2003 (the “Regulations”) are met.
Below you will find a brief description of the Israeli income tax consequences of the Capital Gains Route. PLEASE NOTE THAT THE SUMMARY BELOW IS ONLY A BRIEF SUMMARY THAT DOES NOT COVER ALL THE PROVISIONS OF SECTION 102 OF THE ORDINANCE AND THE REGULATIONS AND IS NOT INTENDED TO PROVIDE ANY TAX ADVICE. IN ADDITION, THE TAX LAWS AND REGULATIONS DESCRIBED HEREIN ARE SUBJECT TO CHANGE. THEREFORE, IT IS RECOMMENDED THAT YOU CONSULT WITH A TAX ADVISER BEFORE ACCEPTING THE TERMS OF THIS CONSENT LETTER OR BEFORE ACCEPTING ANY AWARDS OR DISPOSING OF SHARES.
The main restrictions that are included under Section 102 of the Ordinance are as follows:
(1) Your Awards and the Shares issued under such Awards will be held in trust or controlled by a trustee for at least a period determined in Section 102 under the Capital Gains Route (“Required Holding Period”) (currently twenty-four months from the date in which the Awards were granted to you).
(2) During the Required Holding Period you will not be able to sell, pledge, release from trust or otherwise perform any transaction in connection to the Awards or Shares granted to you.
Provided that all conditions set by the Ordinance under the Capital Gains Route are met, including the above conditions, you will, in general, be taxed as follows: 
The lower of (1) the difference between the fair market value of the underlying Shares on the grant date and the exercise price (plus any transactional expenses incurred in

–Rev 12. 2022
34


connection with the sale) and (2) the difference between the sale proceeds and the exercise price (plus any transactional expenses incurred in connection with the sale) will be treated as ordinary income subject to income tax and employee/employer social insurance contributions (to the extent the applicable contribution ceiling has not been exceeded). For tax purposes, the fair market value of the Shares at grant is deemed to be the average price of the Shares over the 30 trading days preceding the grant. 
The remainder of the gain, if any, will be treated as a capital gain and will be taxed at the capital gains tax rate of 25%.  No social insurance contributions will be due on this portion of the gain. 
In addition, a surtax may be imposed if your income is in excess of the applicable annual threshold.
If you sell your Shares, or release the Shares from trust, before the end of the Holding Period, you will immediately be subject to income tax on the gain, at your marginal income tax rate, and will be also required to pay social security and health tax contributions on all your profit.
In order to enable you to enjoy the benefits of the Capital Gains Route, please express your acceptance and confirmation of the following terms, by accepting the Award through the electronic acceptance procedures established by the Company:
1.    I undertake to comply with all the terms and conditions set under Section 102 of the Ordinance with regard to the Capital Gains Route and the Regulations.
2.    I have had the opportunity to obtain the advice of counsel prior to accepting this Consent Letter. I am familiar with and understand the provisions of Section 102 of the Ordinance in general, and the tax arrangement under the Capital Gains Route in particular, and agree to comply with such provisions, as amended from time to time.
3.    I agree that Awards granted to me, and the Shares that may be derived from such Awards, will be held or controlled by a trustee for at least the duration of the Required Holding Period, as determined in Section 102 under the Capital Gains Route (currently twenty-four months from the date in which the Awards were granted).
4.    I agree to the trust deed signed between the Company, my employer and the trustee available at Trust Deed RSU-Stock Option - Hebrew.pdf.
5.    I understand that any release of such Awards or Shares from trust, or any sale of the Shares prior to the termination of the Required Holding Period, will result in taxation at my marginal tax rate, in addition to deductions of appropriate social security and health tax contributions.
6.    I authorize the Company and/or my employer to provide the trustee with any information required for administrating the grant of the Awards, including without limitation information about my Awards, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the trustee.
7.     I declare that I am a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if I cease to be an Israeli resident or if my engagement with the Company or any affiliate is

–Rev 12. 2022
35


terminated, the Awards and underlying Shares shall remain subject to Section 102, the trust agreement and the applicable equity plan and grant document.
8.    I understand and agree that until the Company will determine otherwise, my acceptance of the terms of this Consent Letter will be sufficient, to apply to all potential future grants of Awards. I hereby confirm that by accepting this Consent Letter, I will be deemed to have elected to accept the terms and conditions herein in respect of any such potential future grant of Awards.
9.     I acknowledge, understand and agree that the Awards are an extraordinary, one-time benefit granted to me, and do not create any contractual or other right to receive future grant of Awards.
10.     I understand that neither the Company nor any affiliates guarantee that any Awards granted to me will be eligible for tax benefits pursuant to the Capital Gains Route and I agree that I will not hold the Company and/or any affiliate and/or the trustee liable for any tax consequences relating to my Awards, including any penalties or other negative tax consequences I could receive or be subject to if my Awards do not obtain the Capital Gains Route tax treatment, regardless of the reason for the Capital Gains Route tax treatment not being available.
*    *    *    *



–Rev 12. 2022
36
EX-10.3 3 ex103-2023grantxrsuagreeme.htm EX-10.3 Document
Exhibit 10.3


Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan
Global Restricted Stock Unit Award Agreement

This Global Restricted Stock Unit Award Agreement (the “Agreement”) is between you and Boston Scientific Corporation, a Delaware corporation, (the “Company”) in connection with the award of Restricted Stock Units (the “Award”) by the Committee under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms used but not defined in this Agreement shall have the same meaning as assigned to them in the Plan. The applicable terms and conditions of the Plan are incorporated into and made a part of this Agreement.

1.    Grant of Units. The Committee hereby grants you that number of Restricted Stock Units as set forth in your Equity Award and Acceptance Summary (the “Units”). Each Unit represents the Company’s commitment to issue to you one share of Stock subject to the conditions set forth in this Agreement. This Award is granted pursuant to and is subject to the provisions of the Plan and the terms and conditions of this Agreement and any applicable Addendum.

    2.    Vesting. The Units shall vest and shares of Stock will be issued to you in accordance with the schedule provided in your Equity Award and Acceptance Summary. Except as otherwise provided in Sections 4, 5, 6, 7 and 8 below, the Units will vest, subject to the conditions described in Section 7 below. Shares of Stock for Units that vest in accordance with this Section 2 will be delivered to you within fifteen (15) days after the applicable vesting date but in no event later than the last day of the calendar year that includes the applicable vesting date. No shares of Stock shall otherwise be issued to you prior to the date on which the Units vest. Notwithstanding anything in the Agreement to the contrary, the Company may, in its sole discretion, settle the Units in the form of a cash payment to the extent that settlement in shares of Stock is prohibited under local law or would require the Company and/or any of its Affiliates to obtain the approval of or complete any legal or regulatory filing with any governmental and/or regulatory body in your country of residence (or country of employment, if different). Alternatively, the Company may, in its sole discretion, settle the Units in the form of shares of Stock but require you to sell such Stock immediately or within a specified time following your termination of employment (in which case, this Agreement shall give the Company the authority to issue sales instructions on your behalf).

    3.    Participant’s Rights in Stock. The shares of Stock, if and when issued to you pursuant to this Agreement, shall be registered in your name and evidenced in a manner as determined by the Company, in its sole discretion. Under no circumstance will you be deemed, by virtue of the granting of the Units, to be a holder of any shares of Stock underlying the Units or be entitled to the rights or privileges of a holder of such shares of Stock (including the right to receive dividends or vote the shares of Stock), unless and until the Units have vested with respect to such shares of Stock and the shares of Stock have been issued to you.

    4.    Death. In the event you terminate employment by reason of death, any Units that have not vested prior to the date of your death shall immediately vest and shares of Stock shall be issued in accordance with your will or the laws of descent and distribution. Shares of Stock for Units which vest under this Section 4 will be delivered within sixty (60) days after your employment termination date.

–Rev 1.2023
1


    5.    Retirement. If you terminate employment by reason of your Retirement, any Units that have not vested prior to the date of your Retirement shall immediately vest and shares of Stock shall be issued to you, provided you have remained in continuous service with the Company or an Affiliate through the first anniversary of the Grant Date. In the event that your Retirement occurs prior to the first anniversary of the Grant Date, all unvested Units shall immediately terminate and be forfeited in their entirety. Shares of Stock for Units which vest under this Section 5 will be delivered within thirty (30) days after your employment termination date.

    In this regard, if you are a local national of and employed in a country that is a member of the European Union, the grant of the Units and the terms and conditions governing the Units are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of the Units is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

    6.     Disability. If you terminate employment by reason of your Disability (as the term is defined in the Plan or determined under local law), any Units that have not vested prior to the date of your termination by reason of Disability shall immediately vest and shares of Stock shall be issued to you. Shares of Stock for Units which vest under this Section 6 will be delivered within thirty (30) days after your employment termination date.

    7.    Other Termination of Employment; Certain Vesting Conditions. If your employment terminates for any reason other than death, Retirement or Disability, any Units that have not vested prior to the date of your termination shall terminate and be forfeited on the effective date of such termination, except if your employment terminates for Cause, in which case, all unvested Units shall be forfeited upon notice to you of your termination for Cause. Subject to Sections 4, 5 and 6 of this Agreement, the issuance of shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the applicable anniversary of the Grant Date as set forth in Section 2 above. For purposes of the vesting conditions set forth in this Agreement, the effective date of your termination shall be deemed to be the last day of your active service with the Company or an Affiliate (if applicable). Notwithstanding anything to the contrary in the Plan or this Agreement, and for purposes of clarity, the date of your termination of employment shall not be extended by any statutory or common law notice of termination period.

    8.    Change in Control of the Company. In the event you are employed by the Company or an Affiliate at the time of a Change in Control, any Units that have not vested prior to the Change in Control shall immediately vest and shares of Stock will be issued to you immediately prior to the Change in Control; provided, however, that if you have entered into a Change in Control agreement with the Company, the Units will vest according to the provisions of the Change in Control agreement. In the event you have terminated employment with the Company or an Affiliate prior to a Change in Control as a result of death, Disability, or Retirement occurring on or after the first anniversary of the Grant Date, and the Change in Control occurs following your termination of employment, shares of Stock for any Units that have vested under Section 4, 5 or 6 but which have not yet been issued will be issued immediately prior to the Change in Control. Notwithstanding the foregoing and unless otherwise specifically provided in any agreement of the Company or any of its Affiliates with you pertaining to the effect of
–Rev 1.2023
2


a Change in Control on outstanding Awards which is in effect as of the Change in Control, if this Award is subject to and not exempt from the application of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and provides for settlement or payment upon a Change in Control, the definition of Change in Control shall be limited to events which qualify as a change in the ownership of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(v), or a change in the ownership of a substantial portion of the assets of a corporation within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii); provided, however, that this requirement shall not cause an event that would not otherwise be considered a Change in Control under the definition of a Change in Control under the Plan to be considered a Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock subject to the Units are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (a) all federal, state and local laws and regulations, as the Company may deem applicable, have been complied with; (b) the shares have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (c) all other legal matters in connection
–Rev 1.2023
3


with the issuance and delivery of the shares have been approved by the Company’s legal department.

    12.    Transferability; Restrictions on Shares; Legend on Certificate. Until the vesting conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement and any applicable Addendum or by action of the Committee, the Units awarded under this Agreement are not transferable and you shall not sell, transfer, assign, pledge, gift, hypothecate or otherwise dispose of or encumber the Units awarded under this Agreement. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    13.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the
–Rev 1.2023
4


Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Code Section 409A. The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of Stock, shall be based on the value of the Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    14.    Repatriation and Legal/Tax Compliance Requirements. If you are resident or employed outside of the United States, you agree to repatriate all payments attributable to the shares of Stock and/or cash acquired under the Plan (including, but not limited to, dividends and any proceeds derived from the sale of the shares of Stock acquired pursuant to the Units) in accordance with local foreign exchange rules and regulations in your country of residence (and country of employment, if different). In addition, you agree to take any and all actions, and consent to any and all actions taken by the Company and the Employer, as may be required to allow the Company and the Employer to comply with local laws, rules and regulations in your country of residence (and country of employment, if different). Finally, you agree to take any and all actions as may be required to comply with your personal legal and tax obligations under local laws, rules and regulations in your country of residence (and country of employment, if different).
–Rev 1.2023
5


    
15.    Data Privacy. You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

    You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.

You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

    16.    Nature of Grant. By participating in the Plan, you acknowledge, understand and agree that:

–Rev 1.2023
6


(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying Shares, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Administrator shall have the exclusive discretion to determine when you are no longer actively providing
–Rev 1.2023
7


services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

    17.    Not a Public Offering. The grant of the Units under the Plan is not intended to be a public offering of securities in your country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filings to the local securities authorities unless otherwise required under local law, and the grant of the Units is not subject to the supervision of the local securities authorities.

    18.    No Advice Regarding Grant. No Employee of the Company is permitted to advise you regarding your participation in the Plan or your acquisition or sale of the shares of Stock subject to the Units. Investment in shares of Stock involves a degree of risk. Before deciding whether to participate in the Plan, you should carefully consider all risk factors relevant to the acquisition of shares of Stock under the Plan, and you should carefully review all of the materials related to the Units and the Plan. You are hereby advised to consult with your own personal tax, legal and financial advisors before taking any action related to the Plan.

    19.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    20.    Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.

    21.    Electronic Delivery of Documents. The Company may, in its sole discretion, deliver any documents related to the Units and participation in the Plan or future grants of Units that may be granted under the Plan, by electronic means unless otherwise prohibited by local law. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic
–Rev 1.2023
8


system established and maintained by the Company or a third party-designated by the Company.
    
22.    Language. If you are resident outside of the United States, you hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Addendum, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Addendum, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

    23.    Addendum. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable addendum to the Agreement (the “Addendum”). Further, if you transfer your residence and/or employment to another country reflected in the Addendum to this Agreement, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Addendum shall constitute part of this Agreement.

    24.    Additional Requirements. The Administrator reserves the right to impose other requirements on the Units, any shares of Stock acquired pursuant to the Units and your participation in the Plan to the extent the Administrator determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local laws or to facilitate the administration of the Plan. Such requirements may include (but are not limited to) requiring you to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

    25.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    26.    Award Subject to the Plan; Conflicts. The Units granted pursuant to this Agreement and any applicable Addendum is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. This Agreement contains terms and provisions established by the Committee specifically for the grant described herein. Unless the Committee has exercised its authority under the Plan to establish specific terms of an Award, the terms of the Plan shall govern. Subject to the limitations set forth in the Plan, the Committee retains the right to alter or modify the Units granted pursuant to this Agreement as the Committee may determine are in the best interests of the Company. You hereby accept the Units subject to all the terms and provisions of the Plan and this Agreement and agree that all decisions under, and interpretations of, the Plan and this Agreement by the Administrator, Committee or the Board shall be final, binding and conclusive upon you and your heirs and legal representatives.
–Rev 1.2023
9



    27.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute under the Agreement, including the Addendum, the parties hereby submit to and consent to the exclusive jurisdiction of The Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the courts of Boston, or the federal courts for the United States for the District of Massachusetts and no other courts where the grant of the Units is made and/or to be performed.

    28.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    29.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

30.     Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.

    31.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be the one and the same instrument.

IN WITNESS WHEREOF, the Company, by its duly authorized officer, and the Participant have executed and delivered this Agreement as a sealed instrument as of the date and year first above written.

BOSTON SCIENTIFIC CORPORATION
image_0.jpg




Michael F. Mahoney
President and Chief Executive Officer

–Rev 1.2023
10


BOSTON SCIENTIFIC CORPORATION

ADDENDUM TO THE AWARD AGREEMENT
RELATING TO RESTRICTED STOCK UNITS GRANTED
PURSUANT TO THE
AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN

In addition to the terms of the Plan and the Agreement, the Units are subject to the following additional terms and conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 23 of the Agreement, if you transfer your residence and/or employment to another country reflected in the Addendum, the additional terms and conditions for such country (if any) will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer).

EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND    

Personal Data. This provision replaces Section 15 of the Agreement:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.
–Rev 1.2023
11



The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU/EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

ARGENTINA

Type of Offering. Neither the grant of the Units, nor the issuance of shares of Stock subject to the grant, constitutes a public offering.

AUSTRALIA

Securities Law Information. This grant is being made under Division 1A, Part 7.12 of the Australia Corporations Act (Cth). Please note that if you offer shares of Stock for sale to
–Rev 1.2023
12


a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on the relevant disclosure obligations prior to making any such offer.

Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Plan, you will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Plan if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.

Tax Information. The Plan is a program to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

AUSTRIA

No country-specific provisions.

BELGIUM

No country-specific provisions.

BRAZIL

Compliance with Law. By accepting the Units, you acknowledge that you agree to comply with applicable Brazilian laws and to pay any and all applicable taxes associated with the vesting of the Units, the receipt of any dividends, and the sale of shares of Stock acquired under the Plan.

Labor Law Policy and Acknowledgement. This provision supplements Section 16 of the Agreement:

By accepting the Units, you agree that (i) the benefits provided under the Agreement and the Plan are the result of commercial transactions unrelated to your employment; (ii) the Agreement and the Plan are not a part of the terms and conditions of your employment; and (iii) the income from the Units, if any, is not part of your remuneration from employment.

CANADA

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

Personal Data. This provision supplements Section 15 of the Agreement:

You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, any Affiliate and the Administrator to disclose and discuss the Plan with their advisors. You further authorize the Company and any Affiliate to record such information and to keep such information in your employee file.

Securities Law Information. You are permitted to sell shares of Stock acquired under the Plan through the designated broker appointed under the Plan, if any, provided that the
–Rev 1.2023
13


sale of shares of Stock takes place outside Canada through the facilities of a stock exchange on which the shares are listed (i.e., the New York Stock Exchange).

Nature of Grant. The following provision supplements Section 16(k) of the Agreement:

For purposes of the Units, your employment or service relationship will be considered terminated as of the earliest of: (a) the date that your employment or service relationship with the Company or one of its Affiliates is terminated; (b) the date that you receive a notice of termination of employment or service; and (c) the date upon which you cease to actively provide services, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. You will not earn or be entitled to any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. The Administrator shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on a leave of absence). Notwithstanding the foregoing, if applicable employment legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the Units, if any, will terminate effective as of the last date of the minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.

French Language Documents. The following provision will apply if you are a resident of Quebec:

A French translation of this Agreement and certain other documents related to the Units will be made available to you as soon as reasonably practicable. You understand that, from time to time, additional information related to the Units may be provided in English and such information may not be immediately available in French. However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless you indicate otherwise, the French translation of this Agreement and certain other documents related to the Units will govern your participation in the Plan.

CHILE

Securities Law Information. The offer of the Units constitutes a private offering of securities in Chile effective as of the Grant Date. This offer of Units is made subject to general ruling N° 336 of the Commission for the Financial Market (Comisión para el Mercado Financiero, “CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Units are not registered in Chile, the Company is not required to provide public information about the Units or the shares of Stock in Chile. Unless the Units and/or the shares of Stock are registered with the CMF, a public offering of such securities cannot be made in Chile.
Esta oferta de Unidades de Acciones Restringidas (“Units”) constituye una oferta privada de valores en Chile y se inicia en la Fecha de la Concesión. Esta oferta de Units se acoge a las disposiciones de la Norma de Carácter General Nº 336 (“NCG 336”) de la Comisión para el Mercado Financiero de Chile (“CMF”). Esta oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la CMF, por lo que tales valores no están sujetos a la fiscalización de ésta. Por tratarse los Units de valores no registrados en Chile, no existe obligación por parte de la Compañía de entregar en Chile información pública respecto de los Units or sus Acciones. Estos valores no podrán ser objeto de oferta pública en Chile mientras no sean inscritos en el Registro de Valores correspondiente.

–Rev 1.2023
14


CHINA

The following provisions govern your participation in the Plan if you are a national of the People’s Republic of China (“China”) resident in mainland China, as determined by the Company in its sole discretion:

Shares of Stock Must Be Held with Designated Broker. All shares of Stock issued upon settlement of your Units will be deposited into a personal brokerage account established with the Company’s designated broker, E*TRADE (or any successor broker designated by the Company), on your behalf. You understand that you may sell the shares of Stock at any time after they are deposited in such account, however, you may not transfer the shares of Stock out of the brokerage account. If the Company changes its designated broker, you acknowledge and agree that the Company may transfer any shares of Stock issued under the Plan to the new designated broker, if necessary for legal or administrative reasons. You agree to sign any documentation necessary to facilitate the transfer of shares of Stock.

Mandatory Sale of Shares Following Termination of Employment. You are required to sell all shares of Stock acquired upon vesting of the Units no later than 90 days following your termination of employment with the Company and its Affiliates (or such earlier date as may be required by the China State Administration of Foreign Exchange (“SAFE”)), in which case, this Addendum shall give the Company the authority to issue sales instructions on your behalf). If any shares remain outstanding on the 90th day following your employment termination date (or such earlier date as may be required by SAFE), you hereby direct, instruct and authorize the Company to issue sale instructions on your behalf.

You agree to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. You acknowledge that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of shares of Stock at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the shares of Stock are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to you in accordance with applicable exchange control laws and regulations.

Exchange Control Restrictions. You understand and agree that, pursuant to local exchange control requirements, you will be required immediately to repatriate to China the proceeds from the sale of any shares of Stock acquired under the Plan. You further understand that such repatriation of proceeds may be effected through a special bank account established by the Company or its Affiliate, and you hereby consent and agree that proceeds from the sale of shares of Stock acquired under the Plan may be transferred to such account by the Company on your behalf prior to being delivered to you and that no interest shall be paid with respect to funds held in such account. The proceeds may be paid to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid to you in U.S. dollars, you understand that a U.S. dollar bank account in China must be established and maintained so that the proceeds may be deposited into such account. If the proceeds are paid to you in local currency, you acknowledge that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the proceeds to local currency due to exchange control restrictions. You agree to bear any currency fluctuation risk between
–Rev 1.2023
15


the time the shares of Stock are sold and the net proceeds are converted into local currency and distributed to you. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses you may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the Company’s operation and enforcement of the Plan, the Agreement and the Award in accordance with Chinese law including, without limitation, any applicable SAFE rules, regulations and requirements.

The above requirements will not apply to non-Chinese nationals, unless otherwise required by the Company or by SAFE.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

COLOMBIA

Nature of Grant. This provision supplements Section 16 of the Agreement:
You acknowledge that, pursuant to Article 128 of the Colombian Labor Code, the Plan and related benefits do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.

Securities Law Information. The shares of Stock are not and will not be registered with the Colombian registry of publicly held securities (Registro Nacional de Valores y Emisores) and, therefore, the shares of Stock may not be offered to the public in Colombia. Nothing in the Agreement should be construed as making a public offer of securities in Colombia.

COSTA RICA

No country-specific provisions.

CZECH REPUBLIC

No country-specific provisions.

DENMARK

Treatment of Units upon Termination of Service. Notwithstanding any provisions in the Agreement to the contrary, the treatment of the Units upon your termination of employment shall be governed by the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships (the “Stock Option Act”), as in effect at the time of your termination of employment (as determined by the Administrator, in its discretion, in consultation with legal counsel). You acknowledge having received an “Employer Information Statement” in Danish, which is provided to comply with the Stock Option Act.

–Rev 1.2023
16


FINLAND

No country-specific provisions.

FRANCE

Type of Grant. The Units are granted as French-Qualified Restricted Stock Units and are intended to qualify for the special tax and social security treatment applicable to shares of Stock granted for no consideration under Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended. The Award is granted subject to the terms and conditions of the Rules of the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan French Sub-Plan (the “French Sub-Plan”).

Capitalized terms not defined herein, the Agreement or the Plan shall have the meanings ascribed to them in the French Sub-Plan.


Certain events may affect the status of the Units as French-Qualified RSUs or the underlying shares of Stock, and the Award or the underlying shares of Stock may be disqualified in the future. The Company does not make any undertaking or representation to maintain the qualified status of the French-Qualified RSUs or of the underlying shares of Stock.

(a)Restrictions on Sale or Transfer of Shares of Stock.

(1)Minimum Vesting/Issuance Period. The Award will vest according to the vesting schedule set forth in the Equity Award and Acceptance Summary, provided, however, that under no circumstances will shares of Stock underlying the Award be issued and delivered to a French Participant prior to the expiration of such period as is required to comply with the minimum mandatory period applicable to the Award under Section L. 225-197-1 of the French Commercial Code, as amended, the relevant sections of the French Tax Code and/or the relevant sections of the French Social Security Code, as amended, except in the case of your death. The minimum mandatory period is currently one (1) year from the Grant Date.

(2)Minimum Mandatory Holding Period. You may not sell or transfer the shares of Stock acquired upon vesting of the Award until such time as is required to comply with the minimum mandatory holding period applicable to the Award under Section L. 225-197-1 of the French Commercial Code, as amended, the relevant sections of the French Tax Code and/or the relevant sections of the French Social Security Code, as amended, except in the case of your death or Disability (as defined in the French Sub-Plan). The minimum mandatory holding period is currently two (2) years from the Grant Date.

Except in the case of your termination of employment due to death or Disability (as defined in the French Sub-Plan), the minimum mandatory holding period restriction will continue to apply even if you are no longer an Employee.

–Rev 1.2023
17


(3)Closed Periods. You may not sell any Stock issued upon vesting of the Award during certain Closed Periods, to the extent applicable to the Stock underlying the Award granted by the Company, as described in the French Sub-Plan.

(b)Termination of Service Due to Death. In the event of your death, your heirs may request the issuance of the Stock underlying any French-Qualified RSUs that have not vested prior to your death subject to the Award within six (6) months from the date of your death. If your heirs do not request the shares of Stock within six (6) months from the date of your death, the Award will be forfeited.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Utilisation de la langue anglaise. Vous reconnaissez et acceptez qu’il est de votre volonté que le présent accord, ainsi que tous documents, toutes notifications et toutes procédures judiciaires conclues, reçues ou intentées en vertu des présentes ou s’y rapportant directement ou indirectement, soient rédigés en anglais.

GERMANY

No country-specific provisions.

GREECE

No country-specific provisions.

HONG KONG

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Plan, the Units shall be settled only in shares of Stock (and may not be settled in cash).

Lapse of Restrictions. If, for any reason, shares of Stock are issued to you within six months after the Grant Date, you agree that you will not sell or otherwise dispose of any such shares of Stock prior to the six-month anniversary of the Grant Date.

IMPORTANT NOTICE/WARNING. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of the documents, you should obtain independent professional advice. The Units and shares of Stock issued at vesting do not constitute a public offering of securities under Hong Kong law and are available only to employees of the Company or its Affiliates. The Agreement, the Plan and other incidental communication materials have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong. The Units are intended only for the personal use of each eligible employee of the Employer, the Company or any Affiliate and may not be distributed to any other person.

–Rev 1.2023
18


Wages. The Units and shares of Stock subject to the Units do not form part of your wages for the purposes of calculating any statutory or contractual payments under Hong Kong law.

Nature of the Program. The Company specifically intends that the Plan will not be treated as an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court, tribunal or legal/regulatory body in Hong Kong determines that the Plan constitutes an occupational retirement scheme for the purposes of ORSO, the grant of the Units shall be null and void.

INDIA

Forced Sale of Shares. Due to regulatory requirements in India, the Company reserves the right to require that you sell all shares of Stock delivered to you, either immediately upon receipt of such shares of Stock or upon your termination of employment. In this regard, you agree that the Company is authorized to instruct E*TRADE or any successor or other third party that the Company may engage to assist with the administration of the Plan from time to time, to assist with any such mandatory sale of shares of Stock (on your behalf pursuant to this authorization), and you expressly authorize the designated broker to complete the sale of such shares of Stock. You also agree to sign any agreements, forms and/or consents that may be reasonably requested by the Company (or the designated broker) to effectuate the sale of the shares of Stock and shall otherwise cooperate with the Company with respect to such matters, provided that you shall not be permitted to exercise any influence over how, when or whether the sales occur. You acknowledge that E*TRADE or subsequent designated broker is under no obligation to arrange for the sale of the shares of Stock at any particular price. Due to fluctuations in the Stock price and/or applicable exchange rates between the date the shares of Stock are delivered to you and (if later) the date on which the shares of Stock are sold, the amount of proceeds ultimately distributed to you may be more or less than the market value of the shares of Stock on the relevant vesting date or the date on which the shares are delivered to you.  Upon the sale of the shares of Stock, the cash proceeds from the sale of shares of Stock (less any applicable Tax-Related Items, brokerage fees or commissions) will be delivered to you in accordance with applicable laws and regulations, as determined by the Company in its sole discretion.

Alternatively, depending on applicable regulatory requirements then in effect, the Company reserves the discretion to determine whether to settle any vested Units in cash.

INDONESIA

No country-specific provisions.

IRELAND

Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, all Units shall be settled only in shares of Stock (and shall not be settled in cash).

ISRAEL

102 Sub-Plan. The Units are granted to you pursuant to the Israeli Sub-Plan to the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Israeli Sub-Plan”), and are subject to the terms and conditions stated in the Israeli Sub-Plan, the Plan, and the Agreement, including this Addendum. By accepting the Units, you acknowledge and agree to be bound by the terms of the Israeli Sub-Plan and consent to
–Rev 1.2023
19


the terms of the “Consent Letter - 102 Capital Gain Awards” attached hereto as Appendix A (the “Consent Letter”). If you do not affirmatively accept the Units (and accordingly, the terms of the Israeli Sub-Plan, the Agreement and the Consent Letter) within ninety (90) days after the Grant Date, the Units may not qualify under the capital gain tax treatment.

Until further election by the Company, the Units and any shares of Stock received upon vesting of the Units are intended to qualify for the tax treatment available in Israel pursuant to the provisions of the “capital gain track” under Section 102 (“Section 102”) of the Israeli Income Tax Ordinance [New Version], 1961 (the “ITO”), including the provisions of the Income Tax Rules (Tax Benefits in Shares Issuance to Employees), 2003 and any Tax Ruling. However, in the event the Units do not meet the requirements of Section 102 of the ITO, such Units and the underlying shares of Stock shall not qualify for the favorable tax treatment under the capital gain track. The Company makes no representations or guarantees that the Units will qualify for favorable tax treatment and will not be liable or responsible if favorable tax treatment is not available under Section 102.

The Units are subject to the trust (the “Trust”) established by the trust and services agreement (the “Trust Agreement”) with ESOP Management and Trust Services Ltd. (the “Trustee”). To receive the tax treatment provided for in Sections 102(b)(2) and 102(b)(3) of the ITO, shares of Stock acquired by you upon vesting of the Units will be issued directly to the Trustee or controlled by the Trustee under a supervisory trustee arrangement, and will be held by the Trustee on your behalf or controlled by the Trustee at least until the end of the Required Holding Period (as defined in the Israeli Sub-Plan), which is currently twenty-four (24) months from the Grant Date, or any other period determined under the ITO as now in effect or as hereafter amended or by the Israeli Income Tax Authority. Subject to the conclusion of the Required Holding Period and any further period included herein, shares of Stock acquired by you upon vesting of the Units will be held or controlled by the Trustee until their sale, unless you request to release the shares of Stock to your direct holding, in which case the release will be subject to the receipt by the Trustee of an acknowledgment from the Israeli Income Tax Authority that you have paid all applicable taxes due pursuant to the ITO and Section 102, or the Trustee withholds any applicable tax due pursuant to the ITO and Section 102. You will not be permitted to elect to sell or release any shares of Stock acquired upon vesting of the Units prior to the conclusion of the Required Holding Period.

The Company may at its sole discretion replace the Trustee from time to time and instruct the transfer of all Units and shares of Stock held and/or administered by such Trustee at such time to its successor and the provisions of your Agreement shall apply to the new Trustee mutatis mutandis.

Any and all Tax-Related Items due in relation to the Units and shares of Stock shall be borne solely by you and in the event of death, by your heirs. The Company, the Employer and/or the Trustee shall withhold Tax-Related Items according to the requirements under the applicable laws, the rules, and regulations, including withholding Tax-Related Items at source. Furthermore, you hereby agree to indemnify the Company, the Employer and/or the Trustee and hold them harmless against and from any and all liability for any such Tax-Related Items or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such Tax-Related Items from any payment made to you. The Company, the Employer and/or the Trustee, to the extent permitted by law, shall have the right to deduct from any payment otherwise due to you, or from proceeds of the sale of any shares of Stock, an amount equal to any Tax-Related Items required by law to be withheld with respect to such shares of Stock. You
–Rev 1.2023
20


will pay to the Company, the Employer or the Trustee any Tax-Related Items that the Company, the Employer or the Trustee may be required to withhold with respect to any shares of Stock that cannot be satisfied by the means previously described. The Company may refuse to deliver any shares of Stock if you fail to comply with your obligations in connection with the Tax-Related Items as described in this section. Any fees associated with any vesting, sale, transfer or any act in relation to the Units and the shares of Stock, shall be borne by you. The Trustee, the Company and/or the Employer shall be entitled to withhold or deduct such fees from payments otherwise due to/from the Company, the Employer or the Trustee.

Securities Law Information.  The Company has obtained from the Israel Securities Authority an exemption from the requirement to file a prospectus in relation to the Plan. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by contacting your local human resources manager.

ITALY

Plan. This provision supplements Section 16 of the Agreement:
You further acknowledge that you have read and specifically and expressly approve the following sections of the Agreement: Vesting, Other Termination of Employment, Certain Vesting Conditions, Recoupment Policy, Issuance of Stock, Satisfaction of Tax Obligations, Nature of Grant, and Choice of Law and Venue.
JAPAN

No country-specific provisions.

KAZAKHSTAN

Securities Law Information. This offer is addressed only to certain eligible employees of the Company and its Affiliates in the form of shares of Stock to be issued by the Company, subject to the terms and conditions of the Agreement and the Plan. Neither the Plan nor the Agreement has been approved, nor do they need to be approved, by the National Bank of Kazakhstan. This offer is intended only for the original recipient and is not for general circulation in the Republic of Kazakhstan.

LEBANON

Securities Law Information. The Plan does not constitute the marketing or offering of securities in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offerings under the Plan are being made only to eligible employees of the Company and its Affiliates.

MALAYSIA

Award Conditioned upon Election to Pay Taxes Directly to the Malaysian Inland Revenue Board. You understand and agree that your Award is conditioned upon your completing, signing and submitting a letter to your Employer, indicating your election to pay any income tax or other tax liability arising in connection with taxable income recognized under the Plan directly to the Malaysian Inland Revenue Board. (You may contact your Employer to request a form letter for this purpose.) You understand that if
–Rev 1.2023
21


you fail to file such an election letter with your Employer, your Award will be null and void.

Consent to Collection, Processing and Transfer of Personal Data. This provision replaces Section 15 of the Agreement in its entirety:

–Rev 1.2023
22


You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data, as described in this Addendum and any other grant materials by and among, as applicable, the Company and Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and Affiliates may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Company and also by you through information collected in connection with the Agreement and the Plan.
You understand that Data will be transferred to the current stock plan service providers or a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817. You authorize the Company, the stock plan service provider and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any transfer of such Data as may be required to a broker, escrow agent or other third party with whom the shares of Stock received upon vesting of the Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data, limit the processing of Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consent herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Company will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company may not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Please take note that by electronically accepting this Agreement, you have confirmed that you explicitly, voluntarily and unambiguously consent to the collection, use and transfer of your personal data in accordance with the terms in this notification. However, if for any reason you do not consent to the processing of your personal data, you have the right to reject such consent by contacting your local human resources representative: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817.
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Lampiran ini dan apa-apa bahan pemberian unit saham terhad yang lain oleh dan di antara, seperti yang berkenaan, Syarikat dan Ahli Gabungan untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan.
Anda memahami bahawa Syarikat Ahli Gabungan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa syer saham Biasa atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir semua unit saham terhad, atau apa-apa hak lain atas syer Biasa saham yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedahanda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (“Data”). Data tersebut dibekalkan oleh Syarikat dan juga oleh anda berkenaan dengan Perjanjian dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada pembekal perkhidmatan pelan saham semasa atau pembekal perkhidmatan pelan saham yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau mana-mana tempat lain, dan bahawa negara penerima-penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh meminta satu senarai yang mengandungi nama-nama dan alamat-alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan anda: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817. Anda memberi kuasa kepada Syarikat, pembekal perkhidmatan pelan saham dan mana-mana penerima-penerima kemungkinan lain yang mungkin akan membantu Syarikat (pada masa sekarang atau pada masa depan) dengan melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, bagi tujuan melaksanakan, mentadbir dan menguruskan penyertaan anda di dalam Pelan, termasuk segala pemindahan Data tersebut sebagaimana yang dikehendaki kepada broker, egen eskrow atau pihak ketiga dengan siapa syer Biasa saham diterima semasa peletakhakan saham terhad unit mungkin didepositkan. Anda memahami bahawa Data hanya akan disimpan selagi ia adalah diperlukan untuk melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa sekiranya anda menetap di luar Amerika Syarikat, anda boleh, pada bila-bila masa, melihat Data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data, mengehadkan pemprosean Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela semata-mata. Sekiranya anda tidak bersetuju, atau sekiranya anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan dan kerjaya anda dengan Syarikat tidak akan terjejas; satu-satunya akibat buruk sekiranya anda tidak bersetuju atau menarik balik persetujuan andaadalah bahawa Syarikat tidak akan dapat memberikan unit saham terhad anda atau anugerah ekuiti lain atau mentadbir atau mengekalkan anugerah-anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lebih lanjut mengenai akibat-akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Sila ambil perhatian bahawa dengan menerima Perjanjian ini secara elektronik, anda mengesahkan bahawa anda secara eksplisit, sukarela, dan tanpa sebarang keraguan bersetuju dengan pengumpulan, penggunaan, dan pemindahan data peribadi anda mengikut terma-terma dalam notis ini. Walaubagaimanapun, jika atas apa-apa sebab-sebab tertentu anda tidak bersetuju dengan pemprosesan data peribadi anda, anda mempunyai hak untuk menolak persetujuan anda dengan menghubungi wakil sumber manusia tempatan anda: Shu Li Lee, Boston Scientific Asia Pacific Pte Ltd, Suite 20-01, Metropolis Tower One, 9 North Buona Vista Drive, Singapore 138588; +(65) 6418 8817.
–Rev 1.2023
23



MEXICO

Securities Law Information. You expressly recognize and acknowledge that the Company’s grant of the Units and the underlying shares of Stock under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Agreement and any other document relating to the Units may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of the Employer in Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Acknowledgement of the Agreement. By accepting the Units, you acknowledge that you have received a copy of the Plan and the Agreement, including this Addendum, which you have reviewed. You further acknowledge that you accept all the provisions of the Plan and the Agreement, including this Addendum. You also acknowledge that you have read and specifically and expressly approve the terms and conditions set forth in the “Nature of Grant” section of the Agreement, which clearly provide as follows:
(1)    Your participation in the Plan does not constitute an acquired right;
(2)    The Plan and your participation in it are offered by the Company on a wholly discretionary basis;
(3)    Your participation in the Plan is voluntary; and
(4)    The Company and its Affiliates are not responsible for any decrease in the value of any shares of Stock acquired at vesting of the Units.
Reconocimiento del Contrato. Al aceptar los Unidades, usted reconoce que ha recibido una copia del Plan y del Contrato con inclusión de este Apéndice, que le ha examinado. Usted reconoce, además, que usted acepta todas las disposiciones del Plan y del Contrato. Usted también reconoce que ha leído y, concretamente, y aprobar de forma expresa los términos y condiciones establecidos en la “Naturaleza del Otorgamiento” que claramente dispone lo siguiente:
(1)    Su participación en el Plan no constituye un derecho adquirido;
(2)    El Plan y su participación en el Plan se ofrecen por Boston Scientific Corporation en su totalidad sobre una base discrecional;
(3)    Su participación en el Plan es voluntaria; y
(4)    Boston Scientific Corporation y sus afiliadas no son responsables de ninguna disminución en el valor de las acciones adquiridas en la adquisición de los Unidades.
Labor Law Acknowledgement and Policy Statement. By accepting the Units, you acknowledge that Boston Scientific Corporation, with registered offices at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, United States of America, is solely
–Rev 1.2023
24


responsible for the administration of the Plan. You further acknowledge that your participation in the Plan, the grant of Units and any acquisition of shares of Stock under the Plan do not constitute an employment relationship between you and Boston Scientific Corporation because you are participating in the Plan on a wholly commercial basis and your sole employer is a Mexican legal entity (“Boston Scientific-Mexico”). Based on the foregoing, you expressly acknowledge that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and the Employer, Boston Scientific-Mexico, and do not form part of the employment conditions and/or benefits provided by Boston Scientific-Mexico, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
You further understand that your participation in the Plan is the result of a unilateral and discretionary decision of Boston Scientific Corporation, therefore, Boston Scientific Corporation reserves the absolute right to amend and/or discontinue your participation in the Plan at any time, without any liability to you.
Finally, you hereby declare that you do not reserve to you any action or right to bring any claim against Boston Scientific Corporation for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and that you therefore grant a full and broad release to Boston Scientific Corporation, its Affiliates, branches, representation offices, shareholders, officers, agents and legal representatives, with respect to any claim that may arise.
Reconocimiento de Ausencia de Relación Laboral y Declaración de la Política. Al aceptar los Unidades, usted reconoce que Boston Scientific Corporation, con oficians registradas on 300 Boston Scientific Way, Marlborough, Massachusetts 01752, Estados Unidos de América, es el único responsable de la administración del Plan. Además, usted acepta que su participación en el Plan, la concesión de los Unidades y cualquier adquisición de acciones en el marco del Plan no constituyen una relación laboral entre usted y Boston Scientific Corporation porque usted está participando en el Plan en su totalidad sobre una base comercial y su único empleador es una sociedad mercantil Mexicana (“Boston Scientific-Mexico”). Derivado de lo anterior, usted expresamente reconoce que el Plan y los beneficios que pueden derivarse de la participación en el Plan no establece ningún derecho entre usted y su Empleador, Boston Scientific-Mexico, y que no forman parte de las condiciones de empleo y / o prestaciones previstas por Boston Scientific-Mexico, y cualquier modificación del Plan o la terminación de su contrato no constituirá un cambio o deterioro de los términos y condiciones de su empleo.
Además, usted entiende que su participación en el Plan es causada por una decisión discrecional y unilateral de Boston Scientific Corporation, por lo que Boston Scientific Corporation se reserva el derecho absoluto a modificar y/o suspender su participación en el Plan en cualquier momento, sin responsabilidad alguna para con usted.
Finalmente, usted manifiesta que no se reserva ninguna acción o derecho que origine una demanda en contra de Boston Scientific Corporation, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia usted otorga un amplio y total finiquito a Boston Scientific Corporation, sus afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que pudiera surgir.
–Rev 1.2023
25


NETHERLANDS

Waiver of Termination Rights. By accepting the Units, you hereby waive any and all rights to compensation or damages as a result of the termination of employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) your ceasing to have rights under, or ceasing to be entitled to any awards under the Plan as a result of such termination.

NEW ZEALAND

Securities Law Information.

Warning

This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Plan and the Agreement, will be converted into shares of Stock. Shares of Stock give you a stake in the ownership of Boston Scientific Corporation. You may receive a return if dividends are paid.

If Boston Scientific Corporation runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of preference shares have been paid. You may lose some or all of your investment.

New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.

Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting or dividend rights) with respect to the underlying shares of Stock.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The shares of Stock are quoted on the New York Stock Exchange. This means that if you acquire shares of Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you invested. The price will depend on the demand for the shares of Stock.

You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.Boston Scientific Corporation’s most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on those financial statements: https://
–Rev 1.2023
26


www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

3.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

4.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

5.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

A copy of the above documents will be sent to you free of charge on written request being mailed to: Boston Scientific Corporation, Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

NORWAY

No country-specific provisions.

PERU

Securities Law Information. The grant of Units is considered a private offering in Peru; therefore, it is not subject to registration. For more information concerning the grant, you acknowledge that you should refer to the Plan, the Agreement, and any other materials made available by the Company. For more information regarding the Company, you acknowledge that you should refer to the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov.

Additional Acknowledgement of Nature of Plan and the Units. By accepting the Units, you understand, acknowledge and agree that the Units are being granted ex gratia by the Company.

PHILIPPINES

Settlement in Cash. Pursuant Section 2 of the Agreement, the Company shall settle your Units in the form of a cash payment unless, at the time of vesting, share settlement does not trigger the need for any approval from and/or filing with the Philippines Securities and Exchange Commission.

POLAND

No country-specific provisions.

PORTUGAL

Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement.
–Rev 1.2023
27


Conhecimento da Lingua. Por meio do presente, eu declaro expressamente que tem pleno conhecimento da língua inglesa e que li, compreendi e livremente aceitei e concordei com os termos e condições estabelecidas no Plano e no Acordo.

PUERTO RICO

No country-specific provisions.

ROMANIA
Language Consent. By accepting the grant of Units, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (the Agreement and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Consimtamant cu Privire la Limba. Acceptând acordarea unităților de Unit-uri, recunoașteți că sunteți competenți în citirea și înțelegerea limbii engleze și înțelegeți pe deplin termenii documentelor legate de subvenție (Acordul de acordare și planul), care au fost furnizate în limba engleză. Acceptați termenii acestor documente în consecință.
RUSSIA
U.S. Transaction. You understand that the Units shall be valid and this Agreement shall be concluded and become effective only when the Agreement is received by the Company in the United States. Upon vesting of the Units, any shares of Stock to be issued to you shall be delivered to you through a bank or brokerage account in the United States. In no event will shares of Stock be delivered to you in Russia; instead, all shares of Stock acquired upon vesting of the Units will be maintained on your behalf in the United States. You are not permitted to sell shares of Stock acquired at vesting directly to a Russian legal entity or resident.
Securities Law Information. You acknowledge that the Units, the Equity Award and Acceptance Summary, the Agreement, the Plan and all other materials that you may receive regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. The shares of Stock acquired pursuant to the Plan have not and will not be registered in Russia and, therefore, neither the Units nor the shares of Stock may be used for offering or public circulation in Russia.
Repatriation Requirements. You agree to promptly repatriate proceeds resulting from the sale of shares of Stock acquired under the Plan to a foreign currency account at an authorized bank in Russia if legally required at the time shares of Stock are sold and to comply with all applicable local foreign exchange rules and regulations. Neither the Company nor any of its Affiliates shall be liable for any fines or penalties resulting from your failure to comply with applicable laws.
The repatriation requirement may not apply with respect to cash amounts received in an account that is considered by the Central Bank of Russia to be a foreign brokerage account opened with a financial market institution other than a bank. Statutory exceptions to the repatriation requirement also may apply.
Anti-Corruption Notification. Anti-corruption laws prohibit certain public servants, their spouses and their dependent children from owning any foreign source financial instruments (e.g., shares of Stock of foreign companies such as the Company).
–Rev 1.2023
28


Accordingly, you should inform the Company if you are covered by these laws because you should not hold shares of Stock acquired under the Plan.
Labor Law Information. If you continue to hold shares of Stock acquired upon settlement of the Units after an involuntary termination of employment, you may not be eligible to receive unemployment benefits in Russia.
Settlement of Units. Depending on applicable restrictions then in effect, the Company has the sole discretion to postpone the vesting and/or settlement of any Units, to determine whether to settle any vested Units in shares of Stock or in cash, or to cancel such Units for no consideration.
SAUDI ARABIA

Securities Law Information. The grant of the Units is not subject to the regulations concerning public offers and private placements under the Law on Capital Markets.

SINGAPORE

Private Placement. The grant of the Units is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should note that the Units are subject to section 257 of the SFA and you will not be able to make any subsequent sale of the shares of Stock in Singapore, or any offer of such subsequent sale of the shares of Stock subject to the grant in Singapore, unless such sale or offer is made (i) after six months from the Grant Date or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA.

SOUTH AFRICA

Securities Law Information. In compliance with South African securities law, the documents listed below are available for review on the Company’s external and internal sites at the web addresses listed below:
1.Boston Scientific Corporation’s most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?CIK=bsx&owner=exclude&action=getcompany&Find=Search.

2.The Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

3.Boston Scientific Corporation Restricted Stock Unit Award Agreement and Amended and Restated 2011 Long-Term Incentive Plan Q&A Summary Sheet: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.

–Rev 1.2023
29


4.Boston Scientific Corporation Equity Award and Acceptance Summary: This document can be accessed at https://us.etrade.com/home -> My Stock Plan -> Holdings -> click on a grant date and select “View Grant Documents”.
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Boston Scientific Corporation, attn: Corporate Compensation, 300 Boston Scientific Way, Marlborough, MA 01752, USA.

You understand that you are advised to carefully read the materials provided before making a decision whether to participate in the Plan and to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.

SOUTH KOREA

Consent to Collection, Processing and Transfer of Personal Data. By electronically accepting this Agreement:

1.You agree to the collection, use, processing and transfer of Data as described in Section 15 of the Agreement; and

2.You agree to the processing of your unique identifying information (resident registration number) as described in Section 15 of the Agreement.

SPAIN

Acknowledgement of Discretionary Nature of the Plan; No Vested Rights. This provision supplements the terms of the Agreement.

In accepting the grant of Units, you acknowledge that you consent to participation in the Plan and have received a copy of the Plan.

You understand that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the Plan to individuals who may be employees of the Company or its Affiliates throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its Affiliates on an ongoing basis. Consequently, you understand that the Units are granted on the assumption and condition that the Units and the shares of Stock acquired upon vesting of the Units shall not become a part of any employment contract (either with the Company or any of its Affiliates) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. In addition, you understand that this grant would not be made to you but for the assumptions and conditions referenced above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, the grant of the Units shall be null and void.

You understand and agree that, as a condition of the grant of the Units, your termination of employment for any reason (including the reasons listed below) will automatically result in the loss of the Units to the extent the Units have not vested as of date that you cease active employment. In particular, you understand and agree that any unvested Units as of the date you cease active employment will be forfeited without entitlement to the underlying shares of Stock or to any amount of indemnification in the event of the termination of employment by reason of, but not limited to, resignation or retirement
–Rev 1.2023
30


prior to the first anniversary of the Grant Date, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause, individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985. You acknowledge that you have read and specifically accept the conditions referred to in the Agreement regarding the impact of a termination of employment on your Award.

BY ELECTRONICALLY ACCEPTING THIS AGREEMENT, YOU ACKNOWLEDGE, UNDERSTAND AND AGREE TO THE TERMS AND CONDITIONS OF THE PLAN, THE AGREEMENT AND THIS ADDENDUM.

SWEDEN

Tax Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the Section 13 of the Agreement, in accepting the grant of the Units, you authorize the Company to withhold shares of Stock or to sell shares of Stock otherwise deliverable to you upon settlement of the Units to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

SWITZERLAND

Securities Law Information. Neither this document nor any other materials relating to the Units (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”) (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of the Corporation or a Subsidiary or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority, FINMA.

TAIWAN

Securities Law Information. This Award and the shares of Stock to be issued pursuant to the Plan are available only for Employees. The Award is not a public offer of securities by a Taiwanese company.

THAILAND

No country-specific provisions.

TURKEY

Securities Law Information. Under Turkish law, you are not permitted to sell shares of Stock acquired under the Plan in Turkey. The shares of Stock are currently traded on the New York Stock Exchange, which is located outside Turkey and the shares of Stock may be sold through this exchange.

–Rev 1.2023
31


UNITED ARAB EMIRATES

Securities Law Information. The Plan is an employee equity incentive plan and is only being offered to select employees in the United Arab Emirates. The Plan and the Agreement are intended for distribution only to such employees and must not be delivered to, or relied on by, any other person. The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any documents in connection with the Plan. Neither the Ministry of Economy nor the Dubai Department of Economic Development have approved the Plan or the Agreement nor taken steps to verify the information set out therein, and have no responsibility for such documents. You should conduct your own due diligence on the securities offered under the Plan. If you do not understand the contents of the Agreement or the Plan, you should consult an authorized financial advisor.

UNITED KINGDOM

Income Tax and Social Insurance Contribution Withholding. The following provision shall supplement Section 13 of the Agreement:

Without limitation Section 13 of the Agreement, you agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company, the Employer or by HM Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay on your behalf to HMRC (or any other tax authority or any other relevant authority).

Notwithstanding the foregoing, you understand that if you are a director or executive officer (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the terms of the immediately foregoing provision may not apply. In the event that you are a director or executive officer and income tax due is not collected from or paid by you within 90 days after the UK tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected tax may constitute a benefit on which additional income tax and national insurance contributions may be payable. You acknowledge that you ultimately will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as applicable) for the value of any employee national insurance contributions due on this additional benefit, which the Company and/or the Employer may recover from you at any time thereafter by any of the means referred to in Section 13 of the Agreement.

Exclusion of Claim. You acknowledge and agree that you will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from your ceasing to have rights under or to be entitled to the Award, whether or not as a result of your termination of employment (whether the termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of your Award, you shall be deemed irrevocably to have waived any such entitlement.

*    *    *    *

–Rev 1.2023
32


APPENDIX A
CONSENT LETTER
102 CAPITAL GAIN AWARDS FOR PARTICIPANTS RESIDING IN ISRAEL
Dear Participant,
Boston Scientific Corporation (the “Company”) has elected to apply the capital gains route in accordance with the provisions of Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”) on awards granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Incentive Plan”) to Israeli Participants (as defined in the Israeli sub-plan to the Incentive Plan (the “Israel Sub-Plan”), which was approved by the Executive Compensation and Human Resources Committee of the Company’s Board of Directors on November 14, 2022) and any future incentive plan implemented by the Company in Israel (“Awards” and “Capital Gains Route”), subject to the Company’s absolute discretion to change such election on future grants, with or without advance notice. Unless otherwise notified to you in writing by the Company, the Awards shall be granted to you under the Capital Gains Route, subject to compliance with the requirements of such tax route.
The Capital Gains Route election will enable you to enjoy lower tax rates on a portion of the income received upon disposition of the shares of Company common stock (“Shares”) issued to you from or in connection to the Awards, provided however that all the requirements under Section 102 of the Ordinance and the Income Tax (Tax Abatement on the Grant of Shares to Employees) Regulations 2003 (the “Regulations”) are met.
Below you will find a brief description of the Israeli income tax consequences of the Capital Gains Route. PLEASE NOTE THAT THE SUMMARY BELOW IS ONLY A BRIEF SUMMARY THAT DOES NOT COVER ALL THE PROVISIONS OF SECTION 102 OF THE ORDINANCE AND THE REGULATIONS AND IS NOT INTENDED TO PROVIDE ANY TAX ADVICE. IN ADDITION, THE TAX LAWS AND REGULATIONS DESCRIBED HEREIN ARE SUBJECT TO CHANGE. THEREFORE, IT IS RECOMMENDED THAT YOU CONSULT WITH A TAX ADVISER BEFORE ACCEPTING THE TERMS OF THIS CONSENT LETTER OR BEFORE ACCEPTING ANY AWARDS OR DISPOSING OF SHARES.
The main restrictions that are included under Section 102 of the Ordinance are as follows:
(1) Your Awards and the Shares issued under such Awards will be held in trust or controlled by a trustee for at least a period determined in Section 102 under the Capital Gains Route (“Required Holding Period”) (currently twenty-four months from the date in which the Awards were granted to you).
(2) During the Required Holding Period you will not be able to sell, pledge, release from trust or otherwise perform any transaction in connection to the Awards or Shares granted to you.
Provided that all conditions set by the Ordinance under the Capital Gains Route are met, including the above conditions, you will, in general, be taxed as follows: 
The fair market value of the underlying Shares at grant will be treated as ordinary income subject to income tax and employee/employer social insurance
–Rev 1.2023
33


contributions (to the extent the applicable contribution ceiling has not been exceeded). For tax purposes, the fair market value of the Shares at grant is deemed to be the average price of the Shares over the 30 trading days preceding the grant. 
The remainder of the gain, if any, will be treated as a capital gain and will be taxed at the capital gains tax rate of 25%.  No social insurance contributions will be due on this portion of the gain. 
In addition, a surtax may be imposed if your income is in excess of the applicable annual threshold.
If the Company were to permit you to sell your Shares, or release the Shares from trust, before the end of the Holding Period, you will immediately be subject to income tax on the gain, at your marginal income tax rate, and will be also required to pay social security and health tax contributions on all your profit.
In order to enable you to enjoy the benefits of the Capital Gains Route, please express your acceptance and confirmation of the following terms, by accepting the Award through the electronic acceptance procedures established by the Company:
1.    I undertake to comply with all the terms and conditions set under Section 102 of the Ordinance with regard to the Capital Gains Route and the Regulations.
2.    I have had the opportunity to obtain the advice of counsel prior to accepting this Consent Letter. I am familiar with and understand the provisions of Section 102 of the Ordinance in general, and the tax arrangement under the Capital Gains Route in particular, and agree to comply with such provisions, as amended from time to time.
3.    I agree that Awards granted to me, and the Shares that may be derived from such Awards, will be held or controlled by a trustee for at least the duration of the Required Holding Period, as determined in Section 102 under the Capital Gains Route (currently twenty-four months from the date in which the Awards were granted).
4.    I agree to the trust deed signed between the Company, my employer and the trustee available at Trust Deed RSU-Stock Option - Hebrew.pdf.
5.    I understand that any release of such Awards or Shares from trust, or any sale of the Shares prior to the termination of the Required Holding Period, will result in taxation at my marginal tax rate, in addition to deductions of appropriate social security and health tax contributions.
6.    I authorize the Company and/or my employer to provide the trustee with any information required for administrating the grant of the Awards, including without limitation information about my Awards, income tax rates, salary bank account, contact details and identification number and any reasonable information required by the trustee.
7.     I declare that I am a resident of the state of Israel for tax purposes and agree to notify the Company upon any change in the residence address and acknowledge that if I cease to be an Israeli resident or if my engagement with the Company or any affiliate is terminated, the Awards and underlying Shares shall
–Rev 1.2023
34


remain subject to Section 102, the trust agreement and the applicable equity plan and grant document.
8.    I understand and agree that until the Company will determine otherwise, my acceptance of the terms of this Consent Letter will be sufficient, to apply to all potential future grants of Awards. I hereby confirm that by accepting this Consent Letter, I will be deemed to have elected to accept the terms and conditions herein in respect of any such potential future grant of Awards.
9.     I acknowledge, understand and agree that the Awards are an extraordinary, one-time benefit granted to me, and do not create any contractual or other right to receive future grant of Awards.
10.     I understand that neither the Company nor any of its affiliates guarantee that any Awards granted to me will be eligible for tax benefits pursuant to the Capital Gains Route and I agree that I will not hold the Company and/or any affiliate and/or the trustee liable for any tax consequences relating to my Awards, including any penalties or other negative tax consequences I could receive or be subject to if my Awards do not obtain the Capital Gains Route tax treatment, regardless of the reason for the Capital Gains Route tax treatment not being available.
*    *    *    *



–Rev 1.2023
35
EX-10.4 4 ex104-2023grantxtsrawardag.htm EX-10.4 Document
Exhibit 10.4



Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: rTSR PERFORMANCE SHARE PROGRAM -
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Relative Total Shareholder Return Performance Share Program (the “Program”) for the period beginning January 1, 2023 and ending on December 31, 2025 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and Appendix B, and the satisfaction of the performance
-Rev. 12.2022        rTSR Program


conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2024, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control. The number of shares of Stock to be issued
-Rev. 12.2022    2    rTSR Program


under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2024, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2023 and a Change in Control occurs after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange  Act of 1934, as amended.

        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

-Rev. 12.2022    3    rTSR Program


    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including,
-Rev. 12.2022    4    rTSR Program


without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in
-Rev. 12.2022    5    rTSR Program


certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Program after the grant date may materially and adversely impair a participant's rights under awards made pursuant to the Program without the participant's consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

-Rev. 12.2022    6    rTSR Program


    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.

[remainder of page intentionally left blank]

-Rev. 12.2022    7    rTSR Program


APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

rTSR* Performance
Percentile Rank
Performance Share Units
as a Percent of Target
75th Percentile or above200%
55th Percentile100%
25th Percentile30%
Below 25th Percentile
0%


*Relative Total Shareholder Return
-Rev. 1.2022        rTSR Program


APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2022. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-Rev. 12.2022        rTSR Program


the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-Rev. 12.2022        rTSR Program


consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-Rev. 12.2022        rTSR Program



You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee
-Rev. 12.2022        rTSR Program


identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide
-Rev. 12.2022        rTSR Program


Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *
406635481-v5\NA_DMS
-Rev. 12.2022        rTSR Program
EX-10.5 5 ex105-2023grantxonsgawarda.htm EX-10.5 Document
Exhibit 10.5




Boston Scientific Corporation
Participant: %%FIRST_NAME%-% %%LAST_NAME%-%
Employee ID: %%EMPLOYEE_IDENTIFIER%-%
Award Type: Performance Share Unit Award Agreement
Plan Name: ONSG PERFORMANCE SHARE PROGRAM
Award Date: %%OPTION_DATE,'Month DD, YYYY'%-%
Total Granted: %%TOTAL_SHARES_GRANTED%-%


BOSTON SCIENTIFIC

INTENT TO GRANT

PERFORMANCE SHARE UNIT AWARD AGREEMENT


    This Agreement, dated as of the %%OPTION_DATE,'Month DD, YYYY'%-% (the “Grant Date”), is between you and Boston Scientific Corporation, a Delaware corporation (the “Company”), in connection with the Award of Performance Share Units by the Company under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”). Capitalized terms not otherwise defined herein shall have the meaning ascribed thereto in either the Plan or in the Organic Net Sales Growth Performance Share Program (the “Program”) for the period beginning January 1, 2023 and ending on December 31, 2025 (the “Performance Period”).
    1.    Grant and Acceptance of Award. The Company hereby indicates its award to you that number of Performance Share Units (the “Units”) set forth herein this Agreement (the “Award”). Each Unit represents the Company’s commitment to issue to you shares of the Company’s common stock, par value USD 0.01 per share (“Stock”), subject to certain eligibility, performance and other conditions set forth herein. The Award is intended to be granted pursuant to and is subject to the terms and conditions of this Agreement and the provisions of the Plan and the Program.

    2.    Eligibility Conditions upon Award of the Units. You hereby acknowledge the intent of the Company to award the Units subject to certain eligibility, performance and other conditions set forth herein.

    3.    Satisfaction of Performance-Based Conditions. Subject to the eligibility conditions described in Section 7 of this Agreement, except as otherwise provided in Section 8 of this Agreement and Appendix B, and the satisfaction of the performance



conditions set forth on Appendix A to this Agreement during the Performance Period, the Company intends to award shares of Stock hereunder to you at the end of the Performance Period. Shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period. Except as set forth in Section 8 of this Agreement, no shares of Stock in settlement of the Units shall be issued to you prior to the end of the Performance Period.

    4.    Participant’s Rights in Stock. The shares of Stock, if and when issued hereunder, shall be registered in your name and evidenced in the manner as the Company may determine. During the period prior to the issuance of shares of Stock, you will have no rights of a stockholder of the Company with respect to the shares of Stock, including no right to receive dividends or vote the shares of Stock underlying each Award.

    5.    Death or Disability. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability (as the term is defined in the Plan or determined under local law), prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period based on actual performance as determined at the first Committee meeting following the Performance Period.

    6.    Retirement. In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued during the period January 1 to March 15 of the calendar year following the end of the Performance Period on a prorated basis based on actual performance as determined at the first Committee meeting following the Performance Period. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months that you worked during the Performance Period (rounded up to the nearest whole month) divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount, as calculated in accordance with the terms of the Program. In the event that you terminate your employment due to Retirement prior to January 1, 2024, the Award shall be forfeited in its entirety.

    7.    Other Termination of Employment -- Eligibility Conditions. If your employment with the Company and its Affiliates or subsidiaries is terminated or you separate from the Company and its Affiliates or subsidiaries for any reason other than death, Retirement or Disability, any Units that remain subject to eligibility conditions shall be void and no shares of Stock shall be issued. Except as set forth in Sections 5, 6 and 8, eligibility to be issued shares of Stock is conditioned on your continuous employment with the Company or an Affiliate through and on the last day of the Performance Period.

    8.    Change in Control of the Company. Subject to the terms of any separate Change in Control or similar agreement to which you are bound, in the event you are employed by the Company or an Affiliate at the time of a Change in Control after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the
-12.2022    2    ONSG Program


consummation of the Change in Control. The number of shares of Stock to be issued under the prorated Award shall be determined by calculating (a)(i) the number of Units set forth herein multiplied by (ii) the quotient of the number of full and partial months during the Performance Period (rounded up to the nearest whole month) prior to the consummation of the Change in Control divided by 36, and then multiplying the product of (a)(i) and (a)(ii) by (b) the percentile performance amount as calculated in accordance with the terms of the Program. In the event that a Change in Control occurs prior to January 1, 2024, the Award shall be forfeited in its entirety.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to death or Disability prior to a Change in Control and a Change in Control occurs after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control.

    In the event that your employment with the Company or its subsidiaries or Affiliates is terminated due to Retirement prior to a Change in Control after December 31, 2023 and a Change in Control occurs after December 31, 2023, but prior to the end of the Performance Period, shares of Stock shall be issued immediately prior to the Change in Control on a prorated basis as determined under Section 6 based on actual performance using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2025, as determined by the Committee immediately prior to the consummation of the Change in Control.

    9.    Recoupment Policy.

    (a)    Current Recoupment Policy. Pursuant to the Company’s recoupment policy and to the extent permitted by governing law, the Board, in its discretion, may seek Recovery of the Award granted to you if you are a Current Executive Officer or Former Executive Officer and if, in the judgment of the Board, you commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.

        (i)    Definitions. The following terms, when used in this Section 9, shall have the meaning set forth below:

            (1)    “Current Executive Officer” means any individual currently designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

            (2)    “Executive Officer” means any Current Executive Officer or Former Executive Officer.

            (3)    “Former Executive Officer” means any individual previously (but not currently) designated as an “executive officer” by the Board under Rule 3b-7 under the Securities Exchange Act of 1934, as amended.

-12.2022    3    ONSG Program


        (4)    “Recovery” means the forfeiture or cancellation of unvested Units.

    (b)    Provisions Required by Law. If the Company subsequently determines that it is required by law to apply a “clawback” or alternate recoupment provision to outstanding Awards, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to this Award, as applicable, as if it had been included on the Grant Date and the Company shall notify you of such additional provision.

    10.    Consideration for Stock. The shares of Stock are intended to be issued for no cash consideration.

    11.    Issuance of Stock. The Company shall not be obligated to issue any shares of Stock until (i) all United States (“U.S.”) federal, state, local and non-U.S. laws and regulations as the Company may deem applicable have been complied with; (ii) the shares of Stock have been listed or authorized for listing upon official notice to the New York Stock Exchange, Inc. or have otherwise been accorded trading privileges; and (iii) all other legal matters in connection with the issuance and delivery of the shares of Stock have been approved by the Company’s legal department.

    12.    Satisfaction of Tax Obligations. Regardless of any action the Company or the Affiliate that employs you (the “Employer”) (if applicable) takes with respect to any or all income tax (including U.S. federal, state and local taxes and/or non-U.S. taxes), social insurance, payroll tax, payment on account or other tax-related withholding (“Tax-Related Items”), you acknowledge and agree that the ultimate liability for all Tax-Related Items legally due by you is and remains your responsibility and that the Company and/or the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Units or the shares of Stock issued upon vesting of the Units, and (b) do not commit to structure the terms of the Award (or any aspect of the Units) to reduce or eliminate your liability for Tax-Related Items.

    Upon the issuance of shares of Stock or the satisfaction of any vesting condition with respect to the shares of Stock to be issued hereunder, if your country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company may hold back from the total number of shares of Stock to be delivered to you, and shall cause to be transferred to the Company, whole shares of Stock that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld with respect to the shares of Stock, or to the extent it would not result in adverse accounting treatment, the Company may, in its sole discretion, hold back shares of Stock based on a rate of up to the maximum applicable withholding rate. If the obligation for Tax-Related Items is satisfied by holding back shares of Stock to be delivered upon settlement of the Units, for tax purposes, you are deemed to have been issued the full number of shares of Stock subject to the Units, notwithstanding that a number of shares of Stock are held back solely for the purpose of paying the Tax-Related Items. You will have no further rights with respect to any shares of Stock that are retained by the Company pursuant to this provision. By accepting the grant of the Units, you expressly consent to the withholding of shares of Stock and/or cash as provided for hereunder.

    Alternatively, you hereby authorize the Company (on your behalf and at your direction pursuant to this authorization) to immediately sell a sufficient whole number of
-12.2022    4    ONSG Program


shares of Stock acquired upon vesting resulting in sale proceeds sufficient to pay the Tax-Related Items required to be withheld. You agree to sign any agreements, forms and/or consents that reasonably may be requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the shares of Stock (including, without limitation, as to the transfer of the sale proceeds to the Company to satisfy the Tax-Related Items required to be withheld). Further, the Company or the Employer may, in its discretion, withhold any amount necessary to pay the Tax-Related Items from your salary or any other amounts payable to you, with no withholding of shares of Stock or sale of shares of Stock, or may require you to submit a cash payment equivalent to the Tax-Related Items required to be withheld with respect to the Units.     

    All other Tax-Related Items related to the grant of the Units and any shares of Stock delivered in settlement thereof are your sole responsibility. In no event shall whole shares of Stock be withheld by or delivered to the Company in satisfaction of any Tax-Related Items in excess of the maximum statutory tax withholding required by law. You agree to indemnify the Company and its Affiliates against any and all liabilities, damages, costs and expenses that the Company and its Affiliates may hereafter incur, suffer or be required to pay with respect to the payment or withholding of any Tax-Related Items.

    The Units are intended to comply with or be exempt from the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Plan and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company determines that the Agreement is subject to Code Section 409A and that it has failed to comply with the requirements of that Section, the Company may, in its sole discretion, and without your consent, amend this Agreement to cause it to comply with Code Section 409A or be exempt from Code Section 409A.

    Notwithstanding any provision of this Agreement to the contrary, in the event that any settlement or payment of this Award occurs as a result of your termination of employment and the Company determines that you are a “specified employee” (as that term is defined under Code Section 409A) subject to Code Section 409A at the time your termination of employment, and provided further that such payment or settlement does not otherwise qualify for an applicable exemption from Code Section 409A, then no such settlement or payment shall be paid to you until the date that is the earlier to occur of: (i) your death, or (ii) six (6) months and one (1) day following your termination of employment. Any portion of this Award delayed as a result of the preceding sentence, which is (i) in whole or in part, settled in cash and (ii) based on the value of shares of Stock, shall be based on the value of the shares of Stock at the time the Award would have otherwise been settled or paid without application of the delay described in the preceding sentence. If this Award does not otherwise qualify for an applicable exemption from Code Section 409A, the terms “Retirement”, “terminate,” “termination,” “termination of employment,” and variations thereof as used in this agreement, are intended to mean a termination of employment that constitutes a “separation from service” as such term is defined under Code Section 409A. Notwithstanding any action or inaction by the Administrator, you are exclusively responsible for any tax consequences under Code Section 409A resulting from this Award.

    13.    Investment Intent. You acknowledge that the acquisition of the shares of Stock to be issued hereunder is for investment purposes without a view to distribution thereof.

    14.    Limits on Transferability; Restrictions on Shares; Legend on Certificate. Until the eligibility conditions of this Award have been satisfied and shares of Stock have
-12.2022    5    ONSG Program


been issued in accordance with the terms of this Agreement or by action of the Committee, the Units awarded hereunder are not transferable and shall not be sold, transferred, assigned, pledged, gifted, hypothecated or otherwise disposed of or encumbered by you. Transfers of shares of Stock by you are subject to the Company’s Stock Trading Policy and applicable securities laws. Shares of Stock issued to you in certificate form or to your book entry account upon satisfaction of the vesting and other conditions of this Award may be restricted from transfer or sale by the Company and evidenced by stop-transfer instructions upon your book entry account or restricted legend(s) affixed to certificates in the form as the Company or its counsel may require with respect to any applicable restrictions on sale or transfer.

    15.    Award Subject to the Plan and the Program. The Award to be made pursuant to this Agreement is made subject to the Plan and the Program. The terms and provisions of the Plan and the Program, as each may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan or the Program, the applicable terms and conditions of the Plan or Program will govern and prevail. However, no amendment of the Program after the grant date may materially and adversely impair a participant's rights under awards made pursuant to the Program without the participant's consent unless the amendment is necessary or desirable to facilitate compliance with applicable law, as determined in the sole discretion of the Committee.

    16.    No Rights to Continued Employment. The Company’s intent to issue the shares of Stock hereunder shall not confer upon you any right to continued employment or other association with the Company or any of its Affiliates or subsidiaries; and this Agreement shall not be construed in any way to limit the right of the Company or any of its subsidiaries or Affiliates to terminate your employment or other association with the Company or to change the terms of such employment or association at any time.

    17.    Legal Notices. Any legal notice necessary under this Agreement shall be addressed to the Company in care of its General Counsel at the principle executive offices of the Company and to you at the address appearing in the personnel records of the Company for you or to either party at such other address as either party may designate in writing to the other. Any such notice shall be deemed effective upon receipt thereof by the addressee.

    18.    Appendix. Notwithstanding any provision of this Agreement to the contrary, the Units shall be subject to any special terms and conditions for your country of residence (and country of employment, if different) as are forth in the applicable appendix to the Agreement (the “Appendix”). Further, if you transfer your residence and/or employment to another country reflected in the Appendices to these Agreements, the special terms and conditions for such country will apply to you to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate your transfer). Any applicable Appendix shall constitute part of this Agreement.

    19.    Governing Law and Venue. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of The Commonwealth of Massachusetts (without regard to the conflict of laws principles thereof) and applicable federal laws. For purposes of litigating any dispute that arises directly or indirectly from
-12.2022    6    ONSG Program


the relationship of the parties evidenced by this Agreement, the parties hereby submit and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and agree that such litigation shall be conducted only in the Commonwealth of Massachusetts, or the federal courts for the United States for the District of Massachusetts, and no other courts, where this Award is made and/or to be performed.

    20.    Headings. The headings contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of this Agreement.

    21.    Severability. You agree that the provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

    22.    Waiver. You understand that the waiver by the Company with respect to your compliance of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of a provision of this Agreement.    

23.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to the one and the same instrument.
[remainder of page intentionally left blank]
-12.2022    7    ONSG Program


APPENDIX A

PLAN: AMENDED AND RESTATED 2011 LONG-TERM INCENTIVE PLAN


The Performance Share Units will pay out in shares of Stock in a range of 0% to 200% of the number of Performance Share Units as follows:

ONSG* Performance
To Plan
Performance Share Units
as a Percent of Target
138.5%200%
100%100%
61.5%50%
<61.5%0%
Linear interpolation between points


*Organic Net Sales Growth
-12.2022        ONSG Program


APPENDIX B

This Appendix B contains supplemental terms and conditions for awards of Units granted under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the “Plan”) to Participants who reside outside the United States or who are otherwise subject to the laws of a country other than the United States. Capitalized terms used but not defined herein shall have the same meanings ascribed to them in the Agreement.

Section I of this Appendix B contains special terms and conditions that govern the Units outside of the United States. Section II of this Appendix B includes special terms and conditions in the specific countries listed therein.

This Appendix B may also include information regarding exchange controls, taxation of awards and certain other issues of which you should be aware with respect to participation in the Plan. The information is based on the securities, exchange control, tax and other laws concerning the Units in effect as of December 2022. Such laws are often complex and change frequently; the information may be out of date at the time you vest in the Units or sell shares of Stock acquired under the Plan. As a result, the Company strongly recommends that you not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan.

In addition, this Appendix B is general in nature, does not discuss all of the various laws, rules and regulations which may apply to your particular situation and the Company does not assure you of any particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country apply to your specific situation.

Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transferred employment after the Award was granted or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to you in the same manner. In addition, the Company shall, in its sole discretion, determine to what extent the terms and conditions contained herein will apply under these circumstances (or the Company may establish alternative terms and conditions as may be necessary or advisable).

Section I.     All Countries Outside the United States

Nature of Grant. In accepting the grant, you acknowledge that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Administrator at any time, to the extent permitted by the Plan;

(b)the grant of the Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants or benefits in lieu of Units, even if Units have been granted in the past;

(c)all decisions with respect to future grants of Units, if any, will be at the sole discretion of the Administrator;

(d)the grant of the Units and your participation in the Plan shall not create a right to employment or be interpreted as forming an employment or service contract with
-12.2022        ONSG Program


the Company, the Employer or Affiliate and shall not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate your employment or service relationship (if any);

(e)you are voluntarily participating in the Plan;

(f)the Units are not intended to replace any pension rights or compensation;

(g)the Units, the underlying shares of Stock, and the income and value of same are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments;

(h)the future value of the underlying shares of Stock is unknown, indeterminable and cannot be predicted with certainty;

(i)no claim or entitlement to compensation or damages shall arise from forfeiture of the Units resulting from the termination of your employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);

(j)unless otherwise agreed with the Company in writing, the Units, the underlying shares of Stock and the income from and value of same are not granted as consideration for, or in connection with, any service you may provide as a director of an Affiliate;

(k)for purposes of the Units, your employment or other service relationship will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Units under this Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Committee shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of the Unit grant (including whether you may still be considered to be providing services while on an approved leave of absence); and

(l)the following provisions apply only if you are providing services outside the United States: (A) the Units, the underlying shares of Stock, and the income from and value of same are not part of normal or expected compensation or salary for any purpose; and (B) neither the Company, the Employer nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Units or of any amount due to you pursuant to the settlement of the Units or the subsequent sale of any shares of Stock acquired upon settlement.

Electronic Delivery of Documents. The Company may, in its sole discretion, decide to deliver any documents related to the Units granted under and participation in the Plan or future Units that may be granted under the Plan by electronic means or to request your
-12.2022        ONSG Program


consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

Language. You hereby acknowledge and agree that it is your express intent that this Agreement and any applicable Appendix, the Plan and all other documents, notices and legal proceedings entered into, given or instituted pursuant to the Units, be drawn up in English. You acknowledge that you are proficient in the English language and understand the terms of this Agreement or have had the ability to consult with an advisor who is sufficiently proficient in the English language. If you have received this Agreement and any applicable Appendix, the Plan or any other documents related to the Units translated into a language other than English, and if the meaning of the translated version is different than the English version, the English version will control.

Insider Trading Restrictions/Market Abuse Laws. You acknowledge that, depending on your or your broker’s country of residence or where the shares of Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws that may affect your ability to accept, acquire, sell or otherwise dispose of shares of Stock, rights to those shares of Stock (e.g., Units) or rights linked to the value of shares (e.g., phantom awards, futures) during such times you are considered to have “inside information” regarding the Company, as defined in the laws or regulations in your country. Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed insider information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any restrictions and are advised to speak to your personal advisor on this matter.
 
Section II.     Country-Specific Terms and Conditions

COUNTRIES OUTSIDE THE EUROPEAN UNION (“EU”) / EUROPEAN ECONOMIC AREA (“EEA”), UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you do not reside and/or are not employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other Unit grant materials by and among, as applicable, the Employer, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan.

You understand that the Company and the Employer may hold certain personal information about you, including (but not limited to) your name, home address, email address and telephone number, date of birth, social insurance, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of Stock or directorships held in the Company, and details of all Units awarded to you or any other entitlements to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor (“Data”) for the purpose of implementing, managing and administering the Plan.
-12.2022        ONSG Program



You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan, including but not limited to E*TRADE Securities LLC (“E*TRADE”) or any successor or any other third party that the Company or E*TRADE (or its successor) may engage to assist with the administration of the Plan from time to time. You understand the recipients of the Data may be located in your country, in the United States or elsewhere, and that the recipients’ country may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative.

You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom you may elect to deposit any shares of Stock acquired upon vesting of the Units. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later revoke your consent, your employment status or service with the Employer will not be adversely affected; the only consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.

COUNTRIES WITHIN THE EU / EEA, UNITED KINGDOM AND SWITZERLAND

Data Privacy: If you reside and/or are employed in the EU / EEA, the United Kingdom or Switzerland, the following provision applies:

Pursuant to applicable personal data protection laws, the Company and the Employer hereby notify you of the following in relation to your Personal Data (defined below) and the collection, processing and transfer in electronic or other form of such Personal Data in relation to the grant of the Units and your participation in the Plan. The collection, processing and transfer of your Personal Data is necessary for the legitimate purpose of the Company and the Employer’s administration of the Plan and your participation in the Plan, and your denial and/or objection to the collection, processing and transfer of Personal Data may affect your participation in the Plan. As such, by accepting the Award, you acknowledge the collection, use, processing and transfer of Personal Data as described herein.

You understand that the Company and the Employer hold certain personally identifiable information about you, specifically, your name, home address and telephone number, date of birth, social security number or other employee
-12.2022        ONSG Program


identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all Units or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the purpose of managing and administering the Plan (“Personal Data”). The Personal Data may be provided by you to or collected, where lawful, from third parties. The Company or the Employer each act as controllers of the Personal Data and will process the Personal Data in this context for the exclusive legitimate purpose of implementing, administering and managing your participation in the Plan and meeting related legal obligations associated with these actions.

The processing will take place through electronic and non-electronic means according to logics and procedures correlated to the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by applicable laws and regulations. Personal Data will be accessible within the Company’s organization only by those persons requiring access for purposes of the implementation, administration and operation of the Plan and other aspects of the employment relationship and for participation in the Plan.

The Company and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your participation in the Plan, and the Company and the Employer may each further transfer Personal Data to third parties assisting the Company or the Employer in the implementation, administration and management of the Plan, including E*TRADE Securities LLC and its affiliates or any successor or other third party that the Company, the Employer or E*TRADE Securities LLC (or its successor) may engage to assist with the administration of the Plan from time to time. These recipients may be located in the EU, EEA, the United Kingdom, Switzerland or elsewhere throughout the world, such as the United States. By participating in the Plan, you understand that these recipients may receive, possess, use, retain and transfer the Personal Data, in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Personal Data as may be required for the administration of the Plan and/or the subsequent holding of shares of Stock on your behalf to a broker or other third party with whom you may elect to deposit any shares of Stock acquired pursuant to the Plan. You further understand that you may request a list with the names and addresses of any potential recipients of your Personal Data by contacting your local Human Resources manager or the Company’s Human Resources Department. When transferring Personal Data to these potential recipients, the Company and the Employer provide appropriate safeguards in accordance with EU Standard Contractual Clauses or other legally binding and permissible arrangements. You may request a copy of such safeguards from your local human resources manager or the Company’s Human Resources Department.

To the extent provided by law, you may, at any time, have the right to request: access to Personal Data, rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of Personal Data. You may also have the right to object, on grounds related to a particular situation, to the processing of Personal Data, as well as opt-out of the Plan herein, in any case without cost, by contacting in writing your Human Resources manager. Your provision of Personal Data is a contractual requirement. You understand, however, that the only consequence of refusing to provide Personal Data is that the Company may not be able to grant the Units to you, or grant other equity awards or administer or maintain such equity awards. For more information on the consequences of your refusal to provide
-12.2022        ONSG Program


Personal Data, you understand that you may contact your local human resources manager or the Company’s Human Resources Department.

When the Company and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems and/or records containing the Personal Data and/or take steps to properly anonymize it so that you can longer be identified from it.

FRANCE

Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1 and seq. or L. 22-10-59 and L. 22-10-60 of the French commercial code, as amended.

Use of English Language. You acknowledge and agree that it is your express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English. Vous reconnaissez et consentez que c’est votre souhait exprès qui cet accord, de meme que tous documents, toutes notifications et tous procédés légaux est entré dans, donné ou instituté conformément ci-annexé ou relatant directement ou indirectement ci-annexé, est formulé dans l’anglais.


*    *    *    *    *
406684311-v4\NA_DMS
-12.2022        ONSG Program
EX-22 6 exhibit22-subsidiaryissuer.htm EX-22 Document

EXHIBIT 22
 
 
Subsidiary Issuer of Guaranteed Securities

Boston Scientific (the “Registrant”) is the guarantor of the senior unsecured registered notes listed below issued by American Medical Systems Europe B.V., a wholly-owned finance subsidiary of the Registrant.

American Medical Systems Europe B.V.:

0.750% Senior Notes due 2025
1.375% Senior Notes due 2028
1.625% Senior Notes due 2031
1.875% Senior Notes due 2034 


EX-31.1 7 exhibit311-ceo302q12023.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:
1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:May 4, 2023 /s/ Michael F. Mahoney
  Michael F. Mahoney
  Chief Executive Officer

EX-31.2 8 exhibit312-cfo302q12023.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
2Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:May 4, 2023 /s/ Daniel J. Brennan
  Daniel J. Brennan
  Executive Vice President and Chief Financial Officer

EX-32.1 9 exhibit321-ceo906q12023.htm EX-32.1 Document

EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.
   
By:/s/ Michael F. Mahoney
 Michael F. Mahoney 
 Chief Executive Officer 
   
 May 4, 2023 
 


EX-32.2 10 exhibit322-cfo906q12023.htm EX-32.2 Document

EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 (1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

   
By:/s/ Daniel J. Brennan
 Daniel J. Brennan 
 Executive Vice President and Chief Financial Officer 
   
 May 4, 2023 

EX-101.SCH 11 bsx-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows (Supplemental Disclosure) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions, Divestitures and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Contractual Obligations and Commitments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Basis of Presentation Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Contractual Obligations and Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Acquisitions and Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Hedging Activities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Contractual Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Changes in Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 bsx-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 bsx-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 bsx-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Deferred tax assets Deferred Income Tax Assets, Net ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block] ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Entity Address, Postal Zip Code Entity Address, Postal Zip Code the Offering the Offering - aggregate principal amount [Member] the Offering - aggregate principal amount Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow [Member] Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Net proceeds from issuance of preferred stock in connection with public offering Proceeds from Issuance of Convertible Preferred Stock Debt Instrument [Axis] Debt Instrument [Axis] Watchman Watchman [Member] Watchman Property, plant and equipment Property, Plant and Equipment, Gross Preferred Stock, Dividend Rate, Percentage Preferred Stock, Dividend Rate, Percentage Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Inventories Inventory, Net [Abstract] Utilization of allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Financial Instruments [Domain] Financial Instruments [Domain] the 2018 Facility [Member] the 2018 Facility [Domain] the 2018 Facility Proceeds from royalty rights Payments for (Proceeds from) Other Investing Activities Range [Domain] Statistical Measurement [Domain] Depreciation Depreciation expense Depreciation Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Derivative Instruments, Gain (Loss) [Table Text Block] Derivative Instruments, Gain (Loss) [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets [Abstract] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Qualified Acquisition Consideration Qualified Acquisition Consideration Qualified Acquisition Consideration Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2021 Revolving Credit Facility Revolving Credit Facility 2021 [Member] Revolving Credit Facility 2021 MedSurg [Member] MedSurg [Member] MedSurg [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Other Intangible Assets [Member] Other Intangible Assets [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Equity Component [Domain] Equity Component [Domain] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Interest Expense [Member] Interest Expense [Member] Statement, Scenario [Axis] Scenario [Axis] Assets, Fair Value Disclosure Assets, Fair Value Disclosure Ownership [Axis] Ownership [Axis] Number of Interest Rate Derivatives Held Number of Interest Rate Derivatives Held Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Total debt Debt and Lease Obligation Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Business Acquisition, Share Price Business Acquisition, Share Price Hedging Designation [Domain] Hedging Designation [Domain] Licensing arrangements Licensing arrangements Licensing arrangements Supplemental Information Supplemental Cash Flow Information [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Finance Lease Obligation Capital Lease Obligations [Member] Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] Other Current Liabilities [Table Text Block] Other Current Liabilities [Table Text Block] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Urology [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Peripheral Interventions [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Derivative Asset Derivative Asset In Process Research and Development [Member] In Process Research and Development [Member] In Process Research and Development [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Apollo Apollo [Member] Apollo Lender Name [Axis] Lender Name [Axis] Geographical [Axis] Geographical [Axis] Covenant [Axis] Covenant [Axis] Covenant. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Corporate expenses and currency exchange [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] Dividends, Preferred Stock, Cash Dividends, Preferred Stock, Cash Revolving Credit Facility [Member] Revolving Credit Facility [Member] Property, plant and equipment, net [Table Text Block] Property, Plant and Equipment [Table Text Block] Interventional Cardiology Therapies Interventional Cardiology Therapies [Member] Interventional Cardiology Therapies New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued Document Type Document Type Derivative, Remaining Maturity Derivative, Remaining Maturity Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Litigation payment exclusion from EBITDA Segments [Axis] Statement, Business Segments [Axis] Segments [Axis] CONTRACTUAL OBLIGATIONS AND COMMITMENTS Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Entity Shell Company Entity Shell Company Investments [Abstract] Investments [Abstract] Number Of Businesses Number Of Businesses Number Of Businesses Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Financial Instrument [Axis] Financial Instrument [Axis] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Inventory step-up amortization Inventory step up amortization Inventory step up amortization Subsequent Event [Member] Subsequent Event [Member] Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Document Period End Date Document Period End Date contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Changes in Other Comprehensive Income [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] TOTAL ASSETS Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Indemnification asset Indemnification asset Indemnification asset Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Equity Securities, FV-NI Equity Securities, FV-NI, Current Shares, Issued Ending Balance (Shares Issued) Shares, Issued Accrued expenses Accrued Liabilities, Current Accrued Liabilities, Current Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share Covenant [Domain] Covenant [Domain] Covenant. Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Cardiology [Member] Global Cardiology Reporting Unit [Member] Global Cardiology Reporting Unit [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Stockholders' Equity Note [Abstract] Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Payroll and related liabilities Employee-related Liabilities, Current Line of Credit Line of Credit [Member] Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Other current assets Prepaid Expense and Other Assets, Current Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Segments [Domain] Segment [Domain] Segments [Domain] Schedule of Intangible Assets and Goodwill [Table] Schedule of Goodwill [Table] Weighted Average Number Of Shares Outstanding [Text Block] Earnings Per Share [Text Block] Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Preferred Stock, Dividends Per Share, Declared Preferred Stock, Dividends Per Share, Declared Schedule of Short-term Debt [Table Text Block] Schedule of Short-Term Debt [Table Text Block] Goodwill, Gross Goodwill, Gross Schedule of Investments [Line Items] Schedule of Investments [Line Items] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Buildings and improvements Buildings and Improvements, Gross Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans Proceeds from Stock Plans Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Derivative Contract [Domain] Derivative Contract [Domain] Net Investment Hedging [Member] Net Investment Hedging [Member] Gross profit Gross Profit foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] Entity Registrant Name Entity Registrant Name Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Estimated Litigation Liability, Noncurrent Estimated Litigation Liability, Noncurrent Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Patents [Member] Patents [Member] Customer Relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town EMEA [Member] EMEA [Member] Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Brazil CADE - # of individuals for alleged anti-competitive behavior Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Operating expenses: Operating Expenses [Abstract] Total equity Total stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest June 2030 Notes [Member] June 2030 Notes [Member] June 2030 Notes Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Minimum [Member] Minimum [Member] Minimum [Member] Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents in Other current assets Restricted Cash and Cash Equivalents, Current Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Intangible Assets and Goodwill [Line Items] Intangible Assets and Goodwill [Line Items] [Line Items] for Schedule of Intangible Assets and Goodwill [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Treasury Stock, Common Treasury Stock, Common [Member] Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Other, Other Long-term Assets Other, Other Long-term Assets Other, Other Long-term Assets Goodwill [Member] Goodwill [Member] Treasury Stock, Common, Shares Treasury Stock, Common, Shares Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Deferred Revenue, Current Deferred Revenue, Current Subsequent Events, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Entity Information [Line Items] Entity Information [Line Items] Effective tax rate from continuing operations Effective Income Tax Rate Reconciliation, Percent Payments for royalty rights Payments for royalty rights Payments for royalty rights ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Other income (expense): Other Nonoperating Income (Expense) [Abstract] Neuromodulation [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities INCOME TAXES Income Tax Disclosure [Text Block] Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract] Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract] Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract] Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Amortization expense Amortization expense Amortization of Intangible Assets Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Net income (loss) per common share — basic Earnings Per Share, Basic Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Capital in progress Construction in Progress, Gross Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements [Member] Renminbi Denominated Factoring Arrangements Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets [Axis] Total stockholders’ equity Total stockholders’ equity Stockholders' Equity Attributable to Parent Ownership [Domain] Ownership [Domain] Segment operating income as percentage of net sales Segment operating income as percentage of net sales Segment operating income as percentage of net sales Payments for Royalties Payments for Royalties Payments for Royalties Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Cash dividends paid on preferred stock Payments of Dividends Retained Earnings [Member] Retained Earnings [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Litigation Status [Domain] Litigation Status [Domain] Common Stock [Member] Common Stock [Member] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Number of reportable segments Number of Reportable Segments Commercial Paper Commercial Paper Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Beginning Balance Business Combination, Contingent Consideration, Liability Ending Balance Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Entity [Abstract] Entity [Abstract] Entity [Abstract] Statement [Table] Statement [Table] Document Quarterly Report Document Quarterly Report the Offering - early redemption of combined aggregate principal SN the Offering - early redemption of combined aggregate principal SN [Member] the Offering - early redemption of combined aggregate principal SN Current assets: Assets, Current [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Range [Axis] Statistical Measurement [Axis] Payment of contingent consideration previously established in purchase accounting Payment for Contingent Consideration Liability, Financing Activities Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Baylis Medical Baylis Medical [Member] Baylis Medical Accumulated deficit Retained Earnings (Accumulated Deficit) Disposal Group Name [Axis] Disposal Group Name [Axis] Statement, Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Scenario, Unspecified [Domain] Scenario [Domain] ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block] ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Non-cash impact of transferred royalty rights Document Fiscal Year Focus Document Fiscal Year Focus Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Proceeds from (payments for) investments and acquisitions of certain technologies Statement [Line Items] Statement [Line Items] Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Other expense, net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative expenses Selling, General and Administrative Expense Deferred Revenue Deferred Revenue Loss Contingencies [Table] Loss Contingencies [Table] Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest Contingent consideration net expense (benefit) Contingent consideration net expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Accrued Royalties, Current Accrued Royalties, Current Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Impact of Foreign Currency Fluctuations on Net Sales Document Transition Report Document Transition Report Local Phone Number Local Phone Number BSX Reportable Segments [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] Operating income (loss) Operating income (loss) Operating Income (Loss) Debt Instrument, Extension Option, Term Debt Instrument, Extension Option, Term Debt Instrument, Extension Option, Term Inventories Increase (Decrease) in Inventories Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Litigation Status [Axis] Litigation Status [Axis] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] Measurement alternative investments(1, 2) Equity Securities without Readily Determinable Fair Value, Amount ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block] ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) Goodwill Goodwill Beginning Balance Goodwill Ending Balance Goodwill Other Current Liabilities [Member] Other Current Liabilities [Member] Transfer of Financial Assets Accounted for as Sales [Table Text Block] Transfer of Financial Assets Accounted for as Sales [Table Text Block] Prepaid income taxes Prepaid Taxes Financial and Nonfinancial Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Income tax expense (benefit) Income Tax Expense (Benefit) Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Geographical [Domain] Geographical [Domain] Deferred income taxes Deferred Income Tax Liabilities, Net Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] All Business Acquisitions All Business Acquisitions [Member] All Business Acquisitions Document Fiscal Period Focus Document Fiscal Period Focus Cost of products sold Cost of Goods and Services Sold Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative Liability Derivative Liability Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Requirement, seventh quarter following qualified acquisition Requirement, seventh quarter following qualified acquisition [Member] Requirement, seventh quarter following qualified acquisition Inventory Disclosure [Table Text Block] Schedule of Inventory, Current [Table Text Block] Derivative Liability, Fair Value, Gross Liability Derivative Liability, Subject to Master Netting Arrangement, before Offset Requirement, four succeeding quarters following qualified acquisition Requirement, four succeeding quarters following qualified acquisition [Member] Requirement, four succeeding quarters following qualified acquisition Loss Contingencies [Line Items] Loss Contingencies [Line Items] Investments Investments Investments Supplemental Balance Sheet Information Supplemental Balance Sheet Information (Textuals) [Abstract] Supplemental Balance Sheet Information. statement [Axis] statement [Axis] statement [Axis] Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 2022 Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Preferred Stock Preferred Stock [Member] Senior Notes [Member] Senior Notes [Member] Other Operating Income (Expense), Net Other Operating Income (Expense), Net APAC [Member] Asia Pacific [Member] Short-term Debt [Line Items] Short-Term Debt [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cardiac Rhythm Management [Member] Cardiac Rhythm Management [Member] Cardiac Rhythm Management Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Stock-based compensation Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Current liabilities: Liabilities, Current [Abstract] Foreign Exchange Forward Foreign Exchange Forward [Member] Proceeds from Royalties Received Proceeds from Royalties Received Proceeds from Royalties Received Common Stock, Shares, Issued Common Stock, Shares, Issued Equity method investments Equity Method Investments Schedule of Income Tax Rate Reconciliation [Line Items] Schedule of Income Tax Rate Reconciliation [Line Items] [Line Items] for Schedule of Income Tax Rate Reconciliation [Table] Foreign Currency Transaction Gain (Loss), before Tax Foreign Currency Transaction Gain (Loss), before Tax Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] Amendment Flag Amendment Flag Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities March 2028 Senior Notes March 2028 Senior Notes [Member] March 2028 Senior Notes Other comprehensive income (loss) Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Preferred Stock, Dividends, Per Share, Cash Paid Preferred Stock, Dividends, Per Share, Cash Paid Goodwill, Acquired During Period Goodwill, Acquired During Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Entity Current Reporting Status Entity Current Reporting Status Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other current liabilities Other Liabilities, Current Other Liabilities, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other long-term assets Other Assets, Noncurrent Other Assets, Noncurrent Net income (loss) attributable to Boston Scientific common stockholders Net income (loss) attributable to Boston Scientific common stockholders Net income (loss) attributable to Boston Scientific common stockholders Requirement, as of December 31, 2021 and through remaining term of facility Requirement, as of December 31, 2021 and through remaining term of facility [Member] Requirement, as of December 31, 2021 and through remaining term of facility Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Goodwill, Translation and Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Senior Long-Term Debt Proceeds from Issuance of Senior Long-Term Debt Charges to expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Requirement, sixth quarter following qualified acquisition Requirement, sixth quarter following qualified acquisition [Member] Requirement, sixth quarter following qualified acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Legal reserves, current Estimated Litigation Liability, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Entities [Table] Entities [Table] Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022 Treasury Stock, Value Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Net change in defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Contract with Customer, Liability [Abstract] Contract with Customer, Liability [Abstract] Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Long-term Debt Long-Term Debt Other, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Licensing arrangement assets [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Common Stock, Shares Authorized Common Stock, Shares Authorized Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Operating expenses Operating Expenses Maximum [Member] Maximum [Member] Maximum [Member] Accumulated other comprehensive income (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Business Acquisitions, by Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Derivatives Not Designated as Hedging Instruments [Table Text Block] Derivatives Not Designated as Hedging Instruments [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Taxes Payable, Current Taxes Payable, Current Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Business Acquisition [Line Items] Business Acquisition [Line Items] Noncontrolling Interest, Period Increase (Decrease) Noncontrolling Interest, Period Increase (Decrease) Entity Small Business Entity Small Business Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] December 2027 Notes [Member] December 2027 Notes [Member] December 2027 Notes [Member] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] Other long-term liabilities [Table Text Block] Other Noncurrent Liabilities [Table Text Block] Trade accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Special Charges [Member] Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Line Items] Class of Stock [Line Items] New Accounting Pronouncements, Policy New Accounting Pronouncements, Policy [Text Block] New Accounting Pronouncements, Policy Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Land Land Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount June 2025 Notes [Member] June 2025 Notes [Member] June 2025 Notes Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Stock issuance (Par value) Stockholders' Equity, Period Increase (Decrease) LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Proceeds from Issuance of Senior Long-Term Debt Cash proceeds from Issuance of Senior Long Term Debt Cash proceeds from Issuance of Senior Long Term Debt Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories Inventories Inventory, Net Accounts payable Accounts Payable, Current Restructuring net charges (credits) Restructuring Charges Other assets Increase (Decrease) in Other Operating Assets Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Acotec Acotec [Member] Acotec Entity Filer Category Entity Filer Category Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Litigation and Debt Exclusion from EBITDA Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments United States UNITED STATES March 2031 Notes March 2031 Notes [Member] March 2031 Notes Accrual for legal matters that are probable and estimable Loss Contingency Accrual Accrued expenses Accrued Liabilities, Current [Abstract] Commitments and contingencies Commitments and Contingencies Investment [Table Text Block] Investment Holdings, Schedule of Investments [Table Text Block] Security Exchange Name Security Exchange Name Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Derivative, Notional Amount Derivative, Notional Amount Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Electrophysiology [Member] Electrophysiology (EP) [Member] Electrophysiology (EP) Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Current debt obligations Debt, Current Debt, Current Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Business Combination, Contingent Consideration Arrangements [Abstract] Business Combination, Contingent Consideration Arrangements [Abstract] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option statement [Domain] statement [Domain] [Domain] for statement [Axis] Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Business Combinations [Abstract] Business Combinations [Abstract] Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Schedule of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Royalty expense Royalty Expense Derivative Asset, Current Derivative Asset, Current TOTAL LIABILITIES AND EQUITY Liabilities and Equity Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Cash Cash International [Member] Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block] ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Class of Stock Disclosures [Abstract] Class of Stock Disclosures [Abstract] Payments for acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Current Fiscal Year End Date Current Fiscal Year End Date Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net income (loss) per common share — diluted Earnings Per Share, Diluted Endoscopy [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Requirement, eighth quarter following qualified acquisition and through remaining term of facility Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member] Requirement, eighth quarter following qualified acquisition and through remaining term of facility Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] Schedule of Other Assets [Table Text Block] Schedule of Other Assets [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Total current liabilities Liabilities, Current Other Assets, Current Other Assets, Current Trade accounts receivable, net [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Accrued income taxes Accrued Income Taxes, Noncurrent Other Sundry Liabilities, Current Other Sundry Liabilities, Current Unrecognized Tax Benefits Unrecognized Tax Benefits Preferred stock dividends Dividends, Preferred Stock, Stock Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Derivative Asset, Fair Value, Gross Asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Entity Address, Address Line One Entity Address, Address Line One Stock-based compensation (Shares) Stock Issued During Period, Shares, Period Increase (Decrease) Contract with Customer, Liability Contract with Customer, Liability Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Current Requirement [Member] Current Requirement [Member] Current Requirement. Credit Facility [Axis] Credit Facility [Axis] Long-term debt Long-term Debt and Capital Lease Obligations Long-Term Debt and Lease Obligation Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-Term Debt Instruments [Table Text Block] Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents in Other long-term assets Restricted Cash Equivalents, Noncurrent Other, net Other, net Other, net Entity Tax Identification Number Entity Tax Identification Number Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Schedule of Investments [Table] Schedule of Investments [Table] March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Schedule of Short-term Debt [Table] Schedule of Short-Term Debt [Table] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract] Other Assets, Miscellaneous, Current Other Assets, Miscellaneous, Current Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number of Shares Outstanding, Diluted, Adjustment 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A [Member] 5.50% MCPS, Series A Commercial Paper [Member] Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other Other Accrued Liabilities, Current Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax City Area Code City Area Code ASSETS Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Payments on short-term borrowings Repayments of Short-Term Debt Stock-based compensation expense Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Preferred Stock, Liquidation Preference, Value Preferred Stock, Liquidation Preference, Value Variable Rate [Axis] Variable Rate [Axis] Payments on long-term borrowings and debt extinguishment costs Repayments of Senior Debt Other long-term liabilities Other long-term liabilities Other Liabilities, Noncurrent March 2025 Notes March 2025 Notes [Member] March 2025 Notes Interest Rate Contract [Member] Interest Rate Contract [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Purchases of property, plant and equipment and internal use software Payments to Acquire Property, Plant, and Equipment Trade accounts receivable, net Trade accounts receivable, net Accounts and Financing Receivable, after Allowance for Credit Loss, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Derivative, Term of Contract (less than) Derivative, Term of Contract Weighted Average [Member] Weighted Average [Member] March 2034 Notes March 2034 Notes [Member] March 2034 Notes Cost of Sales [Member] Cost of Sales [Member] Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract] Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] Supplier Finance Program Obligation. current Supplier Finance Program Obligation. current Supplier Finance Program Obligation. current Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] EX-101.PRE 15 bsx-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_0.jpg begin 644 image_0.jpg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�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image_1.jpg begin 644 image_1.jpg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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Document - $ / shares
3 Months Ended
Mar. 31, 2023
Apr. 28, 2023
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 1-11083  
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-2695240  
Entity Address, Address Line One 300 Boston Scientific Way  
Entity Address, City or Town Marlborough  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01752-1234  
City Area Code 508  
Local Phone Number 683-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Listing, Par Value Per Share $ 0.01  
Entity Common Stock, Shares Outstanding   1,437,698,101
Entity Central Index Key 0000885725  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock [Member]    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol BSX  
Security Exchange Name NYSE  
Senior Note due 2027 [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 0.625% Senior Notes due 2027  
Trading Symbol BSX27  
Security Exchange Name NYSE  
5.50% MCPS, Series A [Member]    
Entity Information [Line Items]    
Title of 12(b) Security 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share  
Trading Symbol BSX PR A  
Security Exchange Name NYSE  
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net sales $ 3,389 $ 3,026
Cost of products sold 1,040 955
Gross profit 2,349 2,071
Operating expenses:    
Selling, general and administrative expenses 1,215 1,060
Research and development expenses 337 319
Royalty expense 11 12
Amortization expense 203 198
Contingent consideration net expense (benefit) 12 12
Restructuring net charges (credits) 20 4
Operating expenses 1,797 1,605
Operating income (loss) 552 466
Other income (expense):    
Interest expense (65) (279)
Other, net (43) (31)
Income (loss) before income taxes 444 156
Income tax expense (benefit) 131 45
Net income (loss) 314 110
Preferred stock dividends (14) (14)
Net income (loss) attributable to noncontrolling interests 0 0
Net income (loss) attributable to Boston Scientific common stockholders $ 300 $ 97
Net income (loss) per common share — basic $ 0.21 $ 0.07
Net income (loss) per common share — diluted $ 0.21 $ 0.07
Weighted-average shares outstanding    
Basic 1,435.8 1,427.8
Diluted 1,446.0 1,438.4
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net income (loss) $ 314 $ 110
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment (42) (64)
Net change in derivative financial instruments (43) 23
Net change in defined benefit pensions and other items (5) 0
Other comprehensive income (loss) (91) (41)
Comprehensive income (loss) 223 69
Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest 0 0
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $ 223 $ 69
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 570 $ 928
Trade accounts receivable, net 2,076 1,970
Inventories 2,050 1,867
Prepaid income taxes 296 264
Other current assets 711 731
Total current assets 5,704 5,760
Property, plant and equipment, net 2,478 2,446
Goodwill 13,269 12,920
Other intangible assets, net 6,060 5,902
Deferred tax assets 3,900 3,942
Other long-term assets 1,482 1,500
TOTAL ASSETS 32,892 32,469
Current liabilities:    
Current debt obligations 510 20
Accounts payable 868 862
Accrued expenses 1,918 2,160
Other current liabilities 787 761
Total current liabilities 4,083 3,803
Long-term debt 8,495 8,915
Deferred income taxes 210 144
Other long-term liabilities 1,995 2,035
Commitments and contingencies
Stockholders’ equity    
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 2022 0 0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 2022 17 17
Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022 (2,251) (2,251)
Additional paid-in capital 20,356 20,289
Accumulated deficit (450) (750)
Accumulated other comprehensive income (loss), net of tax 178 269
Total stockholders’ equity 17,850 17,573
Noncontrolling interests 259 0
Total equity 18,109 17,573
TOTAL LIABILITIES AND EQUITY $ 32,892 $ 32,469
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 10,062,500 10,062,500
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,700,828,873 1,696,633,993
Treasury Stock, Common, Shares 263,289,848 263,289,848
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
Preferred Stock
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Noncontrolling Interest
Treasury Stock, Common
Shares, Issued at Dec. 31, 2021   10,062,500 1,688,810,052          
Total stockholders' equity at Dec. 31, 2021   $ 0 $ 17 $ 19,986 $ (1,392) $ 263 $ 0 $ (2,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) attributable to noncontrolling interests $ 0           0  
Noncontrolling Interest, Period Increase (Decrease)             0  
Stock issuance (Par value)   $ 0 $ 0          
Stock-based compensation (Shares)     4,018,935          
Treasury Stock, Value, Acquired, Cost Method               0
Stock-based compensation     $ 0 57        
Ending Balance (Shares Issued) at Mar. 31, 2022   10,062,500            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock Issued During Period, Shares, New Issues   0 0          
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2022 16,735 $ 0 $ 17 20,043 (1,296) 222 0 (2,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 110       110      
Dividends, Preferred Stock, Cash         (14)      
Total other comprehensive income (loss) (41)         (41) 0  
Total stockholders’ equity $ 16,735              
Common Stock, Shares, Issued 1,692,828,987              
Total stockholders’ equity $ 17,573              
Common Stock, Shares, Issued 1,696,633,993              
Shares, Issued at Dec. 31, 2022   10,062,500 1,696,633,993          
Total stockholders' equity at Dec. 31, 2022 $ 17,573 $ 0 $ 17 20,289 (750) 269 0 (2,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) attributable to noncontrolling interests 0           0  
Noncontrolling Interest, Period Increase (Decrease)             259  
Stock issuance (Par value)   $ 0 $ 0          
Stock-based compensation (Shares)     4,194,880          
Treasury Stock, Value, Acquired, Cost Method               0
Stock-based compensation     $ 0 68        
Ending Balance (Shares Issued) at Mar. 31, 2023   10,062,500            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock Issued During Period, Shares, New Issues   0 0          
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2023 18,109 $ 0 $ 17 $ 20,356 (450) 178 259 $ (2,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 314       314      
Dividends, Preferred Stock, Cash         $ (14)      
Total other comprehensive income (loss) (91)         $ (91) $ 0  
Total stockholders’ equity $ 17,850              
Common Stock, Shares, Issued 1,700,828,873              
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash provided by (used for) operating activities    
Net income (loss) $ 314 $ 110
Depreciation and amortization 285 274
Deferred and prepaid income taxes 19 (75)
Stock-based compensation expense 55 52
Net loss (gain) on investments and notes receivable 31 20
Contingent consideration net expense (benefit) 12 12
Inventory step-up amortization 0 17
Gain (Loss) on Extinguishment of Debt 0 194
Other, net (2) 19
Trade accounts receivable (86) (66)
Inventories (185) (108)
Other assets (41) (140)
Accounts payable, accrued expenses and other liabilities (211) (368)
Cash provided by (used for) operating activities 190 (58)
Investing activities:    
Purchases of property, plant and equipment and internal use software (111) (121)
Proceeds from sale of property, plant and equipment 3 8
Payments for acquisitions of businesses, net of cash acquired (375) (1,471)
Proceeds from royalty rights 9 19
Proceeds from (payments for) investments and acquisitions of certain technologies (10) (10)
Cash provided by (used for) investing activities (484) (1,574)
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (34) (20)
Payments for royalty rights (34) (39)
Payments on short-term borrowings 0 (250)
Net increase (decrease) in commercial paper 0 223
Payments on long-term borrowings and debt extinguishment costs 0 (3,184)
Proceeds from long-term borrowings, net of debt issuance costs 0 3,271
Cash dividends paid on preferred stock (14) (14)
Cash used to net share settle employee equity awards (50) (46)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 63 52
Cash provided by (used for) financing activities (69) (6)
Effect of foreign exchange rates on cash 0 0
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (363) (1,639)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,126 2,168
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 763 529
Supplemental Information    
Stock-based compensation expense 55 52
Non-cash impact of transferred royalty rights $ (9) $ (19)
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Supplemental Disclosure) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Cash and cash equivalents $ 570 $ 928 $ 325  
Restricted cash and restricted cash equivalents included in Other current assets 135 149 146  
Restricted cash equivalents included in Other long-term assets 57 48 59  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 763 $ 1,126 $ 529 $ 2,168
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their financial statements on a one quarter lag. Accordingly, their results of operations for the period following the closing of the transaction on February 20, 2023 are omitted from the Company’s unaudited consolidated statements of operations for the quarter ended March 31, 2023.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies and Note I – Stockholders' Equity for further details.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions, Divestitures and Strategic Investments
3 Months Ended
Mar. 31, 2023
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

2023 Acquisitions

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement consisted of an upfront cash payment of $10.00 per share, or approximately $615 million. The Apollo business is being integrated into our Endoscopy division.

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.
Purchase Price Allocation

We accounted for the Acotec transaction as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase price was comprised of the amount presented below:

(in millions)
Payment for majority interest acquisition, net of cash acquired (1)
$375 
$375 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction.

We recorded the assets acquired, liabilities assumed and the noncontrolling interest at their respective fair values as of the closing of the transaction. The preliminary purchase price allocation was comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:

(in millions)
Goodwill$336 
Amortizable intangible assets334 
Other assets acquired61 
Liabilities assumed(23)
Net deferred tax liabilities(74)
Fair value of noncontrolling interest$(259)
$375 

The fair value of the noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and is not deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG and VersaCrossTransseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.
Purchase Price Allocation

We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805, Business Combinations. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 

We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and is deductible for tax purposes.

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
Contingent Consideration

None of our acquisitions that closed during the first quarters of 2023 or 2022 contained contingent consideration arrangements. Changes in the fair value of our contingent consideration liability during the first quarter of 2023 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2022$149 
Contingent consideration net expense (benefit)12 
Contingent consideration payments(68)
Balance as of March 31, 2023$93 

The payments made during the first quarter of 2023 were primarily related to our 2021 acquisition of Farapulse, Inc. As of March 31, 2023, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $359 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$80 millionDiscounted Cash FlowDiscount Rate6%-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to research and development (R&D), regulatory and commercialization-based milestones and revenue-based payments are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of March 31, 2023.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2023December 31, 2022
Equity method investments$166 $188 
Measurement alternative investments(1, 2)
219 219 
$385 $407 
(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2)    Includes publicly-held securities measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.
As of March 31, 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $209 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets
3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,707 $(7,553)$12,397 $(7,378)
Patents473 (381)486 (394)
Other intangible assets2,005 (1,422)1,960 (1,400)
Amortizable intangible assets$15,185 $(9,357)$14,843 $(9,173)
    
Goodwill$23,169 $(9,900)$22,820 $(9,900)
IPR&D$112 $112 
Technology-related120 120 
Indefinite-lived intangible assets$232 $232 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of a majority stake investment in Acotec completed in the first quarter of 2023.

The following represents a roll-forward of our goodwill balance by global reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired— 336 336 
Impact of foreign currency fluctuations and purchase price adjustments— 13 13 
As of March 31, 2023$4,237 $9,032 $13,269 

Goodwill and Intangible Asset Impairments
We did not record any goodwill impairment charges in the first quarters 2023 or 2022. Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging Activities and Fair Value Measurements
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and actively monitoring counterparty credit ratings. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a
consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of March 31, 2023 and December 31, 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% euro-denominated senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the Cumulative Translation Adjustment (CTA) component of Other Comprehensive Income (OCI). We reclassify these gains and losses to current period earnings within Other, net in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of March 31, 2023 or December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2023December 31, 2022
Forward currency contractsCash flow hedge$2,673 $2,725 
Forward currency contractsNet investment hedge365 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,623 4,235 
Total Notional Outstanding$7,657 $8,321 
(1)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

As of March 31, 2023, the remaining time to maturity is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and three years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.
The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
(1)Interest expense65 (3)(2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)(14)Other, net43 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense65 — 


Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2022
Forward currency contracts
Cash flow hedges$45 $(10)$35 Cost of products sold$955 $(30)$$(23)
Net investment hedges(2)
15 (3)11 Interest expense279 (2)— (2)
Foreign currency-denominated debt
Net investment hedges(3)
24 (5)18 Other, net31 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense279 14 (3)11 

(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
As of March 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below:
(in millions)FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$189 
Forward currency contractsNet investment hedgeInterest expense
Interest rate derivative contractsCash flow hedgeInterest expense(3)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20232022
Net gain (loss) on currency hedge contractsOther, net$(8)$(29)
Net gain (loss) on currency transaction exposuresOther, net(6)21 
Net currency exchange gain (loss)$(14)$(9)

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other
observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2023December 31, 2022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$168 $196 
Forward currency contractsOther long-term assets132 149 
  299 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets19 36 
Total Derivative and Nonderivative Assets $319 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt971 952 
  972 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities37 52 
Total Derivative and Nonderivative Liabilities $1,009 $1,005 
(1)    We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$170 $— $— $170 $673 $— $— $673 
Publicly-held equity securities— — — — 
Hedging instruments— 319 — 319 — 381 — 381 
Licensing arrangements— — 113 113 — — 127 127 
 $172 $319 $113 $604 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$— $1,009 $— $1,009 $— $1,005 $— $1,005 
Contingent consideration liability— — 93 93 — — 149 149 
Licensing arrangements— — 120 120 — — 159 159 
 $ $1,009 $213 $1,222 $ $1,005 $308 $1,313 

Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $170 million invested in money market funds and time deposits as of March 31, 2023 and $673 million as of December 31, 2022, we held $400 million in interest-bearing and non-interest-bearing bank accounts as of March 31, 2023 and $256 million as of December 31, 2022.

Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value in our accompanying unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, Financial Instruments. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to Note D – Hedging Activities and Fair Value Measurements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of March 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$113 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$120 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2022$127 
Proceeds from royalty rights(18)
Fair value adjustment (expense) benefit
Balance as of March 31, 2023$113 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2022$159 
Payments for royalty rights(43)
Fair value adjustment expense (benefit)
Balance as of March 31, 2023$120 

Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C – Goodwill and Other Intangible Assets for a discussion of the fair values of our intangible assets including goodwill.

The fair value of our outstanding debt obligations was $8.467 billion as of March 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Contractual Obligations and Commitments
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt outstanding of $9.005 billion as of March 31, 2023 and $8.935 billion as of December 31, 2022, with current obligations of $510 million as of March 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2023
December 31,
2022
March 2024 Senior Notes(4)
February 2019March 2024— 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,088 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027979 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028816 800 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 344 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031816 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034544 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(73)(76)
Finance Lease ObligationVarious
Long-term debt$8,495 $8,915 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated senior notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3)    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2023 and December 31, 2022, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below.

Revolving Credit Facility

On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under Financial Covenant below. This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility as of March 31, 2023 or December 31, 2022.
Financial Covenant

As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended.
Covenant RequirementActual
 as of March 31, 2023as of March 31, 2023
Maximum permitted leverage ratio(1)
3.75 times2.52 times
(1)Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.

The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times through the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for any qualified acquisitions due to our funding of these acquisitions using cash on hand.

The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of March 31, 2023, we had $457 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022 for a total of $1.443 billion. As of March 31, 2023, we had $1.424 billion of the litigation exclusion remaining.

Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2021 Revolving Credit Facility. We had no commercial paper outstanding as of March 31, 2023 or December 31, 2022. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility.

Senior Notes

We had senior notes outstanding of $9.067 billion as of March 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to Other Arrangements below).

In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds,
and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.

We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in Interest expense within our accompanying unaudited consolidated statements of operations.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring ArrangementsAs of March 31, 2023As of December 31, 2022
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$188 5.5 %$161 2.4 %
Yen denominated188 0.5 %194 0.6 %
Renminbi denominated
14 3.0 %13 3.1 %

Other Contractual Obligations and Commitments

We had outstanding letters of credit of $143 million as of March 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2023 and December 31, 2022 we had not recognized a related liability for any outstanding letters of credit within our accompanying unaudited consolidated balance sheets.

We have a supplier financing program offered primarily in the U.S. where our suppliers can opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within Accounts Payable within our unaudited consolidated balance sheets and were $128 million as of March 31, 2023 and $129 million as of December 31, 2022.

Refer to Note E – Contractual Obligations and Commitments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Balance Sheet Information
3 Months Ended
Mar. 31, 2023
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:

Trade accounts receivable, net
 As of
(in millions)March 31, 2023December 31, 2022
Trade accounts receivable$2,194 $2,079 
Allowance for credit losses(118)(109)
 $2,076 $1,970 
The following is a roll forward of our Allowance for credit losses:
Three Months Ended March 31,
(in millions)20232022
Beginning balance$109 $108 
Credit loss expense16 11 
Write-offs(6)(5)
Ending balance$118 $113 

In accordance with FASB ASC Topic 326, Financial Instruments - Credit Losses (FASB ASC Topic 326), we record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach, applying country or region-specific factors, to determine the reserve to record at accounts receivable commencement for certain customers. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic and geopolitical conditions. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other entities, and, in southern Europe, relative to those in other countries. In addition, we have seen an increase in the volume of our U.S. business conducted in ambulatory surgery centers and office-based laboratories. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions based on collection trends.

Inventories
 As of
(in millions)March 31, 2023December 31, 2022
Finished goods$1,223 $1,171 
Work-in-process176 147 
Raw materials651 548 
 $2,050 $1,867 

Other current assets
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash and restricted cash equivalents$135 $149 
Derivative assets187 232 
Licensing arrangements56 60 
Other333 290 
 $711 $731 
Property, plant and equipment, net
 As of
(in millions)March 31, 2023December 31, 2022
Land$141 $137 
Buildings and improvements1,763 1,695 
Equipment, furniture and fixtures3,367 3,297 
Capital in progress567 598 
 5,837 5,728 
Less: accumulated depreciation3,359 3,282 
 $2,478 $2,446 

Depreciation expense was $82 million for the first quarter of 2023 and $76 million for the first quarter of 2022.

Other long-term assets
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash equivalents$57 $48 
Operating lease right-of-use assets399 386 
Derivative assets133 149 
Investments385 407 
Licensing arrangements57 67 
Indemnification asset170 172 
Other280 271 
 $1,482 $1,500 

Accrued expenses
 As of
(in millions)March 31, 2023December 31, 2022
Legal reserves$207 $231 
Payroll and related liabilities661 830 
Rebates347 352 
Contingent consideration83 74 
Other620 674 
 $1,918 $2,160 

Other current liabilities
 As of
(in millions)March 31, 2023December 31, 2022
Deferred revenue$231 $220 
Licensing arrangements57 79 
Taxes payable281 232 
Other217 230 
 $787 $761 
Other long-term liabilities
 As of
(in millions)March 31, 2023December 31, 2022
Accrued income taxes$608 $597 
Legal reserves209 212 
Contingent consideration10 75 
Licensing arrangements63 80 
Operating lease liabilities360 347 
Deferred revenue290 289 
Other457 434 
 $1,995 $2,035 
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE G – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
Three Months Ended March 31,
20232022
Effective tax rate from continuing operations29.4 %29.1 %

The changes in our reported tax rates for the first quarter of 2023, as compared to the same period in 2022, relate primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include debt extinguishment charges recorded in the first quarter of 2022, as well as certain discrete tax items primarily related to provision-to-return adjustments recorded in the first quarter of 2023.

As of March 31, 2023, we had $501 million of gross unrecognized tax benefits, of which a net $415 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to positions on new entities we acquired through recent acquisitions and restructuring activities.

It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $77 million.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE H – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.
In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to Note I – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.

Our accrual for legal matters that are probable and estimable was $416 million as of March 31, 2023 and $443 million as of December 31, 2022 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in Other current assets of $135 million as of March 31, 2023 and $149 million as of December 31, 2022. Refer to Note F – Supplemental Balance Sheet Information for additional information. We did not record any litigation-related net charges during the first quarter of 2023 or 2022.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.

Patent Litigation

On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In
February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023.

On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages. The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.

Product Liability Litigation

Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand.

We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.
In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.

On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.

Other Proceedings

On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On February 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
NOTE I – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders.

On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of March 31, 2023, our MCPS had an aggregate liquidation preference of $1.006 billion.

During the first quarter of 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, a cash dividend of $1.375 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. On April 24, 2023 the Committee declared a cash dividend of $1.375 per MCPS share to holders of our MCPS as of May 15, 2023,
representing a dividend period from March through May 2023. We have presented cumulative, unpaid dividends within Accrued expenses within our accompanying unaudited consolidated balance sheet as of March 31, 2023.

Refer to Note J – Stockholders' Equity to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Weighted Average Shares Outstanding
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Weighted Average Number Of Shares Outstanding [Text Block]
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING

Three Months Ended March 31,
(in millions)20232022
Weighted average shares outstanding — basic1,435.8 1,427.8 
Net effect of common stock equivalents10.2 10.6 
Weighted average shares outstanding - diluted1,446.0 1,438.4 

The following securities were excluded from the calculation of diluted weighted average shares outstanding because their effect in the periods presented below would have been anti-dilutive:
Three Months Ended March 31,
(in millions)20232022
Stock options outstanding(1)
33
MCPS(2)
2424
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.

We base Net income (loss) per common share - diluted upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive.

For the first quarter of 2023 and 2022, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, Net income was reduced by cumulative Preferred stock dividends, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating Net income attributable to Boston Scientific common stockholders.

We issued approximately four million shares of our common stock in the first quarter of 2023 and 2022 following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first quarter of 2023 or 2022. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2023, we had the full amount remaining available under the authorization.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
NOTE K – SEGMENT REPORTING

We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.

We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to Note L – Revenue for net sales by reportable segment presented in accordance with U.S. GAAP.

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).

Three Months Ended
March 31,
Net Sales20232022
MedSurg$1,252 $1,164
Cardiovascular2,049 1,902
Total net sales of reportable segments3,301 3,066
Impact of foreign currency fluctuations88 (40)
$3,389 $3,026
Income (loss) before income taxes
MedSurg$400 $371
Cardiovascular541 477
Total operating income of reportable segments940 847
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(75)(66)
Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(110)(117)
Amortization expense(203)(198)
Operating income (loss)552 466
Other expense, net(108)(310)
Income (loss) before income taxes$444 $156

Three Months Ended March 31,
Operating income margin of reportable segments20232022
MedSurg31.9 %31.8 %
Cardiovascular26.4 %25.1 %
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.

Three Months Ended March 31,
20232022
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$351 $226 $577 $312 $220 $531 
Urology326 143 469 286 127 413 
Neuromodulation172 62 234 161 49 209 
MedSurg850 430 1,280 758 395 1,153 
   Interventional Cardiology Therapies183 408 591 186 358 544 
   Watchman265 25 291 203 23 226 
   Cardiac Rhythm Management345 203 548 325 195 519 
    Electrophysiology85 91 177 50 68 118 
Cardiology879 727 1,606 764 644 1,407 
Peripheral Interventions275 229 503 256 210 465 
Cardiovascular1,154 956 2,110 1,019 853 1,873 
Total Net Sales$2,003 $1,386 $3,389 $1,778 $1,248 $3,026 

Refer to Note K- Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20232022
U.S.$2,003 $1,778 
Europe, Middle East and Africa712 624 
Asia-Pacific548 517 
Latin America and Canada126 107 
Total Net Sales$3,389 $3,026 
Emerging Markets(1)
$529 $440 
(1)Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $521 million as of March 31, 2023 and $509 million as of December 31, 2022. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $42 million in the first quarter that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.
Variable ConsiderationFor additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Changes in Other Comprehensive Income
3 Months Ended
Mar. 31, 2023
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(63)35 (27)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(12)(14)
Total other comprehensive income (loss)(64)23 (41)
Balance as of March 31, 2022$29 $229 $(36)$222 

Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.23.1
New Accounting Pronouncements
3 Months Ended
Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Pronouncements, Policy
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2023, we implemented the following standards on a prospective basis, none of which had a material impact on our financial position or results of operations.

ASC Update No. 2022-01

ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods.

ASC Update No. 2022-02

ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as
amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13.

ASC Update No. 2022-04

ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50) enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude.

Standards to be Implemented

In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Subsequent Events, Policy [Policy Text Block]
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies and Note I – Stockholders' Equity for further details.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)
3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurement, Policy [Policy Text Block] FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies Commitments and Contingencies (Policies)
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Legal Costs, Policy [Policy Text Block] FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.23.1
New Accounting Pronouncements (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method ASC Update No. 2022-01ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods.
ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)
ASC Update No. 2022-02

ASC Update No. 2022-02, Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as well as
amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13.
ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) ASC Update No. 2022-04ASC Update No. 2022-04, Liabilities— Supplier Finance Programs (Subtopic 405-50) enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude.
ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. In June 2022, the FASB issued ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions, Divestitures and Strategic Investments (Tables)
3 Months Ended
Mar. 31, 2023
Business Acquisition [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Changes in the fair value of our contingent consideration liability during the first quarter of 2023 associated with prior period acquisitions were as follows:
(in millions)
Balance as of December 31, 2022$149 
Contingent consideration net expense (benefit)12 
Contingent consideration payments(68)
Balance as of March 31, 2023$93 
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%2%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$80 millionDiscounted Cash FlowDiscount Rate6%-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment [Table Text Block]
The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)March 31, 2023December 31, 2022
Equity method investments$166 $188 
Measurement alternative investments(1, 2)
219 219 
$385 $407 
(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2)    Includes publicly-held securities measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.
Acotec  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
(in millions)
Payment for majority interest acquisition, net of cash acquired (1)
$375 
$375 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] The preliminary purchase price allocation was comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:
(in millions)
Goodwill$336 
Amortizable intangible assets334 
Other assets acquired61 
Liabilities assumed(23)
Net deferred tax liabilities(74)
Fair value of noncontrolling interest$(259)
$375 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Baylis Medical  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] The final purchase price allocation was comprised of the following components:
(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets Goodwill (Tables)
3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill [Table Text Block]
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of March 31, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,707 $(7,553)$12,397 $(7,378)
Patents473 (381)486 (394)
Other intangible assets2,005 (1,422)1,960 (1,400)
Amortizable intangible assets$15,185 $(9,357)$14,843 $(9,173)
    
Goodwill$23,169 $(9,900)$22,820 $(9,900)
IPR&D$112 $112 
Technology-related120 120 
Indefinite-lived intangible assets$232 $232 
Schedule of Goodwill [Table Text Block]
The following represents a roll-forward of our goodwill balance by global reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired— 336 336 
Impact of foreign currency fluctuations and purchase price adjustments— 13 13 
As of March 31, 2023$4,237 $9,032 $13,269 
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging Activities and Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2023
Derivative [Line Items]  
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
March 31, 2023December 31, 2022
Forward currency contractsCash flow hedge$2,673 $2,725 
Forward currency contractsNet investment hedge365 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,623 4,235 
Total Notional Outstanding$7,657 $8,321 
(1)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.
Derivative Instruments, Gain (Loss) [Table Text Block]
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2023
Forward currency contracts
Cash flow hedges$13 $(3)$10 Cost of products sold$1,040 $(69)$16 $(54)
Net investment hedges(2)
(1)Interest expense65 (3)(2)
Foreign currency-denominated debt
Net investment hedges(3)
(19)(14)Other, net43 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest expense65 — 


Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended March 31, 2022
Forward currency contracts
Cash flow hedges$45 $(10)$35 Cost of products sold$955 $(30)$$(23)
Net investment hedges(2)
15 (3)11 Interest expense279 (2)— (2)
Foreign currency-denominated debt
Net investment hedges(3)
24 (5)18 Other, net31 — — — 
Interest rate derivative contracts
Cash flow hedges— — — Interest Expense279 14 (3)11 

(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]
As of March 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below:
(in millions)FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$189 
Forward currency contractsNet investment hedgeInterest expense
Interest rate derivative contractsCash flow hedgeInterest expense(3)
Derivatives Not Designated as Hedging Instruments [Table Text Block]
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,
(in millions)20232022
Net gain (loss) on currency hedge contractsOther, net$(8)$(29)
Net gain (loss) on currency transaction exposuresOther, net(6)21 
Net currency exchange gain (loss)$(14)$(9)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] The following are the balances of our derivative and nonderivative assets and liabilities:
 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)March 31, 2023December 31, 2022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$168 $196 
Forward currency contractsOther long-term assets132 149 
  299 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets19 36 
Total Derivative and Nonderivative Assets $319 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther long-term liabilities
Foreign currency-denominated debt(2)
Long-term debt971 952 
  972 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities37 52 
Total Derivative and Nonderivative Liabilities $1,009 $1,005 
(1)    We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Assets and liabilities measured at fair value on a recurring basis consist of the following:
As of
 March 31, 2023December 31, 2022
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets        
Money market funds and time deposits$170 $— $— $170 $673 $— $— $673 
Publicly-held equity securities— — — — 
Hedging instruments— 319 — 319 — 381 — 381 
Licensing arrangements— — 113 113 — — 127 127 
 $172 $319 $113 $604 $674 $381 $127 $1,182 
Liabilities        
Hedging instruments$— $1,009 $— $1,009 $— $1,005 $— $1,005 
Contingent consideration liability— — 93 93 — — 149 149 
Licensing arrangements— — 120 120 — — 159 159 
 $ $1,009 $213 $1,222 $ $1,005 $308 $1,313 
The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of March 31, 2023 include the following significant unobservable inputs:
Licensing ArrangementsFair Value as of March 31, 2023Valuation TechniqueUnobservable InputRange
Weighted Average (1)
Financial Asset$113 millionDiscounted Cash FlowDiscount Rate15%15%
Projected Year of Payment2023-20252024
Financial Liability$120 millionDiscounted Cash FlowDiscount Rate12 %-15%13%
Projected Year of Payment2023-20262024
(1)    Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Changes in the fair value of our licensing arrangements' financial asset were as follows:
(in millions)
Balance as of December 31, 2022$127 
Proceeds from royalty rights(18)
Fair value adjustment (expense) benefit
Balance as of March 31, 2023$113 

Changes in the fair value of our licensing arrangements' financial liability were as follows:
(in millions)
Balance as of December 31, 2022$159 
Payments for royalty rights(43)
Fair value adjustment expense (benefit)
Balance as of March 31, 2023$120 
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Contractual Obligations and Commitments (Tables)
3 Months Ended
Mar. 31, 2023
Short-term Debt [Line Items]  
Schedule of Long-term Debt Instruments [Table Text Block] The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)Issuance DateMaturity DateAs of
Coupon Rate(1)
March 31,
2023
December 31,
2022
March 2024 Senior Notes(4)
February 2019March 2024— 504 3.450%
March 2025 Senior Notes(3)
March 2022March 20251,088 1,067 0.750%
June 2025 Senior NotesMay 2020June 2025500 500 1.900%
March 2026 Senior Notes(4)
February 2019March 2026255 255 3.750%
December 2027 Senior Notes(3)
November 2019December 2027979 960 0.625%
March 2028 Senior Notes(3)
March 2022March 2028816 800 1.375%
March 2028 Senior Notes(4)
February 2018March 2028344 344 4.000%
March 2029 Senior Notes(4)
February 2019March 2029272 272 4.000%
June 2030 Senior NotesMay 2020June 20301,200 1,200 2.650%
March 2031 Senior Notes(3)
March 2022March 2031816 800 1.625%
March 2034 Senior Notes(3)
March 2022March 2034544 534 1.875%
November 2035 Senior Notes(2)
November 2005November 2035350 350 6.750%
March 2039 Senior Notes(4)
February 2019March 2039450 450 4.550%
January 2040 Senior NotesDecember 2009January 2040300 300 7.375%
March 2049 Senior Notes(4)
February 2019March 2049650 650 4.700%
Unamortized Debt Issuance Discount and Deferred Financing Costs2023 - 2049(73)(76)
Finance Lease ObligationVarious
Long-term debt$8,495 $8,915 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)    Coupon rates are semi-annual, except for the euro-denominated senior notes, which bear an annual coupon.
(2)    Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.
(3)    These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2023 and December 31, 2022, respectively.
(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below.
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]
As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended.
Covenant RequirementActual
 as of March 31, 2023as of March 31, 2023
Maximum permitted leverage ratio(1)
3.75 times2.52 times
(1)Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.
Transfer of Financial Assets Accounted for as Sales [Table Text Block]
Factoring ArrangementsAs of March 31, 2023As of December 31, 2022
Amount
De-recognized
Weighted Average
Interest Rate
Amount
De-recognized
Weighted Average
Interest Rate
Euro denominated$188 5.5 %$161 2.4 %
Yen denominated188 0.5 %194 0.6 %
Renminbi denominated
14 3.0 %13 3.1 %
Commercial Paper [Member]  
Short-term Debt [Line Items]  
Schedule of Short-term Debt [Table Text Block] We had no commercial paper outstanding as of March 31, 2023 or December 31, 2022. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility.
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Balance Sheet Information (Tables)
3 Months Ended
Mar. 31, 2023
Supplemental Balance Sheet Information [Abstract]  
Trade accounts receivable, net [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Trade accounts receivable$2,194 $2,079 
Allowance for credit losses(118)(109)
 $2,076 $1,970 
Three Months Ended March 31,
(in millions)20232022
Beginning balance$109 $108 
Credit loss expense16 11 
Write-offs(6)(5)
Ending balance$118 $113 
Inventory Disclosure [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Finished goods$1,223 $1,171 
Work-in-process176 147 
Raw materials651 548 
 $2,050 $1,867 
Schedule of Other Current Assets [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash and restricted cash equivalents$135 $149 
Derivative assets187 232 
Licensing arrangements56 60 
Other333 290 
 $711 $731 
Property, plant and equipment, net [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Land$141 $137 
Buildings and improvements1,763 1,695 
Equipment, furniture and fixtures3,367 3,297 
Capital in progress567 598 
 5,837 5,728 
Less: accumulated depreciation3,359 3,282 
 $2,478 $2,446 
Schedule of Other Assets [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Restricted cash equivalents$57 $48 
Operating lease right-of-use assets399 386 
Derivative assets133 149 
Investments385 407 
Licensing arrangements57 67 
Indemnification asset170 172 
Other280 271 
 $1,482 $1,500 
Schedule of Accrued Liabilities [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Legal reserves$207 $231 
Payroll and related liabilities661 830 
Rebates347 352 
Contingent consideration83 74 
Other620 674 
 $1,918 $2,160 
Other Current Liabilities [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Deferred revenue$231 $220 
Licensing arrangements57 79 
Taxes payable281 232 
Other217 230 
 $787 $761 
Other long-term liabilities [Table Text Block]
 As of
(in millions)March 31, 2023December 31, 2022
Accrued income taxes$608 $597 
Legal reserves209 212 
Contingent consideration10 75 
Licensing arrangements63 80 
Operating lease liabilities360 347 
Deferred revenue290 289 
Other457 434 
 $1,995 $2,035 
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2023
Schedule of Income Tax Rate Reconciliation [Line Items]  
Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]
Three Months Ended March 31,
20232022
Effective tax rate from continuing operations29.4 %29.1 %
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Weighted Average Shares Outstanding (Tables)
3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares [Table Text Block]
Three Months Ended March 31,
(in millions)20232022
Weighted average shares outstanding — basic1,435.8 1,427.8 
Net effect of common stock equivalents10.2 10.6 
Weighted average shares outstanding - diluted1,446.0 1,438.4 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following securities were excluded from the calculation of diluted weighted average shares outstanding because their effect in the periods presented below would have been anti-dilutive:
Three Months Ended March 31,
(in millions)20232022
Stock options outstanding(1)
33
MCPS(2)
2424
(1)    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.
(2)    Represents common stock issuable upon the conversion of MCPS. Refer to Note I – Stockholders' Equity for additional information.
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).

Three Months Ended
March 31,
Net Sales20232022
MedSurg$1,252 $1,164
Cardiovascular2,049 1,902
Total net sales of reportable segments3,301 3,066
Impact of foreign currency fluctuations88 (40)
$3,389 $3,026
Income (loss) before income taxes
MedSurg$400 $371
Cardiovascular541 477
Total operating income of reportable segments940 847
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(75)(66)
Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(110)(117)
Amortization expense(203)(198)
Operating income (loss)552 466
Other expense, net(108)(310)
Income (loss) before income taxes$444 $156

Three Months Ended March 31,
Operating income margin of reportable segments20232022
MedSurg31.9 %31.8 %
Cardiovascular26.4 %25.1 %
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2023
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue [Table Text Block] The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.
Three Months Ended March 31,
20232022
BusinessesU.S.Int'lTotalU.S.Int'lTotal
Endoscopy$351 $226 $577 $312 $220 $531 
Urology326 143 469 286 127 413 
Neuromodulation172 62 234 161 49 209 
MedSurg850 430 1,280 758 395 1,153 
   Interventional Cardiology Therapies183 408 591 186 358 544 
   Watchman265 25 291 203 23 226 
   Cardiac Rhythm Management345 203 548 325 195 519 
    Electrophysiology85 91 177 50 68 118 
Cardiology879 727 1,606 764 644 1,407 
Peripheral Interventions275 229 503 256 210 465 
Cardiovascular1,154 956 2,110 1,019 853 1,873 
Total Net Sales$2,003 $1,386 $3,389 $1,778 $1,248 $3,026 

Refer to Note K- Segment Reporting for information on our reportable segments.

Three Months Ended March 31,
Geographic Regions20232022
U.S.$2,003 $1,778 
Europe, Middle East and Africa712 624 
Asia-Pacific548 517 
Latin America and Canada126 107 
Total Net Sales$3,389 $3,026 
Emerging Markets(1)
$529 $440 
(1)Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Changes in Other Comprehensive Income (Tables)
3 Months Ended
Mar. 31, 2023
Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]  
Changes in Other Comprehensive Income [Table Text Block]
The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2022$(1)$269 $1 $269 
Other comprehensive income (loss) before reclassifications(40)10 (5)(35)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(53)(0)(56)
Total other comprehensive income (loss)(42)(43)(5)(91)
Balance as of March 31, 2023$(43)$225 $(4)$178 

(in millions)Foreign Currency Translation AdjustmentsNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotal
Balance as of December 31, 2021$93 $206 $(36)$263 
Other comprehensive income (loss) before reclassifications(63)35 (27)
(Income) loss amounts reclassified from accumulated other comprehensive income(2)(12)(14)
Total other comprehensive income (loss)(64)23 (41)
Balance as of March 31, 2022$29 $229 $(36)$222 
R
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation (Details)
3 Months Ended
Mar. 31, 2023
reportablesegments
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of reportable segments 2
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions and Divestitures (Details)
$ / shares in Units, $ in Millions
3 Months Ended
Apr. 04, 2023
USD ($)
$ / shares
Feb. 20, 2023
USD ($)
Feb. 20, 2023
KRW (₩)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Net of Cash Acquired       $ 375 $ 1,471  
Business Combination, Contingent Consideration, Liability       93   $ 149
Goodwill       13,269   12,920
Accrued income taxes       608   597
Payment of contingent consideration       68    
Cash       400   $ 256
Acotec            
Business Acquisition [Line Items]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   35.00%        
Apollo | Subsequent Event [Member]            
Business Acquisition [Line Items]            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 615          
Business Acquisition, Percentage of Voting Interests Acquired 100.00%          
Business Acquisition, Share Price | $ / shares $ 10.00          
Baylis Medical            
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Net of Cash Acquired       1,463    
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination       1,463    
Goodwill       988    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       657    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets       112    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities       (287)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities       (7)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill       657    
Baylis Medical | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 622    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       11 years    
Baylis Medical | Weighted Average [Member] | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       11.00%    
Acotec            
Business Acquisition [Line Items]            
Payments to Acquire Businesses, Net of Cash Acquired       $ 375    
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value   $ 519 ₩ 20.00      
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination       375    
Goodwill       336    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets       61    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities       (23)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities       (74)    
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value       (259)    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill       334    
Business Acquisition, Percentage of Voting Interests Acquired   65.00%        
Cash   $ 140        
Acotec | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 308    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       11 years    
Acotec | Other Intangible Assets [Member]            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 11    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       13 years    
Acotec | Customer Relationships            
Business Acquisition [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles       $ 15    
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life       11 years    
Acotec | Weighted Average [Member] | Technology-Based Intangible Assets [Member]            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
Acotec | Weighted Average [Member] | Other Intangible Assets [Member]            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
Acotec | Weighted Average [Member] | Customer Relationships            
Business Acquisition [Line Items]            
Discount Rate, Fair Value Input       14.00%    
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Contingent Consideration (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Business Combination, Contingent Consideration, Liability Beginning Balance $ 149  
Contingent consideration net expense (benefit) 12 $ 12
Payment of contingent consideration (68)  
Business Combination, Contingent Consideration, Liability Ending Balance 93  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Business Combination, Contingent Consideration, Liability 93  
All Business Acquisitions    
Business Combination, Contingent Consideration Arrangements [Abstract]    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 359  
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Business Combination, Contingent Consideration, Liability Ending Balance 13  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Business Combination, Contingent Consideration, Liability 13  
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]    
Business Combination, Contingent Consideration, Liability Ending Balance 80  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Business Combination, Contingent Consideration, Liability $ 80  
contingent consideration liability, probability of payment 100.00%  
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
contingent consideration liability, probability of payment 10.00%  
Discount Rate, Fair Value Input 1.00%  
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Discount Rate, Fair Value Input 6.00%  
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
contingent consideration liability, probability of payment 25.00%  
Discount Rate, Fair Value Input 2.00%  
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
Discount Rate, Fair Value Input 14.00%  
Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
contingent consideration liability, probability of payment 22.00%  
Discount Rate, Fair Value Input 2.00%  
Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]    
contingent consideration liability, probability of payment 100.00%  
Discount Rate, Fair Value Input 7.00%  
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Strategic Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Schedule of Investments [Line Items]    
Equity method investments $ 166 $ 188
Measurement alternative investments(1, 2) 219 219
Investments 385 $ 407
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 209  
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Other Intangible Assets (Details)
$ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
reportablesegments
Dec. 31, 2022
USD ($)
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross $ 15,185 $ 14,843
Finite-Lived Intangible Assets, Accumulated Amortization (9,357) (9,173)
Indefinite-lived Intangible Assets (Excluding Goodwill) 232 232
Goodwill [Roll Forward]    
Goodwill Beginning Balance 12,920  
Goodwill, Translation and Purchase Accounting Adjustments 13  
Goodwill, Acquired During Period 336  
Goodwill Ending Balance $ 13,269  
Number of reportable segments | reportablesegments 2  
MedSurg [Member]    
Goodwill [Roll Forward]    
Goodwill Beginning Balance $ 4,237  
Goodwill, Translation and Purchase Accounting Adjustments 0  
Goodwill, Acquired During Period 0  
Goodwill Ending Balance 4,237  
Cardiovascular [Member]    
Goodwill [Roll Forward]    
Goodwill Beginning Balance 8,684  
Goodwill, Translation and Purchase Accounting Adjustments 13  
Goodwill, Acquired During Period 336  
Goodwill Ending Balance 9,032  
Goodwill [Member]    
Intangible Assets and Goodwill [Line Items]    
Goodwill, Gross 23,169 22,820
Goodwill, Impaired, Accumulated Impairment Loss (9,900) (9,900)
In Process Research and Development [Member]    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 112 112
Technology-Based Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Indefinite-lived Intangible Assets (Excluding Goodwill) 120 120
Technology-Based Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 12,707 12,397
Finite-Lived Intangible Assets, Accumulated Amortization (7,553) (7,378)
Patents [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 473 486
Finite-Lived Intangible Assets, Accumulated Amortization (381) (394)
Other Intangible Assets [Member]    
Intangible Assets and Goodwill [Line Items]    
Finite-Lived Intangible Assets, Gross 2,005 1,960
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,422) $ (1,400)
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging Activities and Fair Value Measurements (Details)
€ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
derivative_instrument
units
Mar. 31, 2022
USD ($)
Mar. 31, 2023
EUR (€)
derivative_instrument
units
Dec. 31, 2022
USD ($)
derivative_instrument
Dec. 31, 2021
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]          
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax $ 225,000,000 $ 229,000,000   $ 269,000,000 $ 206,000,000
Derivative, Notional Amount 7,657,000,000     8,321,000,000  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 10,000,000 35,000,000      
Cost of Goods and Services Sold 1,040,000,000 955,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 53,000,000 12,000,000      
Interest Expense 65,000,000 279,000,000      
Other Operating Income (Expense), Net 43,000,000 31,000,000      
Derivative Asset, Fair Value, Gross Asset 319,000,000     381,000,000  
Derivative Liability, Fair Value, Gross Liability 1,009,000,000     1,005,000,000  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Derivative Asset 133,000,000     149,000,000  
Licensing arrangements, asset 57,000,000     67,000,000  
Business Combination, Contingent Consideration, Liability 93,000,000     149,000,000  
Licensing arrangements, liability 63,000,000     80,000,000  
Cash 400,000,000     256,000,000  
Non-cash impact of transferred royalty rights (9,000,000) (19,000,000)      
Debt Instrument, Fair Value Disclosure 8,467,000,000     8,203,000,000  
Accumulated Foreign Currency Adjustment Attributable to Parent          
Derivative Instruments, Gain (Loss) [Line Items]          
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 0 0      
December 2027 Notes [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Long-term Debt $ 979,000,000   € 900 960,000,000  
Debt Instrument, Interest Rate, Stated Percentage 0.625%   0.625%    
Licensing arrangement assets [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Proceeds from Royalties Received $ (18,000,000)        
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 4,000,000        
Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Payments for Royalties (43,000,000)        
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option 5,000,000        
Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Licensing arrangements, asset 113,000,000        
Licensing arrangements, liability 120,000,000        
Fair Value, Measurements, Recurring [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 170,000,000     673,000,000  
Equity Securities, FV-NI 2,000,000     2,000,000  
Derivative Asset 319,000,000     381,000,000  
Licensing arrangements, asset 113,000,000     127,000,000  
Assets, Fair Value Disclosure 604,000,000     1,182,000,000  
Derivative Liability 1,009,000,000     1,005,000,000  
Business Combination, Contingent Consideration, Liability 93,000,000     149,000,000  
Licensing arrangements, liability 120,000,000     159,000,000  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,222,000,000     1,313,000,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 170,000,000     673,000,000  
Equity Securities, FV-NI 2,000,000     2,000,000  
Derivative Asset 0     0  
Licensing arrangements, asset 0     0  
Assets, Fair Value Disclosure 172,000,000     674,000,000  
Derivative Liability 0     0  
Business Combination, Contingent Consideration, Liability 0     0  
Licensing arrangements, liability 0     0  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0     0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 0     0  
Equity Securities, FV-NI 0     0  
Derivative Asset 319,000,000     381,000,000  
Licensing arrangements, asset 0     0  
Assets, Fair Value Disclosure 319,000,000     381,000,000  
Derivative Liability 1,009,000,000     1,005,000,000  
Business Combination, Contingent Consideration, Liability 0     0  
Licensing arrangements, liability 0     0  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 1,009,000,000     1,005,000,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Money Market Funds, at Carrying Value 0     0  
Equity Securities, FV-NI 0     0  
Derivative Asset 0     0  
Licensing arrangements, asset 113,000,000     127,000,000  
Assets, Fair Value Disclosure 113,000,000     127,000,000  
Derivative Liability 0     0  
Business Combination, Contingent Consideration, Liability 93,000,000     149,000,000  
Licensing arrangements, liability 120,000,000     159,000,000  
Financial and Nonfinancial Liabilities, Fair Value Disclosure 213,000,000     308,000,000  
Designated as Hedging Instrument [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value 299,000,000     345,000,000  
Derivative Instruments in Hedges, Liabilities, at Fair Value 972,000,000     953,000,000  
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Liabilities, at Fair Value $ 971,000,000     952,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Forward Currency Contracts, Time to Maturity | units 36   36    
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value $ 168,000,000     196,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Noncurrent Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Assets, at Fair Value 132,000,000     149,000,000  
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Noncurrent Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments in Hedges, Liabilities, at Fair Value 0     1,000,000  
Not Designated as Hedging Instrument [Member] | Other Nonoperating Income (Expense) [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments (8,000,000) (29,000,000)      
Foreign Currency Transaction Gain (Loss), before Tax (6,000,000) 21,000,000      
Net currency exchange gain (loss) (14,000,000) (9,000,000)      
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 3,623,000,000     4,235,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value 19,000,000     36,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value $ 37,000,000     $ 52,000,000  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Forward          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Term of Contract (less than) 1 year        
Derivative, Remaining Maturity 1 year        
Weighted Average [Member] | Licensing arrangement assets [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Weighted Average [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 13.00%   13.00%    
Minimum [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 12.00%   12.00%    
Maximum [Member] | Licensing arrangement liabilities [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Discount Rate, Fair Value Input 15.00%   15.00%    
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months $ 189,000,000        
Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ (3,000,000)        
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Number of Interest Rate Derivatives Held | derivative_instrument 0   0 0  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount $ 2,673,000,000     $ 2,725,000,000  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 13,000,000 45,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (3,000,000) (10,000,000)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 10,000,000 35,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (69,000,000) (30,000,000)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 16,000,000 7,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (54,000,000) (23,000,000)      
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 1,000,000 14,000,000      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 0 (3,000,000)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 1,000,000 11,000,000      
Net Investment Hedging [Member] | Foreign Exchange Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net 9,000,000        
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 365,000,000     365,000,000  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 6,000,000 15,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (1,000,000) (3,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 4,000,000 11,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax (3,000,000) (2,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 1,000,000 0      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax (2,000,000) (2,000,000)      
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 997,000,000     $ 997,000,000  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax (19,000,000) 24,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax 4,000,000 (5,000,000)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax (14,000,000) 18,000,000      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax 0 0      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax 0 0      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax $ 0 $ 0      
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Contractual Obligations and Commitments (Details)
€ in Millions
3 Months Ended 12 Months Ended
May 10, 2021
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2023
Mar. 31, 2023
EUR (€)
Mar. 31, 2023
Rate
Debt Instrument [Line Items]              
Total debt   $ 9,005,000,000.000   $ 8,935,000,000      
Debt, Current   510,000,000   20,000,000      
Long-term Debt and Capital Lease Obligations   8,495,000,000   8,915,000,000      
Exclusion from EBITDA for Restructuring Charges   500,000,000          
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA   457,000,000          
Litigation and Debt Exclusion from EBITDA   1,443,000,000          
Legal payments remaining to be excluded from calculation of consolidated EBITDA   1,424,000,000          
Letters of Credit Outstanding, Amount   143,000,000   135,000,000      
Qualified Acquisition Consideration   1,000,000,000          
Gain (Loss) on Extinguishment of Debt   0 $ 194,000,000        
Proceeds from Issuance of Senior Long-Term Debt   0 $ 3,271,000,000        
Supplier Finance Program Obligation. current   128,000,000   129,000,000      
Litigation payment exclusion from EBITDA   1,000,000,000          
Proceeds from Issuance of Senior Long-Term Debt       3,270,000,000      
Licensing arrangement assets [Member]              
Debt Instrument [Line Items]              
Proceeds from Royalties Received   18,000,000          
Licensing arrangement liabilities [Member]              
Debt Instrument [Line Items]              
Payments for Royalties   43,000,000          
Commercial Paper [Member]              
Debt Instrument [Line Items]              
Commercial Paper   400,000,000          
Current Requirement [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         3.75    
Actual, Covenant [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         2.52    
Requirement, as of December 31, 2021 and through remaining term of facility              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         3.75    
Requirement, four succeeding quarters following qualified acquisition              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         4.75    
Requirement, fifth quarter following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         4.50    
Requirement, sixth quarter following qualified acquisition              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         4.25    
Requirement, seventh quarter following qualified acquisition              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         4.00    
Requirement, eighth quarter following qualified acquisition and through remaining term of facility              
Debt Instrument [Line Items]              
Maximum Leverage Ratio         3.75    
the 2018 Facility [Member] | Revolving Credit Facility [Member]              
Debt Instrument [Line Items]              
Long-term Debt       0      
Line of Credit Facility, Maximum Borrowing Capacity $ 2,750,000,000            
March 2024 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   0   504,000,000      
Debt Instrument, Interest Rate, Stated Percentage         3.45%    
June 2025 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   500,000,000   500,000,000      
Debt Instrument, Interest Rate, Stated Percentage         1.90%    
March 2026 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   255,000,000   255,000,000      
Debt Instrument, Interest Rate, Stated Percentage         3.75%    
December 2027 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   979,000,000   960,000,000   € 900  
Debt Instrument, Interest Rate, Stated Percentage         0.625%    
March 2028 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   344,000,000   344,000,000      
Debt Instrument, Interest Rate, Stated Percentage         4.00%    
March 2029 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   272,000,000   272,000,000      
Debt Instrument, Interest Rate, Stated Percentage         4.00%    
June 2030 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   1,200,000,000   1,200,000,000      
Debt Instrument, Interest Rate, Stated Percentage         2.65%    
November 2035 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   350,000,000   350,000,000      
Debt Instrument, Interest Rate, Stated Percentage         6.75%    
March 2039 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   450,000,000   450,000,000      
Debt Instrument, Interest Rate, Stated Percentage         4.55%    
January 2040 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   300,000,000   300,000,000      
Debt Instrument, Interest Rate, Stated Percentage         7.375%    
March 2049 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   650,000,000   650,000,000      
Debt Instrument, Interest Rate, Stated Percentage         4.70%    
Senior Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   9,067,000,000.000   8,986,000,000      
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net   (73,000,000)   (76,000,000)      
Finance Lease Obligation              
Debt Instrument [Line Items]              
Long-term Debt   5,000,000   5,000,000      
March 2025 Notes              
Debt Instrument [Line Items]              
Long-term Debt   1,088,000,000   1,067,000,000   1,000  
Debt Instrument, Interest Rate, Stated Percentage         0.75%   0.75%
March 2028 Senior Notes              
Debt Instrument [Line Items]              
Long-term Debt   816,000,000   800,000,000   750  
Debt Instrument, Interest Rate, Stated Percentage         1.375%   1.375%
March 2031 Notes              
Debt Instrument [Line Items]              
Long-term Debt   816,000,000   800,000,000   750  
Debt Instrument, Interest Rate, Stated Percentage         1.625%   1.625%
March 2034 Notes              
Debt Instrument [Line Items]              
Long-term Debt   544,000,000   534,000,000   500  
Debt Instrument, Interest Rate, Stated Percentage         1.875%   1.875%
the Offering              
Debt Instrument [Line Items]              
Long-term Debt | €           € 3,000  
the Offering - early redemption of combined aggregate principal SN              
Debt Instrument [Line Items]              
Long-term Debt   3,275,000,000          
2021 Revolving Credit Facility | Line of Credit | Revolving Credit Facility [Member]              
Debt Instrument [Line Items]              
Long-term Debt   0          
Debt Instrument, Extension Option, Term 1 year            
Euro Denominated Factoring Arrangements [Member]              
Debt Instrument [Line Items]              
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 188,000,000   $ 161,000,000      
Average interest rate of de-recognized receivables   5.50%   2.40%      
Yen Denominated Factoring Arrangements [Member]              
Debt Instrument [Line Items]              
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 188,000,000   $ 194,000,000      
Average interest rate of de-recognized receivables   0.50%   0.60%      
Renminbi Denominated Factoring Arrangements [Member]              
Debt Instrument [Line Items]              
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 14,000,000   $ 13,000,000      
Average interest rate of de-recognized receivables   3.00%   3.10%      
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]        
Cash and Cash Equivalents $ 570 $ 325 $ 928  
Restricted Cash and Cash Equivalents in Other current assets 135 146 149  
Restricted Cash Equivalents in Other long-term assets 57 59 48  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 763 529 1,126 $ 2,168
Depreciation 82 76    
Trade accounts receivable, net        
Accounts receivable 2,194   2,079  
Less: allowance for doubtful accounts (118)   (109)  
Trade accounts receivable, net 2,076   1,970  
Allowance for doubtful accounts        
Beginning balance 109 108    
Charges to expenses 16 11    
Utilization of allowances (6) (5)    
Ending balance 118 113    
Inventories        
Inventory, Finished Goods, Net of Reserves 1,223   1,171  
Inventory, Work in Process, Net of Reserves 176   147  
Inventory, Raw Materials, Net of Reserves 651   548  
Inventories 2,050   1,867  
Other Current Assets [Abstract]        
Restricted Cash and Cash Equivalents in Other current assets 135 146 149  
Derivative Asset, Current 187   232  
Licensing arrangements 56   60  
Other Assets, Miscellaneous, Current 333   290  
Other Assets, Current 711   731  
Property, plant and equipment, net        
Land 141   137  
Buildings and improvements 1,763   1,695  
Equipment, furniture and fixtures 3,367   3,297  
Capital in progress 567   598  
Property, plant and equipment 5,837   5,728  
Less: accumulated depreciation 3,359   3,282  
Property, plant and equipment, net 2,478   2,446  
Supplemental Balance Sheet Information        
Depreciation expense 82 76    
Other Assets, Noncurrent [Abstract]        
Restricted cash equivalents included in Other long-term assets 57 $ 59 48  
Operating Lease, Right-of-Use Asset 399   386  
Derivative Asset 133   149  
Investments 385   407  
Licensing arrangements, asset 57   67  
Indemnification asset 170   172  
Other, Other Long-term Assets 280   271  
Other Assets, Noncurrent 1,482   1,500  
Accrued expenses        
Legal reserves, current 207   231  
Payroll and related liabilities 661   830  
Accrued Rebates, Current 347   352  
Business Combination, Contingent Consideration, Liability, Current 83   74  
Other 620   674  
Accrued Liabilities, Current 1,918   2,160  
Other Liabilities, Current [Abstract]        
Deferred Revenue, Current 231   220  
Accrued Royalties, Current 57   79  
Taxes Payable, Current 281   232  
Other Sundry Liabilities, Current 217   230  
Other Liabilities, Current 787   761  
Other long-term liabilities        
Accrued income taxes 608   597  
Estimated Litigation Liability, Noncurrent 209   212  
Business Combination, Contingent Consideration, Liability, Noncurrent 10   75  
Licensing arrangements, liability 63   80  
Operating Lease, Liability, Noncurrent 360   347  
Deferred Revenue 290   289  
Other Accrued Liabilities, Noncurrent 457   434  
Other long-term liabilities $ 1,995   $ 2,035  
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent [Abstract]      
Effective tax rate from continuing operations 29.40% 29.10%  
Unrecognized Tax Benefits $ 501   $ 492
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 415   $ 410
Decrease in Unrecognized Tax Benefits is Reasonably Possible $ 77    
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details)
$ in Millions
Jan. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
units
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Loss Contingencies [Line Items]        
Accrual for legal matters that are probable and estimable   $ 416 $ 443  
Restricted Cash and Cash Equivalents in Other current assets   $ 135 $ 149 $ 146
Brazil CADE - # of individuals for alleged anti-competitive behavior | units   29    
Litigation Settlement, Amount Awarded to Other Party $ 42      
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Apr. 24, 2023
May 27, 2020
Mar. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]        
Preferred Stock, Shares Authorized     50,000,000 50,000,000
Preferred Stock, Shares Issued     10,062,500 10,062,500
5.50% MCPS, Series A [Member]        
Class of Stock [Line Items]        
Preferred Stock, Shares Issued   10,062,500    
Net proceeds from issuance of preferred stock in connection with public offering   $ 975    
Preferred Stock, Dividend Rate, Percentage   5.50%    
Preferred Stock, Liquidation Preference Per Share   $ 100    
Preferred Stock, Liquidation Preference, Value     $ 1,006  
Preferred Stock, Dividends, Per Share, Cash Paid     $ 1.375  
5.50% MCPS, Series A [Member] | Subsequent Event [Member]        
Class of Stock [Line Items]        
Preferred Stock, Dividends Per Share, Declared $ 1.375      
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Weighted Average Shares Outstanding (Details) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 14, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Weighted Average Number of Shares Outstanding, Basic 1,435,800 1,427,800  
Weighted Average Number Diluted Shares Outstanding Adjustment 10,200 10,600  
Weighted Average Number of Shares Outstanding, Diluted 1,446,000 1,438,400  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 4,000,000,000 4,000,000,000  
Stock Repurchase Program, Authorized Amount     $ 1,000
Share-based Payment Arrangement, Option      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,000 3,000  
5.50% MCPS, Series A [Member]      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 24,000 24,000  
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Details)
$ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
reportablesegments
Mar. 31, 2022
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | reportablesegments 2  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Amortization expense $ (203) $ (198)
Operating income (loss) 552 466
Other expense, net (108) (310)
Income (loss) before income taxes 444 156
Impact of Foreign Currency Fluctuations on Net Sales 88 (40)
Net sales 3,389 3,026
MedSurg [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Allocated to Reportable Segments 400 371
Revenues from contracts with customers, disaggregated - performance measurement $ 1,252 $ 1,164
Segment operating income as percentage of net sales 31.90% 31.80%
Net sales $ 1,280 $ 1,153
Cardiovascular [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Allocated to Reportable Segments 541 477
Revenues from contracts with customers, disaggregated - performance measurement $ 2,049 $ 1,902
Segment operating income as percentage of net sales 26.40% 25.10%
Net sales $ 2,110 $ 1,873
BSX Reportable Segments [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Revenues from contracts with customers, disaggregated - performance measurement 3,301 3,066
Total allocated to reportable segments [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating income (loss) 940 847
Corporate expenses and currency exchange [Member]    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Unallocated to Segment (75) (66)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits    
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]    
Operating Income Unallocated to Segment $ (110) $ (117)
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Details)
$ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
business
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 3,389 $ 3,026  
Net sales $ 3,389 3,026  
Number Of Businesses | business 5    
Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability $ 521   $ 509
Change in Contract with Customer, Liability [Abstract]      
Contract with Customer, Liability, Revenue Recognized 42    
United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,003 1,778  
Net sales 2,003 1,778  
International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,386 1,248  
Net sales 1,386 1,248  
Emerging Markets [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 529 440  
Net sales 529 440  
Endoscopy [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 577 531  
Net sales 577 531  
Endoscopy [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 351 312  
Net sales 351 312  
Endoscopy [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 226 220  
Net sales 226 220  
Urology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 469 413  
Net sales 469 413  
Urology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 326 286  
Net sales 326 286  
Urology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 143 127  
Net sales 143 127  
Neuromodulation [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 234 209  
Net sales 234 209  
Neuromodulation [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 172 161  
Net sales 172 161  
Neuromodulation [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 62 49  
Net sales 62 49  
Interventional Cardiology Therapies      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 591 544  
Net sales 591 544  
Interventional Cardiology Therapies | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 183 186  
Net sales 183 186  
Interventional Cardiology Therapies | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 408 358  
Net sales 408 358  
Watchman      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 291 226  
Net sales 291 226  
Watchman | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 265 203  
Net sales 265 203  
Watchman | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 25 23  
Net sales 25 23  
Cardiac Rhythm Management [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 548 519  
Net sales 548 519  
Cardiac Rhythm Management [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 345 325  
Net sales 345 325  
Cardiac Rhythm Management [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 203 195  
Net sales 203 195  
Electrophysiology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 177 118  
Net sales 177 118  
Electrophysiology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 85 50  
Net sales 85 50  
Electrophysiology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 91 68  
Net sales 91 68  
Cardiology [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,606 1,407  
Net sales 1,606 1,407  
Cardiology [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 879 764  
Net sales 879 764  
Cardiology [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 727 644  
Net sales 727 644  
Peripheral Interventions [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 503 465  
Net sales 503 465  
Peripheral Interventions [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 275 256  
Net sales 275 256  
Peripheral Interventions [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 229 210  
Net sales 229 210  
BSX Reportable Segments [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,003 1,778  
Net sales 2,003 1,778  
BSX Reportable Segments [Member] | EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 712 624  
Net sales 712 624  
BSX Reportable Segments [Member] | APAC [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 548 517  
Net sales 548 517  
BSX Reportable Segments [Member] | Latin America and Canada [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 126 107  
Net sales 126 107  
MedSurg [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,280 1,153  
Net sales 1,280 1,153  
MedSurg [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 850 758  
Net sales 850 758  
MedSurg [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 430 395  
Net sales 430 395  
Cardiovascular [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,110 1,873  
Net sales 2,110 1,873  
Cardiovascular [Member] | United States      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,154 1,019  
Net sales 1,154 1,019  
Cardiovascular [Member] | International [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 956 853  
Net sales $ 956 $ 853  
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Changes in Other Comprehensive Income (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax $ (35) $ (27)    
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (56) (14)    
Other comprehensive income (loss) (91) (41)    
Accumulated Other Comprehensive Income (Loss), Net of Tax 178 222 $ 269 $ 263
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax (40) (63)    
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax (2) (2)    
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (42) (64)    
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax (43) 29 (1) 93
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 10 35    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (53) (12)    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax (43) 23    
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 225 229 269 206
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax (5) 0    
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax 0 0    
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax (5) 0    
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax $ (4) $ (36) $ 1 $ (36)
XML 69 bsx-20230331_htm.xml IDEA: XBRL DOCUMENT 0000885725 2023-01-01 2023-03-31 0000885725 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000885725 bsx:SeniorNotedue2027Member 2023-01-01 2023-03-31 0000885725 bsx:A550MCPSSeriesAMember 2023-01-01 2023-03-31 0000885725 2023-04-28 0000885725 2022-01-01 2022-03-31 0000885725 2023-03-31 0000885725 2022-12-31 0000885725 us-gaap:PreferredStockMember 2022-12-31 0000885725 us-gaap:PreferredStockMember 2021-12-31 0000885725 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000885725 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000885725 us-gaap:PreferredStockMember 2023-03-31 0000885725 us-gaap:PreferredStockMember 2022-03-31 0000885725 us-gaap:CommonStockMember 2022-12-31 0000885725 us-gaap:CommonStockMember 2021-12-31 0000885725 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000885725 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000885725 2022-03-31 0000885725 us-gaap:CommonStockMember 2023-03-31 0000885725 us-gaap:CommonStockMember 2022-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2021-12-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2023-03-31 0000885725 us-gaap:TreasuryStockCommonMember 2022-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000885725 us-gaap:RetainedEarningsMember 2022-12-31 0000885725 us-gaap:RetainedEarningsMember 2021-12-31 0000885725 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000885725 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000885725 us-gaap:RetainedEarningsMember 2023-03-31 0000885725 us-gaap:RetainedEarningsMember 2022-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2021-12-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2023-03-31 0000885725 us-gaap:NoncontrollingInterestMember 2022-03-31 0000885725 2021-12-31 0000885725 bsx:ApolloMember us-gaap:SubsequentEventMember 2023-04-04 0000885725 bsx:ApolloMember us-gaap:SubsequentEventMember 2023-04-04 2023-04-04 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember 2023-02-20 2023-02-20 0000885725 bsx:AcotecMember 2023-01-01 2023-03-31 0000885725 bsx:AcotecMember 2023-03-31 0000885725 bsx:AcotecMember 2023-02-20 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-03-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-03-31 0000885725 bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:CustomerRelationshipsMember 2023-03-31 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000885725 bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-03-31 0000885725 srt:WeightedAverageMember bsx:AcotecMember us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000885725 bsx:BaylisMedicalMember 2023-01-01 2023-03-31 0000885725 bsx:BaylisMedicalMember 2023-03-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-03-31 0000885725 srt:WeightedAverageMember bsx:BaylisMedicalMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 bsx:AllBusinessAcquisitionsMember 2023-03-31 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-03-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:PatentsMember 2023-03-31 0000885725 us-gaap:PatentsMember 2022-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000885725 us-gaap:GoodwillMember 2023-03-31 0000885725 us-gaap:GoodwillMember 2022-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2023-03-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000885725 bsx:MedsurgMember 2022-12-31 0000885725 bsx:CardiovascularMember 2022-12-31 0000885725 bsx:MedsurgMember 2023-01-01 2023-03-31 0000885725 bsx:CardiovascularMember 2023-01-01 2023-03-31 0000885725 bsx:MedsurgMember 2023-03-31 0000885725 bsx:CardiovascularMember 2023-03-31 0000885725 bsx:December2027NotesMember 2023-03-31 0000885725 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-03-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-03-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-03-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-03-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000885725 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-03-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2023-03-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2023-03-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-03-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2023-03-31 0000885725 bsx:LicensingarrangementassetsMember 2023-03-31 0000885725 srt:WeightedAverageMember bsx:LicensingarrangementassetsMember 2023-03-31 0000885725 srt:MinimumMember bsx:LicensingarrangementliabilitiesMember 2023-03-31 0000885725 srt:MaximumMember bsx:LicensingarrangementliabilitiesMember 2023-03-31 0000885725 srt:WeightedAverageMember bsx:LicensingarrangementliabilitiesMember 2023-03-31 0000885725 bsx:LicensingarrangementassetsMember 2023-01-01 2023-03-31 0000885725 bsx:LicensingarrangementliabilitiesMember 2023-01-01 2023-03-31 0000885725 bsx:March2024NotesMember 2023-03-31 0000885725 bsx:March2024NotesMember 2022-12-31 0000885725 bsx:March2025NotesMember 2023-03-31 0000885725 bsx:March2025NotesMember 2022-12-31 0000885725 bsx:June2025NotesMember 2023-03-31 0000885725 bsx:June2025NotesMember 2022-12-31 0000885725 bsx:March2026NotesMember 2023-03-31 0000885725 bsx:March2026NotesMember 2022-12-31 0000885725 bsx:December2027NotesMember 2022-12-31 0000885725 bsx:March2028SeniorNotesMember 2023-03-31 0000885725 bsx:March2028SeniorNotesMember 2022-12-31 0000885725 bsx:March2028NotesMember 2023-03-31 0000885725 bsx:March2028NotesMember 2022-12-31 0000885725 bsx:March2029NotesMember 2023-03-31 0000885725 bsx:March2029NotesMember 2022-12-31 0000885725 bsx:June2030NotesMember 2023-03-31 0000885725 bsx:June2030NotesMember 2022-12-31 0000885725 bsx:March2031NotesMember 2023-03-31 0000885725 bsx:March2031NotesMember 2022-12-31 0000885725 bsx:March2034NotesMember 2023-03-31 0000885725 bsx:March2034NotesMember 2022-12-31 0000885725 bsx:November2035NotesMember 2023-03-31 0000885725 bsx:November2035NotesMember 2022-12-31 0000885725 bsx:March2039NotesMember 2023-03-31 0000885725 bsx:March2039NotesMember 2022-12-31 0000885725 bsx:January2040NotesMember 2023-03-31 0000885725 bsx:January2040NotesMember 2022-12-31 0000885725 bsx:March2049NotesMember 2023-03-31 0000885725 bsx:March2049NotesMember 2022-12-31 0000885725 us-gaap:SeniorNotesMember 2023-03-31 0000885725 us-gaap:SeniorNotesMember 2022-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2023-03-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2022-12-31 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2021-05-10 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:RevolvingCreditFacility2021Member us-gaap:LineOfCreditMember 2021-05-10 2021-05-10 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:RevolvingCreditFacility2021Member us-gaap:LineOfCreditMember 2023-03-31 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2022-12-31 0000885725 bsx:CurrentRequirementMember 2023-03-31 0000885725 bsx:ActualCovenantMember 2023-03-31 0000885725 bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember 2023-03-31 0000885725 bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember 2023-03-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2023-03-31 0000885725 bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember 2023-03-31 0000885725 bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember 2023-03-31 0000885725 bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember 2023-03-31 0000885725 us-gaap:CommercialPaperMember 2023-01-01 2023-03-31 0000885725 us-gaap:CommercialPaperMember 2023-03-31 0000885725 bsx:TheOfferingAggregatePrincipalAmountMember 2023-03-31 0000885725 2022-01-01 2022-12-31 0000885725 bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember 2023-03-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2023-03-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2023-01-01 2023-03-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2023-03-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2023-01-01 2023-03-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2023-03-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2023-01-01 2023-03-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-12-31 0000885725 bsx:RenminbiDenominatedFactoringArrangementsMember 2022-01-01 2022-12-31 0000885725 2023-01-31 2023-01-31 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2020-05-27 2020-05-27 0000885725 bsx:A550MCPSSeriesAMember 2023-03-31 0000885725 bsx:A550MCPSSeriesAMember us-gaap:SubsequentEventMember 2023-04-24 2023-04-24 0000885725 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000885725 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000885725 bsx:A550MCPSSeriesAMember 2023-01-01 2023-03-31 0000885725 bsx:A550MCPSSeriesAMember 2022-01-01 2022-03-31 0000885725 2020-12-14 0000885725 bsx:MedsurgMember 2022-01-01 2022-03-31 0000885725 bsx:CardiovascularMember 2022-01-01 2022-03-31 0000885725 bsx:BSXReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 bsx:BSXReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2023-01-01 2023-03-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2022-01-01 2022-03-31 0000885725 bsx:SpecialChargesMember 2023-01-01 2023-03-31 0000885725 bsx:SpecialChargesMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2023-01-01 2023-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2022-01-01 2022-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2023-01-01 2023-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2022-01-01 2022-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2023-01-01 2023-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2022-01-01 2022-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2022-01-01 2022-03-31 0000885725 country:US bsx:MedsurgMember 2023-01-01 2023-03-31 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2023-01-01 2023-03-31 0000885725 country:US bsx:MedsurgMember 2022-01-01 2022-03-31 0000885725 us-gaap:NonUsMember bsx:MedsurgMember 2022-01-01 2022-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2023-01-01 2023-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember 2023-01-01 2023-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember country:US 2022-01-01 2022-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:InterventionalCardiologyTherapiesMember 2022-01-01 2022-03-31 0000885725 bsx:WatchmanMember country:US 2023-01-01 2023-03-31 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:WatchmanMember 2023-01-01 2023-03-31 0000885725 bsx:WatchmanMember country:US 2022-01-01 2022-03-31 0000885725 bsx:WatchmanMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:WatchmanMember 2022-01-01 2022-03-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2023-01-01 2023-03-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:CardiacRhythmManagementMember 2023-01-01 2023-03-31 0000885725 bsx:CardiacRhythmManagementMember country:US 2022-01-01 2022-03-31 0000885725 bsx:CardiacRhythmManagementMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:CardiacRhythmManagementMember 2022-01-01 2022-03-31 0000885725 bsx:ElectrophysiologyEPMember country:US 2023-01-01 2023-03-31 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:ElectrophysiologyEPMember 2023-01-01 2023-03-31 0000885725 bsx:ElectrophysiologyEPMember country:US 2022-01-01 2022-03-31 0000885725 bsx:ElectrophysiologyEPMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:ElectrophysiologyEPMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2023-01-01 2023-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember country:US 2022-01-01 2022-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalCardiologyReportingUnitMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2023-01-01 2023-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2023-01-01 2023-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2022-01-01 2022-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2022-01-01 2022-03-31 0000885725 country:US bsx:CardiovascularMember 2023-01-01 2023-03-31 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2023-01-01 2023-03-31 0000885725 country:US bsx:CardiovascularMember 2022-01-01 2022-03-31 0000885725 us-gaap:NonUsMember bsx:CardiovascularMember 2022-01-01 2022-03-31 0000885725 country:US 2023-01-01 2023-03-31 0000885725 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000885725 country:US 2022-01-01 2022-03-31 0000885725 us-gaap:NonUsMember 2022-01-01 2022-03-31 0000885725 country:US bsx:BSXReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 country:US bsx:BSXReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 us-gaap:EMEAMember bsx:BSXReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 srt:AsiaPacificMember bsx:BSXReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2023-01-01 2023-03-31 0000885725 bsx:LatinAmericaandCanadaMember bsx:BSXReportableSegmentsMember 2022-01-01 2022-03-31 0000885725 bsx:EmergingMarketsMember 2023-01-01 2023-03-31 0000885725 bsx:EmergingMarketsMember 2022-01-01 2022-03-31 iso4217:USD shares shares iso4217:USD pure iso4217:KRW utr:Rate iso4217:EUR bsx:derivative_instrument bsx:units bsx:reportablesegments bsx:business 0000885725 --12-31 2023 Q1 false 10-Q true 2023-03-31 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, par value $0.01 per share BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share BSX PR A NYSE Yes Yes Large Accelerated Filer false false false 0.01 1437698101 3389000000 3026000000 1040000000 955000000 2349000000 2071000000 1215000000 1060000000 337000000 319000000 11000000 12000000 203000000 198000000 12000000 12000000 20000000 4000000 1797000000 1605000000 552000000 466000000 65000000 279000000 -43000000 -31000000 444000000 156000000 131000000 45000000 314000000 110000000 14000000 14000000 0 0 300000000 97000000 0.21 0.07 0.21 0.07 1435800000 1427800000 1446000000 1438400000 314000000 110000000 -42000000 -64000000 -43000000 23000000 5000000 0 -91000000 -41000000 223000000 69000000 0 0 223000000 69000000 570000000 928000000 2076000000 1970000000 2050000000 1867000000 296000000 264000000 711000000 731000000 5704000000 5760000000 2478000000 2446000000 13269000000 12920000000 6060000000 5902000000 3900000000 3942000000 1482000000 1500000000 32892000000 32469000000 510000000 20000000 868000000 862000000 1918000000 2160000000 787000000 761000000 4083000000 3803000000 8495000000 8915000000 210000000 144000000 1995000000 2035000000 0.01 0.01 50000000 50000000 10062500 10062500 0 0 0.01 0.01 2000000000 2000000000 1700828873 1696633993 17000000 17000000 263289848 263289848 2251000000 2251000000 20356000000 20289000000 -450000000 -750000000 178000000 269000000 17850000000 17573000000 259000000 0 18109000000 17573000000 32892000000 32469000000 10062500 10062500 0 0 10062500 10062500 1696633993 1688810052 0 0 4194880 4018935 1700828873 1692828987 0 0 0 0 0 0 17000000 17000000 0 0 0 0 17000000 17000000 -2251000000 -2251000000 0 0 -2251000000 -2251000000 20289000000 19986000000 68000000 57000000 20356000000 20043000000 -750000000 -1392000000 314000000 110000000 -14000000 -14000000 -450000000 -1296000000 269000000 263000000 -91000000 -41000000 178000000 222000000 17850000000 16735000000 0 0 0 0 0 0 259000000 0 259000000 0 18109000000 16735000000 314000000 110000000 285000000 274000000 19000000 -75000000 55000000 52000000 -31000000 -20000000 12000000 12000000 0 17000000 0 -194000000 -2000000 19000000 86000000 66000000 185000000 108000000 41000000 140000000 -211000000 -368000000 190000000 -58000000 111000000 121000000 3000000 8000000 375000000 1471000000 10000000 10000000 -9000000 -19000000 -484000000 -1574000000 34000000 20000000 34000000 39000000 0 250000000 0 223000000 0 3184000000 0 3271000000 14000000 14000000 50000000 46000000 63000000 52000000 -69000000 -6000000 0 0 -363000000 -1639000000 1126000000 2168000000 763000000 529000000 55000000 52000000 -9000000 -19000000 570000000 325000000 135000000 146000000 57000000 59000000 763000000 763000000 529000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE A – BASIS OF PRESENTATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their financial statements on a one quarter lag. Accordingly, their results of operations for the period following the closing of the transaction on February 20, 2023 are omitted from the Company’s unaudited consolidated statements of operations for the quarter ended March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The agreement consisted of an upfront cash payment of $10.00 per share, or approximately $615 million. The Apollo business is being integrated into our Endoscopy division.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accounted for the Acotec transaction as a business combination in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(FASB ASC Topic 805). The preliminary purchase price was comprised of the amount presented below: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for majority interest acquisition, net of cash acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes approximately $140 million of cash on hand at the closing of the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded the assets acquired, liabilities assumed and the noncontrolling interest at their respective fair values as of the closing of the transaction. The preliminary purchase price allocation was comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805: </span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Stockholders' equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established due to opportunities for collaboration in research and development, manufacturing and commercial strategies, and is not deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Acquisition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VersaCross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805, Business Combinations. The final purchase price was comprised of the amount presented below: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our acquisitions that closed during the first quarters of 2023 or 2022 contained contingent consideration arrangements. Changes in the fair value of our contingent consideration liability during the first quarter of 2023 associated with prior period acquisitions were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments made during the first quarter of 2023 were primarily related to our 2021 acquisition of Farapulse, Inc. As of March 31, 2023, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $359 million. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected contingent payment amounts related to research and development (R&amp;D), regulatory and commercialization-based milestones and revenue-based payments are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of March 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Includes publicly-held securities measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. </span></div>As of March 31, 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $209 million, which represents amortizable intangible assets, in-process research and development (IPR&amp;D), goodwill and deferred tax liabilities. 1 10.00 615000000 0.65 20.00 519000000 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for majority interest acquisition, net of cash acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes approximately $140 million of cash on hand at the closing of the transaction.</span></div> 375000000 375000000 140000000 The preliminary purchase price allocation was comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 336000000 334000000 61000000 23000000 74000000 259000000 375000000 0.35 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 308000000 P11Y 0.14 15000000 P11Y 0.14 11000000 P13Y 0.14 334000000 1463000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for acquisition, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1463000000 1463000000 The final purchase price allocation was comprised of the following components:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table> 988000000 657000000 112000000 287000000 7000000 1463000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated a portion of the purchase price to the specific intangible asset categories as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount Assigned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Amortization Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk-Adjusted Discount <br/>Rates used in Purchase Price Allocation</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 622000000 P11Y 0.11 657000000 Changes in the fair value of our contingent consideration liability during the first quarter of 2023 associated with prior period acquisitions were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration net expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 149000000 12000000 68000000 93000000 359000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D, Regulatory and Commercialization-based Milestones</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue-based Payments</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Payment</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 13000000 0.01 0.02 0.02 0.10 0.25 0.22 80000000 0.06 0.14 0.07 1 1 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement alternative investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1, 2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">407</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Includes publicly-held securities measured at fair value with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div> 166000000 188000000 219000000 219000000 385000000 407000000 209000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,357)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in our balance of goodwill and amortizable intangible assets is related primarily to our acquisition of a majority stake investment in Acotec completed in the first quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following represents a roll-forward of our goodwill balance by global reportable segment:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations and purchase price adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Asset Impairments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any goodwill impairment charges in the first quarters 2023 or 2022. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization/ Write-offs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizable intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,357)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,173)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indefinite-lived intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 12707000000 7553000000 12397000000 7378000000 473000000 381000000 486000000 394000000 2005000000 1422000000 1960000000 1400000000 15185000000 9357000000 14843000000 9173000000 23169000000 9900000000 22820000000 9900000000 112000000 112000000 120000000 120000000 232000000 232000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following represents a roll-forward of our goodwill balance by global reportable segment:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,920</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations and purchase price adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4237000000 8684000000 12920000000 0 336000000 336000000 336000000 0 13000000 13000000 4237000000 9032000000 13269000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and actively monitoring counterparty credit ratings. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Currency Hedging Instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax (OCI) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of March 31, 2023 and December 31, 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% euro-denominated senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Cumulative Translation Adjustment (CTA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> component of O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reclassify these gains and losses to current period earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Hedging Instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of March 31, 2023 or December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until the underlying hedged transaction occurs. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.430%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the remaining time to maturity is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and three years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying unaudited consolidated statements of operations. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note M – Changes in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.663%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.114%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.911%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recurring Fair Value Measurements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in money market funds and time deposits are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $170 million invested in money market funds and time deposits as of March 31, 2023 and $673 million as of December 31, 2022, we held $400 million in interest-bearing and non-interest-bearing bank accounts as of March 31, 2023 and $256 million as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring fair value measurements using Level 3 inputs include those related to our contingent consideration liability. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions, Divestitures and Strategic Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a discussion of the changes in the fair value of our contingent consideration liability. In addition, our recurring fair value measurements using Level 3 inputs related to our licensing arrangements, including the contractual right to receive future royalty payments related to the Zytiga™ Drug. We maintain a financial asset and associated liability for our licensing arrangements measured at fair value in our accompanying unaudited consolidated balance sheets in accordance with FASB ASC Topic 825, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We elected the fair value option to measure the financial asset and associated liability as it provides for consistency and comparability of these financial instruments with others. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of March 31, 2023 include the following significant unobservable inputs:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$113 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note B – Acquisitions, Divestitures and Strategic Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our strategic investments and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note C – Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of the fair values of our intangible assets including goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our outstanding debt obligations was $8.467 billion as of March 31, 2023 and $8.203 billion as of December 31, 2022. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of our debt obligations.</span></div> 900000000 0.00625 P1Y 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.430%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-designated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Notional Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,321</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.</span></div> 2673000000 2725000000 365000000 365000000 997000000 997000000 3623000000 4235000000 7657000000 8321000000 900000000 36 P1Y <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="30" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unaudited Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount Reclassified from AOCI into Earnings</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax Gain (Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) Net of Tax</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Amount Reclassified and Total Amount of Line Item</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pre-Tax (Gain) Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax (Benefit) Expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Gain) Loss Net of Tax</span></td></tr><tr><td colspan="33" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency-denominated debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net investment hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings represent the effect of the hedging relationships on earnings. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to earnings as a reduction of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> CTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. No amounts were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to current period earnings.</span></div> 13000000 -3000000 10000000 1040000000 -69000000 16000000 -54000000 6000000 -1000000 4000000 65000000 -3000000 1000000 -2000000 -19000000 4000000 -14000000 43000000 0 0 0 0 0 0 65000000 1000000 0 1000000 45000000 -10000000 35000000 955000000 -30000000 7000000 -23000000 15000000 -3000000 11000000 279000000 -2000000 0 -2000000 24000000 -5000000 18000000 31000000 0 0 0 0 0 0 279000000 14000000 -3000000 11000000 0 0 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to earnings within the next twelve months are presented below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:28.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.663%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FASB ASC Topic 815 Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Hedging Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 189000000 9000000 -3000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.114%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency hedge contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) on currency transaction exposures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net currency exchange gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -8000000 -29000000 -6000000 21000000 -14000000 -9000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span> The following are the balances of our derivative and nonderivative assets and liabilities:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.911%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Unaudited Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivative and Nonderivative Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Designated Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Derivative and Nonderivative Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.</span></div> 168000000 196000000 132000000 149000000 299000000 345000000 19000000 36000000 319000000 381000000 0 1000000 971000000 952000000 972000000 953000000 37000000 52000000 1009000000 1005000000 900000000 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and time deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Publicly-held equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our accompanying unaudited consolidated balance sheets as of March 31, 2023 include the following significant unobservable inputs:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licensing Arrangements</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Asset</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$113 million</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liability</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$120 million</span></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted Cash Flow</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Year of Payment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial asset were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our licensing arrangements' financial liability were as follows:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 170000000 0 0 170000000 673000000 0 0 673000000 2000000 0 0 2000000 2000000 0 0 2000000 0 319000000 0 319000000 0 381000000 0 381000000 0 0 113000000 113000000 0 0 127000000 127000000 172000000 319000000 113000000 604000000 674000000 381000000 127000000 1182000000 0 1009000000 0 1009000000 0 1005000000 0 1005000000 0 0 93000000 93000000 0 0 149000000 149000000 0 0 120000000 120000000 0 0 159000000 159000000 0 1009000000 213000000 1222000000 0 1005000000 308000000 1313000000 170000000 673000000 400000000 256000000 113000000 0.15 0.15 120000000 0.12 0.15 0.13 127000000 18000000 4000000 113000000 159000000 43000000 5000000 120000000 8467000000 8203000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings and Credit Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total debt outstanding of $9.005 billion as of March 31, 2023 and $8.935 billion as of December 31, 2022, with current obligations of $510 million as of March 31, 2023 and $20 million as of December 31, 2022. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, <br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated senior notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2023 and December 31, 2022, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021, we entered into a new $2.750 billion revolving credit facility (2021 Revolving Credit Facility) with a global syndicate of commercial banks scheduled to mature on May 10, 2026, with one-year extension options, subject to certain conditions. On March 1, 2023, we entered into an amendment of the 2021 Revolving Credit Facility credit agreement, which provided for an extension of the scheduled maturity date to May 10, 2027 and replaced the London Interbank Offered Rate (LIBOR) with the Secured Overnight Financing Rate (SOFR) as the Eurocurrency Rate for Dollars, including applicable credit spread adjustments and relevant SOFR benchmark provisions, among other things described under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This facility provides backing for our commercial paper program, and outstanding commercial paper directly reduces borrowing capacity under the 2021 Revolving Credit Facility. There were no amounts outstanding under the 2021 Revolving Credit Facility as of March 31, 2023 or December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Covenant</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended.</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 times</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Revolving Credit Facility includes the financial covenant requirement for all of our credit arrangements that we maintain the maximum permitted leverage ratio of 3.75 times through the remaining term. The agreement provides for higher leverage ratios, at our election, for the period following a qualified acquisition for which consideration exceeds $1.000 billion. In the event of such an acquisition, for the four succeeding quarters immediately following, including the quarter in which the acquisition occurs, the maximum permitted leverage ratio is 4.75 times. The maximum permitted ratio steps down for the fifth, sixth and seventh succeeding quarters to 4.50 times, 4.25 times and 4.00 times, respectively. Thereafter, a maximum leverage ratio of 3.75 times is required through the remaining term of the 2021 Revolving Credit Facility. We have not elected to increase the maximum permitted leverage ratio for any qualified acquisitions due to our funding of these acquisitions using cash on hand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenant requirement, as amended on March 1, 2023, provides for an exclusion from the calculation of consolidated EBITDA, as defined by the credit agreement, through maturity, of certain charges and expenses. The credit agreement amendment reset the starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of March 31, 2023, we had $457 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreement, are excluded from the calculation of consolidated EBITDA, as defined by the agreement, provided that the sum of any excluded net cash litigation payments do not exceed $1.000 billion plus all accrued legal liabilities as of December 31, 2022 for a total of $1.443 billion. As of March 31, 2023, we had $1.424 billion of the litigation exclusion remaining.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to maintain compliance with this covenant could require us to seek to renegotiate the terms of our credit arrangements or seek waivers from compliance with this covenant, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all 2021 Revolving Credit Facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our 2021 Revolving Credit Facility may negatively impact the credit ratings assigned to our commercial paper program, which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial paper program is backed by the 2021 Revolving Credit Facility. We had no commercial paper outstanding as of March 31, 2023 or December 31, 2022. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had senior notes outstanding of $9.067 billion as of March 31, 2023 and $8.986 billion as of December 31, 2022. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, American Medical Systems Europe B.V. (AMS Europe), an indirect, wholly owned subsidiary of Boston Scientific, completed a registered public offering (the Offering) of €3.000 billion in aggregate principal amount of euro-dominated senior notes comprised of €1.000 billion of 0.750% Senior Notes due 2025, €750 million of 1.375% Senior Notes due 2028, €750 million of 1.625% Senior Notes due 2031 and €500 million of 1.875% Senior Notes due 2034 (collectively, the Eurobonds). Boston Scientific has fully and unconditionally guaranteed all of AMS Europe's obligations under the Eurobonds, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and no other subsidiary of Boston Scientific will guarantee these obligations. AMS Europe is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X. The financial condition, results of operations and cash flows of AMS Europe are consolidated in the financial statements of Boston Scientific. The Offering resulted in cash proceeds of $3.270 billion, net of investor discounts and issuance costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from the Offering to fund the tender offer and early redemption of combined aggregate principal amount of $3.275 billion of certain of our outstanding senior notes, as well as to pay accrued interest, tender premiums, fees and expenses. We recorded associated debt extinguishment charges of $194 million during the first quarter of 2022 presented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Arrangements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable factoring programs in certain European countries and with commercial banks in China and Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfers and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying unaudited consolidated balance sheets, are aggregated by contract denominated currency below (in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.912%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Renminbi denominated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Obligations and Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding letters of credit of $143 million as of March 31, 2023 and $135 million as of December 31, 2022, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of March 31, 2023 and December 31, 2022 we had not recognized a related liability for any outstanding letters of credit within our accompanying unaudited consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supplier financing program offered primarily in the U.S. where our suppliers can opt to receive early payment at a nominal discount, while allowing us to lengthen our payment terms and optimize working capital. Our standard payment term in the U.S. is 90 days. All outstanding payables related to the supplier finance program are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our unaudited consolidated balance sheets and were $128 million as of March 31, 2023 and $129 million as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note E – Contractual Obligations and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.</span></div> 9005000000.000 8935000000 510000000 20000000 The debt maturity schedule for our long-term debt obligations is presented below: <div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.847%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except interest rates)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Coupon Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, <br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.450%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.900%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.000%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030 Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.650%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.625%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.875%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2005</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.750%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.550%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040 Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.375%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049 Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.700%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized Debt Issuance Discount and Deferred Financing Costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Lease Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,495</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Coupon rates are semi-annual, except for the euro-denominated senior notes, which bear an annual coupon.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher. Effective May 2023, the interest rate payable will decrease by 0.25 percent and begin accruing at a rate of 6.50 percent following recent upgrades to our credit ratings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These notes are euro-denominated and presented in U.S. dollars based on the exchange rate in effect as of March 31, 2023 and December 31, 2022, respectively.</span></div>(4)    Amounts repaid, or partially repaid as the case may be, in connection with the March 2022 tender offer and early redemption of certain of our outstanding senior notes are described below. 0 504000000 0.03450 1088000000 1067000000 0.00750 500000000 500000000 0.01900 255000000 255000000 0.03750 979000000 960000000 0.00625 816000000 800000000 0.01375 344000000 344000000 0.04000 272000000 272000000 0.04000 1200000000 1200000000 0.02650 816000000 800000000 0.01625 544000000 534000000 0.01875 350000000 350000000 0.06750 450000000 450000000 0.04550 300000000 300000000 0.07375 650000000 650000000 0.04700 -73000000 -76000000 5000000 5000000 8495000000 8915000000 2750000000 P1Y 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we were in compliance with the financial covenant required by the 2021 Revolving Credit Facility, as amended.</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covenant Requirement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as of March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum permitted leverage ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75 times</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 times</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, as amended.</span></div> 3.75 2.52 3.75 1000000000 4.75 4.50 4.25 4.00 3.75 500000000 457000000 1000000000 1443000000 1424000000 We had no commercial paper outstanding as of March 31, 2023 or December 31, 2022. In April 2023, we issued commercial paper to partially fund our acquisition of Apollo. As of the date of this Quarterly Report on Form 10-Q, we had approximately $400 million of commercial paper outstanding, which directly reduces our borrowing capacity under the 2021 Revolving Credit Facility. 0 0 400000000 9067000000.000 8986000000 3000000000 1000000000 0.00750 750000000 0.01375 750000000 0.01625 500000000 0.01875 3270000000 3275000000 -194000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.912%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Factoring Arrangements</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>De-recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro denominated</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen denominated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Renminbi denominated</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 188000000 0.055 161000000 0.024 188000000 0.005 194000000 0.006 14000000 0.030 13000000 0.031 143000000 135000000 128000000 129000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions within our accompanying unaudited consolidated balance sheets are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trade accounts receivable, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll forward of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 326</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (FASB ASC Topic 326), we record credit loss reserves to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when we establish </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade accounts receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if credit losses are expected over the asset's contractual life. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. We utilize an accounts receivable aging approach, applying country or region-specific factors, to determine the reserve to record at accounts receivable commencement for certain customers. In performing the assessment of outstanding accounts receivable, regardless of country or region, we may consider significant factors relevant to collectability, including those specific to a customer such as bankruptcy, lengthy average payment cycles and type of account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic and geopolitical conditions. Our sales to government-owned or supported customers, particularly in southern Europe, are subject to an increased number of days outstanding prior to payment relative to other entities, and, in southern Europe, relative to those in other countries. In addition, we have seen an increase in the volume of our U.S. business conducted in ambulatory surgery centers and office-based laboratories. Many of these customers are smaller than those we have historically done business with and may have more limited liquidity. We have adjusted our estimates of credit loss reserves for these customers, regions and conditions based on collection trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current assets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, plant and equipment, net</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $82 million for the first quarter of 2023 and $76 million for the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term assets</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued expenses</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other long-term liabilities</span></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit loss expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 2194000000 2079000000 118000000 109000000 2076000000 1970000000 109000000 108000000 16000000 11000000 6000000 5000000 118000000 113000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,867</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1223000000 1171000000 176000000 147000000 651000000 548000000 2050000000 1867000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">731</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 135000000 149000000 187000000 232000000 56000000 60000000 333000000 290000000 711000000 731000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,446</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 141000000 137000000 1763000000 1695000000 3367000000 3297000000 567000000 598000000 5837000000 5728000000 3359000000 3282000000 2478000000 2446000000 82000000 76000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 57000000 48000000 399000000 386000000 133000000 149000000 385000000 407000000 57000000 67000000 170000000 172000000 280000000 271000000 1482000000 1500000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 207000000 231000000 661000000 830000000 347000000 352000000 83000000 74000000 620000000 674000000 1918000000 2160000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 231000000 220000000 57000000 79000000 281000000 232000000 217000000 230000000 787000000 761000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 608000000 597000000 209000000 212000000 10000000 75000000 63000000 80000000 360000000 347000000 290000000 289000000 457000000 434000000 1995000000 2035000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE G – INCOME TAXES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate from continuing operations is presented below:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our reported tax rates for the first quarter of 2023, as compared to the same period in 2022, relate primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These include debt extinguishment charges recorded in the first quarter of 2022, as well as certain discrete tax items primarily related to provision-to-return adjustments recorded in the first quarter of 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had $501 million of gross unrecognized tax benefits, of which a net $415 million, if recognized, would affect our effective tax rate. As of December 31, 2022, we had $492 million of gross unrecognized tax benefits, of which a net $410 million, if recognized, would affect our effective tax rate. The change in our gross unrecognized tax benefit is primarily related to positions on new entities we acquired through recent acquisitions and restructuring activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that within the next 12 months, we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $77 million.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.294 0.291 501000000 415000000 492000000 410000000 77000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTE H – COMMITMENTS AND CONTINGENCIES </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product liability, securities and commercial claims have been asserted against us and similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. For additional information, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note I – Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within our accompanying unaudited consolidated statements of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual for legal matters that are probable and estimable was $416 million as of March 31, 2023 and $443 million as of December 31, 2022 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims related to our transvaginal surgical mesh products. A portion of this accrual is already funded through our qualified settlement fund (QSF), which is included in restricted cash and restricted cash equivalents in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $135 million as of March 31, 2023 and $149 million as of December 31, 2022. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note F – Supplemental Balance Sheet Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. We did not record any litigation-related net charges during the first quarter of 2023 or 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our financial covenant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2015, the Company filed suit against Cook Group Limited and Cook Medical LLC (collectively, Cook) in the United States District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct™ Endoscopic Hemoclip. The Company seeks lost profits, a reasonable royalty and a permanent injunction. The case was transferred to the District Court for the Southern District of Indiana. Cook filed Inter Partes Review (IPR) requests with the U.S. Patent and Trademark Office (USPTO) against four then-asserted patents, which resulted in the court staying the case until 2020. All IPRs concluded and confirmed the validity of certain claims of each challenged patent. In </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 2023, the District Court issued summary judgment rulings dismissing certain claims and defenses. Trial on the remaining two asserted patents is scheduled for May 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2017, The Board of Regents, University of Texas System and TissueGen. Inc. (collectively, UT), served a lawsuit against us in the Western District of Texas. The complaint against the Company alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. UT primarily seeks a reasonable royalty. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. In April 2020, the United States Supreme Court denied the UT’s Petition for Certiorari. UT proceeded with its case against us in Delaware. In January 2023, a jury trial was held on the issue of whether the one UT patent still asserted in the case was valid and whether it was infringed by the Company. On January 31, 2023, a jury concluded that UT’s patent was valid and willfully infringed by the Company, and awarded UT $42 million in damages. Following the trial, UT has filed a motion seeking prejudgment interest and enhanced damages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has filed a motion seeking judgment as a matter of law in its favor or alternatively a new trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia. Plaintiffs generally seek monetary damages based on allegations of personal injury associated with the use of our transvaginal surgical mesh products, including design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. We have entered into individual and master settlement agreements in principle or are in the final stages of entering agreements with certain plaintiffs' counsel, to resolve the majority of these cases and claims. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. In addition, in April 2021 the Company's Board of Directors received a shareholder demand under section 220 of the Delaware General Corporation Law, for inspection of books and records related to mesh settlements. The Company has notified our insurer and retained counsel to respond to the demand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a product liability accrual for remaining claims asserted against us associated with our transvaginal surgical mesh products and the costs of defense thereof. We continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims. We continue to vigorously contest these cases and claims. The final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Investigations and Qui Tam Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda. (BSB), as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. Under applicable guidance, BSB could be fined a percentage of BSB’s 2016 gross revenues. In August 2021, the investigating commissioner issued a preliminary recommendation of liability against all of the involved companies, and also recommended that CADE impose fines and penalties. However, on October 25, 2021, the CADE Attorney General's office recommended dismissal of the charges and allegations against BSB and the individual BSB employees who were still individual defendants. Subsequently, on March 30, 2022, the Federal Prosecutor’s office issued a non-binding recommendation that is contrary to the Attorney General’s recommendation. The full Commission is considering both of these recommendations but has not yet issued its decision. We continue to deny the allegations, intend to defend ourselves vigorously and will appeal any decision of liability by the full Commission to the Brazilian courts. During such an appeal, the decision would have no force and effect, and the Court would consider the case without being bound by CADE’s decision.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam. The Company has received related subpoenas for documents from the Office of the U.S. Attorney for the District of Massachusetts and the Securities and Exchange Commission. The Company is cooperating with government agencies while investigating these allegations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, the Company received a subpoena from the U.S. Department of Justice (DOJ) that seeks documents and information relating to its ambulatory electrocardiography monitoring (AECG) business. The Company is cooperating with the DOJ in responding to this subpoena.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2020, Enrique Jevons, individually and on behalf of all others similarly situated, filed a class action complaint against the Company, Michael F. Mahoney and Daniel J. Brennan, stemming from the recall and retirement of the LOTUS Edge™ Aortic Valve System (LOTUS System) in United States District Court for the Eastern District of New York. On December 14, 2020, the parties agreed to transfer the case to the United States District Court for the District of Massachusetts. On December 16, 2020, Mariano Errichiello, individually and on behalf of all others similarly situated, filed a second, materially similar class action complaint against the Company, Michael F. Mahoney, Joseph M. Fitzgerald, and Daniel J. Brennan in the United States District Court for the District of Massachusetts. Subsequently, on March 30, 2021, the Court consolidated the two actions, and appointed Mariano Errichiello as the lead plaintiff. The plaintiffs filed an Amended Complaint in June 2021 that seeks unspecified compensatory damages in favor of the alleged class as well as unspecified equitable relief. The Company filed a Motion to Dismiss in July 2021, which, in December 2022, the Court granted in part and denied in part. The Company intends to vigorously defend itself against the surviving allegations. On December 15, 2020, the Securities and Exchange Commission’s Boston Regional Office (Boston SEC) notified the Company that it was conducting an investigation related to the Company’s decision to retire the LOTUS System and issued a voluntary request for documents and information related to that decision. On February 10, 2021, the Boston SEC issued a second voluntary request for additional documents and information. The Company cooperated fully with the requests, and on January 3, 2022, the SEC informed us that it was concluding its investigation and that it did not intend to recommend an enforcement action. On February 8, 2021, the Company received a letter from The Vladimir Gusinsky Revocable Trust, a shareholder, demanding that the Company’s Board of Directors conduct an investigation into actions by the Company’s directors and executive officers regarding statements made about the effectiveness and commercial viability of the LOTUS System. The Trust subsequently agreed to stay its demand, pending the outcome of any dispositive motion against the Amended Complaint in the class action complaint described above. The Company received letters on behalf of the Union Excavators Local 731 Pension Fund, Diane Nachbaur, and Frank Tripson, three stockholders of the Company, on July 26, 2021, July 29, 2021, and February 13, 2023, respectively, each demanding access to certain books and records of the Company, pursuant to 8 Delaware Section 220, regarding the business, operations, effectiveness and commercial viability of the LOTUS system, and related items. On February 7, 2023, Diane Nachbaur filed a shareholder derivative complaint in the United States District Court for the District of Massachusetts against the Company, Michael F. Mahoney, Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, David Roux, John E. Sununu, Ellen M. Zane, Joseph M. Fitzgerald, Daniel J. Brennan, Shawn McCarthy, Ian Meredith, Kevin Ballinger, and Susan Vissers Lisa.</span></div> FASB ASC Topic 450, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation-related net charges (credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span>within our accompanying unaudited consolidated statements of operations. 416000000 443000000 135000000 149000000 42000000 29 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE I – STOCKHOLDERS' EQUITY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we completed an offering of 10,062,500 shares of 5.50% Mandatory Convertible Preferred Stock (MCPS), Series A at a price to the public and liquidation preference of $100 per share. The net proceeds from the MCPS offering were approximately $975 million after deducting underwriting discounts and commissions and offering expenses. As of March 31, 2023, our MCPS had an aggregate liquidation preference of $1.006 billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, the Audit Committee of our Board of Directors (the Committee), pursuant to authority delegated to such committee by our Board of Directors, declared, and we paid, a cash dividend of $1.375 per MCPS share to holders of our MCPS as of February 15, 2023, representing a dividend period from December 2022 through February 2023. On April 24, 2023 the Committee declared a cash dividend of $1.375 per MCPS share to holders of our MCPS as of May 15, 2023, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representing a dividend period from March through May 2023. We have presented cumulative, unpaid dividends within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheet as of March 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note J – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for information on the pertinent rights and privileges of our outstanding common stock.</span></div> 50000000 10062500 0.0550 100 975000000 1006000000.000 1.375 1.375 <div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding — basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,446.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,438.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of diluted weighted average shares outstanding because their effect in the periods presented below would have been anti-dilutive:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) per common share - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options, stock awards and MCPS from the calculation if the effect would be anti-dilutive. The dilutive effect of MCPS is calculated using the if-converted method. The if-converted method assumes that these securities were converted to shares of common stock at the beginning of the reporting period to the extent that the effect is dilutive. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the first quarter of 2023 and 2022, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of earnings per share (EPS). Accordingly, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was reduced by cumulative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as presented within our accompanying unaudited consolidated statements of operations, for purposes of calculating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Boston Scientific common stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We issued approximately four million shares of our common stock in the first quarter of 2023 and 2022 following the exercise of stock options, vesting of restricted stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first quarter of 2023 or 2022. On December 14, 2020, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. As of March 31, 2023, we had the full amount remaining available under the authorization.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding — basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,446.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,438.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1435800000 1427800000 10200000 10600000 1446000000 1438400000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following securities were excluded from the calculation of diluted weighted average shares outstanding because their effect in the periods presented below would have been anti-dilutive:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents stock options outstanding pursuant to our employee stock-based compensation plans with exercise prices that were greater than the average fair market value of our common stock for the related periods.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Represents common stock issuable upon the conversion of MCPS. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note I – Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div> 3000000 3000000 24000000 24000000 4000000000000 4000000000000 1000000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE K – SEGMENT REPORTING </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aggregate our core businesses into two reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices. In accordance with FASB ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and evaluate our reportable segments based on their respective net sales, operating income, excluding intersegment profits, and operating income as a percentage of net sales, all excluding the impact of foreign currency. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits); and certain litigation-related net charges (credits) and European Union (EU) Medical Device Regulation (MDR) implementation costs. Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income (loss) before income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated statements of operations and are included in the reconciliation below. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note L – Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for net sales by reportable segment presented in accordance with U.S. GAAP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income margin of reportable segments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency fluctuations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income margin of reportable segments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1252000000 1164000000 2049000000 1902000000 3301000000 3066000000 88000000 -40000000 3389000000 3026000000 400000000 371000000 541000000 477000000 940000000 847000000 75000000 66000000 110000000 117000000 203000000 198000000 552000000 466000000 -108000000 -310000000 444000000 156000000 0.319 0.318 0.264 0.251 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE L – REVENUE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,386</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note K- Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are classified within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $521 million as of March 31, 2023 and $509 million as of December 31, 2022. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $42 million in the first quarter that was included in the above contract liability balance as of December 31, 2022. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. </span></div>Variable Consideration<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on variable consideration, refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note A – Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.</span> 5 The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Businesses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Int'l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endoscopy</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MedSurg</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">850</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">758</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Interventional Cardiology Therapies</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Watchman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Cardiac Rhythm Management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">    Electrophysiology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiology</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Interventions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,386</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note K- Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for information on our reportable segments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic Regions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Net Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation. 351000000 226000000 577000000 312000000 220000000 531000000 326000000 143000000 469000000 286000000 127000000 413000000 172000000 62000000 234000000 161000000 49000000 209000000 850000000 430000000 1280000000 758000000 395000000 1153000000 183000000 408000000 591000000 186000000 358000000 544000000 265000000 25000000 291000000 203000000 23000000 226000000 345000000 203000000 548000000 325000000 195000000 519000000 85000000 91000000 177000000 50000000 68000000 118000000 879000000 727000000 1606000000 764000000 644000000 1407000000 275000000 229000000 503000000 256000000 210000000 465000000 1154000000 956000000 2110000000 1019000000 853000000 1873000000 2003000000 1386000000 3389000000 1778000000 1248000000 3026000000 2003000000 1778000000 712000000 624000000 548000000 517000000 126000000 107000000 3389000000 3026000000 529000000 440000000 521000000 509000000 42000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note D – Hedging Activities and Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail on our net investment hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our cash flow hedges recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net change in derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide the reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Derivative Financial Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Change in Defined Benefit Pensions and Other Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss amounts reclassified from accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>R -1000000 269000000 -1000000 269000000 -40000000 10000000 -5000000 -35000000 2000000 53000000 0 56000000 -42000000 -43000000 5000000 -91000000 -43000000 225000000 4000000 178000000 93000000 206000000 36000000 263000000 -63000000 35000000 0 -27000000 2000000 12000000 0 14000000 -64000000 23000000 0 -41000000 29000000 229000000 36000000 222000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE N – NEW ACCOUNTING PRONOUNCEMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first quarter of 2023, we implemented the following standards on a prospective basis, none of which had a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-01</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-02</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-04</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities— Supplier Finance Programs (Subtopic 405-50) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Standards to be Implemented</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.</span></div> ASC Update No. 2022-01<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. </span>Update No. 2022-01 expands the current single-layer method to allow multiple hedged layers of a single closed portfolio under the method, among other updates to these methods. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Update No. 2022-02</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments- Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">makes amendments related to troubled debt restructurings for entities that have adopted Update No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as </span></div>amendments related to vintage disclosures for entities with investments in financing receivables that have adopted Update No. 2016-13. ASC Update No. 2022-04<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Update No. 2022-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liabilities— Supplier Finance Programs (Subtopic 405-50) </span>enhances the transparency of supplier finance programs by requiring that a buyer in a supplier finance program disclose sufficient qualitative and quantitative information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASC Update No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Update No. 2022-03 clarifies the guidance in Topic 820 related to measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, as well as introduces new disclosure requirements for these types of equity securities. Update No. 2022-03 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We do not expect the adoption to have a material impact on our financial position or results of operations.</span> EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 316 357 1 false 109 0 false 11 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false R2.htm 0000002 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows (Supplemental Disclosure) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure Consolidated Statements of Cash Flows (Supplemental Disclosure) Statements 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation Sheet http://www.bostonscientific.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions, Divestitures and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments Acquisitions, Divestitures and Strategic Investments Notes 10 false false R11.htm 0000011 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 11 false false R12.htm 0000012 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Contractual Obligations and Commitments Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitments Contractual Obligations and Commitments Notes 13 false false R14.htm 0000014 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 0000018 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 18 false false R19.htm 0000019 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 19 false false R20.htm 0000020 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 20 false false R21.htm 0000021 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 21 false false R22.htm 0000022 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 22 false false R23.htm 0000023 - Disclosure - Basis of Presentation Basis of Presentation (Policies) Sheet http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies Basis of Presentation Basis of Presentation (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 23 false false R24.htm 0000024 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesandFairValueMeasurementsPolicies Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 24 false false R25.htm 0000025 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesCommitmentsandContingenciesPolicies Commitments and Contingencies Commitments and Contingencies (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 25 false false R26.htm 0000027 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 26 false false R27.htm 0000028 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables Acquisitions, Divestitures and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments 27 false false R28.htm 0000029 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables Goodwill and Other Intangible Assets Goodwill (Tables) Tables http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets 28 false false R29.htm 0000030 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements 29 false false R30.htm 0000031 - Disclosure - Contractual Obligations and Commitments (Tables) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables Contractual Obligations and Commitments (Tables) Tables http://www.bostonscientific.com/role/ContractualObligationsandCommitments 30 false false R31.htm 0000032 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 31 false false R32.htm 0000033 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 32 false false R33.htm 0000034 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 33 false false R34.htm 0000035 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 34 false false R35.htm 0000036 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 35 false false R36.htm 0000037 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome 36 false false R37.htm 0000038 - Disclosure - Basis of Presentation (Details) Sheet http://www.bostonscientific.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies 37 false false R38.htm 0000039 - Disclosure - Acquisitions and Divestitures (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails Acquisitions and Divestitures (Details) Details 38 false false R39.htm 0000040 - Disclosure - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/ContingentConsiderationDetails Contingent Consideration (Details) Details 39 false false R40.htm 0000041 - Disclosure - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/StrategicInvestmentsDetails Strategic Investments (Details) Details 40 false false R41.htm 0000042 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables 41 false false R42.htm 0000043 - Disclosure - Hedging Activities and Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails Hedging Activities and Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables 42 false false R43.htm 0000044 - Disclosure - Contractual Obligations and Commitments (Details) Sheet http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails Contractual Obligations and Commitments (Details) Details http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables 43 false false R44.htm 0000045 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 44 false false R45.htm 0000046 - Disclosure - Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bostonscientific.com/role/IncomeTaxesTables 45 false false R46.htm 0000047 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsandContingenciesCommitmentsandContingenciesPolicies 46 false false R47.htm 0000048 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 47 false false R48.htm 0000049 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 48 false false R49.htm 0000050 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 49 false false R50.htm 0000051 - Disclosure - Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDetails Revenue (Details) Details http://www.bostonscientific.com/role/RevenueTables 50 false false R51.htm 0000052 - Disclosure - Changes in Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails Changes in Other Comprehensive Income (Details) Details http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables 51 false false All Reports Book All Reports bsx-20230331.htm bsx-20230331.xsd bsx-20230331_cal.xml bsx-20230331_def.xml bsx-20230331_lab.xml bsx-20230331_pre.xml ex102-2023grantxnqagreemen.htm ex103-2023grantxrsuagreeme.htm ex104-2023grantxtsrawardag.htm ex105-2023grantxonsgawarda.htm exhibit22-subsidiaryissuer.htm exhibit311-ceo302q12023.htm exhibit312-cfo302q12023.htm exhibit321-ceo906q12023.htm exhibit322-cfo906q12023.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bsx-20230331.htm": { "axisCustom": 1, "axisStandard": 27, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 926, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 316, "dts": { "calculationLink": { "local": [ "bsx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20230331_def.xml" ] }, "inline": { "local": [ "bsx-20230331.htm" ] }, "labelLink": { "local": [ "bsx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20230331_pre.xml" ] }, "schema": { "local": [ "bsx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 628, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 46, "keyStandard": 311, "memberCustom": 58, "memberStandard": 47, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Document", "menuCat": "Cover", "order": "1", "role": "http://www.bostonscientific.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisitions, Divestitures and Strategic Investments", "menuCat": "Notes", "order": "10", "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments", "shortName": "Acquisitions, Divestitures and Strategic Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Goodwill and Other Intangible Assets", "menuCat": "Notes", "order": "11", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Hedging Activities and Fair Value Measurements", "menuCat": "Notes", "order": "12", "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "shortName": "Hedging Activities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i2887ce8cd383457f9ee11384c498b860_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Contractual Obligations and Commitments", "menuCat": "Notes", "order": "13", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitments", "shortName": "Contractual Obligations and Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i2887ce8cd383457f9ee11384c498b860_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Supplemental Balance Sheet Information", "menuCat": "Notes", "order": "14", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://www.bostonscientific.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://www.bostonscientific.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "17", "role": "http://www.bostonscientific.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Weighted Average Shares Outstanding", "menuCat": "Notes", "order": "18", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "shortName": "Weighted Average Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "19", "role": "http://www.bostonscientific.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Revenue", "menuCat": "Notes", "order": "20", "role": "http://www.bostonscientific.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Changes in Other Comprehensive Income", "menuCat": "Notes", "order": "21", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome", "shortName": "Changes in Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - New Accounting Pronouncements", "menuCat": "Notes", "order": "22", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "shortName": "New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:NewAccountingPronouncementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Basis of Presentation Basis of Presentation (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies", "shortName": "Basis of Presentation Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)", "menuCat": "Policies", "order": "24", "role": "http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesandFairValueMeasurementsPolicies", "shortName": "Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies)", "menuCat": "Policies", "order": "25", "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesCommitmentsandContingenciesPolicies", "shortName": "Commitments and Contingencies Commitments and Contingencies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "bsx:NewAccountingPronouncementsPolicyTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - New Accounting Pronouncements (Policies)", "menuCat": "Policies", "order": "26", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies", "shortName": "New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "bsx:NewAccountingPronouncementsPolicyTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Acquisitions, Divestitures and Strategic Investments (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "shortName": "Acquisitions, Divestitures and Strategic Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables", "shortName": "Goodwill and Other Intangible Assets Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "menuCat": "Statements", "order": "3", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Contractual Obligations and Commitments (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables", "shortName": "Contractual Obligations and Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Supplemental Balance Sheet Information (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Weighted Average Shares Outstanding (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "shortName": "Weighted Average Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.bostonscientific.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Changes in Other Comprehensive Income (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables", "shortName": "Changes in Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "reportablesegments", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Basis of Presentation (Details)", "menuCat": "Details", "order": "37", "role": "http://www.bostonscientific.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Acquisitions and Divestitures (Details)", "menuCat": "Details", "order": "38", "role": "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "shortName": "Acquisitions and Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i098c221da06c4b958585f779d2867c19_I20230220", "decimals": "2", "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i112e69f95e3e4061b901b02e1a6de8a0_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Contingent Consideration (Details)", "menuCat": "Details", "order": "39", "role": "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "shortName": "Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "ia1330d5e86f34de7b8796fe68b26f65f_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Strategic Investments (Details)", "menuCat": "Details", "order": "40", "role": "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "shortName": "Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Goodwill and Other Intangible Assets (Details)", "menuCat": "Details", "order": "41", "role": "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Hedging Activities and Fair Value Measurements (Details)", "menuCat": "Details", "order": "42", "role": "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "shortName": "Hedging Activities and Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Contractual Obligations and Commitments (Details)", "menuCat": "Details", "order": "43", "role": "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "shortName": "Contractual Obligations and Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "44", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "shortName": "Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "45", "role": "http://www.bostonscientific.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "46", "role": "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "47", "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i5c8184b4c8c243b8af7637900054690c_I20200527", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Weighted Average Shares Outstanding (Details)", "menuCat": "Details", "order": "48", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "shortName": "Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "reportablesegments", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Segment Reporting (Details)", "menuCat": "Details", "order": "49", "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Revenue (Details)", "menuCat": "Details", "order": "50", "role": "http://www.bostonscientific.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "0", "lang": "en-US", "name": "bsx:NumberOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "business", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Changes in Other Comprehensive Income (Details)", "menuCat": "Details", "order": "51", "role": "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "shortName": "Changes in Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "idadc520412e74e82b77efd62c7563138_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "idadc520412e74e82b77efd62c7563138_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i988810e1696c4da3b18cc0a7b19cf868_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows (Supplemental Disclosure)", "menuCat": "Statements", "order": "8", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "shortName": "Consolidated Statements of Cash Flows (Supplemental Disclosure)", "subGroupType": "", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://www.bostonscientific.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bsx-20230331.htm", "contextRef": "i671dec7af405423f8246f88bd9ce4b5a_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 109, "tag": { "bsx_A550MCPSSeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% MCPS, Series A", "label": "5.50% MCPS, Series A [Member]", "terseLabel": "5.50% MCPS, Series A [Member]" } } }, "localname": "A550MCPSSeriesAMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "bsx_ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method", "label": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method [Policy Text Block]", "terseLabel": "ASC Update No. 2022-01, Derivatives and Hedging (Topic 815): FV Hedging -Portfolio Layer Method" } } }, "localname": "ASCUpdateNo202201DerivativesAndHedgingTopic815FVHedgingPortfolioLayerMethodPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)", "label": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures) [Policy Text Block]", "terseLabel": "ASC Update No. 2022-02, Financial Instruments, Credit Losses (Topic 326:Troubled Debt Restructurings and Vintage Disclosures)" } } }, "localname": "ASCUpdateNo202202FinancialInstrumentsCreditLossesTopic326TroubledDebtRestructuringsAndVintageDisclosuresPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.", "label": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. [Policy Text Block]", "terseLabel": "ASC Update No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions." } } }, "localname": "ASCUpdateNo202203FairValueMeasurementTopic820FairValueMeasurementOfEquitySecuritiesSubjectToContractualSaleRestrictionsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)", "label": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50) [Policy Text Block]", "terseLabel": "ASC Update No. 2022-04, Liabilities - Supplier Finance Programs (Subtopic 405-50)" } } }, "localname": "ASCUpdateNo202204LiabilitiesSupplierFinanceProgramsSubtopic40550PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_AccruedRebatesCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "terseLabel": "Accrued Rebates, Current" } } }, "localname": "AccruedRebatesCurrent", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AcotecMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acotec", "label": "Acotec [Member]", "terseLabel": "Acotec" } } }, "localname": "AcotecMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "domainItemType" }, "bsx_ActualCovenantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Actual Covenant.", "label": "Actual, Covenant [Member]", "terseLabel": "Actual, Covenant [Member]" } } }, "localname": "ActualCovenantMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_AllBusinessAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Business Acquisitions", "label": "All Business Acquisitions [Member]", "terseLabel": "All Business Acquisitions" } } }, "localname": "AllBusinessAcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_ApolloMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Apollo", "label": "Apollo [Member]", "terseLabel": "Apollo" } } }, "localname": "ApolloMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "domainItemType" }, "bsx_BSXReportableSegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSX Reportable Segments [Member]", "label": "BSX Reportable Segments [Member]", "terseLabel": "BSX Reportable Segments [Member]" } } }, "localname": "BSXReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_BaylisMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baylis Medical", "label": "Baylis Medical [Member]", "terseLabel": "Baylis Medical" } } }, "localname": "BaylisMedicalMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "domainItemType" }, "bsx_BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "label": "Brazil CADE - # of individuals for alleged anti-competitive behavior", "terseLabel": "Brazil CADE - # of individuals for alleged anti-competitive behavior" } } }, "localname": "BrazilCADEOfIndividualsForAllegedAntiCompetitiveBehavior", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_CardiacRhythmManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiac Rhythm Management", "label": "Cardiac Rhythm Management [Member]", "terseLabel": "Cardiac Rhythm Management [Member]" } } }, "localname": "CardiacRhythmManagementMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_CardiovascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardiovascular [Member]", "label": "Cardiovascular [Member]", "terseLabel": "Cardiovascular [Member]" } } }, "localname": "CardiovascularMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]" } } }, "localname": "CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsLineItems", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash flow impact of deferred income tax expense (benefit)", "label": "Cash flow impact of deferred income tax expense (benefit)", "terseLabel": "Deferred and prepaid income taxes" } } }, "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_CashProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash proceeds from Issuance of Senior Long Term Debt", "label": "Cash proceeds from Issuance of Senior Long Term Debt", "terseLabel": "Proceeds from Issuance of Senior Long-Term Debt" } } }, "localname": "CashProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_CondensedConsolidatedBalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "label": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "terseLabel": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetParentheticalAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "xbrltype": "stringItemType" }, "bsx_CondensedConsolidatedCashFlowSupplementalDIsclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract]", "label": "Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract]", "terseLabel": "Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract]" } } }, "localname": "CondensedConsolidatedCashFlowSupplementalDIsclosureAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "xbrltype": "stringItemType" }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "terseLabel": "contingent consideration liability, probability of payment" } } }, "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Expenses including hedging activities [Member]", "label": "Corporate Expenses including hedging activities [Member]", "verboseLabel": "Corporate expenses and currency exchange [Member]" } } }, "localname": "CorporateExpensesincludinghedgingactivitiesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant.", "label": "Covenant [Axis]", "terseLabel": "Covenant [Axis]" } } }, "localname": "CovenantAxis", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "bsx_CovenantDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant.", "label": "Covenant [Domain]", "terseLabel": "Covenant [Domain]" } } }, "localname": "CovenantDomain", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_CurrentRequirementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current Requirement.", "label": "Current Requirement [Member]", "terseLabel": "Current Requirement [Member]" } } }, "localname": "CurrentRequirementMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_DebtInstrumentExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extension Option, Term", "label": "Debt Instrument, Extension Option, Term", "terseLabel": "Debt Instrument, Extension Option, Term" } } }, "localname": "DebtInstrumentExtensionOptionTerm", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "durationItemType" }, "bsx_December2027NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2027 Notes [Member]", "label": "December 2027 Notes [Member]", "terseLabel": "December 2027 Notes [Member]" } } }, "localname": "December2027NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DiscountRateFairValueInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "terseLabel": "Discount Rate, Fair Value Input" } } }, "localname": "DiscountRateFairValueInput", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "bsx_ElectrophysiologyEPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Electrophysiology (EP)", "label": "Electrophysiology (EP) [Member]", "terseLabel": "Electrophysiology [Member]" } } }, "localname": "ElectrophysiologyEPMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "terseLabel": "Emerging Markets [Member]" } } }, "localname": "EmergingMarketsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity [Abstract]", "label": "Entity [Abstract]", "terseLabel": "Entity [Abstract]" } } }, "localname": "EntityAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "xbrltype": "stringItemType" }, "bsx_EquipmentFurnitureAndFixturesGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equipment, furniture and fixtures Gross.", "label": "Equipment, furniture and fixtures Gross", "terseLabel": "Equipment, furniture and fixtures" } } }, "localname": "EquipmentFurnitureAndFixturesGross", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_EuroDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "terseLabel": "Euro Denominated Factoring Arrangements [Member]" } } }, "localname": "EuroDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "terseLabel": "Exclusion from EBITDA for Restructuring Charges" } } }, "localname": "ExclusionFromEbitdaForRestructuringCharges", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ForeigncurrencydenominatedindebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "foreign currency denominated in debt [Member]", "label": "foreign currency denominated in debt [Member]", "terseLabel": "foreign currency denominated in debt [Member]" } } }, "localname": "ForeigncurrencydenominatedindebtMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ForwardCurrencyContractsTimetoMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forward Currency Contracts, Time to Maturity in Months", "label": "Forward Currency Contracts, Time to Maturity", "terseLabel": "Forward Currency Contracts, Time to Maturity" } } }, "localname": "ForwardCurrencyContractsTimetoMaturity", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "integerItemType" }, "bsx_GlobalCardiologyReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Cardiology Reporting Unit [Member]", "label": "Global Cardiology Reporting Unit [Member]", "terseLabel": "Cardiology [Member]" } } }, "localname": "GlobalCardiologyReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "terseLabel": "Endoscopy [Member]" } } }, "localname": "GlobalEndoscopyEndoReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "terseLabel": "Neuromodulation [Member]" } } }, "localname": "GlobalNeuromodulationNmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "terseLabel": "Peripheral Interventions [Member]" } } }, "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "terseLabel": "Urology [Member]" } } }, "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Impact of Foreign Currency Fluctuations on Net Sales", "label": "Impact of Foreign Currency Fluctuations on Net Sales", "terseLabel": "Impact of Foreign Currency Fluctuations on Net Sales" } } }, "localname": "ImpactOfForeignCurrencyFluctuationsOnNetSales", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IndemnificationAsset": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indemnification asset", "label": "Indemnification asset", "terseLabel": "Indemnification asset" } } }, "localname": "IndemnificationAsset", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IntangibleAssetsandGoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Intangible Assets and Goodwill [Table]", "label": "Intangible Assets and Goodwill [Line Items]", "terseLabel": "Intangible Assets and Goodwill [Line Items]" } } }, "localname": "IntangibleAssetsandGoodwillLineItems", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_InterventionalCardiologyTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interventional Cardiology Therapies", "label": "Interventional Cardiology Therapies [Member]", "terseLabel": "Interventional Cardiology Therapies" } } }, "localname": "InterventionalCardiologyTherapiesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_InventoryStepUpAmortization": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory step up amortization", "label": "Inventory step up amortization", "terseLabel": "Inventory step-up amortization" } } }, "localname": "InventoryStepUpAmortization", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_January2040NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "terseLabel": "January 2040 Notes [Member]" } } }, "localname": "January2040NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_June2025NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2025 Notes", "label": "June 2025 Notes [Member]", "terseLabel": "June 2025 Notes [Member]" } } }, "localname": "June2025NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_June2030NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "June 2030 Notes", "label": "June 2030 Notes [Member]", "terseLabel": "June 2030 Notes [Member]" } } }, "localname": "June2030NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_LatinAmericaandCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "terseLabel": "Latin America and Canada [Member]" } } }, "localname": "LatinAmericaandCanadaMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LicensingarrangementassetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing arrangement assets [Member]", "label": "Licensing arrangement assets [Member]", "terseLabel": "Licensing arrangement assets [Member]" } } }, "localname": "LicensingarrangementassetsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LicensingarrangementliabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing arrangement liabilities [Member]", "label": "Licensing arrangement liabilities [Member]", "terseLabel": "Licensing arrangement liabilities [Member]" } } }, "localname": "LicensingarrangementliabilitiesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_Licensingarrangements": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements", "label": "Licensing arrangements", "terseLabel": "Licensing arrangements" } } }, "localname": "Licensingarrangements", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsasset": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "terseLabel": "Licensing arrangements, asset" } } }, "localname": "Licensingarrangementsasset", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsliability": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "terseLabel": "Licensing arrangements, liability" } } }, "localname": "Licensingarrangementsliability", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationAndDebtExclusionFromEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments", "label": "Litigation and Debt Exclusion from EBITDA", "terseLabel": "Litigation and Debt Exclusion from EBITDA" } } }, "localname": "LitigationAndDebtExclusionFromEbitda", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationPaymentExclusionFromEBITDA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation payment exclusion from EBITDA", "label": "Litigation payment exclusion from EBITDA", "terseLabel": "Litigation payment exclusion from EBITDA" } } }, "localname": "LitigationPaymentExclusionFromEBITDA", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_March2024NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2024 Notes [Member]", "label": "March 2024 Notes [Member]", "terseLabel": "March 2024 Notes [Member]" } } }, "localname": "March2024NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2025NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2025 Notes", "label": "March 2025 Notes [Member]", "terseLabel": "March 2025 Notes" } } }, "localname": "March2025NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2026NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2026 Notes [Member]", "label": "March 2026 Notes [Member]", "terseLabel": "March 2026 Notes [Member]" } } }, "localname": "March2026NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "verboseLabel": "March 2028 Notes [Member]" } } }, "localname": "March2028NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2028 Senior Notes", "label": "March 2028 Senior Notes [Member]", "terseLabel": "March 2028 Senior Notes" } } }, "localname": "March2028SeniorNotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2029NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2029 Notes [Member]", "label": "March 2029 Notes [Member]", "terseLabel": "March 2029 Notes [Member]" } } }, "localname": "March2029NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2031NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2031 Notes", "label": "March 2031 Notes [Member]", "terseLabel": "March 2031 Notes" } } }, "localname": "March2031NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2034NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2034 Notes", "label": "March 2034 Notes [Member]", "terseLabel": "March 2034 Notes" } } }, "localname": "March2034NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2039NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2039 Notes [Member]", "label": "March 2039 Notes [Member]", "terseLabel": "March 2039 Notes [Member]" } } }, "localname": "March2039NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2049NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2049 Notes [Member]", "label": "March 2049 Notes [Member]", "terseLabel": "March 2049 Notes [Member]" } } }, "localname": "March2049NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_MaximumLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement.", "label": "Maximum Leverage Ratio", "terseLabel": "Maximum Leverage Ratio" } } }, "localname": "MaximumLeverageRatio", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "pureItemType" }, "bsx_MedsurgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MedSurg [Member]", "label": "MedSurg [Member]", "terseLabel": "MedSurg [Member]" } } }, "localname": "MedsurgMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_NetIncomeLossAttributableToBostonScientificCommonStockholders": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income (loss) attributable to Boston Scientific common stockholders", "label": "Net income (loss) attributable to Boston Scientific common stockholders", "totalLabel": "Net income (loss) attributable to Boston Scientific common stockholders" } } }, "localname": "NetIncomeLossAttributableToBostonScientificCommonStockholders", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_Netcurrencyexchangegainloss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "terseLabel": "Net currency exchange gain (loss)" } } }, "localname": "Netcurrencyexchangegainloss", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NewAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Accounting Pronouncements, Policy", "label": "New Accounting Pronouncements, Policy [Text Block]", "terseLabel": "New Accounting Pronouncements, Policy" } } }, "localname": "NewAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "bsx_Noncashimpactoftransferredroyaltyrights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash impact of transferred royalty rights", "label": "Non-cash impact of transferred royalty rights", "terseLabel": "Non-cash impact of transferred royalty rights" } } }, "localname": "Noncashimpactoftransferredroyaltyrights", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_November2035NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "terseLabel": "November 2035 Notes [Member]" } } }, "localname": "November2035NotesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_NumberOfBusinesses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Businesses", "label": "Number Of Businesses", "terseLabel": "Number Of Businesses" } } }, "localname": "NumberOfBusinesses", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "integerItemType" }, "bsx_OperatingIncomeAllocatedToReportableSegments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income Allocated to Reportable Segments", "label": "Operating Income Allocated to Reportable Segments", "terseLabel": "Operating Income Allocated to Reportable Segments" } } }, "localname": "OperatingIncomeAllocatedToReportableSegments", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingIncomeUnallocatedToSegment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "negatedTerseLabel": "Operating Income Unallocated to Segment" } } }, "localname": "OperatingIncomeUnallocatedToSegment", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Current Assets [Abstract]", "label": "Other Current Assets [Abstract]", "terseLabel": "Other Current Assets [Abstract]" } } }, "localname": "OtherCurrentAssetsAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_OtherNet": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other, net", "label": "Other, net", "terseLabel": "Other, net" } } }, "localname": "OtherNet", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_OtherOtherLongtermAssets": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other, Other Long-term Assets", "label": "Other, Other Long-term Assets", "terseLabel": "Other, Other Long-term Assets" } } }, "localname": "OtherOtherLongtermAssets", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PaymentOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of contingent consideration", "label": "Payment of contingent consideration", "negatedLabel": "Payment of contingent consideration", "terseLabel": "Payment of contingent consideration" } } }, "localname": "PaymentOfContingentConsideration", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PaymentsForRoyaltyRights": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for royalty rights", "label": "Payments for royalty rights", "negatedTerseLabel": "Payments for royalty rights" } } }, "localname": "PaymentsForRoyaltyRights", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "negatedTerseLabel": "Cash used to net share settle employee equity awards" } } }, "localname": "Paymenttonetsharesettleemployeeequityawards", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from (payments for) investments and acquisitions of certain technologies", "label": "Proceeds from (payments for) investments and acquisitions of certain technologies", "negatedTerseLabel": "Proceeds from (payments for) investments and acquisitions of certain technologies" } } }, "localname": "ProceedsFromPaymentsForInvestmentsAndAcquisitionsOfCertainTechnologies", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_QualifiedAcquisitionConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Qualified Acquisition Consideration", "label": "Qualified Acquisition Consideration", "terseLabel": "Qualified Acquisition Consideration" } } }, "localname": "QualifiedAcquisitionConsideration", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RDRegulatoryandCommercializationbasedMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D, Regulatory and Commercialization-based Milestone [Member]", "label": "R&D, Regulatory and Commercialization-based Milestone [Member]", "terseLabel": "R&D, Regulatory and Commercialization-based Milestone [Member]" } } }, "localname": "RDRegulatoryandCommercializationbasedMilestoneMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_RenminbiDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renminbi Denominated Factoring Arrangements", "label": "Renminbi Denominated Factoring Arrangements [Member]", "terseLabel": "Renminbi Denominated Factoring Arrangements [Member]" } } }, "localname": "RenminbiDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, as of December 31, 2021 and through remaining term of facility", "label": "Requirement, as of December 31, 2021 and through remaining term of facility [Member]", "terseLabel": "Requirement, as of December 31, 2021 and through remaining term of facility" } } }, "localname": "RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility", "label": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility [Member]", "terseLabel": "Requirement, eighth quarter following qualified acquisition and through remaining term of facility" } } }, "localname": "RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, four succeeding quarters following qualified acquisition", "label": "Requirement, four succeeding quarters following qualified acquisition [Member]", "terseLabel": "Requirement, four succeeding quarters following qualified acquisition" } } }, "localname": "RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementSeventhQuarterFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, seventh quarter following qualified acquisition", "label": "Requirement, seventh quarter following qualified acquisition [Member]", "terseLabel": "Requirement, seventh quarter following qualified acquisition" } } }, "localname": "RequirementSeventhQuarterFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementSixthQuarterFollowingQualifiedAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, sixth quarter following qualified acquisition", "label": "Requirement, sixth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, sixth quarter following qualified acquisition" } } }, "localname": "RequirementSixthQuarterFollowingQualifiedAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "terseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RevenueBasedPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "revenue-based payments [Member]", "label": "revenue-based payments [Member]", "terseLabel": "revenue-based payments [Member]" } } }, "localname": "RevenueBasedPaymentsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations", "label": "Revenues from contracts with customers, disaggregated - performance measurement", "terseLabel": "Revenues from contracts with customers, disaggregated - performance measurement" } } }, "localname": "RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RevolvingCreditFacility2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility 2021", "label": "Revolving Credit Facility 2021 [Member]", "terseLabel": "2021 Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacility2021Member", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "label": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]" } } }, "localname": "ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Line Items]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Line Items]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationLineItems", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Table]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Table]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationTable", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "terseLabel": "Segment operating income as percentage of net sales" } } }, "localname": "Segmentoperatingincomeaspercentageofnetsales", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "percentItemType" }, "bsx_SeniorNotedue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "terseLabel": "Senior Note due 2027 [Member]" } } }, "localname": "SeniorNotedue2027Member", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "bsx_SpecialChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits", "label": "Special Charges [Member]", "terseLabel": "Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits" } } }, "localname": "SpecialChargesMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_StatementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "statement [Axis]", "label": "statement [Axis]", "terseLabel": "statement [Axis]" } } }, "localname": "StatementAxis", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure" ], "xbrltype": "stringItemType" }, "bsx_StatementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for statement [Axis]", "label": "statement [Domain]", "terseLabel": "statement [Domain]" } } }, "localname": "StatementDomain", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure" ], "xbrltype": "domainItemType" }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants.", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]" } } }, "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalBalanceSheetInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information [Abstract]", "terseLabel": "Supplemental Balance Sheet Information [Abstract]" } } }, "localname": "SupplementalBalanceSheetInformationAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "xbrltype": "stringItemType" }, "bsx_SupplementalBalanceSheetInformationTextualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information (Textuals) [Abstract]", "verboseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "SupplementalBalanceSheetInformationTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_SupplierFinanceProgramObligationCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplier Finance Program Obligation. current", "label": "Supplier Finance Program Obligation. current", "terseLabel": "Supplier Finance Program Obligation. current" } } }, "localname": "SupplierFinanceProgramObligationCurrent", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_The2018FacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the 2018 Facility", "label": "the 2018 Facility [Domain]", "terseLabel": "the 2018 Facility [Member]" } } }, "localname": "The2018FacilityDomain", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TheOfferingAggregatePrincipalAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the Offering - aggregate principal amount", "label": "the Offering - aggregate principal amount [Member]", "terseLabel": "the Offering" } } }, "localname": "TheOfferingAggregatePrincipalAmountMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "the Offering - early redemption of combined aggregate principal SN", "label": "the Offering - early redemption of combined aggregate principal SN [Member]", "terseLabel": "the Offering - early redemption of combined aggregate principal SN" } } }, "localname": "TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TotalAllocatedToReportableSegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total allocated to reportable segments [Member]", "label": "Total allocated to reportable segments [Member]", "terseLabel": "Total allocated to reportable segments [Member]" } } }, "localname": "TotalAllocatedToReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_WatchmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Watchman", "label": "Watchman [Member]", "terseLabel": "Watchman" } } }, "localname": "WatchmanMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_YenDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yen denominated factoring arrangements.", "label": "Yen Denominated Factoring Arrangements [Member]", "terseLabel": "Yen Denominated Factoring Arrangements [Member]" } } }, "localname": "YenDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20230331", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "verboseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share", "terseLabel": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "perShareItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "APAC [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r388", "r389", "r390", "r391", "r471", "r586", "r604", "r627", "r628", "r651", "r664", "r672", "r738", "r752", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r388", "r389", "r390", "r391", "r471", "r586", "r604", "r627", "r628", "r651", "r664", "r672", "r738", "r752", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r337", "r587", "r652", "r670", "r733", "r734", "r740", "r758" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r337", "r587", "r652", "r670", "r733", "r734", "r740", "r758" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r388", "r389", "r390", "r391", "r464", "r471", "r473", "r474", "r475", "r562", "r586", "r604", "r627", "r628", "r651", "r664", "r672", "r728", "r738", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r388", "r389", "r390", "r391", "r464", "r471", "r473", "r474", "r475", "r562", "r586", "r604", "r627", "r628", "r651", "r664", "r672", "r728", "r738", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r293", "r472", "r681", "r708" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r338", "r339", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r653", "r671", "r740" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r338", "r339", "r613", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r653", "r671", "r740" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r293", "r472", "r681", "r682", "r708" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r627", "r628", "r752", "r754", "r757" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r343", "r597", "r642" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Trade accounts receivable, net", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current [Abstract]", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r236", "r343", "r344", "r632" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r6", "r193", "r205" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r21", "r635" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued Royalties, Current" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r94", "r226" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r35", "r39", "r741" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedTerseLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r245", "r248", "r250", "r251", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r37", "r38", "r39", "r237", "r598", "r609", "r610" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income (loss), net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r259", "r260", "r542", "r543", "r544", "r545", "r546", "r548" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r36", "r39", "r148", "r554", "r605", "r606", "r691", "r692", "r693", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r33", "r39", "r148", "r260", "r261", "r543", "r544", "r545", "r546", "r548", "r691" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r9" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r476", "r477", "r478", "r705", "r706", "r707", "r745" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r238", "r345", "r351" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedLabel": "Less: allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r66", "r82", "r89" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r190", "r204", "r230", "r272", "r321", "r327", "r333", "r349", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r503", "r507", "r532", "r669", "r736", "r737", "r750" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r222", "r241", "r272", "r349", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r503", "r507", "r532", "r669", "r736", "r737", "r750" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r161", "r166" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r498", "r662", "r663" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r127", "r128", "r498", "r662", "r663" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r501", "r698" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration net expense (benefit)", "verboseLabel": "Contingent consideration net expense (benefit)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r136", "r137", "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Business Combination, Contingent Consideration, Liability Ending Balance", "periodStartLabel": "Business Combination, Contingent Consideration, Liability Beginning Balance", "terseLabel": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r136", "r138" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Business Combination, Contingent Consideration, Liability, Current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r136", "r138" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r141", "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r129", "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]", "terseLabel": "Finance Lease Obligation" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r611", "r612", "r669", "r683" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r68", "r224", "r630" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r61", "r68", "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r61", "r181" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease)\u00a0in cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Class of Stock Disclosures [Abstract]" } } }, "localname": "ClassOfStockDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r233", "r234", "r235", "r272", "r296", "r297", "r298", "r300", "r307", "r308", "r349", "r393", "r395", "r396", "r397", "r400", "r401", "r431", "r432", "r435", "r439", "r446", "r532", "r629", "r680", "r701", "r709" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r2", "r191", "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r198", "r211" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r96", "r385", "r386", "r617", "r735" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r705", "r706", "r745" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March\u00a031, 2023 and 1,696,633,993 shares as of December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r42", "r256", "r258", "r265", "r593", "r601" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r144", "r151", "r256", "r258", "r264", "r592", "r600" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r52", "r263", "r591", "r599" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Capital in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r448", "r449", "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract with Customer, Liability [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r46", "r587" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r197", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "terseLabel": "Total debt" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r232" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Debt, Current", "verboseLabel": "Current debt obligations" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r104", "r269", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r418", "r425", "r426", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "CONTRACTUAL OBLIGATIONS AND COMMITMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r3", "r4", "r5", "r192", "r194", "r203", "r275", "r402", "r403", "r404", "r405", "r406", "r408", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r424", "r551", "r646", "r647", "r648", "r649", "r650", "r702" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r416", "r531", "r647", "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r23", "r403" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r24", "r275", "r402", "r403", "r404", "r405", "r406", "r408", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r424", "r551", "r646", "r647", "r648", "r649", "r650", "r702" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r109", "r112", "r113", "r114", "r182", "r183", "r185", "r202", "r275", "r402", "r403", "r404", "r405", "r406", "r408", "r414", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r424", "r427", "r551", "r646", "r647", "r648", "r649", "r650", "r702" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r184", "r414", "r429", "r647", "r648" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r480", "r481" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r480", "r481" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r688" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r687" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r66", "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r66", "r316" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r243", "r244", "r531", "r639" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r243" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative Asset, Current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r31", "r163", "r187", "r242", "r639" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Derivative Asset, Fair Value, Gross Asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r31", "r163", "r187", "r242", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Derivative Liability, Fair Value, Gross Liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r162", "r164", "r169", "r171", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r159", "r162", "r169" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r159", "r162", "r169", "r171", "r174", "r175", "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r165" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r243", "r244", "r531", "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Remaining Maturity", "terseLabel": "Derivative, Remaining Maturity" } } }, "localname": "DerivativeRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r153", "r155", "r156", "r159", "r160", "r167", "r169", "r172", "r173", "r175", "r517" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative, Term of Contract (less than)" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r459", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r662", "r663" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r115", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "terseLabel": "Dividends, Preferred Stock, Cash" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r115", "r201" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "bsx_NetIncomeLossAttributableToBostonScientificCommonStockholders", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "negatedTerseLabel": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r266", "r285", "r286", "r287", "r288", "r289", "r294", "r296", "r298", "r299", "r300", "r304", "r520", "r521", "r594", "r602", "r640" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss)\u00a0per common share \u2014 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r266", "r285", "r286", "r287", "r288", "r289", "r296", "r298", "r299", "r300", "r304", "r520", "r521", "r594", "r602", "r640" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss)\u00a0per common share \u2014 diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r301", "r302", "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Weighted Average Number Of Shares Outstanding [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r539" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of foreign exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate from continuing operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r108", "r217", "r259", "r260", "r261", "r280", "r281", "r282", "r284", "r290", "r292", "r306", "r350", "r447", "r476", "r477", "r478", "r489", "r490", "r519", "r542", "r543", "r544", "r545", "r546", "r548", "r554", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r77", "r322", "r684" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r231", "r529", "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Measurement alternative investments(1, 2)" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r522", "r523", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r416", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r559", "r560", "r561", "r647", "r648", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r522", "r523", "r524", "r525", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r416", "r465", "r470", "r523", "r559", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r416", "r465", "r470", "r523", "r560", "r647", "r648", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r416", "r465", "r466", "r467", "r468", "r469", "r470", "r523", "r561", "r647", "r648", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesandFairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r416", "r465", "r466", "r467", "r468", "r469", "r470", "r559", "r560", "r561", "r647", "r648", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r526", "r528" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r346", "r347", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r427", "r444", "r517", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r643", "r712", "r713", "r714", "r759", "r760", "r761", "r762", "r763", "r764", "r765" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r228", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r372", "r374", "r375", "r377", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r88", "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r83", "r87" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r533", "r535", "r537", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r639", "r659", "r668" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r162", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r49", "r76", "r679" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedTerseLabel": "Net loss (gain) on investments and notes receivable" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r66", "r102", "r103" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r227", "r360", "r590", "r645", "r669", "r717", "r724" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill Ending Balance", "periodStartLabel": "Goodwill Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r362", "r645" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r361", "r368", "r645" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r361", "r368", "r645" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r124", "r725" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Goodwill, Translation and Purchase Accounting Adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r45", "r272", "r321", "r326", "r332", "r335", "r349", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r532", "r641", "r736" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r159", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]", "verboseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r44", "r189", "r199", "r214", "r321", "r326", "r332", "r335", "r595", "r641" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss)\u00a0before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r662", "r663" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r273", "r484", "r487", "r488", "r491", "r493", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r274", "r291", "r292", "r319", "r482", "r492", "r494", "r603" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option" } } }, "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r373", "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r85", "r90" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r81", "r86" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r184", "r200", "r262", "r315", "r550" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r639", "r659", "r667" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r79", "r636" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods, Net of Reserves" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r239", "r631", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "verboseLabel": "Inventories" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r79", "r638" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Inventory, Raw Materials, Net of Reserves" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r79", "r637" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Inventory, Work in Process, Net of Reserves" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "terseLabel": "Investment [Table Text Block]" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r212" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments", "verboseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Land": { "auth_ref": [ "r685" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy [Policy Text Block]" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesCommitmentsandContingenciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r196", "r209", "r669", "r703", "r715", "r747" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r223", "r272", "r349", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r504", "r507", "r508", "r532", "r669", "r736", "r750", "r751" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r18", "r702" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r18", "r702" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r26", "r730" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Legal reserves, current" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r26", "r730" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Estimated Litigation Liability, Noncurrent" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r5", "r194", "r206", "r415", "r430", "r647", "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r5" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r24", "r101" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r97", "r98", "r387", "r388", "r389", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r387", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "verboseLabel": "Accrual for legal matters that are probable and estimable" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r30", "r195", "r208", "r272", "r349", "r393", "r395", "r396", "r397", "r400", "r401", "r532" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money Market Funds, at Carrying Value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r268" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r268" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash provided by (used for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r61", "r64", "r67" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r146", "r150", "r254", "r257", "r291", "r292", "r693" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "bsx_NetIncomeLossAttributableToBostonScientificCommonStockholders", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r142", "r447", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r154", "r156" ], "lang": { "en-us": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of Interest Rate Derivatives Held" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r321", "r326", "r332", "r335", "r641" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income (loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r553" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r552" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 7.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Noncurrent", "terseLabel": "Other Accrued Liabilities, Noncurrent" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r240", "r669" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "totalLabel": "Other Assets, Current" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other Assets, Miscellaneous, Current" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r229" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "totalLabel": "Other Assets, Noncurrent", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets, Noncurrent [Abstract]" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r34", "r37", "r534", "r536", "r541" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r39", "r43", "r260", "r542", "r544", "r548", "r691" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r144", "r145", "r147" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r246", "r248" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "totalLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "verboseLabel": "Net change in derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r246", "r248" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r246", "r248", "r509", "r510", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r248", "r252" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r248", "r252", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax": { "auth_ref": [ "r247", "r248", "r252", "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "auth_ref": [ "r247", "r248", "r252", "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "auth_ref": [ "r247", "r248", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "auth_ref": [ "r247", "r248", "r511", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "auth_ref": [ "r247", "r248", "r511", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r32" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r37", "r40", "r41", "r253", "r540" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r108", "r255", "r258", "r263", "r542", "r547", "r548", "r591", "r599", "r691", "r692" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Total other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]", "terseLabel": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r35", "r37" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r35", "r37" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTerseLabel": "Net change in defined benefit pensions and other items", "negatedTotalLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r37", "r40", "r119", "r253" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Other Current Liabilities [Table Text Block]" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "totalLabel": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "totalLabel": "Other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "verboseLabel": "Other long-term liabilities [Table Text Block]" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other Operating Income (Expense), Net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r21", "r99" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other Sundry Liabilities, Current" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of contingent consideration previously established in purchase accounting" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r694", "r695" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Proceeds from royalty rights" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "negatedTerseLabel": "Payments for Royalties", "terseLabel": "Payments for Royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r58" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Cash dividends paid on preferred stock" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r54" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment and internal use software" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Preferred Stock, Dividends, Per Share, Cash Paid" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Preferred Stock, Dividends Per Share, Declared" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r7", "r109", "r110", "r701", "r739" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred Stock, Liquidation Preference Per Share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r270", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Preferred Stock, Liquidation Preference, Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r431" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r431" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r7", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March\u00a031, 2023 and December\u00a031, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r689" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r634", "r644", "r716" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "verboseLabel": "Net proceeds from issuance of preferred stock in connection with public offering" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r57" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-Term Debt", "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs", "verboseLabel": "Proceeds from Issuance of Senior Long-Term Debt" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r696", "r697", "r699" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net increase (decrease) in commercial paper" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from Royalties Received", "negatedTerseLabel": "Proceeds from Royalties Received", "terseLabel": "Proceeds from Royalties Received" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r56" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r221", "r254", "r257", "r267", "r272", "r283", "r291", "r292", "r321", "r326", "r332", "r335", "r349", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r502", "r505", "r506", "r521", "r532", "r595", "r641", "r665", "r666", "r693", "r736" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "bsx_NetIncomeLossAttributableToBostonScientificCommonStockholders", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r93", "r225" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r95", "r210", "r596", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property, plant and equipment, net [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r183", "r551" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "verboseLabel": "Average interest rate of de-recognized receivables" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r39", "r43", "r260", "r542", "r546", "r548", "r691" ], "calculation": { "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r39", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r72", "r74" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfSeniorDebt": { "auth_ref": [ "r59" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.", "label": "Repayments of Senior Debt", "negatedTerseLabel": "Payments on long-term borrowings and debt extinguishment costs" } } }, "localname": "RepaymentsOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r59" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedTerseLabel": "Payments on short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r122" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r68", "r69", "r224" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted Cash and Cash Equivalents in Other current assets", "verboseLabel": "Restricted cash and restricted cash equivalents included in Other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "auth_ref": [ "r614", "r615", "r616", "r686", "r700" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash equivalents included in Other long-term assets", "verboseLabel": "Restricted Cash Equivalents in Other long-term assets" } } }, "localname": "RestrictedCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r66", "r382", "r383", "r729" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "verboseLabel": "Restructuring net charges (credits)" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r115", "r207", "r608", "r610", "r669" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r217", "r280", "r281", "r282", "r284", "r290", "r292", "r350", "r476", "r477", "r478", "r489", "r490", "r519", "r605", "r607" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r312", "r313", "r325", "r330", "r331", "r337", "r338", "r341", "r458", "r459", "r587" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "verboseLabel": "Trade accounts receivable, net [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r39", "r748", "r749" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in Other Comprehensive Income [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ChangesinOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r127", "r128", "r498" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "verboseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r24", "r109", "r112", "r113", "r114", "r182", "r183", "r185", "r202", "r647", "r649", "r704" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r162", "r169", "r515" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "verboseLabel": "Derivative Instruments, Gain (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r645" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r645", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r14", "r15", "r16" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory Disclosure [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Other Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Other Current Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r168", "r744" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Derivatives Not Designated as Hedging Instruments [Table Text Block]" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r233", "r234", "r235", "r307", "r431", "r432", "r433", "r435", "r439", "r444", "r446", "r651", "r680", "r701" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares [Table Text Block]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r309", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r341", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r381", "r384", "r645", "r758" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r309", "r310", "r311", "r321", "r324", "r329", "r333", "r334", "r335", "r336", "r337", "r340", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance (Shares Issued)", "periodStartLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r219", "r309", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r335", "r341", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r379", "r381", "r384", "r645", "r758" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Statement, Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r233", "r234", "r235", "r272", "r296", "r297", "r298", "r300", "r307", "r308", "r349", "r393", "r395", "r396", "r397", "r400", "r401", "r431", "r432", "r435", "r439", "r446", "r532", "r629", "r680", "r701", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDivestituresandStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CoverDocument", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r28", "r108", "r217", "r259", "r260", "r261", "r280", "r281", "r282", "r284", "r290", "r292", "r306", "r350", "r447", "r476", "r477", "r478", "r489", "r490", "r519", "r542", "r543", "r544", "r545", "r546", "r548", "r554", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r280", "r281", "r282", "r306", "r587" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r120", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r8", "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Stock Issued During Period, Shares, Period Increase (Decrease)", "terseLabel": "Stock-based compensation (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r75", "r669", "r703", "r715", "r747" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Total stockholders\u2019 equity", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r142", "r143", "r149", "r217", "r218", "r260", "r280", "r281", "r282", "r284", "r290", "r350", "r447", "r476", "r477", "r478", "r489", "r490", "r519", "r542", "r543", "r548", "r554", "r606", "r607", "r703", "r715", "r747" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodStartLabel": "Total stockholders' equity", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r118", "r271", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r445", "r447", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "auth_ref": [ "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in stockholders' equity during the period.", "label": "Stockholders' Equity, Period Increase (Decrease)", "terseLabel": "Stock issuance (Par value)" } } }, "localname": "StockholdersEquityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r549", "r555" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r549", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r549", "r555" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/CommitmentsandContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/BasisofPresentationBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r690" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes Payable, Current" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsandDivestituresDetails", "http://www.bostonscientific.com/role/GoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "auth_ref": [ "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "verboseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r346", "r347", "r427", "r444", "r517", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r712", "r713", "r714", "r759", "r760", "r761", "r762", "r763", "r764", "r765" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContractualObligationsandCommitmentsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesandFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock, Common" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury Stock, Common, Shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r27", "r116", "r117" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost - 263,289,848 shares as of March\u00a031, 2023 and December\u00a031, 2022" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r108", "r115", "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r479", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r276", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charges to expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Utilization of allowances" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r710" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r295", "r300" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r294", "r300" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsofOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e709-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r673": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r674": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r675": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r676": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r677": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r678": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 76 0000885725-23-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-23-000026-xbrl.zip M4$L#!!0 ( .: I%9-?=-'HY4" %1%'P 0 8G-X+3(P,C,P,S,Q+FAT M;>R]:U=;N;(N_'W_"K^LL_?I-48[T:5T2_?*&220+-8.D ;26? EHR25P,38 M+-LDD%__E@SD2CHD,=C3.-TAV/.B.55/53TEE4J__[_3HV[K#0V&G7[O'TOR MGEAJ_;^'O_]_[?:_'VT]:ZWTT\D1]4:MQP/"$>76V\[HH/4RT_!UJPSZ1ZV7 M_<'KSAMLM\?7/.X?GPTZ^P>CEA)*?W9P\""DF*PQIDV07!LTZG:,QK:33](6 MQ*(M_+K_P&A!-I;43J:4-F12;4Q@VZI@*.A+AI)^S0] %\PQ!.\ 0"D95$@B M1Y$I1RS&UV8/1OQV_(:]X8/3..AV_K%T,!H=/[A__^W;M_?J-_?Z@_W[2@A] MO],;CK"7:.GB_-0_Z8T&9^^O&)\]I'1OO__F_L5!OE*IRPLZPSXHZ?ZJB?,S M+B^(P]-/3H[]X:C?&Z8.=WBG=-*]U#^J+6BAM5SZZ#5RY].GNFC WC\_^/Z! M3D=7/TRGU^WTJ KX_FB O6'I#XYPQ "HK8FV4&WY_JU.AY]VVEM]V9R\_^_U M9]OI@(ZP_7GGG0S;^XC'[Z\L.(SCZRX.?-IQIU_K,ZD_>M:+TZ]Z&AE"N']: MA7UY3[[H]5](HAZ..*2/NJK-LOWDBDM9_U5O2=,6OOV1=+YH]Y,GK$??=]%H M\-4'#/?YZ.6)F3I7@Y /?-*/P\'HRP[G+S^<]*"+O?U_+%&O_6)[B;6#,#_\ M_8A&V*J7M>D_)YTW_UAZW.^-&(+MG;-C[J!T_ND?2R,Z'=T?]_']A__U7__U M^Z@SZM)#!G'[$J._WS__[O?[YW>._7SV\/?<>=,:CLZZ](^EW!D>=_'L0:_? M(VZ_<_J@GDB#\U\[.5-O_"L?WV"[,^BD\^9/1UM4_K'4L4YF2@X+" -*%Z_ M%N]C#HD@&GRU,GX4*63[@][T\*@V39T'JZQ7H[/'_#8#[*[U,IW^+YTMM3J9 M;YWUGV=QI?_FF=IZLZO73_+AZIN]I^%P\_"/=WM'3U[O'KXVFRM);*S\<;9^ MN&K6#[N'ZT^W.ORWN_?T7P=[AR_@F=[H[K[KBW6U=[#W=,UL[NQK/E^L'ZZ= M;NZLF=UWC_@^CU[OO=SJ[+[.N*V5?;[/\IO\]$DG/GUAUW?^U=U<63Y;/UH_W3O< M>+VQWD[_=/WH!:ROK)WM MOGMRM*[^$)M/UTYW#]=@5_W973_\\_7NT1J_YZ/N;M>_>[:S.EK?%J?\KUE? M>?UV??E5$,6 9B-+*88VN$AM="6V0\G&R:2-U7;IH> _WANGS._W/Q'K34KY M\86=UU+K7'.YA=/1@\S?M(^XV8-VQ@4(O@D"<04( ML@6C,D%;2G;E0*:THU:RG11BSDI:*F)9+U2SB+NXOI/HMJ>HK MI)I06 D<.[FD;1M,-&VDDML44D'M$97P2P\+=H?TA6#O?TK'!E2(76JBX14D MLG+:!\-Q&,"B;XTY[H,14\=_+ T[1\?=RK''WQT,*C(^YHOW3H>9[W#_TUN< M-_^AS8M'&/9/!N-/XT#NP07:SJ'Q(VB[O!&-2>'EITX^#[YHT!H_$%T9$CQ> M^]]/RMSMI,YHG8XB-Y$[?/1\Q.(BH'RP/>(^J-<\[N)PN%FV1_WT>OFT,UQZ M>'G*X_X1$[[Q@?/[_'[_RMN_[[KW3]$(81)%U"F8X'P!,"DX)).*E>2DM('F M0YAL/QYL4Z_3'VST1Y1/B-_%S:,X8\DQ: -2ZPA%28Q$E%3).6:=3)D?<2X; M(]8?/]_>YLZAX?*<"/.DUSF7Y,DP,T7=/L !O1=0[KSACOWXU+'OQ5'_?35;>]>/OZ5,._NN\GM[C_ MZ=-_=-K5$$Z2F$VBC^Q>LB@A2@K&>?2>V"#%5VMCY(+R,^"-SX0[Y7[>MTL_VO%7X>B+FUT3'%<[?^]=(I^R]AJ,*X%(2NTA0?#16S$V M,.K2P*A9)$WJ^KJL)F:8@_=>"F*7:A-DU%'ZE 2Z*)E9>^LO4#T;W?4IJC_N M@>]#]2<]("73Q%""(4W 448,0D:A2*+-Y%&,>T!)-6L]4.! ^*QEP-OK@9_VR:O_.:F#XOVCXWZ//PX_Y8; MD4[&G(P2P#!U0%Y%YSCRM2HY8S6;N+%TY$(ZWR,=.3'IZ*R$QQ!+3 @.5$A! M$AO4[ '("M%$8CM=,4T_6/%57MGKJ"*!!XV!T.ELN<>)0,$Y) MF<4HA9,I@U.WQG(:+\D8X6$*K+7-/#4ZR@EGF\A9L8BIB M@@\BG3.0A72^CX%,2CH$D2)H+YD>0O(Q.)/ 1J:*.65A[=SPPQL=4[T1%NBF1PS9+=2;( BHW& IH0B) 6.+HW7 MQ@H[?\QPSJGD"GP@DYJO8NVR!( M<["&)024FF-L,C:97.#V6,>T/+L+Y$52)@&2+%=#A8"9X_I2*5,SIEXY/(\S-H M>MLBFAP_YN">//L<2AI93;%^Q4^+(>N[P0BQ<":L9EBD49Y%@V\D>,<\,6;]NH M3HXUFB@L&"]0"U/'YSR'-UH2-\%A#0MK;ECC[5.328F(E4AE-HJL* &Z40M%(^)R:2P*1A1%/^!,#>L>Y88ZW:DLG1QG1HI$Y%(R@P2D*.:)*=6;4IDADYX8RWC(7F5@^)R4-D$!A MLB 04<5@72'MO26A_-QPQ>643HY.NK76W^;H@ ;UO $=U+N]H;5>ZA]10^BC M-1QY16.\,G%<$T* )N8IWEE,0')NZ..T13;!_$\%SJ"Q:'5F.Q@"I0PN9:^+ MLSXU5N$<,YK8<%+#*1R,F!E B$CVODCF=,7]%1X9U(D"_O- M4B0!138:2F!O611J@0SS@L+,19M?"WEE(.5<\-.-_J]^N*#?K?+P<,:=\& MAJ.&$%(3BQJ/K&2(D&JVN#1&:VML%LQR]-P0TBE(:7(=(@=V9#)[JUFV)?I0I!=2.Y\=&0_S1SNG(MNI M,,U,H-&0 Z4L9*]BBDHK#RJ5NGYP?M;E3,&Z3G")C@O%*H-2I B@L@\Z9BF, ML284!W%NR.54F,K$^&3,R2I4-J(!51.7R6OM$Z@2A8AX>TQE6BS B&AB*NA] M3F"#B;8872E,C&:'#1[*D#^7T0="16"Q\NQ3:B5!Q?0FAUH?O#V MJQ54_W?KY7?;=.9(.I2$%**%D%.(F-$5H8O3M5IS@\8*9@(-4Q@12.C8&7M( M.4#Q84QOI1*Q),.?S.Q'C3-@6R<4=8C@DU*U7HQ-$(/Q_%]Q+F3EK4LRS*Z? M&PY&#S;?]F@P/.@<-]2S,2T5WF!FCLIQ'D=[: BCRZ1)U?I_LZ\)3SILI^E9 MYPUECK>QM]^)75H>#FDT?'2VCH?]P;C\_&>+(BD=]/K=_O[9(QQ^>>'M4-?D,#W&]*&H225G.TI]@%&G N MQ:13C,9H*XQWI0&5&VY!VC\%^L 39AF*U$9X C4+'D;>/L:C"L6 3(L!9Q]\XS? [R=VLH,/;G%!QA">#AJQ< M*'6SCL0\W1D34EIXO*;!9/H>KVB20B3I14[ =_9>HTY6:.-EB>D6=]*:82C] MM'^9"[#>C$T37F6CM 25P.H8P)../@7"&+5M4B6DOP3B(SSK=E@HN9/FL^H1 M"0[7!F5MV$Q"RM((B9 M(]R8$$DI(.T$%A&E;,".9G<"6S=/B6?%ZJ'46F1#WA8.JLE%[X(M9'U4MEA3 M9A^0?QT =;M7'&]*=)"\S#8CZ4(1A"G1>"%-)A% L]C$[ OG3^R>C 3<^/U8+MM[ITG#4[S5%S8&\L=E: M[RBQOY$(V3?P,I=,\/T**>XF^F*)U,EHP&\T M^OXUKT7$5*(.08D"23D/)5H3= P^*A"+N*=AG+*YUC5 "DKYD),08$E&C\4: M[W*0VE-L0#;O+"!Q-JUK0_DA0Z_HDK,+&KPKOF!!1<7I')@H-F#EX13F(F9% M>,X$*W)=)*HC8%$!"8L&8T.T!9V>_8)[C1/>Y.KP.6&AE*RU]04H,K=FS;/2 M%1%"T*X!DRX_)+SGS.":X[ 1$&IZ:?90EQDJC,YD:?G+A"85.Z<:=AM"FIPF MY1"$8@5*A X,ZU-69&0*J58I44V(6>]R (&+=%C )YL7>L)R\ M$7.J5[IG*CXCM:;^?WW:Z M34EBL\'_43#X18-"0?I8+F75SA2[_:/ZR,T1-6H;AZ1:PV* MZ, &BEY(54@Z#S[27*O:- 4XP>UYRE@#A89:5]0(%-)H[:,,+BCI&C _]L," MG),Q$*E3R$D7$AQ&YQBM$1ZD <\1-60WQQHX)^,@J P6Y5PP!3#[P!2%!5:H MN" B-F 0ZWTMYLLLT^WS6PP_C$&O4QZ>#/8;(I*@-84@C0M9@\W!%Y,L::0B M!-O()FWD\761/,9![O3?X#"==''0$,E MB2+=@E= "V,5\I%PQ:02O#:-VGY M\S2U9OIK0#@8"[6N>?&"8[1<0O$I.!^+"3F3G#-!WK2N35^>H)U6/F?ADZ@Q MM\^&0S@9'?-)XTP#(KD9\6*38X:9N.-!6B4P00$1!2)I$RC3>->CN1#)+7JQ MR4F&N;HAY\,XRUL7#J$ELMIH4Z0USC9@*/%9O[<_HL'1"L71I]D&*Y3&5_$; MN(W^B&8XCGJ?;D4G7^XQ<%F0>O7%UN7EUTZX8G>FF+L7966!&)/W">L\M0I. M%5]\@YS;/RGO=WK[*S3L[/?PP[JRCS98R1?'*$\JL66%Q?:&&ZO[_PU'@Y/Z MS%N=X>M/FW[2'Q WO'J:#FHF"G]\R\9@'IVKM#I;!2ZBY]!>^6BC#DZ@R8PS M/C;[]N);,%IYCZ'EX<6Y'T1_D[ :/L5.[UE_.'QT=M'NQU7)/JM;=I&_=7%B M PQ;?O_&KSKO7_D+4U?-]I5G?K?A@XSHI"SH$.L^8,$SP]>UM L%KW*9_ )IC=+ MFX4.4I/+$$@C6*@;*01O)(&CA?E;('BV;; UI(%]=D:MQ\N?BD97;"@ZA"(4 M+6SPK8!G@T9KO3@F="N63'$J2XL(0A&)PZ8LD>4.7F5=,*4:D7! MA2%>P'CVK;&JJQM,9,V(%C#%X #1R.2E%\DV(3UJ >.?@G&-S"\@G$X& ^JE M,Q9*_Z@S[K).+U-LBDE&C(9?]=^B+5>ZA_1 M^_R89_UT17<\[@]'FV4;N]],PK@U^GGCHZ+3GZQ'[XMEPRYBL) PA,0*6$N0 MU5H[3C1I-XN9U;=F1#RS9 O6&*$#[H35TV.^_@:JLTQ?\4 SS;:@G8P"*,@H M+=;T?2144@(M%&]^%.\&,-_H88[I:Y]%*$Z 0*TR^!R"]+EHXW)-7DM^H7TW MXEHN(5[K C; KRQXY@17T#B;HU8NB5Q8[2 02E]"4$:)%)(<*YRZ5#BU4+BY MX7)W/JY3U]%OLT/O6R.+;C=N&XJ MBN>\)M8"I;61@!BC#1XXT OH%'E:.+HY4KQ9XYPS%==-1?MTRMH99XRE5%?? M!Q]BD#EGH4ST:N'V%G'=@F=.4N%"E-I:1TZ&#.!#J','Q5O6.72!0H,&4MYC M;/4_)_QO5^_?7G:KYC@E!B7S38TF\4W!(X7J MVU-B%FIUW22B05'& E:S$]8$M$Z!,,99"T8+#EBC8^R@$2B%4+/O8QLT%'C# M5/ 1=K&7:/N Z"OX?CZ@8^SD"SP/EWMYC/C'XU'P4:.*93>)U%FQ)\)E61)Z';T!R3&&E")[RCD956((=]N>S(HN M!3!%*0H^10>):;:248N@(5AKLFR +C7$X$Z TTYER&56S$DMM%Y0F82:@#7 M.Y("I3%>Q)QM \S) J@S#-0)5F+,D:RV4D6*8*+&8B09;9(QPJ)LP#S6@D?_ M,(]^UL'8Z79&G5G>/N'34G6)@K!U7L%)\,G%2)E_!@L68U -L*L+N,X\7">X MF;,*14D17? :O%0>-%$J.=5A"NG+PKHV&RF3,VS:&P4%4G96@?& I6B+_$=+ M[^S%7CT+P]98I$RPOE?P420%E$0&X0,FK73QWK-,)48]^S;EFD)Z_+T2:I;[ MFYUH8H)AKZO;$N04,!A I4+27FAP0F4GP%-F<+FY.SFS&B"RC1UA5F M05,M)!)S2,'D(ATV8)_")]@9_(G=$WIT]O[7?_(=ZZ[P9\_JGO"?@>3RI+7> M\,*5+X MD@B MF@2 ] ) /[SH0*))5@)ZJ<%D$VR16E'6LMHBV2P W1&9U?(M,@F?@PE ,7F9 M:K@&2@(9###[E'A!.Z8[0P/*0U;9.B@@DPD!A(U"1J5!F=R W=X6M&.J )(Q M.)%T H@$,LI@R5I,PB@3DK+Y;@#HSM&.20(HNTC"%NT59!E\R,Q P ZI=""#1Z3 MQEIU,T@B5TH#Y@F?='K82QWL?ABU_%#0ZEDGU?-[^S@8U.'*>A2;E&U>L"[< M(#T8.M>LOSQNK'E]39/ZBS@&]8E_>; MLM[?0K9(66")"A2X6 0*+STXR;IJYE%#NY.;W+@"!NN=7N?HY*@AXE?:Y[HS MIBUUE8DQ6,#X;$WVR:1$,SSI>E77X^DUNGX6@#4SXE=,@ &KJ?=@A?-2N"B+ M9;JC9KBZ8O6*F$EJVRQ-H#4.@0BSRY<>XZ" M.>::?;O]K-_;']'@:(7B:.?LF#Z(<[T&PK6LP$9_U!A'FC,'34H4P2( )(DJ M*S3.0!"(*,OL#R7-A$ FN/>[9@(3 +#F:86J(*I.-CA33#*A"7L,?UL@IE$: MHLBD(C+H4,!&'9UTREGPOJ KH0&C]3,AD F.?IL$:+RM.=F0*2!XQS(ALM+G MZ!JM(?\ZZ5'3%$2135X$$S19T$6B" YIO!4F1!4:4/EA%N0QP;Q*"1A2'::. M'A1$+&S =(X&=,Q:-2 V_K;!LDU2$.XAY11!C"% L!RCRB"D+!%L$C'-A0>Y M!8%,L*J28OVP7@8V69"TCR2!NQ^$CZX(ZYLLD!5*XZOX#5R39*)R8J;.D:&2 M&51,WB;E'$M*BV)-M/-@M?PV]3K]09-LEY:J&"4DU7P5!SE$@S(D99C\*M-L MYW[K8IFO2W+HT,Z#AMR"0"98NRL[UNF@5;$$RB!&J6+Q5IOH0VS"\JEO MQ>U:-$E!4E)1NN*R8=O%- MM=J0^%;O0XXX7!TK))"F)=TIF)EM8Z0B0.#4%$R:3+IVR9$3=906Y1 M()/3$+ V2JE40 40BPB&HT2;E5+)!*:_\Z AC9K-M2X[!598%3($-+%D2S(K MX3*[D-3H@:U;%,@$ZTT5S^A7P0HC09L2%8L"V>B_N1AI MU(V:KPJ"LG1"D(P2BM71*^:]2K(%DXEL ];OS8I,)K@ZQCDC,ILJ)P4DI;$D M8ZU4,GL.V>T,I_->WW U*EJ'@L0ANF=%B2"]#\5$G2E'RRP,PCQ$Z[(BB5AR3N'=>5#DS7D7]@[P<&9$M"H@#T4$47.1BMT4 2@ M<2PB0]9!W0NCT8[D5D4RP7F14B=&:JH<%(ALOS+9(-#' -YXWX#JR=\T6] H M/T+1*F6T]9ZU@H7BK3(A%TGD*;/2-%E';E$@DYP78?"#1!N8:8%TK!E"&F-< M#H*/-794Z_)H\Z;8 VF)-497N9:#L"&1"JC1HXJ44F/'?6];(A,<^75!>3*B M%(?@27LCI,\F\'_12FKL[/KET<=XW!EA]QGAD#9CM[-_OJ=R0_3%^^B2$D$' MC% TH"S,OQ33KVRST(U=LC!-Z4PP^S2P(#0E#J\2]1J'._4LM MTRAF53J/!Y0[HR>8ZCJLSTJ1;-&;?O=-I[?_Z4F36KG[K-.CS7+5 U2^L7- MB@W1Y8&5_A%V>C<$"-D6IBW%! !1M[!4UBIF@@9

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
  •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

  •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

    M/_I^<+&OQ7(Q/@-58G'$R:D$2R<&'058CM\W6/F53K';Q5>Z+_0MO?+T-*V? M1*=O:?7P83K_X^-,S1>/^_$PB E>)+G>+8E(&SZ1Q)#$I(!%Q&.4L(Q+&=DE M73N.[/(.#Y2*W1(X;VKW)+/DXTP^LEZ@O9?6WI@8WEH(BF4'&90R1S!6D M'*'H>-1XYL>P4PD5"81+)"*("(B@0SQ JH4*6)Z M?J38J?][YVAC(XX/Y:RN*VV=Z. !L!UK!(.M9]I8RWF 6!_M/JPP"=4YJ'.L M8;L&V:A]T#'(ZB9W5\];NA#E_!NM^&I*%YNRJ)G("L&XWO8HHC= !88T%P4T M4<)11B56]K5XCPTP-IK8E]&CONQ1%,\[>B[%IGS_/I? ,Y.9QA;Y^AM@WEYNH1N.WDZK_/T\6Q*>=VHS4:M:F6P"1)QFD,I"PE13B34 M]E !9:3W4$@6B!;2J<)NQV!CX[BMK";J?.N#J+R3SSJ!MG3D!(*O;^^-/W+N M+AL+2$+Y:;J&&M8Y8Z'T@4?&YAXW"A&RG+R?++^;=R M9H)J5&%J]"$H:&+\PCF#A D"DSQ3A)%81KFRH8]S XV-.AI9P5K8*U"+JR$% M&X'MF.,LOMVL$1*UGAG#'S!KPK!%XPA95)+_=#__]K-^1,,3^A\[>CC[X$&H MP5:]#2U87W]AXLO'V=-J67V2W^0TWO13I46Z.L<9&#+O$BRO02'L%:GE![%FHNPMH.Z,B$'P],\1%R/DGJ9S&)'1: MRI&17B<1Y;3*)U-/.F[QW)3P!RE64WFC/L_-7I1.F];RU8VZT2,MZ4S4$3P; M%_'MO(GQJ^Y,Q[5="A=E6:&8+& 4FS,@5FC2B>,41DF!.19)BG#FM'\)(]?8 M:&FCEK'7-XJ!M6;F=RW=6I7WP%8[\'NMGW]27JCYMMQ^+?>^X!IQ ]RU: M6+A#[>8"237LQB\LE =[Q,"/=_>N?WGW1=Z;%)+YXEF/]G;^^"@7O*33\G]J MIR2CE12_EE-9+>>S35N2+$41$BJ%J3!QUW&"(*4)A6DB9<0SPE@1V7K??008 M&YU_^1?Z^/1O[Z[ 3I6Z>MF!,K#6!FS5\?!8>TW8>4=_W]/0,Q^/?@;LSQ3Z MGHF!SAQZG!&GXXE+X.PXOO!Z[&#'&Y&5['X/F$Y; M^3X/\Z/1)A^\KKBT_%125D[UQN'@ZTN92"7%FC$3H0WY5&*(HSB#,14T1E'" M!'=*PK8:=6PTN:[AT$@-6F)?3(EVDV!'@<&A[9GR@J#J3&].* 6B,[LQ!Z4O M)QA>TI7;S9?0T_%R%9OR$[=R4\5IRG4QR&E3#'+6U'A&FI9A2+&K/.>NZF8OX3OAX S*GA<)] K4&@+ X[P;Y,GN?N#WJ\7\G9S- M'\N9*2?T03]MOBAG]]>MY-:U*XO'1<111J#,4PX1312D2"HHTT3(W$0P$BOB M=1MV;.1J) Z6YF_3.>,3G_3>LSOS8'2K9Q^ M*_E?))TN'[[(I_G"C/S;K%RNU^!(8X^-AM:">]@\KJ"?-RI[A+)G$FHD!QLPS8%T(SQHI =;\8&1?P"T[F)7X?AZ?K$P:Q/3U7;)JCO(SQ[G?ZND M^#A;]ZO2AJ_I:E6[H2<1*3*6\0SFE$409;F N. 2$EQ@HI(,H01-EJ;-IIU! M:C^TTY*P%:!'B\ID^CVMY0;L&?RP,I$T:K[X$\-[VF--&P\^!A$?O >-8H=GKHP':QC\*'IK'74RXMNWA=5=)4(I:,Q4E!($=1 M"E$1Y9":NFF$LXS1B#"<>99:; 88VWK02J&J!?0MJ;B&S\Y>O024GBG<&H\+ MRB7N*QV\1.+Z\:]4%G%?N=.E$%]B7X1D1>0L@2;@Q8,6K8/O2/,["6&FS$ MKMU$+<$]\_;M)H'A1(H413!G0D*4)C'$6#)8D$SAG!:X*(A;8>W@TS!,6>W7 MG@@[B@X.;L^\'0159TYW0BD0T=N-.2C[.\'P+VB/Q_CN?KH04'[1J)DYLU>Q0;M1[NIAI>[/2)FF=2E"'ZDX4391($@J+ M(M%<)E,."18$8A'GHE ICJ13=Z2PXHUMY6FGZ+3U SL%P49#8%XNT-+1W+31 MTFSHUOW(FDAW[SRJ(&^!'9&^WMSVS+BO,:T7)&6%1#]XME80X5XIC2LDL*?S MNX*.XKO9T&PIJ^47NI2;NH.F 9?\A98S$TI\-W\COT@^I555JE**=RL36?99 M?E_&R:_SV?+!!!M/"":)0"J'B2 $(I4B2&).]9:$I()%%!.[2H)AQ1K;HK'1 M"ABU6GU3:LV 46T=UP^6<\ D:"L(&@V!41'$"6B4K!, 7 WJ(#-N:W$//8^] MF^3#3J&']1X2\6#F?1"A!K;_0P)YN$$(^G3W0\?KI_ET.E]OGXF2F),":^:. M4Q,NET$<13$L2$*48CB)L76%GO:#QT; C6SVIU)[()T_Y_-5O6?.:L3R.)3; M4]_^N,T7AH$.TLZ\!$Y'8L=4[3CLVKM\L&.L8T*V#ZB._MW/G/Q4SK1=^W8A M1;G\0+G)!7ZN6U%A$5%!,@9ES!5$+!>0$1Q#BN,LSGFB^*PO\>KO=1)0._LK!$P]LY,#0L[&T#GU YDW)X<9U& YI^Q+$^3L]6X4 M4"V6NR+VO\CY_8(^/92<3NO75:)(%C0N("VD*2H=8X@S$[]4Y#+.:"8+'-M\ M_YVCC.WC;\OG]/5W8]G]Z0=#J.?OW@4*P$1BCBDBNCO6E 6Y1G&6%A5 M<'[YX+%]RAO9G#[C [3.;R%\,>CY8PVCOD.G+$\8ANJ0M1;OIT ]L8YHV]4+ MJWWY<#VPC@BYU_OJV-_#E_LYZBS9.4IX/?-OI)H;__CW2=7V=UZ!EYI> 5;K:HK3A*L6 MY#C_=MNDUYG5GCG[=28T:(DA/^P'*#7D*-AH2@[Y >I2>LAS!!\S=/$T7VCS M]OWW)RV$K,J9.3FC]GUTFV]J#B6(>181&,(JR'"*I$DBR5$*F5P*4 MQXQ1GME%ZWF-[T(-PT3M;54 SD(XB[F>(_(#V:S!YX!1Q/?$\'.?8#K,P?<+'BJ MN[^C\'V(9U.\]G(GKF?@X$U+M?O-1OZ"S^Y)-UT'^U_SOJW*AKZQN MZ6)YH]ZLM'A2KW_S1V;*,)D:*/N%>S&/&!)*P3Q2A/W+GAY[5T+*^">]O"068H5.?#?H4=MGGB(, ?]%\<9M2@)50^SK[) M:K^RP;8",Y(%9XI$4&3<9#NI&&*B.$SC-*(,29HHQVPG=R'&MXG:"MLR'AVK M8WO,A=V2T"^^/=/\F5HJ.]RO6T9[#S6P_4'LM[Q*EP!C*+-B 9!EN16;)_FQ MX(9E:_9MFB7>2OW^:G*^ES?JKW,SZB96<\O1DQC13!'.8%%$""*48(@3@B") M"*(J9?K73KE2?F*,S43?VE,M-:[ 3A%C0@Q*H)2?XPJXO_O:'5H76[]CBJB$N4 MLQC&&2\@2A2#5(@<%ESRF'(LX\*I$(G5J&.CR9W0L);ZR&[5+U7>;@[L.# X MLCU37@A0G0G.":1 ?&8WYJ#TY03#2[9RN]F-G(0L)^]GRW+Y;%J1SF=?EWK? MW'3/:_7+GFC:8;GD"/+"E B-&8=$H01B+E6&$BHPL8H1L1MN;'342 P:D4$M M\]6FM61+;#LJLD2\FX/"X]@S^5P*H37QN"%SA'$JR7^ZGW_[63^H(1O]CQW' M6#Y^$')Q4W7#*HYW>9X3T7+Q5SI=R5\EK5:+IK_&]I=_*>7"5/QXWG3$*#*5 MI9S #!N;I\AS2*.,PC3/M,$C:9PE;L<^+J./C6R,G* 6%&PEK5WXGZ__ZMD< MPVTV.,:<*I1!GB?F4$=(3F,/>R+D \O! 8_70]Q#W7XUC]'H MXL_SY39Z)XF*@F"%($D4UE9K02$AD8 TCI#**&4)2^RCV8X-,3ZRJJ4$1DQ0 MR^D1)G44RV[&"8%/SZ32%S#V(6*7 C10%)@[4$YA7ETH=$1R';UML&"M+J'; M\5B=UWF6*B[-0<],5+<:'+E82%%;[.80:)*1)%&IHC!A:0)1EN:0817!%*-< M9#DG"CL=LG2,-38S>2OJ%=@*N]E7&GD="QIW@&QG:P6"KF<2]$;-O>SQ>3Q" M54#N&&G88LCG53ZHBVQQBQ]M?)'?YM-O>B>_G[V^7K12A(CB,H81BO4>CY , MDB*.]0:\H)SD1!'FM./N'&ULU+$5%C32@HVXGH<*W5#;T4

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

  • A^EUS(9.A4E]%]+%%=3&226E4G,(,R5T,XGM-?I!! M_N0D=%S#-+-3MVT5=34\*&49 MO -\T&]TCT[*&)YNE2#Z3):OT&JT.Y79:T%[0WU[2F*#B59R)SSBS,/> #.% M++8YXM8Q:3R7#.O*[+6B@KP\9J\;)+E*2'B@.$\TNJ3,>FDMDA:#3'/!D+&. M(Q.-\RK W*;H&[9.'I2I5 7@+*0(Q30>,JHX6G"11K?;-RT7'L!"7H-J^JA& MIYW!' Q1[$^8M*-\3-BGC:$QET8D@%/$00;ZU#8@R%ZRQ& ?.$U&A4\J1 M+JU5:CZ;R7)3E:(VA&^D!.,6$)93T_!9F<040Z<3TGBWW<_791A9AC0ET*:V MA[-2P=!<,%2;8OX(U(3H'#(YLXA;"?J2"!1)R161G.72RK5-LB3*4F7T6':C M1R6D"Q#2B6I76$?C&44YP\ 5",N1)L0CP%)L@P^8F7QYA/2E.8)6[H%?F,VH M(&)%7:Y>NS .=8],)V3=T.LU0Q9.3IOM\Q"*CGB]\\R0442E <*D#F94Z(H*I) [GQ&F\ MMLG%<@CN*PN+N>*0&KJ;RJ8R[9.3E F6S#RI0DWZJIAU2UK MW*0HFE$UF]2NMPJ=>9X&O6EJ4E_/"K_FPZ\IK6524JIP1""O+$%%L(QAP2&C MX>XH Q9P7)$ M5'2"*^-E"F?+Z1+)ZBNH)7E;G?$XI<[DH]09OUXH==E :@5+C5<%M!X*85/R MK:P#[-*RJ((G$$QE1(H; 3^DC5;GN9(&Z,8"2F3,+"HK9 1YQ>+_Y/7&*_%? M@/A/1O!2YR2W""L.XB^=1"98C3!36#.?)IF!^*^ ]%<5Q5]K1?'I^M;[&(,K M8IN!^,$7K2S\F=1BRCNF%(C7+ \'\_ %IF&WE: ^ M_??^/_W&WP#FK5[W2^CV.@W7"[[HV-[R5S\8.[**B%[$QK"W-:7#L56:X%RB M8&CBA1HCHR5!2@=I@^'*$5-%1+]\%%BX+:I"@25&@0D#%XDX^I@CHS1%W!OX M#><>V5SD(5C,8Z#+B ++1@9G8K_/S13G?\A%AD:1I?=>WE"PJ5SEC9)-KA<_ MB_"H 3BM9YT1;I5?)J_E]<_&3GA=A'0Y+(X/VGX^P8NW_RG MR1C?Z,K-K]J7YMJ7IN3K$<65L(8@H3Q+=004@LV(()<3:[S6 F-@IVR*E[0* MSWH)2/!XQL>G1H(J[6^!,'&=OAHOJ;3.(2TE*+&6LF3=S!&3.6>YM]Z%%,J_ M+EYB"?#E)U3O%D.8,M/+;#ALM%K)K]N.V6DAAE4HV W@20@-0D>=!Q8X%L1J M3&PJA6^$#\K@'SL),PF]2Y-?H,Y>(=]#D&]*IJ$&=B0-@!YC!A1W1C'2G&" M/\,CB4&Q/&4:KA,ZZ=NI LE>BJ1'V.$$-106 RA,F!L*$\^4XS1:C*TI))U4 MDKY*DC[IP86A]-XC&JP!CA,]TB+W2 U%M'!G'.WMDG7B5!+).DOR@%YP[4UTHI@@,16CCN#;-$.8>-M$2[ MJ(0J4'\&?^T#4;\"]CF ?4JGVIP2S".G2!#A -@5 #LE.:*$>:><#3BRM4TY MQ<8U%)%G("?W<_FL2FA@!;45U%Z!VIQB);W0.##.@XE:&\(D#R$7+O>1EZIT M!;5+!K77.71TQE/X#TEB%.+$.X#)Z&T]+(?MKN-A(>O.F$INDU_@[_.FOXWM%P0QD[L126-_CR%&/A4?N] MFT^Y+G^+'G*"9QIS>74PQG\>C<3]U!P&9#O!_$0F]D+GC6F>F?/NVC^OKBI8 M4M=&\/K+W_B.,3[:.Y;+&_;I=J?(+W\#JR!TTE'P3&9IGB4[ZB3R\8\&9]%X MJ[62G'-*B:;:86^Q#]Z:F*L??_U1DE>FO=YMUO_NOOGSO;6WGMX]#WXIP8O]C7;_9"]V_KZ[^S#G[O?OV:_ M?:MO?=O>@6-^7_Y7^NWKMT^?_BS>8^O/;*?^8?=+K9B>>SS['1O5U/.*S?$2 M>8LM%MZ]:4Z[X Z(=0UUE/*KZX1M?([J38DY3=^C3?(C=_==EFU(71^KZO>_AU3C_.LW,S-$C[4:&5PGR;LE=V)V(UY1F$>#6G)5TRR\S[Z M4-Q+[7F18TT?)H5WA6$OF7S>,AJW$>FO_=/39J&$@4*VTRI]PW#,O=;IS$/V M*''QSW'UEU*-]$X]OQ"JHE@-LJ9;Z/1CE;_"K_1[>$B,WC/;X&<;@+EM\,M@ M9I_MU9XS%?5KJL+X-BVK=V.KZH48TO^"8VMY?>^OX_KWS[\.CN&Z>_5&[>0; MKU_LX_V+PS/0EW']^PZ^;DA/G]4N?I+Z]QHYV/YP4H=WJ-&=\X/TS,=?CG>W MMTCM^#/<[TL<&=&_8GB/K;RVO?7#$T>MB!QIXSSBP6MD8E H=UI[ZBAE5JUM MYOD298H]D6>P I[E>;7GS'ZM@&<1P'-Q'7BB92I$&Y'7*=#? ?!8ESLDL;0L M$"L#YHLHQ/9TH?XOH [^,G8CF@TAZNT6*N+P&B>GIBPBTNO Y0:]B#KM<]/L MG6?%++^8DK.S#D')%(]:&.L#-FYM\R'Y4E7"P/**[/T#FBJ1?2J1 MG6 _/ @5:1X0=2(B+B1'U@J/,,ZU"#8P0_#:)ED2F;T];N75^O]RJ5;&_Y>S MF^]9^?\>R\.P531*N)?+[T5X#K[ IRW7:#9*$W"OG9E!#-=9HW?4:-T6 V9- ML^ALWCT*H==],XNSX46YIF9R R[*V_>B1FXQ3KWE$L Y7>OOAFEJ=Y4JNK>O MZ_K*>&$FTKE??ZGUB6=*1=MJ74]\V.J],YW..8S:7Z;9#R]#CSBI_ZQ]/X#O MX%[;M?/=O<]Y'72(_8N_FO7C+58[^MZQ#X%O0/N63O^R6L7 M.SEJ&"M@K5'2_NJ8&W!L#9A'C%.!>4I M09(0C3B.#"E .A0)"S*W04EBUS89?;!;^JE@[:GC.V]+QWA,B?PR9Z6$1E%H M#;X!7?!1$O/N2Z!W03/M9*[?ZW6-@E[@3% E>PNF!Y5LONHLCM! ME)PPD5NGD+4:(\YE3+])Y#&A(5(5#*$@NU-Z)R]M&,W"#7++PH56B/26+ZEHA9AS(&;]W91@&>>YDE8A5Q0.P8PB+8#W M4)]3&2+3,MAD,5NBRGM5R,PJD)U*7!<@KI-APCE1@80(>HE,57%MCBR+!@D; M)$R1-8QZ$-?)0)FJ4.8C"MN2%>LKWOJ6U48_Y_B\ ME.V^*O&Z@K@^&0,0E+'$&.1SIQ&WUB%+I4018!XS&3'V^@DKO#X;C,\EPX^3 MX;'XRJ2BNDQUF>HRU66JRU27>?++/!TIJ$I?/WH:T/0Q5S>7ODX/6S#R.XLQ M,[XV/*FJEUW5RW[*7+9B$==W]]Y_S?9VL[U_O\^N%)O^L%/?JK_;V?ISO.ST M;86F;\?/&<5!CL2AU+CJ_1-X,;> RF]7%>_=SJ%I-2Z*5?%N!([P!RC5VH^N:[6Z_$_;@F=XVV^[G,VO@]?.!!GX,FNWQ(=[= M_M#8/W9X?^_+R?[Q0:-^ ?\='X#VO'\!FOEY_?B/)FC3S?#O+^<'W_VIA1&L M;?\\W]W^S&O?06.^^')4_PCGG.PP^(_63SXT#HYKN+ZW0VLG?\7:WL^+VMD/ M!Q,9/0LH!%";.6,2P60Z%'S44D7B2?!K6>@Z#;"O[GW\H M2LB_LK=;7W>*&NN?OKS_FNJ4%]7CGZ8\^7-L97M %HQ+M31-*T5.SL,<$BR^ M;7=[[5;VU37@DT8$>7W7[IP.0#<[,G^'S(;0RDX[X=1TRIBT=+^.+_*O4Z9V M\3<0D'3WTTX#[G+:A!<\#*W0,?H^G/;*SC MUM:GWPN7<'')=%BCU85U5UAM"E[TH=TYR0A&GXO#MI+!HAE*FPK!Z5V^A,-^ MLWCP\M.OZ/];+XZ%JYUGOJ!8P^"Z#)ZLJ -5W&A4M;8X//&GDHUUDC\ZO;4] MST:/F?J?%M5+FZ$7;J!DWX]@S/K=X3LWTJ5@5'OKQ0U3\%QW/5L["^MK&0!; M^MGN=^"?=/NU=,B[]6(PC$\KN5P8OZ6UT^@64]INP13"\:TT1DUX MCQ2]DKX8.^'W8K$U8(>&-VX%%[I=TSDO!BJ:1B>MGA$NCRVJ8:#C1K9[&M++ MP%7AR'X3'B&=6XQ5427]I%U420^75=++*69D/4L;109KLYC>X'%>T>F5]!E&XK2LT4 PO".Y\%TTIW2TVS#Y4YLZ%R]&U#N0@3@B.;Y M>@93-Y?875UC*:8RP/+N'K7[39^>".ACL6[@2L?]5FG1+J0BW>BAMQD/+MV! M0\LW4VF$TN5/8*6E.4Z)+5NM5A\N^:58N; .1A+X?QL5HDX?\R&Z] 87Z0]@ M=DRD_U\W.SMJ)UQLG[6"1U<$M9BT)..]]$=:D6='#76C-%+)A=#MP0IM#OX:O,FP9$9YBZ)VDQE@ZZ5 AF8#=!,SP&HWSJY&$!(; M'5@B_^F;#EP\O5N2B/7L++WP "T-R-9QN]/HG:>Q^9D0]N]00D6Z[I:#%>G& MT>S?[682IF[V)]P_W?VW\IAR1RB>+S1+*84E/#8-Z8D 7Z;O;H",\".,GK5I M#J]);GGV$!62")0XE$9E" =E\!'\V6RVS])HIP\3B2S L9S:L>$LY"383C\! M(,5C\-2&5RL63J=],CZA!761_^K>M-"N;MA3GG#X?C>BX\W*_\I+Z]#V46ZO MY;H=MHVXK",#^^_G#M3=NE@$N 0NT6"[M5"R_O/+T)[]NOA4[/ M%#+9[)\,=OA.^^SR'9.>>WDOX_WP&H4YJ5ML@<7ET@[=3WL:L()/ ]I7SZ$ M4P=[=!+?-!BFZ1*9&E^OI0H^P,3AM0;C6,0WF>,\6"$,':V_2Z<6\>?A(SZ:6@ MWYB-,EWSNUP%6;D,;B8ES_E6M\+7=]C8_C;-?MK*0OD2;3L=4- M&-HLW.1*>:QBGSAM)^M7HR3P[<-6H]RK.J T#"TB"8#2#:9K-'M';0 1N-7) M4"TJV?KEQ1I#?C!E+[ZD&.F,3@$<@&"#FZ>_+K?E6\CETL[C]-$9&]O? [1 M8+0N0JF=#19O.>^_SSA^-PS9T(WP*.$-,XCH]&')ZK#LLKP8^R,"",<5USDWZ.+ &T")G6IXR3++HQ"@$$+ MW4=^_]O?-CW-/?_92D@J7?^K"-66 CZG2*OT =@ M.,WK3.*?5ZC$Y-\/(;.S6;8Y>R++]ML^Z!2AVX4%;I,6!E*R=/9J7!ORFI// MOX##'._OU5A][UL.YYWMGP!/.=ZY./C^5^/@^Q\GP'F:];U)7G.P_1XX3/VH M=N%('7A+??MM8Q\X3>VXWH3SFL")@/-\(R6OV:)P_1\ZM020-B#O".+TZ!NXQ M"'WW^=O.UYUDUOX*$+KSU_NO>SM[W[Z\_UKV2-W[LK7W_N/.NVRGGKXJG3\O M5__;G9$1W6FM:4^U0(Y,&I%[?F*">?2&CUN:?;C5^^6U&UL_SR$/UK7#!I#HRA<#48W M*9_MF2GD=!;XH<3J]2L6#]?NIJ*M(5'(DT7=J_0%I&L.>H/!^Q,4ZJ4. HAU*]LZ[32:&5^_M"]>2D*YL$8#D43OQA#PTMAQ/0H< MV]RZ:)3RC@N=6Q%SEH*'B13!<#[([N&8CT>!TYMV[+%)N32I[,:_V@E0=@8V MV?*H3O*KEA(.S_&K]P:>#_EV,>?I-J/0<$1?WTX/S_7M5VTOQ:+#O0Y_,.&P MIDHC3Y*76I"4X"LTPL"T@C-&F2C7-@F>K&"9S+:%$V-@CVOW>X MI5,G%+PW M?;-UFJRZJ?ENXEB'H7.^#JJ'V\A^*[_Y?3TSV6G?-@NV5]K12X-\.X*^E>Q_ MR7@7 IW!(@:7=?GK< MPE60MJ^V#;!8SY-2'S)SV D%Y&8#IU\H\-XBY8I!V- MB'LM(N@A$?M4_2?U.)@J/5DW#>MZ(AKF%!;NKT;:VIOGMT__M6FW3A&:6YM[ MS3@SW,#_L64V&&HX2.] *X)I1]/F?S+M9HJ.]+473L=60ZG5#D%WIS5 W?#! M-#I%72DR&_X^X>25L54'IAE>&T3 M4'ER 0T\&27$##N8N:W0S&Q(:)5 [[ S\C0/"6("Q:Y^>C^(97BS9*WC. MA+/P&M MVHZ;[;2Q7(:O) =G,+TA_O]MNLDWU"FVGG9INVET@^FF0)/OXW[@*[@Q'T-C MUF(,&.8 LS@+7L%OG"4U7D8>7!AL&)3BBJ$]$T3PVNU E2!$2Q0L!E71 M"H(4L1:F*D:MM>2Y2KVJIW1-&W*55' (!ANVY]:@MK,[S\(O=V1:H(5U"AL? M'#((_1DPFS*4Z5()+/?M0;0.L)GP:Q!&";M.X_0H1<1FQ7PGIU^AOXW.O ,_4FF%+Z#U;E_25=]3[@CE1$CJ\\"C M8$H)*[SCSC--E#3/YVV:TX7\J=\!" 2EH;"PI+C2=FEZ>E;'\9PY3$ND]Y&\ MC/L9A >/!9X/-I-QUTH1ZCO2F]TED9B6AS'*=RJ"7 <9&5\3J38=W\W>MN&? M[+_97ONTX3*%\_7EB6PH1G!(KK(Q=M5] M[&>\]8F*D2)9QV!H'5H.6?#L7IM!"G,U-,*_S1+>VNES&G8TY# M&YKMLS?S+/K;(A6H83HZ UJ;X-H[;8TW,@+IELR&$&8)P'1'P?>;H$!/T:^[ M;\_'_GJM<0OU5 WGXAO9A>>J;[OS'Z!06)E'CXQ,Q4JU $V9.XJP\[!3Y+DR MC,\=D+ R'7$5WY!D\1UQ"=O BLYZV2DER89# \(2YC]R%=JTW@=ARS[C8P'I M$YVE[].H]XE&?2&-G)ZQ@<#=VTTQ/9\&YJ_$'D;FX&'^S[C%>#UKA<)*5E;= M'1IG'V6K%!OY# \_18-,DX+8QA082MD8I5;R&[F6NO[2&OK-./,OKZ/?C"\^ MAS'O7B3G-F/>0-RZ>^V!D6[(?$*W'GJ[L2CY-W(?K+9=;E#>;S^O?__\ZV#O M&X=[G!=$YCL\&ZW#<2ZO[=5P[62'U_::C>OE_0Z.?Y*#XGJ'\#X['.Y']O=^ M7NS3;Z1^\?-7[>+S^?[QX:_=[W_$VF79UO/:'A"HBY\_K';6V^"0%,PA4+<# MTCEVB.6"84QI3KA?VV1R95K\+<4V^-C%5I<929^JH.I2HNF#BZ9B9R0S'/05 MKWE4VF)L#:'81I?#7_FLQ;"G>$2^C')B=GR9#IRTDZVBL] 03S^VV_X,F.A6 MR_\)7S>:12@N' /JK0?TK?!V'KQM7,7;^M[6#YX3&2*)B"H1$&>8(D6%1S;' M0@2I!-5D.MX^D\'E,>NI+C7>WUB&]?%-F_F&NI/FGIRN][A]\7CGU_43_[H9SE1*3^]C%U@\ZM14I@C(R/ M(O<"6V?SU.1P2JC T.\[5(V+VC0IFK9W1XV'9_34/H.C8I2Q6YBFBXUY9$58 MSYJ7&W+Z,NW(PYI+&0S*>)F22^-$[S)199A#4]0)2JG0Q75&911NGH/LR6S< MDQ0E^*L$92HQ*9R1E?F[,']?_'!,:T5UZLVB4RB_,0CPT2 1G6(:L)*H>-V' MBKV./AH>*'.<\EQ'RXW3VF ![7)9X&:O>,5S+<1"; MGVIW#7UPP_-&2[> DD&ECJ&DP/GC,I)X;"KR=!G@.:I2$E*QKY3K6=CU!G5G MIOGY)OQ,R35T/4]V8?[1J>[P.Z>F\DW,X9NH_ AW^1&6RN;_',K.4 =^/-OO MDEEL*MOWT4^M$A0Y1T-,]M%&QMD[$'-V)_*G/V M2G+S_PU.)?:XBPE8%Q#4P/RL#1A'+X# QQ"J:\J:KOO1/*JM_3IJJ7QF/ M^VW%X6KLDPJDY@&IZTKIQ>L.$M 5E[$7RJ'GI%\9]4X"SKF5_C?H-71JM6':BV!].X9WY5F'5/S+JN M9@)F1>&FEMBVBM66#P#%H_E%.[&/^&[9,"#)QR4\ZE?67K#DAJC0AH5],X# MO>?CT/OSO'[\[0?/@\;&*A2,%8C;X)'2PB,/RJQDPAFL%=#%?+*^QDKRQ9F# MXZ^Z7*9'E2XUH#TT,G[^ 5@6N*O"XBO,NP'S!BJRDSD7C""'=0HPI0Q9%@ " MB;(N$"E54"L?%C^W_#X(DD?QZ]>BRE:QDL>H7>#5 ,#;(E]3W.&5]F+7*S2> MF,[/T+MZL4XX,8U6NLY\)11A1W:4$F^P<-SJ7,'_HI3:4R6D(WK&$HJU1JM( M+AYRJMVS5NATCQJGEX44WYY?I5_E(545Q3N#V'>W:[QV^",7,>0Y$0B+U-PB M"H9,!,@A40;+.-8A"@":>U51/ N9;_BR*URY<8S%5X_7FBF:3!6]9,>;P971 MJ4M3^Z6L_G.UCTUX_CXV@QC>>_7GZFYDPYV\P(?3#LA'T< 6A W0L@%'C;KY MM4]3O;@D]\,&H44DK1WV FZD#EO=D'I EAVVPM^AV3XMV_Q>EGTMVHNUTE.= MG, **ELOE,V70G=]N K2F@%02CV8TTY0U"DROU)8]6D[%7M=3*&YQPWC_]!( MW:;_;/Q=6.IV6C[$RT^N!X:,;'K=3Z;3NZQN,T;,JJC^RZA^_"-*@TD4'#'F M%.*8:&0L#8A%:Y1CPBL\?U&;YY#@[Z/T@*)_;1*RL0C_:XD$@ZZ:*7>E:%][ M/3PL2YEH>Q=G,'6 M X\R%HMP"SP\]O,N)+7C2FV>:K8'8_6]^ -VERUXZ-3791A@7&PTGXILKQ5= M N? -Y]\_LMQ6"K3X9=&]R?:\FD/AWE.O1L+ 2\V\2]%_>AA3X4[BZH^?H3J MJASYBC*_;MPF;DY$>#-#0MW#AF@&*9W;FU(]Y**" PI+K"RKBB_'(IZ^3>P% M=]2">QV>HZ(LR&3H9144L)Q>L@?'O7O-L,J-I[EUG#*F3!Z,E3ZP0)WCY'DS M@EY(4-;)A^/"4'/R&>_N?;ZH77P^JY_\<53[OH_KWS_C_;UOI/ZQ=I[N>]U+ MMO^]WC@X/CP_V/X,]ZI=U+>WZ/[)^U\'QY_)P?:7(W@&O'_Q1WK'6+OB)7.X M=O'^!_^I5EFMA:)!>".MX3@:*UPN0C @Q"$X%F>PR@Z%\\/-MMBAOC10E[YU0^PW M_VS$<,6M!._GWOA^)ZD@E?S.(K\7U^57>IE;D7,DA6&(>ZR1QLX@#?*<>^)R M2FVY,V+ZGCERW=KN MKS=#]3,IGJ,PN)W6:;^W\J[7IQ89I+_%D'/)_SZ/?SQ64MFO9MFOXZAQ^MHR&^8@SI0(AB.A MP)5S+J6SCCEK\YP)G"L9;46<5P=%KJ:)EBB2.P!Y+A7REJ206FN0LE@@BSTS M/&AB,0846521ZZ?DS0LTK:SD-C^5-S.'I=:WFH/D.BL19X$JEV,9S>)X\VL7J%F[1IL00DZ]%#QR MH[ FQ(:HH_?&$R5YQ9N?4F0F>+/$QFL?,8I*@\@$1A!\P)&+43)E*0DX/ 9O M7FW;>5EGI:I!-3-Q#MP+'07+L0K-'7 G M(,YYD!I@)$1D.(U("A4U67V^:G$60GO# V.$N(,ZL,C@_'7&. M+,!ICBCL'0&3RUUU,^39,[/.#3+HKNM>D[] M:ZX?_$3[V^X45\C]ZP>_M$S[V>1]!?TW2WF-B@M4@U -0C4(U2!4@U -0C4( MU2!4@U -0C4(U2!4@U -0C4(U2!4@U -0C4(U2!4@U -0C4(U2 L>A!&!:'+ MJE'7(KY6K!QTZ8WSP0W*L;[IMWSHI*/6-BFF-!MK8K'P:I!+,@9KF[NM[$.P MG;[IG&>$KV?IS==3'>)4&+<94FVLLE#N:"Q2G_KZ<2G9W&WZ87FN=P\Z;/!D5WL[.CACL:EKU-?;12 6WC&^W8 M"?_IAY8[SW[[\N'WK/[EXZ.XCL5&/LM".6V7;_ZFS(7]._PK>7P1VYA29#,5 M#"_7T/_\0W%%__6LI8Y3;>"_0J=KWG7:W>[*CF'VG(.XE\IN=\-I#Q;Z)WCV M%%]4;!ZG?;IT7FW411F*B[:[77Z MJ4 T/%AYA=-..Q6 +BKBQG:ST>YN9'O7*H>GVM:-HN8=/"Z,9O\T=F ,,F>Z M1]FI.3\95"C_KSGB@!16U.>4$4X=%\QJK@*SRNE@K&4BGQKS?5M T*?R.;I[ M[4&LSS!"*'3KH;<;W\'##J. 9JMOW:7WK!_.".<%5RMI2B,.* M1@K+@$1DWA(3O6VK!:ZGK5"L22*)3+L'0WKNV^/85FFU>R: M(-ZI3'E13[&8NHTLE6GN%&7PPF':8N'[!/#7]@X[F-ET7+M8[.],QP]6.>R8 ML.NT6]>JET\VI'C,+7G)SAN $Z=E,MPDL X*_I;!?&,G#H*8\.4IQG;;S7[O MYE.N!RP]$TDA^-K\C_T\Z@R?YM0PGCN".5$2-AV0@JK5TI8X1UW MGFFBI"DW*#@G^*VT,TALE<62J.@8UP'V)R(T"SX2FS/"W(W+_M'9>7'%V=MI MW%F,]EEXYLO5C](FYHI4&6!,15.-HW"'-E10PM&VYBYCFE,QX72QCB\:BJ0^ M)-F'K:]OLZVO[[*]]FG#90KGZ]F0[&1C\= #)A?AS^;U%@>I$4E2J3J-;DGK MBFQH&2=O7FBJ;HM0? ^9/$J/?SJCH+O-\-ETX\Q7;W[]GSLK]?: M_:.VMT7KVX<_G)&">Q50+B-%,-0YTH)$Y (+49.+*9Z\NC7!IX_B M0)DM=H^QG6.Z6G7/!(6[1VG9$K(>6H9Y[O=?EJRK!U?,6 %KRTJG5AW7?QX< M[]#ZQ]K9[O9/>K#WF=4^[O/=C]]^[6[7C^L?]^$9/M/Z]\\7$TU,Z9>3VO$^ MWK_8XKM[!\WZMCL[.#[D!WOO>8W6\ &\;WU[GQQLUV/MLE@&O,=67MN>V5RS M/LU<\Z $IYE0]C&:.R^Q:^ZAE8MF3KL=G'=KKMFRP_E#\VOO-0;+ ND/3J0- MF!+A-:&&2(ZI,B[5&F1:2!%T[F\H(?R$S:DKT%\,Z(^5%AV!OO1<2^,%DCP5 M6K,L(..$1!Y0WQIM-;7D)M!?H8S:^TCXPMI7C\20!+ M/5_OK /PJGN_EM:?GS^438I'8!D5ID?9# )SDQ\!W'FETWE0!\#QW)CC%J,E#"))&/F$MNM$L:4:VZ>D6RK+5:G(+IJ^ >+6*%EDWU)%Z M;'/EI(_ASH&H#&5S&,H6QKN7S/3S'":U1]1A7IKQ;4AM*[M:95=[(B7LA14: MVC^O[?WQ\V#O)]T_ 75F[S/?!Q9R $I2[1@4G>W]\_KQT<_]BWUR73$"A>I7 M[>1+$Y2B!GS_J[Y]U-BG'W[N[L$Y\)QP7[K[\)KFUH]N%G94]G"GL[VM J8=&NOU*I@]I+:BEY)P>PG M0KW&).I1)W3PN0:8DQ;Q'&-D50!-69MJX2KQ136VRW7[W3@Q/*,"F'G0-AI!G?,5;0\^5:9"X@+$Y%V MRB)JF7:$NZ"-2"T)Z-(W\WI)"+N"#/;/29OZ*^.MOZTXP(Y]4L'J/+ ZA;A* M9PD-1*) 3?)C1H&T<@)1+G0N+,N9B6N;5$T2UPE#Z$IQUA=!%NNA!T(70R?Y M"WOFU[B_\)5QQE7'M.W!-.Z97Q6\W1/>SB?A36FLG;$.:4Q3!UA0SBT.'+'( MWN%!4]!PI).94( M"Y(C;CQ#AA.+I \X=8OT6-\8"/W"8N*>I5^0C=- :-[A$P9=\/136/\U;H'"8S0/B5 NG*&A\V9(<&KNJSV&F?9,U0 M-"M, 4]%38]?C6Y1%*%]&LH\Z^[Z>%F1#AS>@LNGX+TB12@VVV>IQ$_T./$]P1ZU4/Z&1JI"DTQM=0,A4&:1PL!59K,#P3_N= MTW8W=#<6$V/UN/& 8[T@ 9%W6J"KW-P=9)3JV!53A@4EC5UA8 M;0.RVA'$.63AQAJO2&QO$^$ M89YO4,P?(\)02W&OR][^7888Q?N:Q*:+VTA(GD.5V2H++,". M X\R9OB_!1X>^WD7$HM:EEY92$3J"YKM8X:'M5ET#J MCOWD\_^L39BG3_&71ONY.CB_T(1<4W5!8;&19A6XY%O'T;6)O:%(X M1T69P3GJE,P:V[!T[SRW^7XIS? /#HMCEF$ND^'&Y5SSW,K<")&#GL.XX,I4 MX<:+R#[_G#+/Z3[=9W#NS]H%W.MD)X??&_6]+T>UO<-\]_N'G[7O!Q/=G.O; M*?/\X/C@V+'ZR>>+]%[PCO#[#JE_?/]K=_MGOO_]\Z^#DR^Q-L6MR8W0BEJ% MC,$1<>,$4M$2Q)G !.85&Y+"C>F#@^$>/71C;E?E@L+2GI7*WBK?4XVQN1)2 M\*@X3#OGCNJ@%.<\<$EY=#;.8(P="N>'FTVP0WUIH"Y]ZX;8;_[9B.&*WPS> MS[WQ_4Y202KYG45^+R;D5T07222(V:! ?C5(LC4Y8KD@BH?<:6Q3,.N-B=65 M0#UDPVSU3RSH\U=%C!@/T!BX]0I^.&,"I3PPB4W$EA Z?<^D0S&SW5]OANIG M4CP_F$;GKU218:=UVN^-=CQ$*Y&9163(1%YAKG >@D51)N>RMA%ISSERT3%! M2&X,P^,B,]KQ_GL>_7ZN^)X5T '*=)+%).JM;G @$\N6 _"HFO%JH702V?O; M4U[C>#T0T:I8P"H6\!7$ MYAA"@/+O;'O2/3>EGU'YZ(ITT+ E0N.$5%1)%: MBCC.@:>%'".C@++!S$=8#],SH:L0P!4QIRSE-2K'734(U2!4@U -0C4(U2!4 M@U -0C4(U2!4@U -0C4(U2!4@U -0C4(U2!4@U -0C4(U2!4@U -PJ('851E MHDQ&NQ:Y>&L.]>"3Y"K35X,"GC-%O7P.GYHT%5[G-_V6#YUTU-KFNZ*,QF%J M$0N_=AM^4 [BY395K\-\I^3\5 9CK+-4-^L=F5[FFNUN45JCDZIC%)V"&IUN M+_M/WW1ZH5/TI$KN_JS=2?_2+(4*E'4VW.50NO&AS$RG8^#SHLWI[;VKA"0P M3=)$CG-.6524BZB4]=H%;G,S2ZV*8;SF6-! +9ANOQ/\;@HXZ'?2J[TUW4;W M6ZMM813_3NN]".],\0@M!V>9U]Z^O';\[8>)(40B%N.J&M9(/+]QL8[6ZO5:+:>=!BS?TR)O^*H,G(5.N%IWXNDZ8HVRDZ]K4VCI\>(/?6-$W+A4$;QNW@ M0LHUR!A9+_:]5]/2ZJ$AE2O;TNK!<9.$T"!TU'E@@6-!K,;$8AJ($3XH@XNX M20J0-7_[-/][[6SW;T:WK]P;'?[\Z_]BY_\X&3G M?/_XVZ_]XZU?M;W/>?W[SD1;X(/C@Z/]BZV\=O'EN'[A>'W[P_'NWM')_C'< M<^]#H[;]_E=]^R?9/Y[>"Y[ %IM3Y9$)P2$NE$ ZCP(%3*1C4A//_=HFX7J5 MHQ^K+O0/O/B+Z*/P[B:"W0J]HJ)BJQNRWVQHA=CHWG*>SPL*P+&53?RK'^T8HJ@!H M'@":0E:IT0ST4XYBB 1QS"A2.F>(Q4 IMM()[=8VQ62GUF?ICO"R.-4LQH.: MZ;BCH>6 +30YZ=;\I)=N6EC\ "T+@C_8]J"54@0'(K1PW!MFB7(.&VD)4!,E MU -R-BO;PR+A?$HK+VNE$#A@%*D".*?2(!VP1C8:[4.D3@BQMJE??.^%N43W M0;O1:^JKL)=JL@\8<'9B?+C;?58XQ2Y;, R*$*92[LE!!X>0<2=:.NV#Z9C3 M?K,;UK.=EMO(MB[WP7*A##?#]>*V)^97XZ1_DIFRJC,<.NBF<*/S[S=82X,B M/<'_7EZS\%^?I9/Z39_Z/W1"F4&>GA1>><(-6+H73TZ;H:A5P\^HY; +ZDWW;C;K\' M+Q>ZA3/\W[ "7G33G'L[NW>WOYW7SGX0ZJV7AB&9?G"C07^7"I 7W1\X"/CHA>QM]C__4)20?V5;X^L\-2CY MVNNDG@L-![+Z=^CV2FAXILVD>.(!LIB^;R3)C+#V6R"X37@.>-+R^2[C3AJM M; <^S=0P9."D#2#6"!EWW _,9.'&R6^/(4 M8V%?[/=N/N7ZEOA,6\]8A:!R7,=^'G4NW=&' =E.,#^1B; -O3'-,W/>7?OG MU=BS1@M=&\+K;W_C2\;X+*%F_VN6YEFRHT[:J/[1X"P:;[56DO-DN=14.^PM M]L%;$W/U0P)C*,)*0+;2WE,:SLSDNKYYT8\Z%$T&M4ALE<62J.@8UX&KI+&P MX".Q.2/,78\NTM2""D--A&.X9D(%SA77UAE,*N&("\Z!6HB%2HMBC*<_^#'^'9L;&0]M.RH52;F2SQ[D-"6[9YFS0Y&R< MY,*2[!65[EVS#\2^8/1%(%MZCM0I);5<,G"'_EC@(QQ^VN_=TF)IGC#?Y^N< ME MRGU@THC?$8W1.$AM"+#[$36]@1A=^54HV%%[\P\(0J/L][.UWS,7BA^#^ MSWKK*L ;6,R\N)X\>J&4RF0 GF)\U"-F%PVHG+5\%P.SWAZ15;D5]PX.OKUC4YAIEO4*UZ MA[A'L5Z)C7R&AYEBRDG#C]C&%"IK33>4UH'?R.Q=X!9""ZX9HDA>!/]?NTRG M?;84ZW&Z_)XTO&^&YY+?_S$GI__:7L^^A,,^3'2[]N^T:=?CFN?ZR=[W[?8;L?:V<'>X?GNWM_G-2/MWCM^Q]38^^UXT8X MPI&0CB'.54!:*8Q"'H77-$05U=HFF?1_#STQCR%?+T& MD<>T^Q=ZFG_H=D^ M6T /Q-I?9U1B' M^1 AQP[D'POA ^>Y8"80HJCD2A A1!8A-YQC)H3H1/[FX#6ZL5"&".(<:Y3%$)PH5["]+368EF#/.] M07)72P _==IVZ)!OQVR0W/20AIXO:72>G/??98T9FZ[=.)BL"K;F@JW&I$;@ M:QXF?R]! MP!86^3./3OZ2!N[^D3^O;<1NA/)49.!ZE&;TG,2@K7*$YTH;03F/6OC<,\., MK+S\3PG7$U9^[H3)B!1SWTL0A0=Y %[0 M.,QGUHS8NFB9UA1'[JA4/%J1:V:ULI3C*ACP24%AP@G I,JC2&GYVDC$@8,C MHX'#14(YS8UU1-)4&7V)G "O092F[*Z:.TVITMYAS$4@5IDH:!_R(#19VY25&V!IQ&_.X!_]ND9G MOGW^?H:F%#,6,WO5'$J(7Q2]FE+$E M;LQ6'5E-UDH<60WL8P[LJ''#]9JE SPNT9R)JX@\J Y;?M1H>0#H-X@4]9D6 M#,VIJJ>8;:T:1NXI&E;T/)G\^2@4L/5/]VV^3U67+'A)GPRI=]KPH M3CM\V6MMW]-7=Y?#W4BEW+/3$=\^'_#M07.+LK/$H*-$)YQV0K,-5N:G2S5KN7F[PK^D!B&7&LS8' P&=3">W?$> M(&E@BPJ1:0!]*G;OW=3CF2HDL=T.)K)-1B:SBL,Z5&+Q1TQ(# M*^FR^4>6"%]ZCF+5]#N=XG'AU=M^?:QI28KV.H2)'3O1I4B8V&R?92=M'YH; MV=>Q"LF-ENL$N&\W@T7FP_"/1FMLQ0V>KYON,[2/-$+WRB(S!A&7S::(Y&MC'HQG)6="\Y@G671K;?[)4=#LQX_69X'WCLU*&EDQW!U,%O MTZM+CU?PO-IX92.;?R6NQ@J^K03_U%87BQF(QZT[?_FX_VXWT\[6_>J.@N\W MPVX<>Y577T>^OK?S@T828,A3'7F-$3>6(D4%0R00QHVQ4A$VK8[\\Q6+-X>' M@)"P,@&3.IWS JE&K9!2>NWYWJ#JIN_OG?E;K7!^/W*PM_^7Z6'%3)>]0QT9FC%P M,F*LW=77XV9WYVI5XBVZDUVQA\PX3$O23K.XXDS]H,I&P$ G!O'4W9O[N3\D M1&W%*C'/7^#\_B,RE*S7/-[;P87DQQP..9U']A9>*VWI&I>__T\_Q9>]__\9JV_ < M'^O-^L?Z\<')#MNG^WSWXSX\R<_\8/NOYL'V44K]G\B XC;PD+N(M!<"<94K MI%FT2'BLL73$LU1"@XC)H/HY&^S> Q3OU3_WGKG/U[?!"LHJ*+L&9830('34 M>6"!8T&LQL1B&H@1/BA3EG"GA%90]B10=C&1"*!P'B@ & ,80SSR'%GM%)*I MMT@LSA6HN]/$F^Z=, M>[Y[]T\!7>*N%BITOMF4&$9<[8)!*(^6Q0PX[;125TBNUMDG) M9*/R.6%W.KH]*DF\=LL;;26O7HP7RXTJ,7YT,9Y@3\[F$<"7HEQ8C+A3 :EH M*<*$6Q*%RPUFRR;&][7,/5#I&WB2&#RU;_>37VJ^HN[+IA).-XK>5R5\\.@L M"RA.'Y9GX#:5DG@_F*M/L7: "Y?M0YD5&J:M5C%%_QECTF\+C9["!%H'&IYW& MWZ87FN=PV:;/0NF;[XXTYNRL5)FS3JDS XA=*LUC4;DI\-STBDL.XG-]9E)L M>[>7-4.WFS5.3N'@,FBX$3/3.E_/C$^+H RS'@OPC>U.^CX;B[*'QW0AI MIW@1I5RL:GB<7@?&KI3>;G%B$?&>%E.:K!1 G"*+8=Q-9^S=A\&$7<#@K-'M M]D,G!7&[]F$+AKX(2'[<.9T]I*F8Y5UX6'C"5N@]XU(KED(:^CX,JDN!F3!) M*9:SWS)]WQA$U!< 4\3.=WOP3[G24ICGZ2##H;MQ8^#FZ\ +NHQXL=-RS;Z' MVYS"[M%P0SP8 X)QL1X3UK0HQ@5S[*M*H)Y%H*8D[ZQ2?D,1,MZ=W*E-[./6UJ6EXX7Z10Y6=PI4.I?8YW!)'>$#"*RIZ4MK0^2 [NC MU(A1[L2(G$T&3F;A%V@#/I2STCU*XC)@.&5R4#'S@]-A9@'V!DLT92K.4YW\ M<>/OMALQADZ %?IWR"FN)\YV8'CS:K]Z;5O\$ M^7:1')7NO.J*]$,RA7#]XML/B1F--C(D<&K!F4N/+(XY"MYCAYFG6NA4+6'2 M"3,,H%_/SHX:[F@\P=2S:=<5[.?"< (O0;78S_3TQ9BPUDTWFJM).><4J*I=MA; M#(!C3^N_?-JKA:LEVOC?GW( M;AR9&)\ER?)_S=(\2W;42;#\C[NG2 *M*D06]H54#:T,@C*3PG!+/M03Y(%^ M'( !0/W."%NV"FA)E5J;[:2"+$L"Z.[7 :P??SBJG>RPW3WWJWZ\10ZV/Y/Z MQ3[?W?ZK6?]^<+1_W&P4]L[M^M%U6*]]?W^^?^SR^L5[6MO^ZV=]^QNK'Q_R M.D Y/'MC]_M.LG?R&OT0ZWN?\_K6#\Q5-#C7R/@4F&AE0%K0B+@A.N)LSL!?C4=_?>9^^R__F'HH3\*_NXN[O]?>?//[.M^G:VN_?O]U^R MG?K>5OWCSML_WV=;7[^^W_NZ(-!_W$4\GKI\=0W#LAZN\*5*97Z&ECDB%)Q76N?](?_#Y@7 4Y3S;.R=.[?9N*-B1#ZI6CTV7'+S5ZEDMS;#+> M=)+Q)FD-ICM(L.ZN4'JUUAL2R_MD5W.\P72^^(1ENJ'E; G+\V97L^IA5^MA MU6/DK;^LU/1L[@3E%SX>#TH@7K)4X,=.WE]H[XMGG?N/!8$8FKRRTN:UJ"&8 M)2__Y0SEUACEV1KC0__,OG<:O8#:,=[:ZW)6F'F1@U>MP^=;APLO#C$URD>6 MAK;EB$RLUB2QZ+S7C2D85330T1,F\ MSJ7)9_5.?6C /<*?C;_#A!6R ,?5\#K=TZ@S"-\\.-K=WH+CWC;J>Y_/X;^S M^O96?K"W0P].:GB?'C1K)S6V?^$GVT:U[6^L]G&'U+?3?UNXMMULUHX/ M3E+[B8.3;^=PWG&=_C&UAD1T6%LE%<+28,254TAAQQ#&$D?F/&8X=6"CZW)* M!.>2YEY7920JS)OCQ7];+M ;HS'C+*:"P07"X$04>R1$4<$Q2MX(Q'.7(R6L M0#3PR'QDC >_MBG7\YQ-H."$YEP!8 6 JP2 <^"?S+7 WD:7,\M-I-H$$QG/ MA;8B&LEFS<"I2-\3HAVYCG;:8J4Y,4C!3*5>81Q9X2.B6N&H1/*3O"4"O(GV/#X,3+1-I8)H2X5!N:4 \)MV7$(ZPYL*JP*21,I$^ M)B?+CBT?Z5M0Q;%5L5E^,KUI96RKLCXCU,*"Q^@9$RKR8)F1H*H*(B/66C,9 M%V>?JV!H=AB:4H3+&/(!% M5+*[O#NMX88+[*A7\ N.U%B9>R+@0V=R%\7BC"*5H,XCJ!-V#V6==2S(Y.?2 MB$L>D+)6 NN/6&*% S,<=EKUX(+IE;0N\4[[!.):[;0+$> )C=W0G&-C+:+2 M&,19($C1G""C-3<:\E!?Z?K&$\6IKR?,V6)_"4O7)CGX15/(,V5F^#QY7M"O2>8:*<< M0RH0T!I$C,@Z'9$6FF@A60X4$<4#AB#U+=@$@7XASA9$QCB,IC -:)H(, MI-BG\:1\/\L^_=0]PIXE*>NV E;SVF16-OCJH07AYW[_94'KI>G#45&O)X/F MKU/ZC F%,;,YDBH - N1'"\F(JX!L"D7\%T :,[7R6HW[YA73I_9*53A[>O MVWG8\1, ;L6.'Q^")WO$&9DKIAGB7GO$I?)(JTB1-9A)EN.<2[.VJ==9/AGR M/[?SK + "@"7Z<6?H<=013B?$.TF;'VY#D1YA9$,//43]P:9/.5STJ""Q+"V M;;+U\77%)\-J*\)9X6V%MT]%.)\ <"O"^?@0/&&.M0)+16F.4JXU)2><\MI#9YG=ZO&LQK/:CQ?R7@N M,DV5+%-,[ WU'0VH;UJ&KQ*''@."NR""%9&JEC(.:P>I[R$?3_9^_=F]HX MLKCAKS+%OL]3296;]/WB;%%%#/9ZGR"2&,=E_G'UU0@+B=4E&'_Z]_2,!$(2 M(($ "693BT&CF>D^W>=WKGV.-]HY:PV//#EFB&9.))\#'D8,"Y/.X46M5*B M/V+5$'"57-9+>7P]Q'4=X@NK2GG1:_T^Y49637VX;^G@65-<%27AWF>#C==4 M>A&)5(Q'KXTB*C',@[;8@?8PKYOI?3O$='T*R^YWWQID\HUTB5H;6$ ;V)]Q M)H6*D!3)Q8,$-Z -Y$P5V T(>^,P)M00)S>V")D^U/]\BH$]\3-J4'RFH!B5 MTBPH9[E37)KH-#!4BD1IKEV/#M###Q[(LA3(%F[Y#1"B/NA4+6.XZ(""#+%--"Z=PJ MYSF7C%F59[QX&%&$>1,\2Q$G'H-S4F#-B>":6<6#JM6J%8&1QB2,<&X%D80C MJU)$''.27<\:6<(39@*6E8H:1A[4A;@BRM3LJ-0E1Z)69LFEU77<'P^/FN-22HY8Q$CZ52NQT8) MLM1JQ+!+WJ04-%6UY'@^DJ,TH7[IYRJ<\&]H_K,U6MC&X 06PV_]&SX#7K^9SH=8M/5OU_WE8@M4SYGGOD?<*(1FU_11+C;JN]'V\B]%9] MG&W9 MMH]%)Q5?ASA2V'8H[$T%2HMFKQ@ZMXO3+@!8%P9;]#OE$ZW_WZ#9:Y8H"4^U MQ8D][G2;_7.8KOV6G_9/[/5S:E\>P[;O]*.'I3PY;<5^:>$5?1AG:G9[_>)_ M ]OMQVY^3M:V-XLI(E^_ E<6/!,;>W/_T_L?A\3>^1]\F0&BV]^<7&;W( M!<,1#3(B[K1'1H2 N. A4,>"#'RCB""B3C-/= =Q8VP!GX(54J?5ZIP!*,!> M/NW&7NZ;"]NU"Q^CU.F>V6[(&R_OZ0O6&+&+.R^^MCKP5[X7.*7DDU[\FK?U MZVN1 !CE:[,]PEP.(QU^DG'65$F*U9.&:%:A,!"E94][\?7HEU]#LW?:LN>O MF^UR:N5-OUY]>HZ338!P"435Y5_/FJ%_E 7()J[TFZ$G:?CFX>7-\M*$2*FN M";')&+WV,MXDUUZ[Z;&$;AHF[O38FZ\)=OU+'V>P,\35:!T!J.*=OKD*!-!S M/?86=^6*>27+)[YN]N%M?@X5[">06O"B%LB\WE1*]&*S]8 @L;M2ML]>#!\& MW:\+S&L.36V]2/ &A$&S\X_M^4'+=N>@Q+TY^R51]Z #C':_155G+IHC&M%UL<<.'Y/QL/D[)4V$25,B)Q&[0QPE)* M4DS*8&?9H@>P7L+YJK];>S_\]\\'1T=[[][3O8._3CY_VA6'QY]_['_ZZQO< M=]SXT6CN'>SR*;?2IX\_&C_>'NV_VSW[?/SY>^,=O..@==(XWA.'[_X$@VB/ M[='WW_<.CM+>C(QJGIRR/@I$.05[2).$C*,>16P8BU)C&LC&%G]%V72)Z37R M*RW*CD\UW#ZIRP^A!F3 W5-52O2HRU MANH'@.JI"@.1:II,8H@8[!%G,>9L<8:"49+F?@3,Y.,S])59[Y(NCX75MWA' M'@*T7\8W:\(^#6'7+%EY-EB\NXB?YPAX]XX'O^8]X[O6)S9XD)$DIKQ5AC,L M-*7*Y73_F(QFVL\,P,\CQ[>'I-\9=(%Z?\!$.N&J;$_-[S&@'[';J<7Z F*] M\6;:L>6DD39:A&A2Q7Y_QR=@7S\Z>4B.= M%4GCR%, 54][H[1+PH00R;+9N6;;1=AVRG%"2;1!*X5D4 %Q3@RR6#(DLD-% M$RQ3/G15+_\S77[!)!884#N0G.1J:X_UW2;.L<>%Q<&'*26.IE-SYA!C-A9](X,AH0Y )A$E/3,[FG(T+ M3P<#SRM-Y)K:>2>G0.><*@)F#%QH%W[0[<:V/R]2:^#[@[)I7Z_,VCX==/U1 MSNX^[39]+&S(">#!;=&#+DR@5:[.=CO\,5R:;>^!Q'V@Y_;E MZM0FZC) ;4;N!3%6<0K4#)P[Q!5.R 5.D9-84JUT]-@NS41=X2(#+Y[+'\Q& M68C+:VY>A)NG3!>CE =UA"()Z@GB+FGDDB5(<$&]VR'3CU%5CY)4( MJ]?@\."&2@T.#P8.TXV5$U$\ER0CWD@0]0 3EF"!O'="1RJCTVK%P.%Y1<5N MRG+?L[#U1RGNK"[:4Y=>>)"T(,X4HSKDYI,X=R;105CLB%.8"*'$W%7'Z[2@ MI2-V<]HX"TQ:F@Q#2GJ..)4)&64T$EZ+J''2SN)GD!C_? HNU#A=X_12<#I$ M0&-.),76<]"Z';8V,F%BB%8X06J1U PT:QXEK#( M<>.09B##==(Q>9Z]*J^H-#7XW]\;]*RJD3:!NA^*RW&%1UCLL+EN" M]JZ=W%@YI7(4JU!ZK9S:IU@$V"OM3K_H1@_;".9X?EE6JGDQM\(?P1S@Q;/J MH/5*[UG1Z9:%(C8+ -38S777'IC1%ES'1JN M[^(/X![?C+TG HERI!MOM]@#N_JLL"E: ('P+LJD@&/V_+*6*-.C"HG9A+_3\ MH-<;EL@K1U#=>*4&WV3=O?%MTH^]3,7-JZRP3+PHQ25GR09GC%:<14T4?H^#>6YCYW[8UB#M NU:G-^C&WHJ4W".-D7 _^#]R#_3/;)_\!GO@8 __/21-([_%),E]PZ/CXX;=!<4 O\# M!#5IO-OEAP='(.(_"OC^=QA_Z_#@(VWLM-+>P9_?&P<90]P1 M^*WLX8L-T81;;T.JM*]F>Q##=M:1G..)24IBDH;GUF.)1\6T 8TL.47UK!I] M3R$[KE,W*X39/]@M=BX0YC^[.^_>-]X5VV\.WO_]_N#][H=BN[%3O-U^_U?Q M]_;O'W>+O=WM#Q__VMW;;1Q\6%PTKH-(G4VH'7C0/[;?_">"0.W!BE:0EM'E M/S%\S3B\#;K:/\W^&!*O)6%N$[^@H %B] I0$;X!E':;O6]%ZG9.LL!M#P7N M5()=_%Y=+;H@#7HC4([PH/[PH_X1J)%?CZKGP3CMUU)J%*?=SM>N/>D59T=- M?Y3+KK8&(98B?= KRZV&RZ7)SP7H'/OD4A U+Y=MLX!Y5._(3)T%3M>.ZJR6 M*2,& F=HIXQVOO](]NO!EJ.LJ31)/U@,="I/2]G"N2U13FXLO9; 8*XWZH6.< 6R)/) MSX%W%5]MJ;7!\\\Z@U8HCBPL92=+_+,F++J+L5TJ"F4KDW+SY3O'W[Q9;+?Z M1^6.RKKBJ"PN4"+F(;=SR=U7Q1EHDYWA%]J]9LA*X'53"3'90:N?A^EBT1O3 MQ6Q9[33V\E6X"YY0)H[F>KSEFF\6;RMUY56F1QQI*F.[M#D.*;"NO8$[AIOS MNWPN50J#@/6%3572 "@'C)4+ 8^O1WYX-T\'OG(^TK7R,/YI]LJ=5](S/SW$ MTP@\4BU)'LG535 1-*O55SXO@%N E3>?*[A5-D[(1D6)!:\'&4?RMS:VWHQP M;(3U8S+@N=)C8VL?ML9,>+\.UDLFZL$>OJQE#7L=H"?V;?=\5/,ZXU*K:5VS M50K+5Z6T\!EHAD(A,VO>?OF+_:-F-Z"* _LY":CRB,!=)=9G7?X"2ZNQQ6ZY M\8&%@*&;,(IX%>]GCKV:9^:/8FY#8$@K3JM>F@#)9:WNUV5!;^#JR]+ _^>J M]C=TBN#+6ZSK=5J#_O6W3#I GFA'$#9!G;&?1]W+FIE?(W+=:+\AFV ]7]O6 MF3WO;?QRU<70;*,)$D[._MI)IO0D,/!ONS)C*8ZZV2#\U^V&I=K8.B@5%6#% M-]F6+#'+3N//]>!T898.+:!*5RHMQ=NMH*M64\!4)4T$"91QK()E.DF5B(4)<:1[,2H(8JUXWJ[)BB\&H,94=5UB_ +1,].X_A6U?'6>+< MT%D3;;=="OS\'@#@HR*U.F>]C-,=4%SS5$MM]7;DG]%/X-E(P5SAOC< ?;_7 M&VEN%U2XQE@9:EA _*R!@>QZE36MD9B[LO+PU79GJ(^.+2C<%P?=SJOB-]#S MFK RI]G'7F1E'$;X]57Q 13AK*F!B?&J^*\%NF2E\SRV7Q5OCIKE'S!$>+!K MELN[#30$';()] M9H^P.96)>R5,@3,S%^ =@L8!VWCPM1S.]UEDM[V4UM-4! M4=X;:>RP4J4G+9LJ^1A5JS([LH+:A DV4P)#K_R"O:3")NA0V98L!>"K>;2+ M4:,,>&O6#@;MS&OY[W%RYADUAP>]KM_BSU:)!55UJ/],;M4;K(T0LS53TA9, MF0LJE5@& RN%3O%V^\-OQ?:'-\5!Y[3I"X#P5\6E4^2J)^2GZ2__7"EL^759 MQX-'E@LYM)+*O?-Q\\/F<',6_V0'Y>BHWE WO J8F2U+,W&X'2OS,X#[,:C M"*9*N4O@[UC\E+<0[-%L4&03WGXO?MI_\_[GAY[!C>/-PG?870B0>1A9N:*) MC 572G?%M3,K^Z\8<")5VV/T9;HP7J)8C'B[TQKE"LY);8!B!XZMCJI1[3K_QX?7A# M)03'%/97#^[__ MTDSR7Z_-:0-*3>2TI8A%5-I(&2)G26E&K,>R>[ #I MUR*O[?%#WS_^/-__\TOR#B<25)4@'9Q#-B0;1BA"HW-@R>+J<[*A/ M4]Y4]NO7;OR:F0!,V'8V(%MC4:MKUQ_6 G;84K: F-P!>>4OO?3OA\'&OV", M'S).A3]B-\?]P'*_V *(OKP]0!M_?E'$&$IT1%A(@KB)%AG#9#Y-%)-S)E@: M-[;PIJ1B:A?\GVFXZ\5V$T1ZNY.-]F:O-ZB I]'YI^K/0S$Q)<2$06G.P'*J MXJ?R9TYXZOV\F9-]AF&T&]Q?)1+EO*VAOCF"SC+;:S( W07)9'/,M JZEGI' M&8BXHGC K:NE>Q1O!B>#*IQ0C)V!+B[/.Q<_O3G8_GEU3+[]U2)@:?*]N6(8 MO1\:1MF^>TJZE1ZXJPIQ+TYOS1P#+G=QOS@M"W2MN 6U/XQTQ_Z3;LJAAFK] M,)J8%=@%;:BBTVZ=%VQ5*\&J:G5.D*I]S2+*?/:SP9ZOYOT%^_1AFC1G9(_BZ"&(^W[![E5.44TYR.L_U@8S+ M](64-D-W@_?CVO$G7*D'"I28^EU-P4(AXS ML6Z):Y=_C[X^T_=?VF^5C$-C$[FL2C8BQ@4-RCP8F]TI39@K;*-L!E8SZ5<9 M(<,0?$:+TB88V[@7SQVWUT?SAAW\-;9SF@EL^5:.=93>^IMR44,RU&"7J"2) M.^>U]A8'^-LHFG32<^2B7CJ0L[*^G]X,9WI%98=]Y5^'0?>LTPV@6[PP':T< M_]L+]?I=LMF[+TJU[($]"KM("T+!A9/A/&6SD] M+\92^3.RP[25\U=+6F>[,SX!M\VA*\DZ'89\MM)1JY)$-USN;+NG[Y9*^D]VP M) N2V1<;0HJ@3Z*(%4:<$8>TP!X)Z5Q@3C(C;ZJI/\\B\V"M(B1992UG M5AAM16*",A*-IB'-;GE6+_+R%CDYS[FG#DG&!.+:,60]5\4721#3.>%CV?#OOC,<%YGAJ_& M6)X@,_RN:N3,C/);,\0G,LJ3,,D':K@A)I>^TZ"G!4ZPHE)Z02ZUA8GW\YY>()#.O2^"ZJLZ&G(.J'9R7CA1MW<&$'7B24 MCWS7XTK F-;P^K8Z'4.YD0L^C57N,%<+=^1P=^P"=:JQ78B].O5]V5DGJC$4KZONCP$;6,V%589MX<%>H==K@K$[W7G38"F[\V,??[#$;'*JUFBP[/K+XX\=UH&> MT,.(* NP3=1OZW;.JM\OJ[:O6#GH^17J4B_Z"53\84Y.[R*P/:MRW0TSO[:T M_<($J]!FI6JK3;O#P**KC#2@V4T4FY=*9DTI4Z8"7B' (IRTP!ZZ*G3F:NR] MXJ2[N2#[7>?^LF@X\JN,R$AG;<6%VW7?OS>.=]G>\5?Q^> O M>/:?YXV=OYM[.W^RSR@3_?WVD=-6 > MC9WWN/'I_5EC)S0/#[Z=[>5PQ])L:3-5V3#ESG*MZ$LX"X)P+I MZ RRU'B>NVHIX3>VZ"NIEM4L9Q' ?374U5 W"75$!LP,85$%;B*S/#>? ML]AH02)7<7;8M8:Z)X$Z.@EUVCIIM+$ < $C3J-"-@J-K \BQN!QH"E#G9IQ M1F1%H>Z1FH8])]-AWH[M]Z/B"EH'C1E''!^4@K-];/-WC 2V67V1($5DW(H4 M+&-< +HD9E62)C%C$J;Q_MIOC?KSH_[YM(+K!*>!,H-XB#D;RU&D,36(*:D4 M9Y;RJ#:VF%P0\^^&WM66KKGMSIV;G;8IQY: M6[IR:GBJBL.#)*S)33''Z&9DD675&+'-&5%X9WNQ2DSZB?P\D;'S1*[B%ZKO MU:W#YY1.5.+@A -]STENO3.*6RN(UT1C+_7<'6=KZ;0$Z=1X,ZT+4N>MLXPB ME1(HA!I+9*A42!.FG8Z@3P2_L67,=(O9I^L+7G/IDKG46B>B\BY1+\ Q*K81'($@+^KY'T-B!. D6.QPB2@&+%(S:&L(TM]DK2>P>G9R/)@VIL-1//&W:U M5E(I.*COB5LGM0" B:GBR"IB@(FC M M.H?U(9\Q9X[#_1K:KUB&U.SUOVN&U/U(LRI2?#9-%I'B6FN"(Y%&>AXL$T?,)8Q&51,&KB+A/#IE$(C)*&<UC07;U.OI)AV MRSQ1C81R@]XK<>M>G+L>Z:LU;M>X?3-N$T*C-*"D1Q8YEL093!RFD5@9HK:U M];5*N#UE?7%K.&8*(Q.P0CQDR#82H^P[4E)5!YDW+6.JPS5RE*JK] M,?WSUOR7W"XHE[*H&WNL;F&5QO%[WOBZC,8>Y8J/U:Z<*-Z9"Y=<=FV8JRO, M1/G)&YHKKWTYRFN[Z[RJJJ7&$]MLEY5B)DMX-R\+MEVK:, OO0D.TUI04"RB M])9PSY4A*81H>4@2;$4K9W/8^\;;$8NYWO?7PS#EJ-_YJ!YW+Y.FW]D;#O'E MUB_,RL>?7VPP-!KI4-!&(TXP128*CY@SCDL2,28\)VI>XY(] :H>]3)X%;;5 MNJGF_6VMNMKA::NV_S7:Q:.=0>K*[6.;Y6/>+(2DR 55R#,N$;=!(T,=1M%S MJSD+( ?C]97;+W;)1). ZS=-U15N[DTUNRG9Y:XJ8>FR0G(>9U5SN1NK$0]? M.+OKV:7TF*MIV%'5GG6L4-8%*@*87I2)J)!4S9 FUY9D7+H\N>6^EU@"4M0E M(%=C+$]0 G)F*<=;2S-.E'*4D2HEE(F28H!,:DU,,0FOK4_)6[H6E?^NU/RK M.JJ.ROR-E?O-&'IM;[-KY7YYUTS OJY)]S+Z(&T6?Y5]UD!)7:T2PMGP*/:R M-4H)^;5X?_:OE]/6G,X57WM@)+]L2*0E4S(ID!G_BTRW&9#8^S.JWQ# MS^@E]0IXK.*KEUKI6-.0=Z">_@Z3>=_^,)KV?GH[:IK^1^R6VFK;O_ RK%^_ M))%D-,HA)G(95A83LCY[#V3,D TFCM,+EV%]W$*CH!ILXDH]6+32*-&;W,Q7 M8G*1QZI-3?2S?^IM%4&73U+(\XF5EY-6L3C?IL)\=<=R]4"-'C;'^NM+E,'>$];YJ%0LB_G;M9RG4-I/$ M7NDZ@/-1N@JK GG+EL(_JM;%^V_>9Q+_IU2U'[S$IYQ[#R^SPN4%T6<+]8OB MX4^P)A\O%-DWXXKLARN*[/Z%N?(@&OZ,>."LP2XA'GC[,>U[[:[GS;15+^7< M]2UU.R?%=N;<9AOLJMUA1[J[ ."3YNF8Q6WCQ:J!/S#6K-YN^:,;T8']7F3; ML/@I6X@0,2:0N,4&MLY1:X4 >('B+8$$JV M;K!ZU/Z]XR_ZI,]"^NPGJXX7#*_"]WZ'IQ3O03UXC$5YB2PP M&?,B_\7&1> MJ"%B D1_&J+HS\4016L*C2LHESOG.A"=K9_-<2ST^5#IH(RS[U49([OMW(W] MAHX3,PEF;L^#?Q!#\@FH]3"=$I;6L:-^0?V"57K!(Q5>>1Q$F*NMQQ0.+#+5 M)SZQ,]^$YS^P,VN&3W3P9KZI+71>T@J"F1/6*VX\UY01Y;W@VALAA)H96;XI M[[QTJ5_QJ%<.]:R^Y#WV%K98Z1\>19Q_BZG3C9>&2F7#;+<#*#GKGIL^/)C3 M.&F\>W_6^/3WT?ZGO[XU#OZ$ZXTFO \WZ'N^=_R5[WWZ_*-Q_)%,'LSY3#_C MS\?;Y/#3KCA\!_?M?*3P7IC;G^SS\=?S_9VOWP^/]V <95F$[U/5Z)E+))B$ M@A84\108"WQX(=6K(61AR MSJ=Z_0B1I&0),88EXH119!PU2*JH6*3<[EK MG%D89WY,XHR7-K&0"#*,&,2QUL@*JY EAL; 6+2"@6HS?6SO^=1L6Y^BE7/: MH)U>Z=X\[7;"()_ =-\JG1EC=?/$J_OE.)\$U[GS;2?WG4ZH0?&Y(?8_:?I M8^\#[*AG?1SZL7%YJA:$4)9X!\M$"-&(4QV194XC:A@ETBF=J 5(:-!M_1,^ 2?LTC( MQI8TM>E:H\WS-EUKO]B]T45,H@M6E%"N,Z8(G&L;>DT M"M8F %D&*EWT%(Q(1ZAES N=P&I4ASIII%V;:J22%B"W6'%,4J':(.QR1 MX4P@1FS0W$F70@X>WD,QJOEU_27J?;BTMF+NQJI3<7X70Y*YQ3LSF"-N'4%: M2(XD[!WB+1>A[.RTHO+U934-GX_=W^[UTL%MZ3'Q$^>$QNQJ; M%L.FZ;X'3"BB$T;6.X]XR!$CR@/L&\5TL)PXDG7_>[><6V%P>I8\^JP,B#&E MI(X5WY'SIV+%D6+M4B)(*8Z!\R5#CH IP4C@)+"HB'?WRW*N#8@794#4!OY] M^',JV@HK+!T-&@S\!)(9&X.TMP(ESZSV@N'(W"P#?S4$\[-DTN M]*EXI5#42ZT\$IHXQ"/3R'$3D:6:&Q$MEDQN;-'5$*H+EY!8Y3/AUU:)N+G- MU9V*13S Z8;Z&6OPC#J^OV[Q??8BX_N+Z"F<"48E9XHXS*,ACDC+N PV6DH( MCP^CI]21_@?73_;?3$?Z8:F]DXRA$'(&IW(&6>X4$L:0* +U*I]L)O?)#Z_M MB0$"TF)05BI M@#AF$CDJ. +-@FHI:*(>+ !^[W)J*XQ2+YUE5]64F!WE'R]TD9K?8T _8K=3 MX\!B.# 5_??)$1%I0DGDG'_K)2A#P0E!,K$(!AXBX2KER&!,H*!?SZ0"B;:I9N&;AI24'U'R\%*?\ M5-( I<%(QBR*#-B7"PZRF&C0R:V+F&$N' FKR,@O('_@(M$?S-$XWK'[?MTF MUB'873]C=1(([M'A=M6JE]S6I6$1U6 1LCP[U4%:GA3FV#(:N X&1$9(3*A M) M>+U=UN$/?@UI;N+>VL'>P76K\5[2%?)+0PAHC@4'CYUH(9!G\2:Q(TCN> M2&3+UA86Q)_', MJWE]!WJ\9?XF,WYPT$X3%#G8_$M)+Q*6AR&&3DW>\YEHF MC-W2[?V:\6O&7ZPG0,W]R^'^\\E*:+#WE;<.UA4SQ),TR.:F),EI1:,(%L>X M[MR_1$MH"=WU[F)MK5X.PS)+%;QLZ*U+&:P61#8F%:1'KF7P'-&Q!H%5U[_J MXOG+PH_]J<.;Q#F;<@D$IPCB1%@$OS"D!-6 ]SH0&Y9WXKHVK6K6GJ-F?6U/ M+8?9I]RH5 !'BX L]3R?U/;()K"LI(A6$2R3Q73=[:F:Y=>-Y>N#&'?UEUR& M2L3>SK>SO>TORE*#@V(H8@GF@*($N2 2LB:W#6 1_L#K)<[+\/$O?>M:<72@ M&7Z,AC;VK)R\TTSG0P;<^K?K_K)U]2#T0]U7#NZ"6!5-@% M>]J+KT>__!J: MO=.6/7_=;)?\6][TZXGM?FVV1Q2<<:Z[?&%U^=>S9N@?98[?Q!77#Z/JPS\EFA0&&7?Q5EK[H MM'M'S=-> 9K-MO>#DT&KK&53:A[%%=6CJ'2/*X+LOM0VD\3.93C6G-+;)R#. M^T!>W_G:AMM"T6P7^V_>9Q+_Y^8<);88.:XEJYQ[#]^5[+?5F9DAU*N5>IHU M^=BV@]#,&_L-;/@\R7*7?^C#/V56MY,.[2?8'>D;N>DV,ZA?2V'8J##N#BZ"I\ M[W=X2O$>U(/'6)27R (C$/TI\\+/1>:%&B(F0/2G(8K^7.S>DF[S$BDTMG.N M ]'9^MD#Y4.CKHQ%GOPO:->L=L.@'=[MNN/"D9>%113>CO!;CJ$=]5? MO5Q#\@FH];;3/;/=<%'A]YXG\Q:ASA)R#.L7U"]XU!,0)4<@(+)!2EG$O2)($@(:MF&[S5!5U M5LR)=XT1VNF5_LW3;B<,?+^7;?-06Z(O J^IULI'[0/3C N53(R$,,T]-]II MB1?&Z[R9]M.[3B?TP)K\$+O_-'WL?8 =54/O8M [50];>96X#02Q) CB#'XX MJR)B3EHLJ.,N^(TM(YXA]M;HLS[HLZ:VZ3,_K/IXN#55OQMCP"OI&**"6<2- MT\B!H$$2&VF84=:K""IC;9O6://,;=/:\W5O=)DJ+5 WT$*Q13AA$$X -3]X" MV#"/8L#*J91L)&9CBT[W)7H2?:9N!+UNC:#IBVP$O4@M!,R#H$$)0BQGC%J; M@@-0U5IQ#;\O59%[R>V?'PMEF],Y%)X[1P*L($A4,!HC2IGUDY\UVBT]ZOTLZR,_'CA-A;J35X104"$H<0IQ MK QR2@E$.*9$>>]D2AM;5)EGC$[/DDF?E0DQNPMTS?J+L/Y4M)A3*U4*%%GM M#.+*$&1#"LAYS0$2N-58 NO7)L2J"=55-2%>4HOGQ^/;J3AL$-$S'3F22D;$ MM:1(>XN1,8%J'(PLL]-6KS/LLV?AYRIR:T_ '5WM4P%-*:)AFC(4G53Y\)!# MU@ G1R,)9]8)J=3*B-R9\4QR$^>N\K'P:PM%P)_MBT(1*,1VYZ39+@L+ANCZ M=2?G%_*,.GJ_;M%[5D?O;]8QE&818Q W3!!NK7/2: Z&G;&*1AV7FX991^\? M7*6XZ$TT9@S(Z(W$/B*3L$=<1):- 86$)92H8,# UZ!1\-H.6$T[8 D\6D?O M5YUKIZ+W,5J#M;!($,,1-T(@32)!F&G&$M$\6+&Q-9UR4[O>7I)(K:/WC\^J M4]%[XB,G@7HD= 0!ZZ-&1N5V@-A[KIQG5.?T.+VB K:.WD_S>\ESKXIVO-ZZ M?^DXM_2X?4GS86^&]M<*XX8Q?+ <:I1:#*6FPOB!:!4X$2AZEAL71H><8_32679559/9L?LZ-K@,')B*Z1-BM62 XS9B$ _"<@D M^,%A'U#O*1'>U;'!FI'K\/ZJL/!4>)\YHY1.%FF<>Q [I> WDH"C.9?)*2F= MK5FX9N&E!?5K/EZ*9WXJV&\841ZX$3D20!9[RY!-VB'#%??42&(<645&7KAY MQ/J%_2_R]\$R?4(O^H>AG/C EE! R>AYD M--HX0T((F JGZ7*3<^_0<:"6]O>6]GL'VZ7&?D7:$R.R?A>1C<:!M#7?U>;=FW"4R;G."<1UQ!)C3(;#3".)1&F0VPQ%KQE>?> M.D9_@X5^6\O4EPY]]0G[%8.HQJ2"41^QK[GTZ164NNKZLAA\?]+1G^U[A15' M,42#.*PN6/T!6-WQB+4G@E.VL47J'/P5S<%? G,^5"WAFC_OP)^3KCFJ<*1. M!I1RN7*>C$!6@84?I<8L:.YHMA'J6GFUU*QK>S^8X7[I,Q=[.]_.]K:_@+24 MVH+!KI048+H'CJP5V71GDA&FJ$MLQ>KBE8&^7_K6M>+HU"G\&+UZ[%DYS:*9 MSH<;WFLFK_#M\4O51LQW 4G^-B"[5[$<_KDOO M<5R7_/P@IXQO!1V:0:?:,M,_W[<+VVH5I_#03N@5@ N][ H)1;-= %84Y5(7 MUG7^B:_*#^ ;J&^_%S]]!83XN6@!1A3V!+9;OU=T+\ "'I"ZG9/B86=8X4M%M;\Z M[=Y1\[17@*08W;U9O'!6HJO(2F\[W:(SR/_O]_JVG9[W/;#=XS*\! M,9UUYK+.ANWELSC350DJCLN7,K,5\/R2W6HVFYO-@+(6Z)6;C695"QALI4AU M71G5IR#;!2+UREW7@VV:+Z/\U8SPP(L_[(B*)6@-DRUA3P^S+3.Y@5_]H%5M MZPK<0DXQ@WM&&QX>L5D<'#5[L.&!^VVK^,>V!O&&QQ[!R3-P?X6C@"-M^#"+,.M]IQMLV\?BK-D_*MYN?_BMV/[PICCHG#9]H8G8 M+-Y7DJYB49A#.X"0:P*S54+Q57$&%KYR57]D9L&4N( M+I\T&G@>PG# 0W%Z=;@EET\/^@+F7SC*LW5!^3CH=J8*)^5-U/;-4]C?5Z'> MS@3["NO]D6W#EH!-D&RS.V0,V^]WFVY0J6* ;M67>J,]U3OM#/,XFZ5L@ U_ ML>%6"NV*-P?;3XEPEX"R:G+@:24FJ)/SNR2,(TQ*%14Q@7-M#/8I)"U)"%:9 M:$J7!!NY)-BD2P)/>B0F'0QO =FW.[[YIH+C/TH,;L3^?CJPW[?'..&@\X?- MW[@UM0"OIX>B%?_SU_GAIW#J*)>'QT?'#;I+#G?\C\_'GTGCW2X_/#@Z_OSC MHX#O?X?QMPX//M+&3BOM[VS3QO87:J0V,41$^359><=E<%X29$3NMY X1UIR@[R@T7&- R-IH9474E(AN&8*:TZDT8(H MH:DBWD0K.;O%#5FO_&.MO(>EP8)31(6QB&.ID=4AH:225I%YSW&]\L]RY5.@ M)@5+D0N& ,\SABR/"D494F)$,,'DQE:C,^5+OL,'%_Z^,S!>:V_$K=Z(D659 MV9/7F7=#*C<&)_ U7_V=>;'9'MAJ'<8,P.$[.-U4V8::MK#.FJ%_- HXC=U8 MN?-?X\M;K.MU6H/^];=,1@B6;482/!-]ANR.53U MVK;.['EOXY;9&6RAVS"E4O^>@#6>[>RAO]M5V8L MQ5$W"X=_-3E+-CACM.*@7U)BJ/$X. SVI[-)Z"]J8^N@M%K!X'J3Y4H['RRT MTY&@Z\-$]PLR3?!0)1IDI$H)4%DEQ5Q0:DU,,8&N9'U*WM)*!L(],6QG00-? M=E0E9GU@W$BBO=0C)(;'$(XA+$>"' M-0&YE/+!!Z.HD+FCN]\H(B@6IWG?=0?Q6F"\NA,?&QJW>YG!]FS7'U5.*D9> M%7DSO;H(UXV""./NRC1T98T=_VU>[K$QK]6K?!,\Z9]F9]!KG5^Y4KI\1T*$U=&'YJQ@P?;_F^ZO)0[AJS*23)HG=XBGCXXJ%4WBRE M\D2B0W6-ZDU.Q+67\2:YXS7!^)WNO&FP1&UJ3M=DL%1L)CVPY",XL34.7!9FR&,J+UH0__ M5!H#*"'#"I?PA9J$%0FW2V=)ILT?H(L=@"Z6M??BIZR__WQ%_1E7XK.H'ZGO M5RBY_NAU([5V+D.E_QFF05W:/4O:4DOZZEV+G@R5J1P#SVF8)2<5(\JNYEK- MEBMOKTUNNE/QH"6>]+PKB9\4/N:J.U-3=GF4[?1*6#[M=G)^6"]/)CP$?9=& MTYGG&U8.%OZ_11/3YY__$YWKF'/B"\35?(K4<>93(H(SR2Q.+A!F,*5>DLB_ MO)\50I\^SS%LW_9FB, SCW <='Z[XA_<&72!H T8"Z&5-_"9'.;8_?'Y!SR7 M_G7<^!&:^SLPUIVWS3WZ\>SPTWNV=W)XLO_N[V_[.X?-J<,C4% M%Z'@=6G@#T*]!?N7/O69RN7+7J.UDXE*):SFU&&7B%(.*X#NG-X6;I.]5Z-R M'WL1:'5]\[]^Q]TB?9]/^X]'$L#GTP)8V4AQ/D")I4Z(L^"1U<:B$)U1Q L? M/-O8NK?XG8TNCR-A5ZEDZJ*XMMPJP\^O)-1Z^@+6BWA+$;+/M-S/G"1 $3")&*18\2D])C#Q>+V6O*24R6K^_ $ON:.?6DG8Q2=N8T6B+ M64QY5!&I0!CB42BD$Q<(,T)8H#8HR5>FELB,<@63:9;WR"Q[@(ROT6;_X 'A M!ZVXG\J*'9?J9J_1Z5_&2+9[PR#)6&[893QN/[UMMFW;-VWKC]@M\Z;;/FZW MP^7'PR3049COQ:>%P;B^!!)4,TM8+@Z/%:I(4U+G*^ M%Y8)Z4>/-F=CR65C;V@S-NZ> 4\ MN=T;2@L0O)W> #!\L>RDJ^E$64@./\GN+U/%/1\U60F$X2:NK,Y%LY6$VC3R M;MDO-U]C^@&REA[F0A=,/)J#KH\Q+;/90W6)1EG M!5()%__J6B8AS-Z^V0"8QQ,QSXQ?'.7H@S/X X+&R\T;&]DEQ4^M,@?R!I/D MJ5V<:\DOLZE>.A)>99NMSG&JPP7L-:>*,ZQ$PEP2HK70T7DO";8^,G=+ MP9 ;?,$CE^]^>R(!:N9IR5M=9L_$*1R^'69G+GW//M./?'_G3WJXXT5CY^/9 MXIOSG_"D4YA';H.4&@GA+.(A>&2\Q3LI-&ZK*WK9_9FN*OK9QD$6A5I.ILR3ZL2YU-*P*@C/AVQ M:>;2S*.U#%U AC;>3*N_.%=4MX8AG"Q!G"F"0 $*B"D99:Z';IF:V?/TKCZ> M)3#,>CC%:^BLH?-)W>HU="X5.J?,#VJ(R"F%)A2$Q*9B#,D]T,N+:Q,8IQ"G/2KS-[9;^+MLM[46;O>V HC[\<_MCH_X#M[,^KGR_[4,_V%Q(=]DGXG)R@X0<'S+$>T,=YX;,' M,_?:G3S4\Q2'=F;4I>S&_PV:Y;&95FO\%'59;;G3OJ9\<[\S+*E<-:P;M>.# M;7[96JQLD!B;.?!1MJ;K5^6AF]8U6\U^\[*EG;.MLHE>[RC&_F;Q*9_F[L?N M2>X-F*^/=2OKI,FBTC>/<]#+!XS*AW1A2Y]UNM_*LT&^VW3Y<-#Y5-5HBE^M M6&'H:]"CG/E.L^=;$_&X"6A]BGU6_#1-UI_+ 0,T]9IYL8;+$@'!3JH#854I MR[-8G'4&K9 W5\S+F:N#V_.\X\HP9(+=!#?VKJ[SL!MD-Y[F5I+P[+(O9-F5 M$4ASFOO?CO7*F/8OY1H"O5?PR+&: L,.J;X;0[,/.R=7Q,Y-%(>M)'T>;NR> MVF[_O*QV/FAW(RQIYH;2735J@E&M5-G6[ZP]_;B)6\LFK!>WE@TD/2@!^8%Y MPIE1>F77R%S7<]!OYKN*-#IS69QT0FR5_'E2[95[<$_Y\M#)Y.QURG<.2K*? M#LHVGK8_ZD!9_&_0R4MX"AMN6/J]UX1M9:]C_+)Y9OFZ$]O]!E]X->,1S=Q< M,BL_Q3S/&SZH&E<^ IC/&U8O>55T2A":;HE2MT 9:X&BZA8HJS&6)VB!,K.5 MR:VM229:F20=,5><1![@9\):> 9J$04;+%)!R(J>9.XXN/&?DHQ#;,OH,VJH MVQ_'FO,2,(??*D&S@JRJ%6OKO#R?7#:T@&7M=EQ>VU+-@,\NWU)!5191-FL@ M^:O#9NSYS@JK +TS^C]:)8"9R7SOVQ>' L>/^P^1[<(J>,GJ?^/'QR_:ONC<8S6$%#!&8\QZ$2$%TDFX/B4G)DT%PZR M"MMIM3IG61QG^3:F.??FDNQ#T5F>IK^4G:^G>X,M:F#/W1OIUDG?_KY'[QRB M!;O+67RF-X52#]+?XFXM/F[I;X'QPS3C6/Y@B=PT:S58,M^ KCGNJ]?GN.^- MZ3^SLSL>Y3S^C;2XI5/1BA[6_VWH,OF072:]!_%7R$TQQVAGF$;9X8W8Y@R M=;87*VW[)_+SA!KZ JL+E)W5YNF_41_YKX_\S[FG+LI3%/7A_[NWB?'QQ($1 M-B0CG<6C3WK"_J090NOA@PC7D>>*D=&X8F1LET;&ZZ=.TEM#8M]3;5H;I-'^<9N8RMS?&Y5GK&FV[VFV(,#Q TE>U-)J'Q]L_]M[MYO>>'Y[D?W\[F4SHW7_WW];>N[^;.2%X_]-[&.=?K3WZ MWY.]G;VSSP=YCO\]*?]]=SCS+(375&NG+=)<.<0#2<@8CA$S3CGC''8Q;&P1 M.5T Z&[MS];H3$,-1:LTMP6@B'@#R!,3U59S;YW&'+"'FV BXT&K$HHHH344 M/24439\M4$I8*BU*@4G$O0I($Y7C_I:(*'.J;P(H,M-U"9X.BEZ6/?ZL&B^N M@+K=ZK2_HIR+?1^%NZY[,:=88$1(IK1+UG"NO78BMS<*VL1H/$B&6D-]>K'P M85I#C8E+;R-HJ(Y3Q(5@R'+.$+<\&:VBI,R"6&!TY4M>U+Q[]YHU4@9B./"F M2_ P;#@1F.L W*OA%U>K=*O N]/5%#4U),0$^X>#2H>= >O2 N\:B1E8G-3Z M;%WR%]C=LXY[UA2;'^274GMXO25 /F).*/&*.>Y4B%@R07(]W7M+@#6K,EYS_5QM3L"CSB]Z MX/RB1?3JYZTZ&RX2I=%H[Q3WQ!M*',,FUQJ0(I#[&I:I;Z;2KT_ MJV@I928Z'U&*8$-S9B/2F 4DK$V2&29#8CDZOD+!\9JEEYW88CU.E@IO6>1@ M]VH5";9$"(U="/)^UG#-T@_,TE-6<@(\CB90)#@!EM;>(X,31\P+07S45%L" M5O(:Y;NL7G7,%:C-^?"MK9[TP.)!IV];Q1S'%I_:+%M-HCZV(7MGXW6E\V'O M6Z5[L]:+V A::X(CD49Z'BQS!(00MLH1XY.6>G$;X4([&"]Z5?)_ MK2XLH"[L'6SW&V_P]U)E./AV!BK#V1>EF++:$,12;MOE.4=.4(=DB$G%Z#'S M&/2%&3; Y=,K=Q$"XRU'>)+,(EO-(9_OU(=M#:)G]XD?D"*K5KXMJ98 M'?!>H8H[*R9NGR"I?=6V>TVQ)0/$Z@4EGD5(9!$\?=(=\XQ.3#\I'2=/3(\5 MV:^/33]DTH$,+DHF"771<>&838)$P807 DM+XE(.WHP9176&P5W=7!^G0P:& M&>F8U\A0G1"/A"%K!4%<<\N92)I*M[&%5^CX9FQ#A/#1Z#\_=>$E+KATVE]\&?[0NL#D[K=.6E6UG.(KO](325FVOAW M;"I!YV\J42>^C[4;&6FLX\M>Y\<^A*CSU"1*L%-&,ZX)U9S%F.N&Y3(A1*=: M55T54?=Y6E4EGH,U@1UR"H.J:DU"3BN+P/S 5NKH" %19]2]A5V=X;ZZ',RT MH#QQ'Y2D7("1DA*3%O['B%92VEI972$.GE16<1*>6!R1Q\R B1D8TB%0Y+P+ ME/) '2? P>+>E;KJA/8U]]ZN< 1L3<.FSYUB<[AQ[I%MN=8R\U$J(]4R(X*02VKT*@)'O%.8]4FJPIL[7@^CI%ZH&+(]4U-U>Q MG>"Z)R[5M*S[,M993:M4%JG.:7HDY5D;[;"G/'H<.-;&>D99TEICK8EU[&%K M(XVTZO-:I[ZC3GT\XW0TQP%+D0)*.B*;!S%*8!D7 ,G[8 DDU7R^#KR=M94T=-\0Q)!T1 MB#-JD+7<(&6L$XXESHS:V+I_4&F-XHSC'&5_?K^G.E.;O8_?(X;Y[T_2K1KW%-B^43:%5D[KK4$+H0KAM%ZG1/;!]>_;W_NCTX0:%3^N/R MDVMQNY"XW9U6HZD-V(,]A*C,A3$84TAS[I!EECN5-&7";VR15QBO=9FAI3/T M$Z>0U=!>0_NZEC2JH?UAH'TJZDB(M8H19!UQB%NIOUF.J\^:H)1U>Z_1D0O_SR+V-2W MGAFA-YT9(3?CXPF5_=A3;1?\H%O#%?BMF/U 1;#\6G51^/(J+%,U>T6G'XCS:;M'I M%JW8ZVU>/4_SXO;&Y8&B)]@#UVW+6T]NY97,*_M__Z69Y+]>*T[CH#LA3E/$ M(BIM)$A/SI+2+!=TS\=PB11JF-P^AZ64CQ0=Q.[)#HSF68O,5OS/7^>'G\*I MHUP>'A\=-^@N.=SQ/SX??R:-=[O\\.#H^/./CP*^_QW&WSH\^$@;.ZVT?_#M M^][7+\D[G*Q@R#'F$5>6(!V<0521$*,5(5 0> 9/GW\N8,.U\G*6*W[:;;9] M\]2V,B!T?+/<"V?-_E'1&70+6#15-#I]V)KA,O<#,,(6[0C;I?U/[/5+8#C* M256;Q79QVNF6FZ4$"=A/[4[^$YX/O_<&[C@"8/0[\#@T>F+^=H:A[M6/,C<% M );"']GV5QA!LT*C*B?E/">?E"\-1;,?3R8 )T\Z;]!F>V K(3\&0=. ,X27 MK7^[[B];UT+7M?<]HM9 ;\[2^2MFYLZTR>IH4>JCQ5ZTO4$W7DW2F9SU^ M;;8KE0'/1.4GF>S&UC[L#M@;HWG!MFCV7A5GL3BIIE5X0&$+FR,!DL%>KK;R M2+9=?GA%RO6+E.GS3TF?:J<-3F&O_6_0R3L[[5*0D&K#DV^Y.QW;%9'&3!#@/XVNF>YR_: M2;+F&=L99#TO46/(H[,& ?P_1NC\K5;G#.915..&=Y5T@RNV%$09"9H)Q&N[ M!(Q\P]A0KTZB&G=)ANIQO9&2YJZ"US M\@P(<$KEP^BA\V'4U0/K?+,\K_Y[N=(DZQ>4D%^+]Q6C#%?WG$?:''IPHM[#7R^@G]]:Y#?<_WZ M]YHP.; Z9JY^B?_5/6 _=[L=EP5FUA?*%]2;X]$W!UMXH,_8SZ/NI<_@:T2N&^TW9%,_ M=E_;UID][VW\!P<#C$XFX3^HC:V#DI^!/9ZDYT I5EAI^VFZXVJZN<$+U1V?-(1 M<\5)Y %^)JR%9SX)*K")5!!2.1[@GABVLVO )B8QH50H8SA5PH:(280/G;=$ M^W 1%6@,3H!D?J("7#:7O;*)8\%SGB18XTEK%XR/W G[9:?T6Q!,T*4#XZK+ MXH,',W30BOOI(@(P[+K>#F-I(D,C+.RW+VRTW[(I4Y+R ;T6ZOCO[TP9\;> MP9_?&S]VOSB93P:9@(S$"G'I ])2>N2(2D)8$6/2DPLOM:..!Z=45#Q&^%TP MJBTCB5DB6-@ .>#M:<:Z[F"BG-*$A%\96W=[ME-V*';"A-W:F6$99R+!/_V1 M_5.9.=G=?YNZ,Q0B.?IYE3RYUT')[Q?2I@PN $U:]K077X]^^75TJK[9+F=6 MWO3KU:?/\)J6Q*\N#_':F$TM6(;L8:+9\,5#--\LT7PB5E)=8WP3,W/M9;Q) MKKUVTV/E)I/J3D^]^1ILV'JL]5CKL=9C?9"QZKF>>DM*[ZTYJEQF;K,L]-)MK,7<9&S<&M^TN_*>0LRN:AS)1.L^(KN95=PP^;O;A;7X.IOFIV1Z%3WL_+VO[K,>J M#WWW#\XSSYAXM";>W8GW\&C]+(E7GF6:@W0ODSHUJ-6@5H/:VA%O&M3N>BSU MKD19L4,A-\68*I_R?M-SWI[UN2LR?E"R%F#9[T] M:W*N0B' E9[V7J<=ST?9@@GF4B5C].$=18AE>MV4*KW(_%?MA/EL*LQ_PGS6 M%%<;=A5(Y,\R(D(BR9-Y#;>6FVBOWU-N\I;;[;VRW MFT\P/:,Z6B>?:>.'_]XX^0C7_VX='O\)UUM'>\?_;>[M[,)8&T?[._"\'ZUO MDZ>_#X\_L\:/77IX\.?WPT]_GS1V/M+]3[OG>R?OS_8.8,QTES=V_(_]3W^E MBZ(>'S#,8UOL[6Q_881;IS5#EA"/."<).8$%4H9PKQRVVH(=3-0S[ 5:8\\S MQ1X6O!")8)U\Y$H$%S3!@HBHF0B6S5UZZ%;L&3]CFYK?8T _8K=38])BF/1C M$I.\%2S%%!!Q0%(."XD=(2P>ZDJ8*:<8T(J#@,E[FSY,: MEVI<6HFY+8!+@ECA)1@"FC N@C R$49C8"1K3F1YN%3CSR+XPR;Q)PKL"64& M6546ZM("66$$RN?+I(@RVJAJ6ZW&GB>?VR)="E-PQ&,=C# \.J^)ST<).24\ M"FOXO+4$:^Q9*O:(2>RAD1GA)&@\04>PR8@"[/$&,0&@I ( DP+=1ZIEM2:K ML:?&GH?&'@DZ.P\T2,43)UX8P[%TF#@*VKP(<6G84]MC2_%=9SRZVB75.J5 M6*"0O$+<$PRF&4O(>&4"E:"QZE@;9#4PK<3<%BFP[(S"GGG.7>3$$2.CE-9C M087Q5(8:F%8,F,XGF]/PX"W'&G%. 9BBM0AL:X]L\ FLZQ"PHS4PU<"T$G-; M")B">LF1X](A'B-! M%C@54:.5YCYESVC-O2^ >Y>5OU'KQO?GTJFD#:8EV"K H$QPX%+.)=+8>J2< M5%RGX$#@UKKQL^;/9>4XU/QY?_Z<2FQ(,GL3B$"P(!AQ:T ;#M(CRW(A;QXY MJ,$U?SYK_EQ6'D"M_3Z@SVDJ^"\MB\">%+D@&.+)*91+H:,D:.!*6^VDK]7? M%\"^RXJ6U^S[D.P[&2*/3I.HA4)!$8NX9!*9* DBV$B&+:QD<#7[O@CV74Y, MN=:.E\"F4X'D2"P3UCKD%8C:W L<&>TXLH8:C&&I'%LQ\_4EE-KX3PQ?<]N2 M9KO7[PZN-B==!&#FS<=9:X!95NAXYZ(!>%46L-8-E@$ZS>EPLHG>64I:E@L4NY> X&6]5*F0U6BS07H ECJIU2.JIH0;!J M4K/G\V7/906*:\'Z4&P[&22VS&,9C4,X>H)X" QIH@.2DM! F%)!V5JRO@C6 M74Z0N):L]V31J0"Q3D(GC FRA'+$0=U!-GJ.5/24)J]5RJ4.5DNROH23QK\W M?6SW/4K\(M)0[ALE=KWOKR]H/DYRFX&F5A&6@3_G,_H72&RY M!L6>*D9R"2B-K/<"J4!L5!JDAJBS0%\"_]XW5ESS[V/P[U0DV6H'JR4X,D:I M7*@$(R>41"QP+$&U T--U_S[ OCWOM'DV_BWYM-%^'0J=DP3,T\8M4GYM+%%R+T+"M4\NKH\>M^X<BQHLDXF4M]:9ES MM>$W["T"!'5".\6CEC6//G,>O6_TN-:#'X-WIV+()B70>!0%[9<+Q U3R%!F MP:+]_]E[\Z8VDBUO^*M4,#/OTQU!)_'+F"L!9& MBS'^],_)*@F$)!:! %U^S8-6JJR,L_YG?T'+-I$METIFH,A,X M$4XIPHJ .JRQ1UI1AK)F9*U1FEF^:DSZ$@J/;Q>S=]U>B#TTZ!Z_RIO;[[:: MH1@O=I6' :CE# .X^?.O"L#.?_!'*+JNTG3>VF:OG RPW>S[5K<_[-4S A;! MV-W7LY%SZ6)0TFBD6,@3W7!")KGLT:?,1Y:2%]E;J&9[.XS)_QD"T(H/3JF! M],4!Z;)JX&L@71*0SJ0P!!6CL&!!!J;S%#JJD$N1(!X3B]08H1.=7[17 VD- MI#60/A"0+JM=00VD2P+2F1P33IAFBO$< P-3/P:''*<.@?B36CC,@V/SX]BC!M(E >E,5A:-2E,#!KT@)"'NM$=.88+ D A$""QU MB'F,:@VD-9#60/IH0+JLOBLUD"XKV#23'N==!.(4',F0>R3Q&)%F%B-G Q9. M*JIUFE\F7B-IC:0UDCX0DBZK14Z-I$M#TNG\1::TMEIY1&**B%// $F%1!P, M!^&3(5I=DAI5(VF-I#62/AB2+J=CT15(.EG*T1FV4>@.T.A2-'YC1QCXRF 4FM,*-4!0_E1NQF1=LU6.I;JT ],--F/BE!B<0^@.72M>=DPKLE6+4.E2:QSJ_:SW ML][/>C_K_:SWL][/>C^?VWZ^A'*S&\RYO'-?Y)5[Z(6]*ROI0'GTAJRS+9\G MK+"Z#\82_"8[>UN#F4!?"D039@2*0*^("VV0U9PC)VDD06KK%7W&+=MK.'JF M<+3\6:27PE'MR[TC)DV'S*BVS U@E3# MT4H\VZ,.E:T5I/O"I)DY6]IAJK!&R8<\&5H*9#"WB*B@L%#Y&%VM(-6(M +/ M]JB#=&L%:?E@M#NM( EF@K4B(:=T0MQH@1S7##''?&+!>IN>\]"_&HZ>*1PM M?SIPK2#=EP=I5 <(N"1VMK^?[&Q]2]I*91U#&NQNQ$&0 #Y)B7R"%Z+P-IJ1 M#TG4F%1CTA/!I.6/1*Y5I/N HYUI.+(X..]M (C/\YA\3D\&-1=)P;B7. E- M8JTDU8"T$L_VJ(.>:R7IWE#I\S0J>982]PHCAQTH2=IJ9(GP* 0M;0PZ66I7 M3TEZ7K4)\UGP-7P"UAH[@\QO_6:(595"T1JQQVD]&OJ^,Y'^'/9A&?W^ZV[; M-3OE]I\?R^O)4QECUFFM0BT%K-[,YBFIR"B@$D=4Y#PERR32B0HDF8K!.1V8 M=_6\GA? WSJ@)3WP+TX!1<,"X@E^ RT2S"/MK)9886[K<7HO M@;N7E21S*^ZNN7@A+IY)E:'.<]"O/'+)$3 GA$$6FX2B#I%39B6S8FW3U/-L MGS$#+RNMI&;@!V#@:3&,>63>!H6HHPEQ[C"RUG(DJ8K<&FJIJQGXF3/PLK(P M:OWZ\1A[)D>#\A0=QA'%//*6DP#ZM60Q1T,#9T2+0.MIMR^!NY>5U%!S]R-: MS[/9#D(3)0,%UO8" W\ST,$#H4A%[X/B08MH:OY^ ?R]K 2!6OU^"#Z>21.0 M3#DGK4;$X("XI!%9*C1R+('-% (E+FLW##\'#,T%U M0I3W.EHDN2:(*Q61,5BAZ'@D6H9$C5DU'GX)S4G.YK\7DP/@;Q5&OVG6TI.& MH;N&T5W_YZNS/9_<\E9M$2P5A=[/1LNM=C1ZX1&/CB)NA4'&*0U_ L(8'HUU MRXNGK5ZZ8 G"UB*<.]5P[0@R3&!D4\ DP;DID;5^ MBFM&?;Z,>M?@=\VHRV?4::FJ"$Z)< Y:,6@J/!"&K"<*$>H$#M1I2V7-J,^< M4>\:Y*[5X@=CX-E8-I,R1S50\%Z 6FP2TH:!I(V">5"799++BV773+RZ3'S7 M6';-Q ]GV\Z&K&T2(D9"4&+!(.X-R&&N*<(2:\\"I=C4;/P2V/BN(>M::;X' M=IV)3',:@2M#1-JRG&9B%=+26^2=QM1XYL"^ ;59/,.&8S6K+BLR7;/J/;#J M3 !:*Y<46+)(,NP0QP(49*$24H"T)DBC6&[IOEJL^A)JNF\7WA\-1:E6/F\N MRHL=5KK\#5H5H+[S---EE.YLMJ>; (FM?=ENX(Z=-Q M)R&-(Y%$9(1D*#=]0X8EBTBP,081O:#XLI[=-:#7@+XBL%4#^A( ?5E=+JX# M]!JS%\+LV8867B0FA!8IT+L-U3APZ=8V*9DMB*\1NT;L%<&E M&K&7@-C+:FM2J^ /".?3*CC!-FCL-))!E:72,7M5##(\@?!,MGL@!QQ#HKX #>R2'.M$=Y*AK**;Q>8BP2O6)N M=8WF-9JO"&;5:+X$-%]66Z-:/7] #_EL3JACG,0(4&Y('B7'J$8:1X%LI-QB MI;U1[K)Y!#6DUY"^(L!50_H2('U9G:QJ'_F247LV-5A93XB0B";&$%?.(T>2 MRJ,9L')E?TE ;89UC=DU9M>8_:PQ>SF=RVHU_"$!?2:!W%"MM,0\-_\FN9LH M1TYABTC4PIJ8U&AV*JL#G\M+?O_7P,)-X;^A^6-SO*V-81NVPF_^-[PX?I") M:Q\-^X-F.AT!P^9_N]Z_S@Z@NLY-OO> QT3S,>T.>T6S\R/V!V7M!_Q>M+N= M>%JT;>]['!0)SJA?V$XH!G!; (KC;K\)G[.]6/B6[?>;J1E#<=(<',)7_XX_ M8JL@13<5@\-8),"+XD<&C.*P&7NVYP]/"Q>]'?9C_L!I>9GR Z$8ENW@_G?8 M'< ?H[L?PW['_D:Q=QCA&Y/KG+J_[1?W3.SE%5\U!W!H_@;[^MKV#\MM\_F7 M^+_#)CSF9(^[QSCL\3%UX="M]]TVK.$T[_JP8X>AF3<^#[C+/&7S'\ZV;,?' MHG\8XZ"_GHDC?ZT7RE?SQ8K/&Y\VBG=;6_^4#SN^\+#L;%D_@F M\&8ILP;=XC\?(7U^)Y/U3DE7;S-1;PU>VUXO/WXITIZU(&O%__EX^O5+.':4 M@U Z/&K0-^0K")[]HWW2>/>&?]T[/-K_]5G YW_"^EM?]S[3QG8KM]6D()B^ M,<*MTYHA2XA'G).$G, "*4.X5PY;;2-((37;J*, .F[E(ZZX%ZCJQA#3SSBR MDU&C$B:,K!?YK,O/+D)"RXHOU21T2Q)J_#KX1B,SPDF%=- 1%!FBD!7>("8$ M]BI@3Q19VY1J5HTY(Z&*(K:CCVT7>Q>(@JX7)R!E8FLQRC!::X(CD49Z'BQS M1'N/K7+$^*3EC;.Y,]S7QW_9\>_N??_F +2IT!()^!_BI6,Y1H:,M$%X(92R M:FT3Y-95" +_'\0>P ART?;*]K$ !?!A-/.&LYWO8UFT3"PAA$9IDA&118XE M<6!/.4PC"*@0M<4WQ9*:8BZGF"U8U^>?._F:O[9.&A^^:9EB*$>F!)7[1"F- M=%048<,#=RIR+\ (HD+>#CLV%M?3GY)^WXM^V"N98D(A;T>;[?=*FZYT[TI[ M9\!DQ\/2%/"M8A>4[UYLE3HA:&]9R\L\T;QR)O)& 0P3>_D+JZ6:-\#" M*/XLRG0$\D>QY4$Y[Y>J*:BXV\VLI30'L#653O)I \6#YH>=-AS\^,QM7C MC,(6H=GW0S!_8,M'UI8_S"7\I0DW97S!!VYZ9A.*^GKYI5L2SQ2YM.;V^UX? MT5A^O7P"6&!FW*%M%:6IGK\."XAP** FYD,I>MU3VQJ<%L?VM+K]Q)WR-;Z> M#IH'%@Z7:_I'L=T;'FP47V#%%B2$S09,D9H=L%^:< \P'T'_S*<,OW7AI7R= ML\W(X'S%XL>; %\>3.[-K>VK>>;5VZU/?Q9;GUX7>]UC($%-Q?J*<=/;L]U\ MW^D/>L/V8QNYY7''5O0E44PQPO'8 AT=7O6!FQ($R)!F=DIT?P#O]$OZ*!D) MS)J./ZW,_7SHO?$7*L[L3]ZB>;Y+U1%WX1.]_FJCY?896OY/# >9HK= O/XH MG<+E8V?/<%$:0<7.!#8\JK-C!#UCSCL_@OX SK4Z@8PX@ J55?H>7BWT&"W; MW?Z@!!^ RZU.)V/21S!->X,"*.@MZ&T%P>C_ED0P1LSR>"N5#OY:DE8!"DT% MW,,*K$M=4&I''0].J:AXC/"[8%1;1A*S1+"1T@K?B6$KJY=,I)@X5CHDQ9,% MLYWQ0 G&GBDJ25A;3>UE[S!."*"QB+E,$(T.[A*XANMT#SIP\W 'B+[\-G8$9X#=J-7 MLN?;7(S?91*-/3BBTFM]YF.O/.5P5"U[W(^OQK_\ 9K#<OFIVR@TOO_3' MQ?N)XQDO>7F_ZNT_3IIA()=_]:K+R@TIU=(O:S8PHTN_*B4;&B]_L; %^G:+O?J.0BY_"VZ_UBNI M &]@>3/BNJ[14<5!.3P^)]BT2"1JEEM7*JI\/HUGZR;3>%[@#DWH-Q,BH!BC M?[U5YUN5=ZG25/:B/^PT_W<8Z^TYWY[/DUK ^ZP%7+H[9GIWSK6!B2WXX\5L MW<<,3[ZO2UV+W! W6,P? M9< /$.-5ZQ4NSH!:)+,5 >1[^'GCRG&;[ M'C-IJ;>!V1SMN/7 DM*K]=3#254NWM''PP;]P!OMK\W]O9V?7[<_P+]OQ'[[ M#6O\.FQ^W3ML[__Z+;[[J_6[KNO1XWMO]J[VU_360] ^._NWI;8V=[Z1J),QEB#>,[&XU$:9+1P MB+MHB722&)S6-LF<-+QQ#.H^>.@Y,$G.)LUA6A!&9=K4VU;WY"9B_IHDPI>S M<<5'.[A<,3)WV;'+MVMEE<<%.VMWACD@/),78JA7/!!J)9=&6\]L<(P:$J-* M*/#R6=SECA=*OQG4(QHC<4WP6(\C<5!8Q\BD2@I^,%]KDT43.4_ MM3!4T>AX[JH] \7_=3^X\H(TFL7X*-G(>(@V&.FX<-XZ:PC'DD9.HXU$W MYZ8NX1L.<5AQ4D#W]*CS/&J/?:SBGLC[&OWA:1$$[!.?)Q_NZ)*;Z_V>V+P7 MY&RZSF4WKMD\O9W+H=[II^#6>V9SFAY(#6Z\GG7MP7%HXPE&)'F,N/$W?CL.3!2[?J[5]??54/R[K9CMQRN]X1<%Y(':6/ M-CG**5C?X#9L./"HC+,,+NHR P!,T6^^R"2LW!'$Q0*1,!^N=D4E@ MT&B%35SH($707L"VL!H0'Q(0Z30@6J%H.7"( M\YSJ(9U&@=HHF>,2;'I@I=E,CSHLYGK7R,IU M6_6TJ.E.D9<[;,4J1F;DXW'0"PC>7&R(-Y'./GJX:FN8'#]>LQ/@T5XA4N9P M+_M1Q(:>SBN?5S]Z>5XYN3*Q_#?R>^4DF/UY+UGRYD:UL)]GRT='O0]RI;,M MD.BI-Q<8 [+0M:Q_LWU50BOS51 MS[Z1RZ)S>?Q(Q)V.1-RH5<-Z^7G;+MV6O7C_VHZA:3OGURR7DY?> M[)<+LN=+LE6]PE1U];^FRJ3GO;*$OBZC$^%T0V42FB6P<0UB:1-,?'$$+?C\ M*]8!3 P'EW]E6A _4@TV,5,[/?'SL'>. P<1N5ZTWY%-@&FO;.O$GO;7_G6Q MJKG905-;./WTESYD2O?VD!5F@:'5K1JBO ()$7L5&/RW79FU%(>];#W^1Y.S M9(,S1BO..$0@[-)Z&]J;7.O9&Q@J-?9\"S+.>TL75].]%)_.+4-7#'MHM7_FF_H&Q9H+U3W33<,D\NH^UXQ%VYYQ1LU;"G/X[?<7[.* M2O=_OX%2/+_[G[98?O'S6: MN]NMUM?M S+MX]WY]1DWZ >RLWW8WMU^PQKOWI#==V].O\*S[?\Z;,(:^.Z7 M?W_?W?[WW'(^$U)R(45D;**()YF0Q=PBXG6DB>%(M,GQ8_5\NNK?<]/\1<3% M[;)_'S58^D^O"[L90'WK==MG;0C+S;F\5A+H()NEFKY?$YO(5C^%B>0C/V/U9-(D,- MBXO 8G,6%FEP*D;.4# V1Y'AAV5& TH& J*,>:%RE?/L^*@957-!WG\8W)D: MQ/04<.?MN;UI0[:$LQ)0_!9_'H-J$'\O7.S$U+P\@'2#', G"$&/B4#O.[X7 M;3^"55#^]WWG+ "_=79"_=U.V3BCO]4)$R.4\L" 9F[*>/:5S]F_<_;7;MFA MM(:Q16#L=$Y&M\.2*!N1X[G;/.,:.2LT"@%'+41*0>.U3;ZDY,!:A;J-47UU M"[7%0G;U3+S[W*!5$05WMLD-<2):E:3T@@NE7#*16>^)EU%(:^H6.P^&VO/J M<+C7B6.B$0G)(JZ9029Y@RC!AEKGDHYQ?HN=)V23+YT]ESCI[CE-OEA"V.:\ M\WL=NJE#-W7H9F7VM0[=U*&;IQBZ>68EV^W&]\:[#[_V]UJM/*VX\>O#:2.O M:0_6MO?O(U#Y6KO;;UN-[49S6E7.U\^P[/\-3=\XT7"V/J$, X$Y=922">'@71<\H$F&IC*U2[F*:N*=?AF MB>&;\;RH/+"ECM[<$ F%!*X2)%%M L=).JL !&7 %&,10EH\>C,ZAK?=WEGP MI@;#1X!Y%(.MRZ5UPLUGWE"[^#0#@K;BY>-K.[FL=C E>A\UJJS_689.SN&E74# M7#-7]<$+<,4\G;L:IEJ.N2WV9L)K=G(P:P%6?NQUJ@+2YMD0]7%I9QZWWBYG MK3;+ZL\<:"O+4 &*X6/-!)IW$7]4$UY[DU/.?;/GA^W^(*LGHX=LV]/BT,)] M[(71JS8 0X'A!7I?].4 W]F08%5X.E[=:L]COMOT^D>=RCQO>GV.QO;/5GI^ M"-4SK.#^OS[;_W?=;CAIMEKE2G-+-(J(S)E=OOB\1_-CBY>;[P M$9!40XTS'AR,GG-)0ZU7$4QG82QO2G2VXO]\//WZ)1P[RN77H\.C!GU#OF[[7_M'^Z3Q M[@W_NG<(2NYG 9__">MO?=W[3!O;K;2SM\-WM@^^>H-+F=K?@I7A>6O& "> 6 16B"$1FF2$9%%CB5Q!A.':216 MAJ@MOB[(6-/";6GAZ,.WY(53,E$4J'1 "R0A&YA DE'.HF9.&9]I@>(YX]PN MTL(XP> ".="- G2S$$'Q:0/0A$E@<:?%L$P[^M]A-ZL];=O['@?%<:^9U9B, MUQEWCL&F:/K6*:A:!\T^7 <^V8^=)KP-6E,$8>];@-*5>@0K^1M4I%9!BI/F MX' VY>FP&7N99D_72SI-UL?1._E^OMMNQUZ9\G1L0>%;+_*ZBU87T+3\O(>[ M-[/*Z*MT*#!Q>N6 ^_XD/JZVSO3F3&;GC@CY,(?PO+L3:)Z?]#5L17.%U:1I M$71M&Y3[E-!ULY3I<\L>CLN:I>35EF![;?L.2=;J#BLOI\,*")<&"&_ _ZDN MH5HK'[4/3#,N5#(Q$L(T]]QHIR4N8V!T' .CE=HXJQSD3J&M;K;&]^#2?[:Z M_OOC2GVZJ[E#/[9WOGPX_=IN-+]N[\-G_DR- M7]]_-4Z^11,U#MCG^!)!/"A0 "4E"&2]P5@JHG&JE#2 SQSNR],[X+@9\3X( M$[GQPABO%:AG45 B= 1M+((J=9P1J#>,C][!9L;97LF_W;TWD_)O%]2KK==[ MG[?^+G;__/O]NZV]][N-3\568QO>V]EYO[?SIK'WJ5B:0'AX/6#^/OQYKK:4 MLK[2:K8F0@+/U[K-KD(;0#>#S1II$1.6+:#88]FQ6YWPVA[G,_P[Q^4G%+(G M8<(\!IA]L]ISD2A'PI;F"P,DBXXBI[@5UG*EF%C;-!L8ST;+5]R4K"0^4P)4@R' @C #Z@F?&"4%YMF8-NY83@0/;< M3[K 'A$Y7E?+N1E=/')H]\'I8F=OAWX#9<<8K 6**7@$D"&0L4(@*9T7E#DF M@E_;%.3RP58KBA+UT5]Y])]/OY$\=DXIBKQ5.9F*>&1($"JC2<@;*)8\$I2QH>(&GM@O&1.V'G)N]=/.1/_C"&82ONIHO^ MS?X+MF%.=PZ^4>.HB%PCL)#SY'/80H>=0MYI^!U8"X<9&X8RY7TB6(5DN:,> MK " 7>D2<33"/],V3 Z$E!HB<-:PE_U]_=%IG'DG6]W. 2J=A#,QD6:_&+7V MS?V#8ZM[\JH8$]F(6J;4Y;G-0J]?])2A)A)A 9N0B.4 )X9)3;V/)H@8N)UJ M+GI=F>:#%V4:LZ&PNDU-)C4;S.A;U61>_9Y@[#XJ/34U]6+O8;%L@Y.;U=#6 MBUUHL6I#<[5(Q)\^'@]R2D$$83 H:(;L945\F5L MP'+A9[ZW\ZRYQ6/LU.ON\!@4RC@HGZ[I$E\CPP7XPJ5TC-_TXE1-]F E[61%SIGC/=RIGW&DVQ+>!U"TK>F_"5\NFCT=EN$N* MAJ/K#6WO%.AC8NA.O:_+8[I[W=0;U&S?K;SQ21=T2YI=_M$F*0TGC!D3HTX" M,\VLUH;>-/#S=[=SL!=[[>P6ONC^3\V?,:!?L==]ZI[_43W?7ZW=+W\=?6TW MVKO;?WUO[.7:OGW^=?OMX?[17X>-O?=\YVB+-/:^G\S4\[7AVO"]?;K/=]H? M2&.[<=@X.OR^\^5M4(LE0G MQ*W1QG%!DU:Y?DY30O]84CWVO9?-U?S^D/P> I:4XH2!P[F-Q-) K5""&VRM M)>FFT;Z+_%[S]2)\S:?YNMQZ0%EDA0%N)HPB1Y-#W&%I'+5$&[&V*?"R&F,_ M.9Y^68K18D/K;R?!WS?>7EVQ\G[D(L[.FD^#7 CZ3^SES;('<65&V3\5CO^Y M,Z[.AVL!UY]\8]9196P>7H\CXL%'9$-DR O'<%#"DSS+GFUP,9L*L- X^Z4W M.WE\(UT\=2.=W<5(GSJ^6V'F]22P@K!X=OXW<7;5^S:';^YUWYYG5\8%5&O* MF Z&62?>P4OC3K#TMG; *+&=DDC.@;5.+ M+!<>P8'QD"<-8AE>N:<6]J$],H?,*!,Y.X=,PIHJB2 M7.MD53+7]I6N&?>>&7?&8 Z>.JD\1Y@D,)@%F,XF*HZ8$9JKR"4UM&3<.3T# MG@_C/CM-93'#]W;RMC9\'Y)S9PU?%PV)G$0432Z*D<"_ELF$%(Y>4BO!+/9K MFWA#W=7P':< PP7BU=Q3?W*5/OD2^E#_->S$RST9C^5"?5K"8L?FB/Q$9X=Z MUQ:AO,>.N3]ODX* !6F%EIK;!*:DL;GHBZ@8)='!J5OZ FJKX>:ZQ^F<\#FU M&#,P\K%V G%#,+*Y*%<8D634EGE2AMEF%8_':V5><^:RO711>HV-,"Q*SA*Q MV"@;90@1-JP/@]\^9,_:\#T8#,D9$%2.(ZY #X& 4D%Q@R+VRWL7GSIG/ M3M58S)J_G<04M2W_8%P[:\M;*2(C($$C-@%Q3C1R M@V&II< G$K>%C;)!MF M#N.^]""V?.I![#MEFK]8%^?=D\E?[-:=LTX=Q[Y/#=D1;HV/*B6G.>7.IB@\ M"TYPY@*83[7M>L^R=G=.ZK>-. 9+),+)J-Q@)"++4T*4>4V<-=%@L[9)Q9W' M<*UPO.O%TYT+-ZZ@;LG;*P7ZQ7K]'] M,2:!QZ^&?EI;=X%[ZOCK?6K**6(1E392ALA94IH1ZS%G(A$IE*QMV'N7N'/2 MK;$%D\69!!*6@, -8,,Z)00HSD)+X:3B*JQM&F6><93GQ7,FHZ I2TV,89%[ MIETD'"Q6CK53"8\Z3="A#!@PUH)YBO6!''GDM11&B5S MXWI9QU^?D+JQF U[.XE9QU\?CFMG+5A,9 PR!.2D9RA/R(/?M$'4)&*I\L8F MFW.I)9UU/KWT^*M^T>;KBW7LU47$=^6;.OAZK^F)P6/*HTV4!$Z=U])3I4!I M9CAE&ZDV7.]9T.[L;0T:S2E!JQ1QF!"+@BN%00D,66DHC=E/75XA5GSV6D;"Q8"WTIFUN'7!V7<\M]/)?.*G>WO M)SM;WXP0B0G)$&81I*IF CG#.4HYU8DZ8[Q).7V8J:6;KT\U /M\S-=5:53] MM(!Q,GWX=I;8B]VZ.UJP=8#GIDF*GF%LHM8V"V5&'"681IFXTT%8[VH+]MZE M[9M9"Y8(Z@3S 5%!(N(^).0L8%X\:RHAA=$A MY1&?G'-@34R4H3%XDD+4I+9@'X U9RQ8:XS01'%D<\DK5V"\6IPH4L12ZST' MX,3/G36?G;:QF 5[.YE9!U\?D&WGV*_$<)P\ULB(W(4.YYH<"Y8L#EIKG(@% MI%W;Y!NX+G^=4<+-B[9?7ZQCKRY_70+KU!'8^U22I>7*^"2HEKD;+-6.">%Y MSJC!,M01V >0MN]G[5=)A<5"2"2UH+E5LT/::H5\PE+)H'PHJ^P4?<9AGA?/ MFD /! 2,=&*6RD.!6L%QD00A21-"G&:/'+8*$2$ MC\'I2,"#PSI"7=*2 M":>-8[J>X/.X,FQGUB[4";;2!86L+W.(E$*.VH2,(2(8YHAR/D\"H<^Z=^B+ MYUSO*1QU4D& *NJ X\009 M9R0*BBMI1!".RK5-NB'KX;73T1M&GGK@LZX[K>M.'X-OZJCGO:8&&A*4XR($ M+'AB&@2SQYB80)/6F-4#:^Y?U'Z84W>*<=3,@G5K1>Z8E#RRVGH4C10F)4IE MU'7=Z3-G3:D\"TI(QICC+E+#.'9$AZ1]D-BS.NKY *PY8[X2*V+"EB)A)4-Y M"BER-$^13L%K&9G1LJX[?6K:QF+&Z^UD9AWU?%#&G6.^!BTXD8PB$EE G*J( M-"$1,1^3\(1X'_/TZ/MHF_34ZTX9?]'FZXOUZMW1?'WQ^\9X';F]3QV92^D( MH=18RKE+V C/O R44B\,4:8V7^]=U'Z>-5]I2!R49(.BP EQDS!RGDJD-0\" M3BP)Q=NLN?,FL].VUC,?+V=S*S-UP=EW#GFJ[!8 M,>DD(E):Q(F2R)H0D93!J>0 6Y7-YJM>?MNDIQI]G1A:PL13MV#I[T4=@;T3 M#6!1!V%OS3YU'/9>$QF3!H%+C<2"Y.;[CEK0E!6FT3KG@JH-V7L7NONSAJRS MU.!@%<(V3U]-5"/-=$*6.$=2C,$%$+EL3KK3\PGVO'C6-#@&DB/RQ!&>)'.: M4IK%;=\XZ=2CV/M7DJ "O0_9"$LP]939Y(26A!%2S1"2K M+=A[E[9^3O\D9;Q4%$@QRH"X5V"\1I"Z)%A.G%"1&$!E?G87C/2^>-7FR M43BLP8IUG&AMDG LQ."D5)Z;NG_20[#FC 7K1;!..(4B&"\(SL@B(Z-'/EDB M90P^Z&?/FL].VUC,@KV=S*PMV =EW#D6K%>6ID0)PEJ5%JQ!5CB#L%0V8)HR MT.;^26+E"F$?I8N-[8QL%[Z$%DHOUCFV'?U9(+/NH7MK"JSCF/<:+)'8<(:Y M#M)Q%XRS%'1,&;52%EM\RU9*M:JY@,0ZF+4"$QA_<"8,\4 YXM(;9**@2%%M M?'38!:+7-MFS+EJK63-AAT,0C%K%$^96*&!5$:7B,A!3QS$?@C5GZTF-DURD MB*0!?9(;HY!U-B"CI&44!\6Q>.ZL^>STC06;(=U*9M96X(,R[KPYILQY[#U# MCA*;,^@)TA)+1!S!(4E.<.Y-K^HYIK/!&%[',5^D>ZR.8RZ!=>HXYGVJR3CE MH6Q)>,$3=P[K$*7!5CO#M= ZUA;LO4O;[[,6+!-<$B=!0PY.(RYP0$Y+@8+W MB4LKM(EV;7->X\'G$RQY\:P9G:14,*DUV*S GEI284(B,>H8P*2M+=@'8,T9 M"S8ZH?/0",2\\(AC%Y FR2*L6004C3IA\MQ9\]EI&PO.,;V5S*PMV =EW'D- M?34'2'41I*H2B!NND+;8HD249=Q+P:C/<4RUWX6&PW^QX>;E#83GXKQ5X//O.VV8%WX>F*U]W^8&6BG:MRC:^5D\#1LWVIGP5'W_8:URC'H=D_ M;MG3O%_QZMO6GURE3[Z$V9>5#1.+OZ/MQV+7P8IL9NA5B=VLRC6>AC'S;]MK M=H?W.[KTQ7NIE3)4Y\Z725FN(],"$QV$@7^<)-'5 :1[UUS>S]HBN;3"L"20 MQ-G592D!6T1JI'@0W NKI!!KF[.)&L_'1_WB&5-KISS%AAGK>&+],Z\A4*/:P)%N4+O0[_\:UWW/=7LA]E!%%:\8\%#H#ETK%F-B&'T@9]%E M#NMW6\UP]N:U$F;E*/ _%_5<+'D7TSM^913R!6FN"(Y%&>AXL7D2>\[L=:]$=O]I9%D,B$M)D,%Y MK(Z0)M"HE,L3G/4Z-[-2^UXR?6^H*MZN8&)Y[/S(;LP:V&M@7SJP$T*C-,F( MR"+'DCB#B<,T$BM#U/96*7DUL#\,L,^88A8.S5K-$"9< + 'BG00"7E)$F?: M2AY=!G9#:F!?(6!?3GSJ7P,+#S\N9X$?XVN-OH(R@+\B^B*J'PW[@V8Z7390 MF>MPBE;]R0?QU;T0WO3]9^BNO'^Q=QB+V-#7EE[1JTJOR-6U5^3W MBN-G?SXB,;SN#H]!5N:3[!>V%XM^;#>1[72&MK5>Q)\^ DJ ^"H&0#1QV.N" MW.ITV\WJF/M5-5PG5\.M%R>'37]8N&A[!3Q'=0T@CWR#C1=^]G0US[YWW*UX MN!=#L^3GG/?9;!_W\@R%F/F^;4^!]_O#5H:'PF9UJ%=&5>&O3!,VY$,"6KB( M"D!3W6&NDYP<95)6368$*8GIYP!N +_:0?E10(K\[:FE]$<8]>>??Z("2.U/ M:]E&B6 7[M>?OF&UN1-W/6FV6D";Q3&H:[8#=V[EYVIV^H,QK.5%-<>YL>5# M-%/YXKR5P;KZ&>W.OMJ/%[@AKSPVX?5>L54N?(OEGX>P_;&W4;Q)*?I,/\6. MS66%E*U7][^PB)W^F%\L7AL<'/1NJ8\D;>/$I7SK?LE7DV[V2VBHRRY ] M \N9(HZ!C'(H/S-F\7GCTP:(^5;+]OI%?KR0^:7B0G]H.P=C@N\4L:3,+,"! M=,KJS>IY&5DOZ724+.XGN&ST%EW/0'%GXQ MDV^F;I_Q,DLP%]?.1\67(! M,)"#_%7DGGH,J4UPRQ M?5Q^"WC"P_G:9OEKQLON< BI)/)]Z( R)P)N.I[31J"H.[ G?YS >^5,]P*%CUF1G&WURO5A-?V&-X9G)ZYJ8._=C>^?+A]&N[ MT?RZO0^?R35H'W#CY%N0&/9;$41@YQ%7/"&MN$!"1"649MYRO[9)YTY_*!SH M;_E,>V?T/]*RTIC^?\LG5ES*'[]7<&6+@U;7@5'5/P7 \2/]SG?;;=#N /] MM'>^]^&DP.(>MBK5M&T'PUZICT^0H5RO+C@BNL80+M#T%ZF,$2&IE#0Z*;A* MT8CLBL$A>4LQ)O[;]IC*T#FY503F^C^GDM[?9&6_#WNP6^)H]IE>\(H"=_E7 M8=@[Z?8"H.@+H['&K^^_=K>^&:H%(QXC+@70F 1J,R1/N374:$DI<9*N;78! M84Y!,(W);'1XFY5!U2^E5+G)8)'WA^XH:W- !V.Q!6<<2NVEOU&4V)2EWTBW MFP-.8%3 ^85\AIG6LL"\FE3'I&T/>K$T(<=^@6Q3-@-<.'L3X+H3RZVN>TZV M)"2X3%EWFSF@V,T"'-[,%;C%;W^_ M_W/WX^_G O]3],/\[BYH:IV,U!,EC]4W/NV^A2^,=(@WH%W#%WJQXT^K]_,# M;%?*]/K(9U8:7:Y,#$LUY9Y]UPO*]M$> @B]!A,%#:).X9 M=TG87%SGL;26$G.[9-;Z\.8=GM-';!UUJ5ST@R# MPW%FP<071X%7?/X5Z_K=UG!P^5>FPZN/9(E2,K6K$S\/>^>NN(.('.@MWY%- MH%"]LJT3>]I?^]>%1VHW.VAJ"Z>?_M*'3.G>'K+R$0)PY+!&/IN22$?N-[LR M:RD.>QD-_Z/)6;+!&0.F).> >Z#H>QP]SD#:R1TY M["Q=7T[TU<_YOD>X"1@__?83/;P.[T!A)\/8OPT@T0P^4!0:#< Y *(_F8TRA'K^3@B"FC-572R9D@ M+?.4?#:DC_OQU?B7/\9%R\U.N0OEE_ZX>/4Y<9;RH*JW1Z+(F V%599&HVJ3 MT8U'@FJC%%13:5?5>XQN&*(N?1MOD%N^)QB[U3>O7"S9 +!^2HLU-[KL-75" M"Z25W>*CJU88/3_C=8STP+HE/V=Y<(-BHV>['UM^,+2M13J\K691V2+YHB_I M?"FMTGV,>? MK$@?_]L2R@IV&5FL=VPB7@3.="2>HD3FDY:>R.R_'M$ MBQ\S*3YUG^6H&N0SV=][_VO_UW>QL^?Q[M['YM=W_S[-H]V][S\;OSZ(QKN_8%UO?L+:CQI[.^SKN[='N]OY MWB'M-/%I60GR"<-S;(F=[:UOCACE&$T(*ZD1-RXA8[%&0#N2RA2$4&1MDVW, M&6Y2##(Y/7:+H!?+49EKL&?"4F4X]L9&L,&D$S8Z$4VX9*ILS5%+YB@\S5& M;9HR'I'#>0I?\@E9%2V2/&%B#74J-TJG&X+>A*.><5.Y!>J1GFN*ZX1>\N ) MI7]?CWO51OE'M6/\:EV.[*D+H%;;5&J?0CG>YU\N9Z%6> M3%D6)LHT5)SSJ,Q5.!$-!$Z6.WL)5W/ MGKW0N7WH^>C#:C>#\JIODQ2I/L#X%.$W2^: M[3:\ B*I=7I.D),9AOG;HT_G8$]%CF41W@2A=KT?YL3$&P%FL[\@8%I/HM;) M.J<<%]YH(3Q8P4IRK(SSJ@;,1:7 :8%2K.GG=US/U!/ ;EIGO2.:?"9AH<\GR.]5#_*'+O8 M47H2' "+"7!Y#@JN4U[P$."6AGE.0GV4BQ\E(+=A,E$1$PK!2L0I=@CV4Z&R MIA-[V&=G\U'.TQ]&+'FA:K9*BBY3[T!M/4/TNQHZU M):,08V)E[';3GP2FK M9&+,R"CKTU_X]"FHCQ ,8L(HE)0!Q;GMO )B2(D0+@V041KC9TFOWS;)S+ MC9Z;U=YL%%]B<6A_E,7AE;$S[M@RZAUP(Z6P*M YG6\(@1HQC.-F 6E8Y0)7 MJ^O'BQ\<]JNZ@/YA+C\[!,BZ/'OH6;A(KG9[3/J.JGJ\"Z57%^S8LCX*U/ZR M/BKUNNU1.7/+#UOVK!+Y=DZL]3,Z&]=9K4_6-?M#VSL829CX\SAV^F/MMU^V(;#9 MTLXD6S[]A1@WR>0W3APOSG+&BW_F7ZOJ:90)&M@/E>0X^8S#XWRY1LP03Z +.R(4(H308(.R@<:U33%/^+9'1;G-7)<[L>T7B./".VC< VO, M%KD'3-Q M%-KK_AE+F@7PRB3[^AR*=M/K"2"J:+DFVOE$^YGL;'U+01 94D*:Y]'@F$AD MHDR(:.$4C8XQ"TH#%^IRHAVI _,(=T)PG.D0I8UNW8^ZQSPS#K (LDZ MBW"0"G&KLRLD&@3'HIU/+-J,]U>[:P&!A_TR_E3VRRKUWP/0V5I-Z[(:W2R! M/9/5_.*T2D$;!13A4X]'1*.!@7-TB9J(YM:$['T0#<#@W>W<5M;_!/-=&&*$ MP!S%R#CB/&%D-9,H4&PS22D@M$Q0G,_.^SSW_Z^>,/\[D_0(9.Y9BK\T*MKY M]?UG[M:A3.":8P2'Y1$7G"(CN46.Y88IE'DN4TDYE%\.12,Y/B&IYDGOYVLU M;W5RYD"%NZ=5NYI1O'^VDJG9/S>K?7?8"F/CNAB6$8I^C-_S?T'[C@?=0;/L M'9);W8)9V+\JUP#@O/SNB6W^R-&.4F&Y\O[KA>MF=3^=A82KY9RUR1RI6KDE MSWF#A#S/=:-X.^SEKAYE@*Z7E:).;DO9Z69C8M@K;WC>$[-L2-8O3LKKEYI0 M^:39GE7RM?'3Y$;_)5O@Y2+QU7I%7QWV-^H(*J,63;+/KUQ MO12'US5VZ;;!O*ZVK%I0OG[9/789[U*RHC3^$+5EUV$"\8+ M0<_L62I[%U9]+\_VJMWMQ4IK'=]QQ#MYCZY9=>[^!O1@*_=J[FUJ_6#2+S*O MG^?573*J,\\7'ETM?WR"AGLQC>9/EDL^C)VKFVJ L@'KJ/:C/[T)5^13\:2) M"_?(G4\;>!:L"7Y]?BS_E,?RI!_^ZIYT5Y!W=DCGY.2;%H=N7-E$3*8@>5"> MJEIY3[*PJBQZT^/HW:0NVF3X?=WF#<]>,%US6?[)R ]D&% MDM@AYW*O,*<%LLY'1*C0UA)E*7'3=Z[?G.A[K5SE,^O"6V MVIG!Y4G5X3:M=++K;^NXUVR=&Z2YRWD,L[<"W>6\DVZ.[56:S61R68)KY=2T ML6TTB)DYR"3^#ECZ #6],-)B*F\YD.Q?WI;2O'=;7.TP^9+.7::8(U@R, M76.SPX0CS95#,EDG)?.*^ISO<%7$Y6+/TADJ'RO8,[WF,C'>I=_<3,?,)ZWA M+:C>?JIZ4U?#$)[T@U_YF",=YT(G[DD$7=!?*RT "2=6&H(Y)\H9CHD00@4# M8I3YVTU%K[UJ\R3I09:D!C02G>\,UKM(US;-!I9S MHF-CK]K5PPL6W=W):H^_[/S%SFAB@LN M L-@R'")N+4*68XE(A%D/4E24:O7-O6&T?*Z\[],'\K6[P5\J)HG53I1LU,< M#QU :C4%('N&JG!F'@(0VZ47#92I;N^LMW;9XC![OWI5VM5$S^5^LU,U7AUV MPF0F4'_.(O+7AYU^U9MX/?\ZS*7 HXD>W?-I@E5>0FYS7,8UR_N7'LHR9:;L M&%RFZUP<$3*>-P/B]&C8&:U_,N(U\J;!7?O-T(3+PFN_]6*JU,+5ZC6\6\W5 MF?#A/GZOX=^?MK/LRB=\WYF8DK%>;)7J$RQC)^8N]*WBTVE_$-O]LE7V<2S^ MW/CW1O';ULZGT0LY6R#GV50*75;ONMG Z)YD;^L9P9UF$ORSVQ\ 67_R33C5 M9FKZ]!32_LE&A:G8$QXL!P() M.V2-HV XB1-OB(:%(A^[<5@G\S4#"!/0F:!;&VB>?.6_FO MXH*QFP-J<$!B_3;\'3RF/.82\<"I\UIZJA2CAN$DA;M'B?#R7$V??X'^KT6, MQ 2%(M<$<4(#G+L!(\"H!*:75#8!?\^=LM.^)7??ZHAK[K[M*>.=DV\T:$]# M<(C3"%9>BA'I!&H %SCDV7Y3>+Y"[Z>Z';S37Q&%OD;*Y+P0V!&DK(V(*S'OAG)?.+9>[;W?$ M-7??]I19UM%\(MR:A&+R''%M#3(N"RMPMYY2WSN5N1DJGQ^(, MSJ5TA("!82GG^=;",R\#I104-Z),S>#+._K]DT;9+,Q@)2DB20C$09XB%RQ# M*2;ME=%.^.OJ<19D\-L=<HT=>Z/^C_]"_[4\_CAV0W7B]G>7I<.+WZ)HV1H/4IF-=:R M*J-D5GQL(P.7:C$&_7:.[]^/XN_4:;\ MG&VIEC/VO(^64%VGO.EQKUMU2%LP](X-2\(QZT)07"1B->4D8"Z8YA2(K4P= MI>/4T2MBL+D_ ++G3'/:QDWU=U YE6 MFZ/#&55,/-^XVI=;(*%H?D^!Q+[:;PS9\*<69EB%?^<7_3<,V9_Q)(Z2A6L M;/+QHS05$[!EM^I:4U6'E;V9QI*DLB!LKM6%+Y898UD"E,EH$PG>SG:^E]][ M#81HRX_\9?.#5FG>XP9-<(OI0JHY6>S3.?LTJ077U MX+%SY^W6IS^+K4^OB[WN,1AR(!K65PPS]H#6^BG7[>;]^11[/YH>GN@QH6.R MFQP013[R"1U@;"<.1@O/.5GGE ,:0653#PY+^FB-&F]7F9*AW>PT^X,*6D93 MYTO[N-L*ZZ.&QK/$6"58%BW0'K/>^\,V6^.BYCY'Y L9U";/-;5:.E,+<':SL MKLE> M^K#?W,R=,"^U4AQ%;D#OI)X@9[$!>TDF!4JC#D;.#/M]\*&T6K#;#*6E?$/* MV\UYO>JR1&X8?#_C8VF]V">U6'*SRXY&.$V%OPBO1CQ?')?4ZYY4O],5'[DZ M?\#FVS/-]'S,=9N<-,IOB CJ7"RX*EZ_E'^ YKI5]>$N]_7,BY134)8[Y?@9 M;5U-B(](B"LU7OHQ)IQF#]BDZ3E-=4O;"%P\A>WXS_M[_C^F,Y]6ZL$7B%DI MS(Q146OL-"G'J&JIN(>?28[ M7]Y^;]!&XOOYR$[V^]QH_W^I/$.5K.W3Z>GXN8RH_TO']@^ M??^SL=?ZWGCW!N]L'S9W][9.=HX^T/VC+;S_ZVNKTQCM'!#8-"!_/_+Q?FH/#]^WC(6# M6':_&=?_[S=C*TPF-S_Y9.:'AH)?,R/GC6%$"89BR"5,G@(4P N(6$&DBBK9 MW A8;%R6H[%*4/ 8;/-?-]'5%\6A6O.J-:_IAHA<,*9U$HEH'KG5U%/MX;], M@"XV*N.^02^?6O-Z2+@ETW KO<@=^@.*7EK$B8U(2VP0MMAZS )+TH+F)L>5#M$)KZ_)+*\UKT>" C:C>7%C-><2 M:4$U @N:(1=H0$9IS@B3F&N_MDDW9O,,5P\*'E_S6MB;E\K_/2F'W7[L7.6O MNQ&&SGGLIPZ3L\J2C\2'*(QD&H"1,H>%X$8)["7QBEP[@Z96EAX>(4]GW524 MB^2M\0")C" N%4?&JSRD1K&8M(TVV:6XJ>9CP;WJ0U.WO)4^] QY>:[*8PR< MM%;<@#+"7> .#M_(D)@S*6C/:F?3:C+TC+,I*9PB3@)YR7DNK7#(&1T1]I$J M18@RU.2^6'=V-BV'H1]?JZG19,F: 0=#.UJI&;>>DT27FN9@"LJUU@ M#-,@N-;6$$F4AA>\!C*@KG:&K"9#SSA#F*"1J1212B0!0UN&'#86669MUOYS M+7'6#&;[IK]0S>"VV4NW]7=6P8CDB";$,< M!X,L&$G(.CA+JU4,CH.6LRP'\1,-!STG5IX?\9&Y/TUR)D^@#"DZT'>X$B11 MFEM%B-K]L9K\/./^$'!$P3.'!$\"\>0HREUCD5;8*A(U'#0M!P:L!D,_OI)3 MH\F2%0-#>31<(Z$."<1UUXA MXUGI1^6$>^I3RNX/MAHX4K/R/2D&@G*O?&"))LD9#49;9:/"VHLDK+>U]V,U M^7G6^P$,+93S2/IH$+?>(\T%0:#[$Z,Y$4SXK!@L*ROLR2L&I??C7V4?@\WI MP:A/L\O1I6U29FK=)IH\O1XU$!G:5K$[-60OCPAN#BZ6?#_%C;G)P-3)=H"M M.!CD3D2Y:6 U0G?!OGQ&:TV \:21G@?+'-'>@X+NB/%)RQLGC_Q=+60W59-\ M=\_76&E$=1.^^PD (BY$F1)@EB =CD&7!H>SV2$$;%K#.KH]9%>>L M"=_RYJ@20J,TR8C((L:<(P' MT%]&G?/7.)X_GP>U3O3^RI,E6V7OJ/%(U-.J'UCG]!IDO%-'JZ?=5/%F706+ M_O#XN-4$43OJ*'[>IJ_J8'R!3D9MVSYO?-H :LIS>:NAM-4E^D6>.MH]+H?K M5GW-XJCY\;$]+3O)6OA_444Y6F<=!$O*S!WD6JUJ=ORP;&W;BIT#N%MU>N,+ MP/FV*^*$^S3;\,@E68XFSF?M8C2\-].$[84+7[RP_F:_,+@(]C33:IY!,4%( M\*6R3=X9W<%R\A>G-BN>;579IKUE^_UF:L8P)KO5:CRW-6XY]T_U=*O2]_1& MO%BUKLP4]Y":3NY-_VETYI4?*/Y3G?BY,OJZ;&=7B[:YHFT'[+_=/#)R;__7 M[A[8F5O?K(Y16LZ1"PE,P0"_:<8E/&C&BBHD):5!$Z4]+@G$W$X/>L92_>-JSH//HZ2*-^6T M%4+^6-2F?Q3Q!'M8ZHPCP31WVDH&DG'3W>(]O%K1F1ZW\&]W^Z46F[6/K4XG M/^['>-SM@;W>*=X"%A0$H_];*;)A/!L+KE7!1#D6H!*0KMOKE8K12"NO5%M[ MT(LC77N!:5@+TW@U/NC:Z45R;6+^T#WV7"W!MGQLV_JSTA ^905A&W3)5AG1@1C!)6_0]Z<[VQ]8X]T;\77O.]W=>WNT ]_+KWT]^G=S M&DIWM[^/X/* [1^]/VG .O?W6JW=O7VQ\V7G=.?=!W@MM!M?_DH[1YXVMKXE M*W."J$7><).GO^6N)U8A0_\?>^_>U<:.K(U_E5Z<]_QF[[40HU:K+]KS_K(6 M"23#/K%)@"0'_LE2ZX(-OC!N.P0^_5LE==O&-@D7 P9Z9DT&C+M;+565GBI5 M/65=::Y-\M3O@B @1F_BAF2-HDIQ::7->1@QH4,MI:$\DLK03,ZQLCZM]5L< M,6SN'FP'[\=F9O_+IT\?MQO;S8/-C\';S8^;S7?;P?Z_M[GK=Y7+:-'';-K*X_0]7K\V(=9VNSI]U4<8')8]HHM:@@>"YXV M6LXE27D,@%2$C&1:,1B8S M.7MBGNN0T@WJ#V1O2W2=L U&^4,P'&?9W8B3?T?'?/U#[S78F\W!;]*85Z(Z M6]SH@'+Q2>S+8!.^3>;Y2BS979PQ][I7VBTLBX;U>:STK1FT:PK:N3F\$>OV MZV6V]O.47>;-CX,I3(JS)22P-5UG(TBA" MRJ/U)13N/C/^L]K@U0;O@;*.:H/W: 9OKN*'"<5I'L4D8902GO&8B-1*$C*6 M"II)KHJ5)"8?U(R+1E(#!4D);*A*& M1<;A?,+)7'RD9E%YCFJ[-)Q1J^W#J>T